{"docstore/data": {"1ec9f0f6-ddfb-4773-8c5b-9608fcb4639c": {"__data__": {"id_": "1ec9f0f6-ddfb-4773-8c5b-9608fcb4639c", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n02-Aug-2023  \nMcKesson Corp.   (MCK ) \nQ1 2024 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n02-Aug-2023  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f1a04c9-62a9-4615-bcb1-4492e1bcee63", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b19affb631c2aa173697363d41d6e08ec58320507be1c4fa9f8dc064bd25609d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4e052e2-2bde-4d36-87b0-ebd8dd84eab5", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n02-Aug-2023  \nMcKesson Corp.   (MCK ) \nQ1 2024 Earnings Call    ", "original_text": "(MCK ) \nQ1 2024 Earnings Call    "}, "hash": "18a48d7c48e259e6a666cadd8a668ea6ecc8a24068615b8591d800fa2b2d05b9", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n02-Aug-2023  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4e052e2-2bde-4d36-87b0-ebd8dd84eab5": {"__data__": {"id_": "c4e052e2-2bde-4d36-87b0-ebd8dd84eab5", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n02-Aug-2023  \nMcKesson Corp.   (MCK ) \nQ1 2024 Earnings Call    ", "original_text": "(MCK ) \nQ1 2024 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f1a04c9-62a9-4615-bcb1-4492e1bcee63", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b19affb631c2aa173697363d41d6e08ec58320507be1c4fa9f8dc064bd25609d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ec9f0f6-ddfb-4773-8c5b-9608fcb4639c", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n02-Aug-2023  \nMcKesson Corp.   (MCK ) \nQ1 2024 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n02-Aug-2023  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30c6654867ba408bbe11f2906cdedb94f63501e798ade8c64c3fd7cc502ade6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37f0b981-a739-4f4f-a0a2-4e4c7c3855ac", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "3c87cd227ecad8b209e6f98bf64c3897ecc123c3bcc59d3f42039f038ec2b397", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37f0b981-a739-4f4f-a0a2-4e4c7c3855ac": {"__data__": {"id_": "37f0b981-a739-4f4f-a0a2-4e4c7c3855ac", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4e052e2-2bde-4d36-87b0-ebd8dd84eab5", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n02-Aug-2023  \nMcKesson Corp.   (MCK ) \nQ1 2024 Earnings Call    ", "original_text": "(MCK ) \nQ1 2024 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16361d61a68e08e1ab9fba5989d2bba56559fcb81ac02949ed885919f7404d38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "767f484d-0e88-436b-8d0b-31c0f551f972", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n"}, "hash": "eaa28fa2e39b6ada9e1dfe65aa49395724c5dfd06a73c61acdd39f69df2f7ec8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "767f484d-0e88-436b-8d0b-31c0f551f972": {"__data__": {"id_": "767f484d-0e88-436b-8d0b-31c0f551f972", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37f0b981-a739-4f4f-a0a2-4e4c7c3855ac", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e738a82087d481454557742925922da7b33505d92b6f1eff93000a2cb6defd66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ceb9e48e-ae8d-4c0e-a214-7f9f703c045c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "ac820940bc929fdb04677fcf91bac67557fa31812302eb632c661d7206abfe65", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ceb9e48e-ae8d-4c0e-a214-7f9f703c045c": {"__data__": {"id_": "ceb9e48e-ae8d-4c0e-a214-7f9f703c045c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "767f484d-0e88-436b-8d0b-31c0f551f972", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b2e7c3bb5b3e8d99c2e8d3ea2635feb46ca27b9c3a0d927dc65d3625abb6ea2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03427b1f-5b9e-47cb-8f63-ef1061960587", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J. ", "original_text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n "}, "hash": "3c4eff7083eb855bdac6f960a5d95f9b314da6898c4b403170db6bbc4e870efa", "class_name": "RelatedNodeInfo"}}, "text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 283, "end_char_idx": 355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03427b1f-5b9e-47cb-8f63-ef1061960587": {"__data__": {"id_": "03427b1f-5b9e-47cb-8f63-ef1061960587", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J. ", "original_text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ceb9e48e-ae8d-4c0e-a214-7f9f703c045c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a43bd57c137416e9b811edc41b37e4fe717394067dd5a1ef3a8f9c1726bda09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "452a77cd-46f4-432a-863c-55ee682bc998", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "99590f86d711de08179a01b30e3e9897a49af0c7b8395dbfca7168c961823976", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "start_char_idx": 355, "end_char_idx": 445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "452a77cd-46f4-432a-863c-55ee682bc998": {"__data__": {"id_": "452a77cd-46f4-432a-863c-55ee682bc998", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03427b1f-5b9e-47cb-8f63-ef1061960587", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J. ", "original_text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f97ecbd44474e0e0489256f73c353d712b66a0df078e4460c5999f1048b819a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f0072f1-57aa-4883-ae57-5d6ee9790961", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n"}, "hash": "714eda4b844e722ac43fed2c0050028f2daad0a91652c70d260adfd92d626e63", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 445, "end_char_idx": 842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f0072f1-57aa-4883-ae57-5d6ee9790961": {"__data__": {"id_": "4f0072f1-57aa-4883-ae57-5d6ee9790961", "embedding": null, "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "452a77cd-46f4-432a-863c-55ee682bc998", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88e42a2d52da27394ed2d245c308132ccc789874047403b1f1a084edd3318bf9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d73c376-9867-41a9-af43-d573f6520e98", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call. ", "original_text": "Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J. "}, "hash": "f7b03294a26a7505f8d2eab59c743c11229521f3cd200a2423ec92af26c82e4a", "class_name": "RelatedNodeInfo"}}, "text": "Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "start_char_idx": 842, "end_char_idx": 903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d73c376-9867-41a9-af43-d573f6520e98": {"__data__": {"id_": "5d73c376-9867-41a9-af43-d573f6520e98", "embedding": null, "metadata": {"window": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call. ", "original_text": "Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J. ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f0072f1-57aa-4883-ae57-5d6ee9790961", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cac5376e9adbca474651546aeb85c66ad2cad8bf5fcb4e69d2d5b259d0423e03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3a5d367-5036-4fd8-ac0b-79ed13607aef", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n", "original_text": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n"}, "hash": "f3d861ecd8cc955fab820c9dcd9376cf762ce2cafca6579636cd7663f5baef75", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J. ", "start_char_idx": 903, "end_char_idx": 1001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3a5d367-5036-4fd8-ac0b-79ed13607aef": {"__data__": {"id_": "b3a5d367-5036-4fd8-ac0b-79ed13607aef", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n", "original_text": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d73c376-9867-41a9-af43-d573f6520e98", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call. ", "original_text": "Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J. ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53f83a60dad1b4c9e9b68865ab62839029d20e9302ff17a143cffa04602da66e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4489f470-6222-468c-b9b2-4b13f096175c", "node_type": "1", "metadata": {"window": "Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n"}, "hash": "0ac75a907fd56f11cb480e5fc2a91ecbf238437a91e9eac3271b131701c47fc0", "class_name": "RelatedNodeInfo"}}, "text": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "start_char_idx": 1001, "end_char_idx": 1116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4489f470-6222-468c-b9b2-4b13f096175c": {"__data__": {"id_": "4489f470-6222-468c-b9b2-4b13f096175c", "embedding": null, "metadata": {"window": "Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3a5d367-5036-4fd8-ac0b-79ed13607aef", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n", "original_text": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1555ee963ee022c74bebfb0f17ed75bfa65f2f23c2760dc92504cb9181b25b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "004d145e-61f6-4210-830a-2d8c6e5a7342", "node_type": "1", "metadata": {"window": "Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call. "}, "hash": "866ef9ffc4a65d3140c820fc675bceed22ea15f5969f377cebf91414086b2ea7", "class_name": "RelatedNodeInfo"}}, "text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "start_char_idx": 1116, "end_char_idx": 1172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "004d145e-61f6-4210-830a-2d8c6e5a7342": {"__data__": {"id_": "004d145e-61f6-4210-830a-2d8c6e5a7342", "embedding": null, "metadata": {"window": "Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call. ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4489f470-6222-468c-b9b2-4b13f096175c", "node_type": "1", "metadata": {"window": "Eric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "354faad6889f543fbf68040aa4123890cf558ce0528a1f8dea42f0aff5f331a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4204660c-9a85-4c3d-8471-38a8b2882200", "node_type": "1", "metadata": {"window": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n"}, "hash": "9d79b684ade32f42fbdb2754c02b381de4574d4e9927c0c40837526d12759bc6", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call. ", "start_char_idx": 1172, "end_char_idx": 1612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4204660c-9a85-4c3d-8471-38a8b2882200": {"__data__": {"id_": "4204660c-9a85-4c3d-8471-38a8b2882200", "embedding": null, "metadata": {"window": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "004d145e-61f6-4210-830a-2d8c6e5a7342", "node_type": "1", "metadata": {"window": "Kevin Caliendo  \nAnalyst, UBS Securities L LC \nEric Percher  \nAnalyst, Nephron Research LLC  A.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call. ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16cf0d5da072d69084105dcf511e8e06b7cf57565cdfcd8121ffb1beddcb7749", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43016a68-8cb0-4f94-a247-e274775219ed", "node_type": "1", "metadata": {"window": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. "}, "hash": "6c54725b63ab485d4175bb6d700a55673e91fc906529b10fc7da938708b7e13f", "class_name": "RelatedNodeInfo"}}, "text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "start_char_idx": 1612, "end_char_idx": 1678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43016a68-8cb0-4f94-a247-e274775219ed": {"__data__": {"id_": "43016a68-8cb0-4f94-a247-e274775219ed", "embedding": null, "metadata": {"window": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4204660c-9a85-4c3d-8471-38a8b2882200", "node_type": "1", "metadata": {"window": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13f3c5897b9c80f8e84ebb13ee4ff006d517e3993e6126060273344a14c09bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "489115f9-e3fa-40f7-aa73-982f729a742d", "node_type": "1", "metadata": {"window": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall. ", "original_text": "Please go ahead.  \n "}, "hash": "1688fbe5000f3ae782cdf1c29ad609e7ee18d3ae4a1b471d271edcb8e6d029a0", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "start_char_idx": 1678, "end_char_idx": 1774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "489115f9-e3fa-40f7-aa73-982f729a742d": {"__data__": {"id_": "489115f9-e3fa-40f7-aa73-982f729a742d", "embedding": null, "metadata": {"window": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall. ", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43016a68-8cb0-4f94-a247-e274775219ed", "node_type": "1", "metadata": {"window": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10d99c7c96ca6c7aae04ba167df512ae1f3adb43ac73a007d52f633766c674f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2381de58-fc90-41ab-b6d8-72563f04b20d", "node_type": "1", "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n"}, "hash": "4cdd2ddcafc02328c8acdbee255b63c3795160ab8b14102680d47874454bc01b", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1774, "end_char_idx": 1794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2381de58-fc90-41ab-b6d8-72563f04b20d": {"__data__": {"id_": "2381de58-fc90-41ab-b6d8-72563f04b20d", "embedding": null, "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "489115f9-e3fa-40f7-aa73-982f729a742d", "node_type": "1", "metadata": {"window": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall. ", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99f4309ec8d82dab02aa244ca7b0f9869c2565b65fb280555338c4f71bf92bd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbb8d283-9428-400f-ab22-bb5065cd27d6", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n", "original_text": "Thank you, operator. "}, "hash": "89de5e68a3c70bb85e2316d3e2a276256198234f2bb33b9fec448b26cdd99363", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "start_char_idx": 1794, "end_char_idx": 2140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbb8d283-9428-400f-ab22-bb5065cd27d6": {"__data__": {"id_": "dbb8d283-9428-400f-ab22-bb5065cd27d6", "embedding": null, "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n", "original_text": "Thank you, operator. ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2381de58-fc90-41ab-b6d8-72563f04b20d", "node_type": "1", "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "512b72f64964e0210739c3f006c02a29307e0c02dc88f1367f7140793321401d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7dfe3ce-80e1-4408-a81f-7ecd425997db", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall. "}, "hash": "b9068964229c3baa855e7a7a8a8495f79393d982348462bee4b0ec8e09c46561", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, operator. ", "start_char_idx": 2140, "end_char_idx": 2161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7dfe3ce-80e1-4408-a81f-7ecd425997db": {"__data__": {"id_": "d7dfe3ce-80e1-4408-a81f-7ecd425997db", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall. ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbb8d283-9428-400f-ab22-bb5065cd27d6", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n", "original_text": "Thank you, operator. ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79fa88f8c8c3a9829821b620e8ecce6fe0a248bd67c9f00913affc97f420fdb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "214f1ff4-e754-4102-8b7a-71d5a8ff81e0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "original_text": "Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n"}, "hash": "f30b32a10ef45df0e778c06aba5ef36ce3c409632871f4104e677c38ef2e9f19", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall. ", "start_char_idx": 2161, "end_char_idx": 2255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "214f1ff4-e754-4102-8b7a-71d5a8ff81e0": {"__data__": {"id_": "214f1ff4-e754-4102-8b7a-71d5a8ff81e0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "original_text": "Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7dfe3ce-80e1-4408-a81f-7ecd425997db", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall. ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "298faf0f0e7ab1f079bac21e7bc276dfab7c4c4765b74ee8a8220682400b68ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "562be26f-69b1-4a3a-bf93-ee728d91faaf", "node_type": "1", "metadata": {"window": "Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "original_text": "Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n"}, "hash": "81319a4dee92e7516c423cc340df7d8b7cdcf7ba63a3c4d978bdbdb3b649a227", "class_name": "RelatedNodeInfo"}}, "text": "Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "start_char_idx": 2255, "end_char_idx": 2368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "562be26f-69b1-4a3a-bf93-ee728d91faaf": {"__data__": {"id_": "562be26f-69b1-4a3a-bf93-ee728d91faaf", "embedding": null, "metadata": {"window": "Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "original_text": "Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "214f1ff4-e754-4102-8b7a-71d5a8ff81e0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "original_text": "Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f59ec4dfb7c4f0783596dcc6ce6b5052139d86fa47c21d4d74c80f2b7307039a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3e57ff7-4a27-472c-b71e-26f7d7736d47", "node_type": "1", "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. "}, "hash": "7b3a62b8dfe6bd0e268d411229677435cbc5c1a8d01665a3528564f6ed9e3556", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n", "start_char_idx": 2368, "end_char_idx": 2465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3e57ff7-4a27-472c-b71e-26f7d7736d47": {"__data__": {"id_": "a3e57ff7-4a27-472c-b71e-26f7d7736d47", "embedding": null, "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "562be26f-69b1-4a3a-bf93-ee728d91faaf", "node_type": "1", "metadata": {"window": "Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "original_text": "Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "839404e1777a07e4ebfdac4df8627cd0c4c14ba8e5ee9a2c21b23b0cf78b0f06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68b0fa61-126a-4545-b51e-7e0d71ba3c2a", "node_type": "1", "metadata": {"window": "Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n "}, "hash": "fd144628bb91649900336f66455a4e1f9088249ac6efae82c37c3e755849de86", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "start_char_idx": 2465, "end_char_idx": 2592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68b0fa61-126a-4545-b51e-7e0d71ba3c2a": {"__data__": {"id_": "68b0fa61-126a-4545-b51e-7e0d71ba3c2a", "embedding": null, "metadata": {"window": "Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce84f197-3760-4cf2-86ad-93434da74016", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b17d75b43a489d1a95fc7f09f7233150fe2bee0da680f7a0b52e8af3917784", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3e57ff7-4a27-472c-b71e-26f7d7736d47", "node_type": "1", "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's first quarter fiscal 2024 earnings \ncall.  Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "360569da81ace6ecd9bab9e7fc8e68eb789bb8b720b9d365b8b32ca04da09e0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd3ffb9b-2b55-44e0-b69c-2e36414c3dd1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "McKesson Corp.  "}, "hash": "14375b91825b3bcee6d7f97d34feebdcd0cb16808d28b4fdcfea14fed3a80ff6", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "start_char_idx": 2592, "end_char_idx": 2989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd3ffb9b-2b55-44e0-b69c-2e36414c3dd1": {"__data__": {"id_": "dd3ffb9b-2b55-44e0-b69c-2e36414c3dd1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68b0fa61-126a-4545-b51e-7e0d71ba3c2a", "node_type": "1", "metadata": {"window": "Today I' m joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off followed by Britt and then we'll move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our most cu rrent recent \nannual and periodic SEC filings for additional information concerning risk factors that could cause our actual \nresults to materially differ from those in our forward -looking statements.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44aaf61b7ef5844f85b01906c77d1981e5cda97c477551a79b5b94fd72a4aa54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94356b8f-c1e4-4510-9b95-681950125b4c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides. "}, "hash": "14ccf4e6207f8757d229d80056ccf5883498dba4fbb054082531a444aeb295d4", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94356b8f-c1e4-4510-9b95-681950125b4c": {"__data__": {"id_": "94356b8f-c1e4-4510-9b95-681950125b4c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd3ffb9b-2b55-44e0-b69c-2e36414c3dd1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4da3e2557f486ea0924ddc2fae16a43d1357be8d40ceb0065607c793f6d0cd8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e02e8d1-4228-43a8-a524-e9f414db46b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today. ", "original_text": "The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n "}, "hash": "98834e1a25f6bcb1a36827349ad6aaabe978cca2ba4c4fed71c83a53346f1f42", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides. ", "start_char_idx": 16, "end_char_idx": 399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e02e8d1-4228-43a8-a524-e9f414db46b7": {"__data__": {"id_": "7e02e8d1-4228-43a8-a524-e9f414db46b7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today. ", "original_text": "The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94356b8f-c1e4-4510-9b95-681950125b4c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "560f1e2c26cbeac66d47853b259f6829ae9e99f884379e219f0c2316a27c4810", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0850248f-6f87-4b26-9586-444fd93b8403", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "3de48c711538ececbf579889b5cd184254dd889f852e48bb82904cf889af0800", "class_name": "RelatedNodeInfo"}}, "text": "The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n ", "start_char_idx": 399, "end_char_idx": 547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0850248f-6f87-4b26-9586-444fd93b8403": {"__data__": {"id_": "0850248f-6f87-4b26-9586-444fd93b8403", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e02e8d1-4228-43a8-a524-e9f414db46b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today. ", "original_text": "The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff899463c369c7eb04695e1ca8eb17fa4e44d95223dc7de73dc3c83d3526f78b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8823ca9d-82ff-4bdd-93e4-d4fcdca4d591", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n", "original_text": "Thank you, Rachel, and good afternoon, everybody. "}, "hash": "765605e4ec9ac14075b4500f1683fc9b1313b4f90b8259f4ea9bdae86ce455b3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 547, "end_char_idx": 892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8823ca9d-82ff-4bdd-93e4-d4fcdca4d591": {"__data__": {"id_": "8823ca9d-82ff-4bdd-93e4-d4fcdca4d591", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n", "original_text": "Thank you, Rachel, and good afternoon, everybody. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0850248f-6f87-4b26-9586-444fd93b8403", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c7e03dd577668863cdbf8a16733998f36c831bd2b0e0071f872679ec9067c4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e3f3fe8-cf28-4d13-948b-ed67c19848c4", "node_type": "1", "metadata": {"window": "The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n", "original_text": "We appreciate you joining us on our call today. "}, "hash": "8f187c9c2a2b370a1b99f0e369fb24ccc92f49a3f74ac39cde796ab0e5bab3bf", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Rachel, and good afternoon, everybody. ", "start_char_idx": 892, "end_char_idx": 942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e3f3fe8-cf28-4d13-948b-ed67c19848c4": {"__data__": {"id_": "7e3f3fe8-cf28-4d13-948b-ed67c19848c4", "embedding": null, "metadata": {"window": "The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n", "original_text": "We appreciate you joining us on our call today. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8823ca9d-82ff-4bdd-93e4-d4fcdca4d591", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n", "original_text": "Thank you, Rachel, and good afternoon, everybody. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7ca9aec111b113338c1f30384fb4306794e4186143b6d4bda82ccf04ee1ab9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c5cfd06-28c0-425a-bd0c-1f05c18dcad8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing. ", "original_text": "McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses. "}, "hash": "3fb7cba44ef5371f9442fe496c4ffdafe8a61609eda5e53e61030ed7934642b1", "class_name": "RelatedNodeInfo"}}, "text": "We appreciate you joining us on our call today. ", "start_char_idx": 942, "end_char_idx": 990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c5cfd06-28c0-425a-bd0c-1f05c18dcad8": {"__data__": {"id_": "3c5cfd06-28c0-425a-bd0c-1f05c18dcad8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing. ", "original_text": "McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e3f3fe8-cf28-4d13-948b-ed67c19848c4", "node_type": "1", "metadata": {"window": "The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n", "original_text": "We appreciate you joining us on our call today. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b63e2bd5f709a11fb70c226f74e59d6c78644e4d5b83df7724e6154ffa175e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47d23fee-5c97-48c3-9e8f-eeaf7789ecdf", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits. ", "original_text": "We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n"}, "hash": "b653a89615f96370f0f84ef880044322e3260e055ed2d10fc5c7a7a16af6d04a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses. ", "start_char_idx": 990, "end_char_idx": 1102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47d23fee-5c97-48c3-9e8f-eeaf7789ecdf": {"__data__": {"id_": "47d23fee-5c97-48c3-9e8f-eeaf7789ecdf", "embedding": null, "metadata": {"window": "Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits. ", "original_text": "We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c5cfd06-28c0-425a-bd0c-1f05c18dcad8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing. ", "original_text": "McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d07bdab6c5a5a09051db09c9a3fe90c28feff0a96087541e6aba0c453393a49a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b12ae4d-890f-4cf9-9848-6308534917fa", "node_type": "1", "metadata": {"window": "We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n", "original_text": "The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n"}, "hash": "8e623fe34ced7e15f9141428a6500ac15efe93bf16bf21913f473259700aa06e", "class_name": "RelatedNodeInfo"}}, "text": "We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n", "start_char_idx": 1102, "end_char_idx": 1235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b12ae4d-890f-4cf9-9848-6308534917fa": {"__data__": {"id_": "0b12ae4d-890f-4cf9-9848-6308534917fa", "embedding": null, "metadata": {"window": "We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n", "original_text": "The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47d23fee-5c97-48c3-9e8f-eeaf7789ecdf", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits. ", "original_text": "We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40c5c189276180110daa3f127db10e2e4705839c241748c55c2ea79d9de15dfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62805d47-3eef-4909-8940-a643268b2b4a", "node_type": "1", "metadata": {"window": "McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter. ", "original_text": "Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing. "}, "hash": "6c93ac9aacd193ce58d39a4ef7cb6f7615ead763f0d32669520cfe7d803c8466", "class_name": "RelatedNodeInfo"}}, "text": "The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n", "start_char_idx": 1235, "end_char_idx": 1638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62805d47-3eef-4909-8940-a643268b2b4a": {"__data__": {"id_": "62805d47-3eef-4909-8940-a643268b2b4a", "embedding": null, "metadata": {"window": "McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter. ", "original_text": "Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b12ae4d-890f-4cf9-9848-6308534917fa", "node_type": "1", "metadata": {"window": "We appreciate you joining us on our call today.  McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n", "original_text": "The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "942edf4022fef1a003cf3073c1465f4e6f1c7ca12a898e17b818eb498bd2a4aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5603e1b4-d0e5-40b2-8fe8-55540e6b0825", "node_type": "1", "metadata": {"window": "We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n", "original_text": "In the first quarter, we saw solid gr owth in prescription volumes and patient visits. "}, "hash": "921eb06e9c294f5e5d16a3a9d4d554a74a3938e6dcd47316a9154a60bef10beb", "class_name": "RelatedNodeInfo"}}, "text": "Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing. ", "start_char_idx": 1638, "end_char_idx": 1777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5603e1b4-d0e5-40b2-8fe8-55540e6b0825": {"__data__": {"id_": "5603e1b4-d0e5-40b2-8fe8-55540e6b0825", "embedding": null, "metadata": {"window": "We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n", "original_text": "In the first quarter, we saw solid gr owth in prescription volumes and patient visits. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62805d47-3eef-4909-8940-a643268b2b4a", "node_type": "1", "metadata": {"window": "McKesson \nreported a strong fiscal first q uarter driven by really broad -based momentum across the businesses.  We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter. ", "original_text": "Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c707dd440f1f4eeb2a098df2aa5cdf56fad50d85254da0979654ef53cd423c0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cc20f45-0920-40f7-8961-96c54cdb94ec", "node_type": "1", "metadata": {"window": "The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services. ", "original_text": "In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n"}, "hash": "2cfab1c8cd3a1bf3566b8993466d45249e1bb0f7448366a0ace0900fcd77617c", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter, we saw solid gr owth in prescription volumes and patient visits. ", "start_char_idx": 1777, "end_char_idx": 1864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cc20f45-0920-40f7-8961-96c54cdb94ec": {"__data__": {"id_": "6cc20f45-0920-40f7-8961-96c54cdb94ec", "embedding": null, "metadata": {"window": "The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services. ", "original_text": "In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5603e1b4-d0e5-40b2-8fe8-55540e6b0825", "node_type": "1", "metadata": {"window": "We delivered \n$74.5 billion in total revenues and $7.27 in adjusted earnings per diluted share, both exceeding our expectations.  \n \n The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n", "original_text": "In the first quarter, we saw solid gr owth in prescription volumes and patient visits. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "700f3d15fdaaa5132a6cb66b0533112558361db522e6be9ef645da2c4d92863c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53de1a3d-d2cb-4b16-8604-7ce5a26bf8d4", "node_type": "1", "metadata": {"window": "Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n", "original_text": "The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter. "}, "hash": "8eb67a90bb6e221fba56cc860dd89a6d887853a9596f4e0370b4086d35103c14", "class_name": "RelatedNodeInfo"}}, "text": "In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n", "start_char_idx": 1864, "end_char_idx": 1984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53de1a3d-d2cb-4b16-8604-7ce5a26bf8d4": {"__data__": {"id_": "53de1a3d-d2cb-4b16-8604-7ce5a26bf8d4", "embedding": null, "metadata": {"window": "Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n", "original_text": "The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cc20f45-0920-40f7-8961-96c54cdb94ec", "node_type": "1", "metadata": {"window": "The performance in the quarter included a favorable timing impact from a discrete tax item but the thing we're \nmost importantly focused on and pleased with is the strong operational performance of the underlying business, \nwhich gives us the confidence to raise our guidance range for fiscal 2024 adjusted earnings p er diluted share \nfrom $26.10 to $26.90 to an updated range of $26.55 to $27.35.  \n \n Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services. ", "original_text": "In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60b2d30dab2fd63c9fe729072da62b2c171ea5b478a9602961b3309ee9db4b94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b96d8fab-ce28-4698-bcd4-53e4fc750479", "node_type": "1", "metadata": {"window": "In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth. ", "original_text": "As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n"}, "hash": "08d4c40f033ab6904ad1f5638afb93f65af44e7f47a95afd190c9830f51139d3", "class_name": "RelatedNodeInfo"}}, "text": "The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter. ", "start_char_idx": 1984, "end_char_idx": 2141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b96d8fab-ce28-4698-bcd4-53e4fc750479": {"__data__": {"id_": "b96d8fab-ce28-4698-bcd4-53e4fc750479", "embedding": null, "metadata": {"window": "In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth. ", "original_text": "As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53de1a3d-d2cb-4b16-8604-7ce5a26bf8d4", "node_type": "1", "metadata": {"window": "Before I review our business performance in the quarter, I want to provide an update on the utilization trends that \nwe've been observing.  In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n", "original_text": "The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd591745034ca5c9ef328d7497d77d1146042496e05e743a50776f6028d04988", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ddfaf67-7d5f-40a0-848c-4a1aaab48cb8", "node_type": "1", "metadata": {"window": "In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S. ", "original_text": "Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services. "}, "hash": "6d3d9b9cb3b1f506bc6ec16a07a8d4c0c060731ce384a57f217f0a9fddef1179", "class_name": "RelatedNodeInfo"}}, "text": "As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n", "start_char_idx": 2141, "end_char_idx": 2310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ddfaf67-7d5f-40a0-848c-4a1aaab48cb8": {"__data__": {"id_": "5ddfaf67-7d5f-40a0-848c-4a1aaab48cb8", "embedding": null, "metadata": {"window": "In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S. ", "original_text": "Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b96d8fab-ce28-4698-bcd4-53e4fc750479", "node_type": "1", "metadata": {"window": "In the first quarter, we saw solid gr owth in prescription volumes and patient visits.  In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth. ", "original_text": "As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4c26a0b38c0dfe77a9b10badbb0e9243458f96235d6904b282869f192eab92d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4f714c4-5ed4-4202-b28f-ddfdffe10a46", "node_type": "1", "metadata": {"window": "The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year. ", "original_text": "I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n"}, "hash": "d823ca74ce859caf4dc77b22042f35cb6da04a5aa837fc05ca83d1c91464dc9f", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services. ", "start_char_idx": 2310, "end_char_idx": 2558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4f714c4-5ed4-4202-b28f-ddfdffe10a46": {"__data__": {"id_": "b4f714c4-5ed4-4202-b28f-ddfdffe10a46", "embedding": null, "metadata": {"window": "The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year. ", "original_text": "I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ddfaf67-7d5f-40a0-848c-4a1aaab48cb8", "node_type": "1", "metadata": {"window": "In US \noncology, same -store patient visits grew at a good pace while we continued to expand the reach of the network. \n The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S. ", "original_text": "Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57cf4ad6f06e633329913099a2b2dd4a9cf81992ae99bf65abc40464b41ea210", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1183fa0b-3e23-4f63-9825-0e4148550dd0", "node_type": "1", "metadata": {"window": "As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n", "original_text": "So, let's start with our priority of driving sustainable core growth. "}, "hash": "887ab6bab0c169b6fc5c1c8e728c005c271a6dbca8535b7d6c1dcbf9e385aa1b", "class_name": "RelatedNodeInfo"}}, "text": "I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n", "start_char_idx": 2558, "end_char_idx": 2711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1183fa0b-3e23-4f63-9825-0e4148550dd0": {"__data__": {"id_": "1183fa0b-3e23-4f63-9825-0e4148550dd0", "embedding": null, "metadata": {"window": "As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n", "original_text": "So, let's start with our priority of driving sustainable core growth. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4f714c4-5ed4-4202-b28f-ddfdffe10a46", "node_type": "1", "metadata": {"window": "The solid growth in prescription volume trends, particularly in weight loss or GLP -1 drugs  contributed to the strong \nrevenue growth in the first quarter.  As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year. ", "original_text": "I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1a8d0719be6e923d23d81dd52ee540c6e143966978260a718170709f3a04f52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efadd836-07dd-4d38-b1c0-c4ff31a876d9", "node_type": "1", "metadata": {"window": "Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies. ", "original_text": "In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S. "}, "hash": "3710249e9620680e2e5931a6915cb013ba8aebcf4beabe2f13afc583456eecd9", "class_name": "RelatedNodeInfo"}}, "text": "So, let's start with our priority of driving sustainable core growth. ", "start_char_idx": 2711, "end_char_idx": 2781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efadd836-07dd-4d38-b1c0-c4ff31a876d9": {"__data__": {"id_": "efadd836-07dd-4d38-b1c0-c4ff31a876d9", "embedding": null, "metadata": {"window": "Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies. ", "original_text": "In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1183fa0b-3e23-4f63-9825-0e4148550dd0", "node_type": "1", "metadata": {"window": "As we closely monitor the trends going forward, we're well positioned to deliver \nproducts and services to support the evolving needs of our customers and patients.  \n \n Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n", "original_text": "So, let's start with our priority of driving sustainable core growth. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303f30cb8b663188a18fe51d323753d583bc566113fdf44b923095d6da1e1ee7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3094e7b-3023-4ff4-8cce-f1810b4d8a97", "node_type": "1", "metadata": {"window": "I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n", "original_text": "Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year. "}, "hash": "7218b85a9610688dba83f994ff79453c607e4e435066105ca21c6c78967f457b", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S. ", "start_char_idx": 2781, "end_char_idx": 2913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3094e7b-3023-4ff4-8cce-f1810b4d8a97": {"__data__": {"id_": "b3094e7b-3023-4ff4-8cce-f1810b4d8a97", "embedding": null, "metadata": {"window": "I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n", "original_text": "Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efadd836-07dd-4d38-b1c0-c4ff31a876d9", "node_type": "1", "metadata": {"window": "Now, let me move on to our business review and I want to focus my remarks today on the progress we've made in \nexecuting on our company priorities and our differentiated market positions in the key growth areas of oncology \nand biopharma services.  I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies. ", "original_text": "In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3841af6e3cf55d96fbe2e8556364e876542f7d6c0e971792aea6b781d288451", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a164599-b19f-436a-bc4d-cefdead83dfc", "node_type": "1", "metadata": {"window": "So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees. ", "original_text": "We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n"}, "hash": "61bfbd15d9fc6eb13e97f28c800bef3c29588822afc90c4e98830cb0644f629f", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year. ", "start_char_idx": 2913, "end_char_idx": 3085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a164599-b19f-436a-bc4d-cefdead83dfc": {"__data__": {"id_": "2a164599-b19f-436a-bc4d-cefdead83dfc", "embedding": null, "metadata": {"window": "So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees. ", "original_text": "We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3094e7b-3023-4ff4-8cce-f1810b4d8a97", "node_type": "1", "metadata": {"window": "I'll also discuss some of the key gro wth drivers for the quarter and as always, Britt will \nprovide additional details about our financial results.  \n \n So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n", "original_text": "Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7e8da3098776c9ff3ae4bbb25b667a5181a725c565e63d94e9a27433b8909e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74f6f97d-687d-429b-9845-a6977cb9a5cc", "node_type": "1", "metadata": {"window": "In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n", "original_text": "We also have a long history of supporting and investing in the growth of community pharmacies. "}, "hash": "c443ff922f93a091c7b848bc443c1aeee57955f41f236605f0f8854d42e3941a", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n", "start_char_idx": 3085, "end_char_idx": 3274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74f6f97d-687d-429b-9845-a6977cb9a5cc": {"__data__": {"id_": "74f6f97d-687d-429b-9845-a6977cb9a5cc", "embedding": null, "metadata": {"window": "In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n", "original_text": "We also have a long history of supporting and investing in the growth of community pharmacies. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a164599-b19f-436a-bc4d-cefdead83dfc", "node_type": "1", "metadata": {"window": "So, let's start with our priority of driving sustainable core growth.  In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees. ", "original_text": "We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77badbbc696e5776ff71406a4dacc760976e74ac36f6850275c1de646facbb04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "768a9e8c-71aa-466f-bbb2-e3ffde772077", "node_type": "1", "metadata": {"window": "Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S. ", "original_text": "In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n"}, "hash": "dc911fe25951514935aa7fe9f6d19f825959cc8d2bd7db47a69d29795760661e", "class_name": "RelatedNodeInfo"}}, "text": "We also have a long history of supporting and investing in the growth of community pharmacies. ", "start_char_idx": 3274, "end_char_idx": 3369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "768a9e8c-71aa-466f-bbb2-e3ffde772077": {"__data__": {"id_": "768a9e8c-71aa-466f-bbb2-e3ffde772077", "embedding": null, "metadata": {"window": "Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S. ", "original_text": "In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74f6f97d-687d-429b-9845-a6977cb9a5cc", "node_type": "1", "metadata": {"window": "In the first quarter, we saw strong performance in \nthe pharmaceutical distribution business as reflected in the growth of the U.S.  Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n", "original_text": "We also have a long history of supporting and investing in the growth of community pharmacies. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8e2747ec9108b3d179d220e95c93991a6888d8253d011185c65bcbf7b07b93d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0753336-3aff-48f1-99e5-7668777bc474", "node_type": "1", "metadata": {"window": "We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency. ", "original_text": "In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees. "}, "hash": "3286bd2a4ff9d52e9ad33ddd9f991a320d29a8332959200df75c9b6e2dbfd391", "class_name": "RelatedNodeInfo"}}, "text": "In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n", "start_char_idx": 3369, "end_char_idx": 3652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0753336-3aff-48f1-99e5-7668777bc474": {"__data__": {"id_": "a0753336-3aff-48f1-99e5-7668777bc474", "embedding": null, "metadata": {"window": "We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency. ", "original_text": "In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "768a9e8c-71aa-466f-bbb2-e3ffde772077", "node_type": "1", "metadata": {"window": "Pharmaceutical segment where \nrevenue increased 18% and adjusted operating profit grew 14% when excluding the contribution from COVID -19-\nrelated items in the prior year.  We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S. ", "original_text": "In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2164c0a3171d175e1fbff7862cc731e96cc469b1b82694cfa98b2d33f4ced0b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b2bcba6-b682-493d-87c3-783eafd82f30", "node_type": "1", "metadata": {"window": "We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals. ", "original_text": "Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n"}, "hash": "86abeea14b402e26febcf7a7914233398400d1e407d3bfa4cee6d42080d04856", "class_name": "RelatedNodeInfo"}}, "text": "In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees. ", "start_char_idx": 3652, "end_char_idx": 3804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b2bcba6-b682-493d-87c3-783eafd82f30": {"__data__": {"id_": "1b2bcba6-b682-493d-87c3-783eafd82f30", "embedding": null, "metadata": {"window": "We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals. ", "original_text": "Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0753336-3aff-48f1-99e5-7668777bc474", "node_type": "1", "metadata": {"window": "We're pleased with the bro ad-based momentum across all customer channels \nreally, including higher volumes from retail national accounts and good growth in our Health Systems segment.  \n \n We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency. ", "original_text": "In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9eb6f87dc8a7136494c0f0555b039a3bbc3114b1cba6de6405fc5f111a329f5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "268768c1-0610-4272-8d00-96f47f4e90f4", "node_type": "1", "metadata": {"window": "In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals.  This new facility incorporates the latest ", "original_text": "To support the sustainable growth of the core distribution businesses within U.S. "}, "hash": "a7993d2556d8cacb0c9318971bfe97043e61b4144b927e1105e3089aa2cdd44a", "class_name": "RelatedNodeInfo"}}, "text": "Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n", "start_char_idx": 3804, "end_char_idx": 4030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "268768c1-0610-4272-8d00-96f47f4e90f4": {"__data__": {"id_": "268768c1-0610-4272-8d00-96f47f4e90f4", "embedding": null, "metadata": {"window": "In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals.  This new facility incorporates the latest ", "original_text": "To support the sustainable growth of the core distribution businesses within U.S. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b2bcba6-b682-493d-87c3-783eafd82f30", "node_type": "1", "metadata": {"window": "We also have a long history of supporting and investing in the growth of community pharmacies.  In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals. ", "original_text": "Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c3b6ef068277123ea62a70b76063e245a35f870d88c01bad90c9edea6d53b63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb9fabf6-7a73-4a75-942b-8c15df8f6dfb", "node_type": "1", "metadata": {"window": "In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals.  This new facility incorporates the latest ", "original_text": "Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency. "}, "hash": "689bb980edeb82dc508fadc1ba622685310d551b9ccdfa22016ecd60c0dab629", "class_name": "RelatedNodeInfo"}}, "text": "To support the sustainable growth of the core distribution businesses within U.S. ", "start_char_idx": 4030, "end_char_idx": 4112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb9fabf6-7a73-4a75-942b-8c15df8f6dfb": {"__data__": {"id_": "fb9fabf6-7a73-4a75-942b-8c15df8f6dfb", "embedding": null, "metadata": {"window": "In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals.  This new facility incorporates the latest ", "original_text": "Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "268768c1-0610-4272-8d00-96f47f4e90f4", "node_type": "1", "metadata": {"window": "In May, we \nlaunched Pinpoint Community Solutions, a new inventory management system powered by our proprietary \nSupplylogix software that's designed to help independent pharmacies improve cash flow, increase inventory \nefficiency and to maximize their operation al performance.  \n \n In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals.  This new facility incorporates the latest ", "original_text": "To support the sustainable growth of the core distribution businesses within U.S. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50b73148b9f5e5ea10a663cf6215fc3a7eaa8c13a28f4ce92e5f7bd42cb37eca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad8f501a-a61c-49ef-bdb6-643bbd9a2a74", "node_type": "1", "metadata": {"window": "Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals.  This new facility incorporates the latest ", "original_text": "In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals. "}, "hash": "314c8517efe7a8b954eb3e682f9a5aa88b4bf8be6b8a00f8572e47ff5eee8f7b", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency. ", "start_char_idx": 4112, "end_char_idx": 4219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad8f501a-a61c-49ef-bdb6-643bbd9a2a74": {"__data__": {"id_": "ad8f501a-a61c-49ef-bdb6-643bbd9a2a74", "embedding": null, "metadata": {"window": "Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals.  This new facility incorporates the latest ", "original_text": "In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb9fabf6-7a73-4a75-942b-8c15df8f6dfb", "node_type": "1", "metadata": {"window": "In June, we were proud to host the annual ideaShare conference, a nationwide community pharmacy event that \nbrought together more than 2,800 attendees.  Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals.  This new facility incorporates the latest ", "original_text": "Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1529d675e969282ef9fa29253a1bafa56cb3e75abb4fe7bd30b6bb4fe09e8720", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26cd9cf4-788d-432c-aa2b-e8d3484d701b", "node_type": "1", "metadata": {"window": "To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals.  This new facility incorporates the latest ", "original_text": "This new facility incorporates the latest "}, "hash": "c846000cea12844fc06d5757e5972bbfb401b75f3f0c0cb5d6065172b4306848", "class_name": "RelatedNodeInfo"}}, "text": "In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals. ", "start_char_idx": 4219, "end_char_idx": 4317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26cd9cf4-788d-432c-aa2b-e8d3484d701b": {"__data__": {"id_": "26cd9cf4-788d-432c-aa2b-e8d3484d701b", "embedding": null, "metadata": {"window": "To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals.  This new facility incorporates the latest ", "original_text": "This new facility incorporates the latest ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c00a008c256571622f6214be054464436f495a2e391cc1d80f1c03b9109b7d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad8f501a-a61c-49ef-bdb6-643bbd9a2a74", "node_type": "1", "metadata": {"window": "Through this forum of discussion and education, we help \npharmacists foster deeper commun ity connections, strengthen their collective voice, and discover ways to \ninnovate and thrive using McKesson products and services.  \n \n To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals.  This new facility incorporates the latest ", "original_text": "In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals. ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "442e47dbe976c48ee7c6b2a3ff5da7112603b700b3589f0190abab62656d8595", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab77c1b5-1ae4-4346-ac4b-070efee2f110", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n", "original_text": "McKesson Corp.  "}, "hash": "aa2063206bba5e8815084c75f59bdb21db75988eed20172782f29756fcd666cf", "class_name": "RelatedNodeInfo"}}, "text": "This new facility incorporates the latest ", "start_char_idx": 4317, "end_char_idx": 4359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab77c1b5-1ae4-4346-ac4b-070efee2f110": {"__data__": {"id_": "ab77c1b5-1ae4-4346-ac4b-070efee2f110", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26cd9cf4-788d-432c-aa2b-e8d3484d701b", "node_type": "1", "metadata": {"window": "To support the sustainable growth of the core distribution businesses within U.S.  Pharmaceutical, we're also \ninvesting in ou r infrastructure to enhance automation and improve efficiency.  In the past quarter, we opened a \nnew distribution center dedicated to specialty pharmaceuticals.  This new facility incorporates the latest ", "original_text": "This new facility incorporates the latest ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1a048dd843ea81bfb208315025e08ad4ad7401c2a413f61e944ec122a3fa8aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0fe4375-9202-49a9-83d2-0bc5d96619d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n"}, "hash": "dc74c8dd1671ecd9455b16f34a927890290c4668f4d0b48a482816e5849efd9e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0fe4375-9202-49a9-83d2-0bc5d96619d1": {"__data__": {"id_": "c0fe4375-9202-49a9-83d2-0bc5d96619d1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab77c1b5-1ae4-4346-ac4b-070efee2f110", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce363afe34f492094a9c46d986f618eae1fddbe842e3c6373fabd804f081cf77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f279f272-842a-4ac1-93b5-a172cc3553d4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n", "original_text": "In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships. "}, "hash": "89239a97e289018d4db851b709f62bccb9934e47ba4e3a2b64abad3b5e87ce34", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n", "start_char_idx": 16, "end_char_idx": 315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f279f272-842a-4ac1-93b5-a172cc3553d4": {"__data__": {"id_": "f279f272-842a-4ac1-93b5-a172cc3553d4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n", "original_text": "In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0fe4375-9202-49a9-83d2-0bc5d96619d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9629685b627c688e505f5f996ecd7acf118ba0ce7d3cb3e1f8a9b5522e1d776d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbd86fe3-794c-4cb8-9cd5-a5cce384cc7f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity. ", "original_text": "In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n"}, "hash": "92e8926ea461286decfafa8d9d600543a1fe1f8671722fd182c4e60134a3c321", "class_name": "RelatedNodeInfo"}}, "text": "In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships. ", "start_char_idx": 315, "end_char_idx": 480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbd86fe3-794c-4cb8-9cd5-a5cce384cc7f": {"__data__": {"id_": "dbd86fe3-794c-4cb8-9cd5-a5cce384cc7f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity. ", "original_text": "In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f279f272-842a-4ac1-93b5-a172cc3553d4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n", "original_text": "In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b45f5df723b60faf7e62a4f56c5a2611861796302bcfdb0bf2d2f6330cc9f6f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2afda1b-24ce-4f2f-908d-4973ac0d1b13", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing. ", "original_text": "Since then, we've grown our state government business through participation in cooperative purchasing \nprograms. "}, "hash": "0630a29e111dde8bb458d0f9a5f34cf79f906bd85147775b6078e6dabc5653b5", "class_name": "RelatedNodeInfo"}}, "text": "In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n", "start_char_idx": 480, "end_char_idx": 732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2afda1b-24ce-4f2f-908d-4973ac0d1b13": {"__data__": {"id_": "a2afda1b-24ce-4f2f-908d-4973ac0d1b13", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing. ", "original_text": "Since then, we've grown our state government business through participation in cooperative purchasing \nprograms. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbd86fe3-794c-4cb8-9cd5-a5cce384cc7f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity. ", "original_text": "In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9122f24db04aa539a7e1814ac2b94656f20798bf295d91072298a977bcb4b768", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4cb1d27-9236-451f-902e-b8c07709a0ae", "node_type": "1", "metadata": {"window": "In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n", "original_text": "We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n"}, "hash": "3a7510d47f916d49698fcf4d4d1d26bc1879d709cdc2536b7f469454e89287c2", "class_name": "RelatedNodeInfo"}}, "text": "Since then, we've grown our state government business through participation in cooperative purchasing \nprograms. ", "start_char_idx": 732, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4cb1d27-9236-451f-902e-b8c07709a0ae": {"__data__": {"id_": "b4cb1d27-9236-451f-902e-b8c07709a0ae", "embedding": null, "metadata": {"window": "In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n", "original_text": "We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2afda1b-24ce-4f2f-908d-4973ac0d1b13", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing. ", "original_text": "Since then, we've grown our state government business through participation in cooperative purchasing \nprograms. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a450bf67cd7b57b8bb92bd4582b551e52212c9a629bb3c05f4d1ed94b37d41a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6f522ac-4300-46ea-ada4-e52ec0a4da3e", "node_type": "1", "metadata": {"window": "In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms. ", "original_text": "As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity. "}, "hash": "9dfb5a547ac10e18701106f718a35b7c45020682b74f3459b71a21dc92be90dd", "class_name": "RelatedNodeInfo"}}, "text": "We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n", "start_char_idx": 845, "end_char_idx": 1146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6f522ac-4300-46ea-ada4-e52ec0a4da3e": {"__data__": {"id_": "e6f522ac-4300-46ea-ada4-e52ec0a4da3e", "embedding": null, "metadata": {"window": "In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms. ", "original_text": "As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4cb1d27-9236-451f-902e-b8c07709a0ae", "node_type": "1", "metadata": {"window": "In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n", "original_text": "We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "080760c1ca556bc3b8e47e38b77e581e07c901f9bef0d8907ed5b8692f4cbb67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba43908a-dc03-4de9-bdaf-00441d642097", "node_type": "1", "metadata": {"window": "Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400. ", "original_text": "We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing. "}, "hash": "34fc059e8b961fb3e9d674d3251ed19409ab7b53b0c513804a828aa30a32f624", "class_name": "RelatedNodeInfo"}}, "text": "As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity. ", "start_char_idx": 1146, "end_char_idx": 1289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba43908a-dc03-4de9-bdaf-00441d642097": {"__data__": {"id_": "ba43908a-dc03-4de9-bdaf-00441d642097", "embedding": null, "metadata": {"window": "Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400. ", "original_text": "We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6f522ac-4300-46ea-ada4-e52ec0a4da3e", "node_type": "1", "metadata": {"window": "In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms. ", "original_text": "As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f353efbb33db0370177a2472525b140867f0c62d24b78499a06081c714c10b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "141343ca-8286-4e09-b542-c8dc4bf9fdd9", "node_type": "1", "metadata": {"window": "We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n", "original_text": "Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n"}, "hash": "68639e14df02f391e43e863375d3e68820c2d5a0af630affd9f5830068582889", "class_name": "RelatedNodeInfo"}}, "text": "We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing. ", "start_char_idx": 1289, "end_char_idx": 1489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "141343ca-8286-4e09-b542-c8dc4bf9fdd9": {"__data__": {"id_": "141343ca-8286-4e09-b542-c8dc4bf9fdd9", "embedding": null, "metadata": {"window": "We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n", "original_text": "Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba43908a-dc03-4de9-bdaf-00441d642097", "node_type": "1", "metadata": {"window": "Since then, we've grown our state government business through participation in cooperative purchasing \nprograms.  We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400. ", "original_text": "We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c04c339d5397c78cff397f25fca9bb5fb153cc22e64a0b85bfd126a23238ab92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f55035d3-72ee-4adf-9b16-b138990ddf09", "node_type": "1", "metadata": {"window": "As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings. ", "original_text": "Let me move on to the next company priority and that is expanding our oncology and biopharma platforms. "}, "hash": "4ad280369c7056a71ef2658e0d3f9364186cd9ddaf9a851b70436d6e62a13428", "class_name": "RelatedNodeInfo"}}, "text": "Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n", "start_char_idx": 1489, "end_char_idx": 1672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f55035d3-72ee-4adf-9b16-b138990ddf09": {"__data__": {"id_": "f55035d3-72ee-4adf-9b16-b138990ddf09", "embedding": null, "metadata": {"window": "As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings. ", "original_text": "Let me move on to the next company priority and that is expanding our oncology and biopharma platforms. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "141343ca-8286-4e09-b542-c8dc4bf9fdd9", "node_type": "1", "metadata": {"window": "We've also built a dedicated government solutions team stacked with experienced sales, customer \nservice, sales administration and legal teams, with a shared goal of supporting successful government \nprocurement and providing best-in-class fulfillment and service at every level of the government. \n \n As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n", "original_text": "Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fe4c0bd56eae4216e96f01996fcdc725583d19dd1611aec4d4059ef9673a0e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d32db43b-07a9-4ce0-8f83-9efec3792a2b", "node_type": "1", "metadata": {"window": "We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n", "original_text": "In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400. "}, "hash": "083bc3b9782bc7b817ed45399dbb8241d9ce4ef97823dc12aacf2b7c46a41301", "class_name": "RelatedNodeInfo"}}, "text": "Let me move on to the next company priority and that is expanding our oncology and biopharma platforms. ", "start_char_idx": 1672, "end_char_idx": 1776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d32db43b-07a9-4ce0-8f83-9efec3792a2b": {"__data__": {"id_": "d32db43b-07a9-4ce0-8f83-9efec3792a2b", "embedding": null, "metadata": {"window": "We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n", "original_text": "In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f55035d3-72ee-4adf-9b16-b138990ddf09", "node_type": "1", "metadata": {"window": "As we expand our customer relationships, we're also strategically managing relationships with manufacturers to \nensure supply chain diversity.  We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings. ", "original_text": "Let me move on to the next company priority and that is expanding our oncology and biopharma platforms. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "adb71da079010e1423ed90843382b463d40bb07622e219f453bbb6ab2f8a91cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f50d233-fae8-41bb-b4bb-a16962c03113", "node_type": "1", "metadata": {"window": "Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes. ", "original_text": "The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n"}, "hash": "1b1f057605c8521bd7f9b67e0f614b2926fc247a2b5c9c96a20f06c09f835e5f", "class_name": "RelatedNodeInfo"}}, "text": "In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400. ", "start_char_idx": 1776, "end_char_idx": 1938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f50d233-fae8-41bb-b4bb-a16962c03113": {"__data__": {"id_": "9f50d233-fae8-41bb-b4bb-a16962c03113", "embedding": null, "metadata": {"window": "Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes. ", "original_text": "The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d32db43b-07a9-4ce0-8f83-9efec3792a2b", "node_type": "1", "metadata": {"window": "We serve a broad portfolio of national brand and private-label Medical-Surgical \nproducts and we're enhancing our procurement tools and processes to better track domestic and international \nsourcing.  Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n", "original_text": "In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0605a4cb3ce6681df1d85984088dfb139b1fd1f131077f46ac5cd609fb3cd22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea0febec-c1a2-4d22-a012-4416d0be1fd0", "node_type": "1", "metadata": {"window": "Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n", "original_text": "With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings. "}, "hash": "18ee99e376067382386a32b4ced425b5a9cc5f1eb81f1ddd85baeff83c7691c0", "class_name": "RelatedNodeInfo"}}, "text": "The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n", "start_char_idx": 1938, "end_char_idx": 2119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea0febec-c1a2-4d22-a012-4416d0be1fd0": {"__data__": {"id_": "ea0febec-c1a2-4d22-a012-4416d0be1fd0", "embedding": null, "metadata": {"window": "Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n", "original_text": "With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f50d233-fae8-41bb-b4bb-a16962c03113", "node_type": "1", "metadata": {"window": "Last year, our sourcing team traveled to more than 10 countries representing our continued effort to \nexpand our manufacturing relationships and diversify our geographic presence. \n \n Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes. ", "original_text": "The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a30716ee8fb08d0174d35ecc40105c263e0839889502b619983d86f9ce177104", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7948fa0-84ad-4533-bb70-d25feeaf3b80", "node_type": "1", "metadata": {"window": "In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network. ", "original_text": "The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n"}, "hash": "9e1526a03af5e1009db14d73508fc4b486b5ff151f84238f603b2c922b0eee3c", "class_name": "RelatedNodeInfo"}}, "text": "With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings. ", "start_char_idx": 2119, "end_char_idx": 2255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7948fa0-84ad-4533-bb70-d25feeaf3b80": {"__data__": {"id_": "f7948fa0-84ad-4533-bb70-d25feeaf3b80", "embedding": null, "metadata": {"window": "In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network. ", "original_text": "The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea0febec-c1a2-4d22-a012-4416d0be1fd0", "node_type": "1", "metadata": {"window": "Let me move on to the next company priority and that is expanding our oncology and biopharma platforms.  In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n", "original_text": "With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25bce646dfa906642cbdd602ff5cdd514cf47a36656eac549060897745c4b4a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "494371e0-8d8c-4d89-b6ea-4a3f82a7c3d3", "node_type": "1", "metadata": {"window": "The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n", "original_text": "As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes. "}, "hash": "1436ded629dd3947e41ee51ca10697368d7d5f1584640dff4b3837c858911dd3", "class_name": "RelatedNodeInfo"}}, "text": "The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n", "start_char_idx": 2255, "end_char_idx": 2510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "494371e0-8d8c-4d89-b6ea-4a3f82a7c3d3": {"__data__": {"id_": "494371e0-8d8c-4d89-b6ea-4a3f82a7c3d3", "embedding": null, "metadata": {"window": "The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n", "original_text": "As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7948fa0-84ad-4533-bb70-d25feeaf3b80", "node_type": "1", "metadata": {"window": "In \nJuly, we were excited to welcome the Cancer Center of Kansas to the US Oncology Network, growing the total \nnumber of providers in the network to over 2,400.  The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network. ", "original_text": "The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8da0288255933c76267bf00c2bad64ab1ac766b5cff6201ab718def5372ee6bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ae6e2af-8ec1-411e-a480-4c636660d70f", "node_type": "1", "metadata": {"window": "With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter. ", "original_text": "Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n"}, "hash": "5a4d3dc446607e78f993ca6fe67a659735a6e95ab4ae3e6b7968aa736b023c97", "class_name": "RelatedNodeInfo"}}, "text": "As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes. ", "start_char_idx": 2510, "end_char_idx": 2660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ae6e2af-8ec1-411e-a480-4c636660d70f": {"__data__": {"id_": "1ae6e2af-8ec1-411e-a480-4c636660d70f", "embedding": null, "metadata": {"window": "With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter. ", "original_text": "Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "494371e0-8d8c-4d89-b6ea-4a3f82a7c3d3", "node_type": "1", "metadata": {"window": "The continued growth is a strong testament to the value \nproposition of the network and an example of how we continue to evolve and grow our portfolio of differentiated \nassets. \n \n With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n", "original_text": "As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc43c48236a6a76bf5c0197667acb6630d25a7e6d61cbcc2cd4e9084e398deca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1e70a96-2411-4739-b14b-57c66333a7ce", "node_type": "1", "metadata": {"window": "The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit. ", "original_text": "Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network. "}, "hash": "935e362bfed64f3ca964c4a967aadaf468534edb8ad7be694e7f84bbd43f72da", "class_name": "RelatedNodeInfo"}}, "text": "Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n", "start_char_idx": 2660, "end_char_idx": 2921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1e70a96-2411-4739-b14b-57c66333a7ce": {"__data__": {"id_": "a1e70a96-2411-4739-b14b-57c66333a7ce", "embedding": null, "metadata": {"window": "The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit. ", "original_text": "Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ae6e2af-8ec1-411e-a480-4c636660d70f", "node_type": "1", "metadata": {"window": "With over 20 years of oncology practice management experience, the network brings significant value beyond just \ndrug purchase savings.  The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter. ", "original_text": "Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38396367b4fa2cad2f34e789d902ab471649a971243d74935ebf96e1acfaf827", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62e9fd2d-2bb8-476b-954b-656cd55c6af2", "node_type": "1", "metadata": {"window": "As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n", "original_text": "The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n"}, "hash": "43913d56edb51f7be61349807c322d07911c69d54329ce06f33ebb6265819c7f", "class_name": "RelatedNodeInfo"}}, "text": "Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network. ", "start_char_idx": 2921, "end_char_idx": 3084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62e9fd2d-2bb8-476b-954b-656cd55c6af2": {"__data__": {"id_": "62e9fd2d-2bb8-476b-954b-656cd55c6af2", "embedding": null, "metadata": {"window": "As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n", "original_text": "The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1e70a96-2411-4739-b14b-57c66333a7ce", "node_type": "1", "metadata": {"window": "The practices in the network have access to substantial expertise and ample resources \nincluding clinical and business services, innovative technologies that support high-quality patient care, efficient \ndrug management and revenue cycle optimization. \n \n As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit. ", "original_text": "Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4722bc803530c12f9e7552449300006e9b4788e821fe7edab22a8a024fd89b9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a050a31-ddde-4519-bccb-f45244be9364", "node_type": "1", "metadata": {"window": "Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter. ", "original_text": "In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter. "}, "hash": "b03773b10de0dd8a21f2155bec574e6446a76ac06d7d44fd17d0bbea72f0f281", "class_name": "RelatedNodeInfo"}}, "text": "The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n", "start_char_idx": 3084, "end_char_idx": 3168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a050a31-ddde-4519-bccb-f45244be9364": {"__data__": {"id_": "9a050a31-ddde-4519-bccb-f45244be9364", "embedding": null, "metadata": {"window": "Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter. ", "original_text": "In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62e9fd2d-2bb8-476b-954b-656cd55c6af2", "node_type": "1", "metadata": {"window": "As one of the largest organizations of its kind, the US Oncology Network is dedicated to advancing cancer care \nand enabling better patient outcomes.  Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n", "original_text": "The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54431d40bd25ca742236e5d041209aed10aba58f82bdeec1a455f9ce86f065cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa6fe6ce-66f1-4f8b-b0be-ff5507e1b09d", "node_type": "1", "metadata": {"window": "Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars. ", "original_text": "Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit. "}, "hash": "4e47a6a2ea1387ccbc3aa9de2aabfdc62664bc07cf4c1e046326d21e2bdebc95", "class_name": "RelatedNodeInfo"}}, "text": "In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter. ", "start_char_idx": 3168, "end_char_idx": 3307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa6fe6ce-66f1-4f8b-b0be-ff5507e1b09d": {"__data__": {"id_": "fa6fe6ce-66f1-4f8b-b0be-ff5507e1b09d", "embedding": null, "metadata": {"window": "Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars. ", "original_text": "Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a050a31-ddde-4519-bccb-f45244be9364", "node_type": "1", "metadata": {"window": "Since its initial participation in the oncology care model, more than 120,000 \npatients have been enrolled in the program across the network, participating practices delivered high-quality care \nto patients while generating significant savings for Medicare. \n \n Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter. ", "original_text": "In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28ef5c8062ce30af6e0eb2d16021e58df1b35c28b4d929f66483027891b8cb7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9aeef17-fb1e-44c4-b551-adbaf029e369", "node_type": "1", "metadata": {"window": "The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars.  We continue to strengthen the relationships with biopharma companies who are the ", "original_text": "We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n"}, "hash": "3b752c7f48a53a36728c645aa59d978ea148184a7058e592154e7bda9e344fc6", "class_name": "RelatedNodeInfo"}}, "text": "Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit. ", "start_char_idx": 3307, "end_char_idx": 3424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9aeef17-fb1e-44c4-b551-adbaf029e369": {"__data__": {"id_": "e9aeef17-fb1e-44c4-b551-adbaf029e369", "embedding": null, "metadata": {"window": "The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars.  We continue to strengthen the relationships with biopharma companies who are the ", "original_text": "We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa6fe6ce-66f1-4f8b-b0be-ff5507e1b09d", "node_type": "1", "metadata": {"window": "Recently, we announced the network's participation in the enhancing oncology model, which includes \nrepresentation from over 70% of the physicians in the network.  The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars. ", "original_text": "Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cbbb2982278a993b11bcac7afc31065a5675fac10aa75dd3d96fcb8f01af2aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0b93953-044e-4195-b2fe-148e87f62d7e", "node_type": "1", "metadata": {"window": "In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars.  We continue to strengthen the relationships with biopharma companies who are the ", "original_text": "The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter. "}, "hash": "9a0563d9a7c642f1dd5e88bb2549cb75d318c57f85b255db22bc9c28f37faa45", "class_name": "RelatedNodeInfo"}}, "text": "We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n", "start_char_idx": 3424, "end_char_idx": 3559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0b93953-044e-4195-b2fe-148e87f62d7e": {"__data__": {"id_": "a0b93953-044e-4195-b2fe-148e87f62d7e", "embedding": null, "metadata": {"window": "In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars.  We continue to strengthen the relationships with biopharma companies who are the ", "original_text": "The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9aeef17-fb1e-44c4-b551-adbaf029e369", "node_type": "1", "metadata": {"window": "The US Oncology Network continues to lead at \nthe forefront of value-based care. \n \n In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars.  We continue to strengthen the relationships with biopharma companies who are the ", "original_text": "We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cb8d86b35d89dbffdb5f86365eb408cacb3490c1809fbe6009f3695f256d168", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a742ed1b-9d14-4199-858e-66684f9d00fe", "node_type": "1", "metadata": {"window": "Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars.  We continue to strengthen the relationships with biopharma companies who are the ", "original_text": "We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars. "}, "hash": "2284ceed7f184626f314a276793515e11ee5f001dbc35ac165389bd5e03b1a85", "class_name": "RelatedNodeInfo"}}, "text": "The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter. ", "start_char_idx": 3559, "end_char_idx": 3802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a742ed1b-9d14-4199-858e-66684f9d00fe": {"__data__": {"id_": "a742ed1b-9d14-4199-858e-66684f9d00fe", "embedding": null, "metadata": {"window": "Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars.  We continue to strengthen the relationships with biopharma companies who are the ", "original_text": "We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0b93953-044e-4195-b2fe-148e87f62d7e", "node_type": "1", "metadata": {"window": "In biopharma services, the success of our innovative products and solutions is reflected in the growth we \ndelivered in the first quarter.  Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars.  We continue to strengthen the relationships with biopharma companies who are the ", "original_text": "The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6aafd51d89f0e2d878946620f1eec6e2e54969625b9c95cc59a1e4e86d3baf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31d39711-f0dd-4acc-aa49-94918a227756", "node_type": "1", "metadata": {"window": "We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars.  We continue to strengthen the relationships with biopharma companies who are the ", "original_text": "We continue to strengthen the relationships with biopharma companies who are the "}, "hash": "6c3e44bb24a4904e4799123177f4821f1144eab81591993424ee0d285c80496d", "class_name": "RelatedNodeInfo"}}, "text": "We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars. ", "start_char_idx": 3802, "end_char_idx": 3920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31d39711-f0dd-4acc-aa49-94918a227756": {"__data__": {"id_": "31d39711-f0dd-4acc-aa49-94918a227756", "embedding": null, "metadata": {"window": "We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars.  We continue to strengthen the relationships with biopharma companies who are the ", "original_text": "We continue to strengthen the relationships with biopharma companies who are the ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c550e733efc3331dbda807a0dac11bc0d9be4d76e4bda2ecd9204aedb1c652bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a742ed1b-9d14-4199-858e-66684f9d00fe", "node_type": "1", "metadata": {"window": "Prescription Technology Solutions segment saw a 17% revenue increase and 35% \nincrease in adjusted operating profit.  We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars.  We continue to strengthen the relationships with biopharma companies who are the ", "original_text": "We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars. ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f51cc5ff67439ab42f0acc38d6a30d736ccbf8d9bb97fdd41821c76926e20508", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08d44b30-e3d0-4abe-8664-10397fdd43de", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster. ", "original_text": "McKesson Corp.  "}, "hash": "60b2f1cfc30c9a6ffe7b0046fdd733d48942cb4191327a9ae82e4763c6efca71", "class_name": "RelatedNodeInfo"}}, "text": "We continue to strengthen the relationships with biopharma companies who are the ", "start_char_idx": 3920, "end_char_idx": 4001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08d44b30-e3d0-4abe-8664-10397fdd43de": {"__data__": {"id_": "08d44b30-e3d0-4abe-8664-10397fdd43de", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31d39711-f0dd-4acc-aa49-94918a227756", "node_type": "1", "metadata": {"window": "We continue to receive positive feedback on our products enabling us to \nfurther penetrate the market and expand our channel reach. \n \n The solid prescription trends particularly the commercial success of the weight loss GLP-1 drug as I mentioned \nearlier also led to higher demand for our prior authorization solutions and contributed to the strong performance in \nthe quarter.  We remain committed and focused on expanding the biopharma services platform as one of our \nstrategic growth pillars.  We continue to strengthen the relationships with biopharma companies who are the ", "original_text": "We continue to strengthen the relationships with biopharma companies who are the ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c348c7bc849a5338fd2e8cc930b3fea721b220922833433b91d793b6bfc8a285", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "149c365f-be9c-4bd8-a199-1a87bf41933b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business. "}, "hash": "5695b1c0b8b7d20d594086c30d656f8dbda2d345a93452cf69b2875c1ba27dc0", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "149c365f-be9c-4bd8-a199-1a87bf41933b": {"__data__": {"id_": "149c365f-be9c-4bd8-a199-1a87bf41933b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08d44b30-e3d0-4abe-8664-10397fdd43de", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e4c363eb1c4c3806405f00e5247aa23a3d5f1211befaa099d72cf5cff0fd9eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6f7b39a-f5f1-45a9-ae33-25f8fa326c4a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n", "original_text": "We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n"}, "hash": "8102e7e6be7a0899c7442c3a0a8c4bff8f48ddc12dc9abfcf93e4f9c5f4734ca", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business. ", "start_char_idx": 16, "end_char_idx": 214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6f7b39a-f5f1-45a9-ae33-25f8fa326c4a": {"__data__": {"id_": "d6f7b39a-f5f1-45a9-ae33-25f8fa326c4a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n", "original_text": "We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "149c365f-be9c-4bd8-a199-1a87bf41933b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0dc3f91126d6597ac89e5862523b9a7580154a57fc5b4ea03b81984af3937137", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9208d2bf-fc66-4d32-9228-dd73be87cfa2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies. ", "original_text": "For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster. "}, "hash": "2dc12375ba960c55cd14d163ae503c2bbd53ff92e51bfd5ad66c00e123a39c49", "class_name": "RelatedNodeInfo"}}, "text": "We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n", "start_char_idx": 214, "end_char_idx": 328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9208d2bf-fc66-4d32-9228-dd73be87cfa2": {"__data__": {"id_": "9208d2bf-fc66-4d32-9228-dd73be87cfa2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies. ", "original_text": "For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6f7b39a-f5f1-45a9-ae33-25f8fa326c4a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n", "original_text": "We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b6d6c7ab5e5461b782e525493b6785a75ebc8e36793fb433a1e8bbd40771ae1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e55c7b6-d80b-49c6-b374-8e6cc2e0bc5f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture. ", "original_text": "Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n"}, "hash": "75c303dc51a3f948b97f5e5653726084797b2dae9473c617dcd806755c71774f", "class_name": "RelatedNodeInfo"}}, "text": "For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster. ", "start_char_idx": 328, "end_char_idx": 520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e55c7b6-d80b-49c6-b374-8e6cc2e0bc5f": {"__data__": {"id_": "6e55c7b6-d80b-49c6-b374-8e6cc2e0bc5f", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture. ", "original_text": "Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9208d2bf-fc66-4d32-9228-dd73be87cfa2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies. ", "original_text": "For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3b2f20a1ba6b256dc5047d7eba105fb9f1d64fc9c8febd61a83a0bdb85f0892", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8804b8cc-9143-489c-add1-7d7f5e392a5f", "node_type": "1", "metadata": {"window": "We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n", "original_text": "We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n"}, "hash": "b31fe4dac7edc8ae7ab53770318bbcc83bf7219e267d28a77e960f4949fb3e41", "class_name": "RelatedNodeInfo"}}, "text": "Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n", "start_char_idx": 520, "end_char_idx": 728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8804b8cc-9143-489c-add1-7d7f5e392a5f": {"__data__": {"id_": "8804b8cc-9143-489c-add1-7d7f5e392a5f", "embedding": null, "metadata": {"window": "We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n", "original_text": "We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e55c7b6-d80b-49c6-b374-8e6cc2e0bc5f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture. ", "original_text": "Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f90472a9cdbeab88b2b57ae5b31ba99180014b8acf8e51b42d559decfa96df9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f592919e-849a-42b1-a49c-977946233075", "node_type": "1", "metadata": {"window": "For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer. ", "original_text": "Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies. "}, "hash": "217e9db34747b9d8fbca6d77c056a0e4eb30d6b4d0b06c8d42db9a93858bedb7", "class_name": "RelatedNodeInfo"}}, "text": "We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n", "start_char_idx": 728, "end_char_idx": 975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f592919e-849a-42b1-a49c-977946233075": {"__data__": {"id_": "f592919e-849a-42b1-a49c-977946233075", "embedding": null, "metadata": {"window": "For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer. ", "original_text": "Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8804b8cc-9143-489c-add1-7d7f5e392a5f", "node_type": "1", "metadata": {"window": "We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n", "original_text": "We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07d47836ad4b471954e8836ae963f396f29b31ac28d43f986237848a975b1428", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8fae14b-75bc-4b89-a90b-ffb1d3c57103", "node_type": "1", "metadata": {"window": "Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson. ", "original_text": "As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture. "}, "hash": "960ecbb9e0e7f8817feb5e24dcd41fd173bf8ec7ad68556a0738d4e89e0df72a", "class_name": "RelatedNodeInfo"}}, "text": "Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies. ", "start_char_idx": 975, "end_char_idx": 1150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8fae14b-75bc-4b89-a90b-ffb1d3c57103": {"__data__": {"id_": "d8fae14b-75bc-4b89-a90b-ffb1d3c57103", "embedding": null, "metadata": {"window": "Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson. ", "original_text": "As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f592919e-849a-42b1-a49c-977946233075", "node_type": "1", "metadata": {"window": "For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster.  Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer. ", "original_text": "Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "135f6f777e99e629cb51a15a833b6e9a8d6e5a252e6b8f7a43cd13877a711a84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c02d7f6f-ef8d-4e51-9ec4-628562f94478", "node_type": "1", "metadata": {"window": "We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups. ", "original_text": "We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n"}, "hash": "a6541ff50fa7d60d5eff396e56203bf648f151a0c9cc1486ae000cce2b6ffa27", "class_name": "RelatedNodeInfo"}}, "text": "As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture. ", "start_char_idx": 1150, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c02d7f6f-ef8d-4e51-9ec4-628562f94478": {"__data__": {"id_": "c02d7f6f-ef8d-4e51-9ec4-628562f94478", "embedding": null, "metadata": {"window": "We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups. ", "original_text": "We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8fae14b-75bc-4b89-a90b-ffb1d3c57103", "node_type": "1", "metadata": {"window": "Through our electronic payer \nconnections, we support payers who represent 94% of prescription volumes in the US and offer real -time \ndecisions and simplified support between providers and health plans.  \n \n We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson. ", "original_text": "As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b19c9e2ec53fbbbdd5e461ffdb025a6f93d80c0cdbccf1f6dbe5623bb5d2c042", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06db4685-fba9-46fa-8fb2-72ca57ef9eea", "node_type": "1", "metadata": {"window": "Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n", "original_text": "As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer. "}, "hash": "f8cb53a8fb00b3844065985866835daa06d3ebd93dfa60068f2c44fdb8277eb3", "class_name": "RelatedNodeInfo"}}, "text": "We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n", "start_char_idx": 1292, "end_char_idx": 1415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06db4685-fba9-46fa-8fb2-72ca57ef9eea": {"__data__": {"id_": "06db4685-fba9-46fa-8fb2-72ca57ef9eea", "embedding": null, "metadata": {"window": "Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n", "original_text": "As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c02d7f6f-ef8d-4e51-9ec4-628562f94478", "node_type": "1", "metadata": {"window": "We're also connected to more than 50,000 pharmacies and we offer solutions like automatic coupon programs \nand central fill distribution helping them improve operational efficiency and ultimately, helping their patients lead \nhealthier lives.  \n \n Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups. ", "original_text": "We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f95e665fad3e5eb218f75fd1d2bd42b92156f9dcd40d6178481c0897440bbcbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e66e1387-78e6-49e7-aa60-146bb4d541a4", "node_type": "1", "metadata": {"window": "As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact. ", "original_text": "Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson. "}, "hash": "28f6deff17bc769353b72fffb673107910db814af490cfcee3e89d60c00ef5dd", "class_name": "RelatedNodeInfo"}}, "text": "As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer. ", "start_char_idx": 1415, "end_char_idx": 1616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e66e1387-78e6-49e7-aa60-146bb4d541a4": {"__data__": {"id_": "e66e1387-78e6-49e7-aa60-146bb4d541a4", "embedding": null, "metadata": {"window": "As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact. ", "original_text": "Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06db4685-fba9-46fa-8fb2-72ca57ef9eea", "node_type": "1", "metadata": {"window": "Recently, we were honored to receive the 2023 Retail Excellence Awards from Drug Store News, recognizing the \nvalue of our retail solutions and what they bring to pharmacies.  As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n", "original_text": "As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ca23c9c18b0f2fbdf34bb265ef753041fe21c975381d6f7ec892bc74a18d2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc924b69-fc69-4624-ae9c-81ca33e6ebca", "node_type": "1", "metadata": {"window": "We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization. ", "original_text": "We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups. "}, "hash": "3ed3372e9d1776cc1fcf4a6bca7aeaed0bbee21260e208949d88de73f9739380", "class_name": "RelatedNodeInfo"}}, "text": "Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson. ", "start_char_idx": 1616, "end_char_idx": 1771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc924b69-fc69-4624-ae9c-81ca33e6ebca": {"__data__": {"id_": "bc924b69-fc69-4624-ae9c-81ca33e6ebca", "embedding": null, "metadata": {"window": "We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization. ", "original_text": "We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e66e1387-78e6-49e7-aa60-146bb4d541a4", "node_type": "1", "metadata": {"window": "As we continue to make significant progress in our \ncompany's priorities, I want to highlight our unwavering focus on our people and culture.  We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact. ", "original_text": "Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5687855ac4771c6ee8783e342c5234b7d3d5932a5ef54caf96cec8d87cfbabe7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ead7b87-486b-40df-8b22-9f7bfa44ac33", "node_type": "1", "metadata": {"window": "As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations. ", "original_text": "We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n"}, "hash": "99d5ee9a6135354a88b549cef55cf426f04d58ee1100f87c1c2cf851224047bb", "class_name": "RelatedNodeInfo"}}, "text": "We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups. ", "start_char_idx": 1771, "end_char_idx": 1926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ead7b87-486b-40df-8b22-9f7bfa44ac33": {"__data__": {"id_": "9ead7b87-486b-40df-8b22-9f7bfa44ac33", "embedding": null, "metadata": {"window": "As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations. ", "original_text": "We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc924b69-fc69-4624-ae9c-81ca33e6ebca", "node_type": "1", "metadata": {"window": "We at McKesson believe \nthat having the best talent i s essential and it's foundational to our culture and strategies.  \n \n As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization. ", "original_text": "We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab5b270d65e6ba2a004050fafdbef94e342e57cbb98a133e89c683e4e6b54393", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36627a81-bf43-427f-8a99-00781914d105", "node_type": "1", "metadata": {"window": "Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n", "original_text": "Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact. "}, "hash": "97bc4f826ca86e99c61924885a5ed33d2005c5c03fd173e6fb73773d252feb5f", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n", "start_char_idx": 1926, "end_char_idx": 2204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36627a81-bf43-427f-8a99-00781914d105": {"__data__": {"id_": "36627a81-bf43-427f-8a99-00781914d105", "embedding": null, "metadata": {"window": "Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n", "original_text": "Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ead7b87-486b-40df-8b22-9f7bfa44ac33", "node_type": "1", "metadata": {"window": "As a company, we further defined our employee value proposition, we call it The Future of Health Starts with You \nto demonstrate our commitment to our employees and what makes McKesson a top employer.  Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations. ", "original_text": "We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6a859a90c72c01932c1f19ebb9a8c3afe234638b2d3b7ce74030c67c6c5e752", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bec63223-c37b-4753-9747-c989dfa46d01", "node_type": "1", "metadata": {"window": "We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars. ", "original_text": "We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization. "}, "hash": "940eea182e466ff5133d9428ec9c223c34e892598f035eb0f49411e7cc14c634", "class_name": "RelatedNodeInfo"}}, "text": "Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact. ", "start_char_idx": 2204, "end_char_idx": 2383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bec63223-c37b-4753-9747-c989dfa46d01": {"__data__": {"id_": "bec63223-c37b-4753-9747-c989dfa46d01", "embedding": null, "metadata": {"window": "We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars. ", "original_text": "We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36627a81-bf43-427f-8a99-00781914d105", "node_type": "1", "metadata": {"window": "Focusing on care, \nmeaning and belonging, we strive to build a culture that supports the well -being and growth of each individual who \nworks at McKesson.  We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n", "original_text": "Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1b1dbf96186160f361d47e34113bf439dc6efdbfcf9d02e628ddafee5c1a9c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a51e6ff2-973a-477a-8634-931fb488aa6b", "node_type": "1", "metadata": {"window": "We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n", "original_text": "In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations. "}, "hash": "679016a03275e289b3afd3906f3233f5accf71aadc95a808e4b4f8f0efcacb9f", "class_name": "RelatedNodeInfo"}}, "text": "We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization. ", "start_char_idx": 2383, "end_char_idx": 2548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a51e6ff2-973a-477a-8634-931fb488aa6b": {"__data__": {"id_": "a51e6ff2-973a-477a-8634-931fb488aa6b", "embedding": null, "metadata": {"window": "We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n", "original_text": "In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bec63223-c37b-4753-9747-c989dfa46d01", "node_type": "1", "metadata": {"window": "We also offer employees the opportunity to form authentic connections and advocate for \nadvanci ng the company's culture through employee resource groups.  We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars. ", "original_text": "We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9876357582ec09fd952c5644b9fee293b75b26db4577cfe6e3835453f9210ef2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cf0c175-c12d-4ddf-86b8-93f92f6f0419", "node_type": "1", "metadata": {"window": "Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities. ", "original_text": "We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n"}, "hash": "121a0505b73b1a166990963f347937112b5706240fd5fba2163f4b9580aaabca", "class_name": "RelatedNodeInfo"}}, "text": "In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations. ", "start_char_idx": 2548, "end_char_idx": 2753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cf0c175-c12d-4ddf-86b8-93f92f6f0419": {"__data__": {"id_": "3cf0c175-c12d-4ddf-86b8-93f92f6f0419", "embedding": null, "metadata": {"window": "Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities. ", "original_text": "We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a51e6ff2-973a-477a-8634-931fb488aa6b", "node_type": "1", "metadata": {"window": "We're pleased to see the ERG membership \ngrew by more than 70% in the past two -years, supported by increased employee participation, these resource \ngroups are becoming an important channel to promot e and strengthen our culture of inclusion, belonging and \ncollaboration.  \n \n Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n", "original_text": "In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37bf3f544d7cd3d58fd6df52681b9aaab757a1db42df608b23acbd62a21f474d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e15da4ca-2600-4156-b247-72716b729aac", "node_type": "1", "metadata": {"window": "We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024. ", "original_text": "I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars. "}, "hash": "04113c919d2b24570ac207e0487379dc4cbaebedb1f8e2758e94e418fccf704a", "class_name": "RelatedNodeInfo"}}, "text": "We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n", "start_char_idx": 2753, "end_char_idx": 2909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e15da4ca-2600-4156-b247-72716b729aac": {"__data__": {"id_": "e15da4ca-2600-4156-b247-72716b729aac", "embedding": null, "metadata": {"window": "We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024. ", "original_text": "I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cf0c175-c12d-4ddf-86b8-93f92f6f0419", "node_type": "1", "metadata": {"window": "Our focus on people and culture is an important pillar of our company's priorities and it's also part of our broader \ninitiatives focused on enacting positive and lasting impact.  We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities. ", "original_text": "We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f465f25fd826677d3d7b72458d1446adb037e5a02f768f1ec7e77d68c0cdcd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21bda11e-5417-40cd-898d-d797a4de0ad7", "node_type": "1", "metadata": {"window": "In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees. ", "original_text": "Now, before I hand it over to Britt, let me pull everything together.  \n \n"}, "hash": "6236afae4095de051614d46b71f0369e48077e2f594c8905d3f82418a4cd6d49", "class_name": "RelatedNodeInfo"}}, "text": "I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars. ", "start_char_idx": 2909, "end_char_idx": 3055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21bda11e-5417-40cd-898d-d797a4de0ad7": {"__data__": {"id_": "21bda11e-5417-40cd-898d-d797a4de0ad7", "embedding": null, "metadata": {"window": "In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees. ", "original_text": "Now, before I hand it over to Britt, let me pull everything together.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e15da4ca-2600-4156-b247-72716b729aac", "node_type": "1", "metadata": {"window": "We st rive to deliver value to our customers and our \ncommunities not only as a diversified health care services company but also as an impact -driven organization.  In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024. ", "original_text": "I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ead323f5d22a0a9114eb4219936be578eb039f3a9c1b45b03ff1a0d69147770f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76f05b66-37f7-45f8-99c6-420af9cf8245", "node_type": "1", "metadata": {"window": "We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson. ", "original_text": "McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities. "}, "hash": "731cd704f72b81db3dd6f2500671e94fd317b173fccb543328542262ae140fe7", "class_name": "RelatedNodeInfo"}}, "text": "Now, before I hand it over to Britt, let me pull everything together.  \n \n", "start_char_idx": 3055, "end_char_idx": 3129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76f05b66-37f7-45f8-99c6-420af9cf8245": {"__data__": {"id_": "76f05b66-37f7-45f8-99c6-420af9cf8245", "embedding": null, "metadata": {"window": "We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson. ", "original_text": "McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21bda11e-5417-40cd-898d-d797a4de0ad7", "node_type": "1", "metadata": {"window": "In \nJune, we published our FY 2022 and FY 2023 Impact Report that detailed our progress in advancing  our strategy \nin driving meaningful outcomes to build a healthier tomorrow for all future generations.  We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees. ", "original_text": "Now, before I hand it over to Britt, let me pull everything together.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e8cd0e9fd79eab08f6dff3497ab296ce3ecb38d34a0129569dffc396d1cde2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecf4f618-27c6-4b1f-8cf7-a1a295ae15a8", "node_type": "1", "metadata": {"window": "I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them. ", "original_text": "We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024. "}, "hash": "723ba229ac7895de89a88fe4618a5b57f3f62657751becbd96cfa0d608cf9e15", "class_name": "RelatedNodeInfo"}}, "text": "McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities. ", "start_char_idx": 3129, "end_char_idx": 3253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecf4f618-27c6-4b1f-8cf7-a1a295ae15a8": {"__data__": {"id_": "ecf4f618-27c6-4b1f-8cf7-a1a295ae15a8", "embedding": null, "metadata": {"window": "I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them. ", "original_text": "We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76f05b66-37f7-45f8-99c6-420af9cf8245", "node_type": "1", "metadata": {"window": "We shared many great \ninitiatives focused on making an impact through our four impact pillars, our people, our partners, our community \nand our planet.  \n \n I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson. ", "original_text": "McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "621bdf4722b14c986d8c9343e1b228e06aff42d5a8890fb2217b9c450cd9bcd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60168cfe-8ab2-4c72-b007-88174a7ec8af", "node_type": "1", "metadata": {"window": "Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n", "original_text": "I want to sincerely \nthank all of the McKesson employees. "}, "hash": "f23f0afea3bc58c345ee701a772db7bc8957972a81a480cc6bf942b24d603c3a", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024. ", "start_char_idx": 3253, "end_char_idx": 3435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60168cfe-8ab2-4c72-b007-88174a7ec8af": {"__data__": {"id_": "60168cfe-8ab2-4c72-b007-88174a7ec8af", "embedding": null, "metadata": {"window": "Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n", "original_text": "I want to sincerely \nthank all of the McKesson employees. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecf4f618-27c6-4b1f-8cf7-a1a295ae15a8", "node_type": "1", "metadata": {"window": "I'm very, very proud of what the team has achieved and will continue to track, measure and communicate our \nprogress around these impact pillars.  Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them. ", "original_text": "We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ac63a2a63bd147043fa4477c374bb2451ae9313060bb5b3c5f55c0abcccf40f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddc6f3f2-1b35-4b9f-a7c3-82dab78c18c8", "node_type": "1", "metadata": {"window": "McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n ", "original_text": "We refer to them as Team McKesson. "}, "hash": "4a341a1872b084188c2257690725cca7ff242ff3f958418ab1f99197d16bbace", "class_name": "RelatedNodeInfo"}}, "text": "I want to sincerely \nthank all of the McKesson employees. ", "start_char_idx": 3435, "end_char_idx": 3493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddc6f3f2-1b35-4b9f-a7c3-82dab78c18c8": {"__data__": {"id_": "ddc6f3f2-1b35-4b9f-a7c3-82dab78c18c8", "embedding": null, "metadata": {"window": "McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n ", "original_text": "We refer to them as Team McKesson. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60168cfe-8ab2-4c72-b007-88174a7ec8af", "node_type": "1", "metadata": {"window": "Now, before I hand it over to Britt, let me pull everything together.  \n \n McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n", "original_text": "I want to sincerely \nthank all of the McKesson employees. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63546529dbdf8aa92b9cc69338c6b74b7abe79b2a58175acc217dca584b52929", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50c78d4c-255c-4cea-99ec-1634d6ac210e", "node_type": "1", "metadata": {"window": "We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them. "}, "hash": "7aa376b0eae2cd876a6a9c0eab491f5caa58ff3fab7a59a870d9c44d0ee252ff", "class_name": "RelatedNodeInfo"}}, "text": "We refer to them as Team McKesson. ", "start_char_idx": 3493, "end_char_idx": 3528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50c78d4c-255c-4cea-99ec-1634d6ac210e": {"__data__": {"id_": "50c78d4c-255c-4cea-99ec-1634d6ac210e", "embedding": null, "metadata": {"window": "We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddc6f3f2-1b35-4b9f-a7c3-82dab78c18c8", "node_type": "1", "metadata": {"window": "McKesson delivered a strong first quarter and we're making consistent and meaningful progress with our \ncompany priorities.  We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n ", "original_text": "We refer to them as Team McKesson. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca1bd5af1733db25cf319994a886400799c292eacf31013363596a90f1ae638", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61c1fba8-15ca-44b3-88b2-b8b16aacea38", "node_type": "1", "metadata": {"window": "I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n"}, "hash": "8c6749715a82f70a37e3c4a6ba0ab5bd821bf6bddf6289a2844a424c5ee9b7eb", "class_name": "RelatedNodeInfo"}}, "text": "What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them. ", "start_char_idx": 3528, "end_char_idx": 3648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61c1fba8-15ca-44b3-88b2-b8b16aacea38": {"__data__": {"id_": "61c1fba8-15ca-44b3-88b2-b8b16aacea38", "embedding": null, "metadata": {"window": "I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50c78d4c-255c-4cea-99ec-1634d6ac210e", "node_type": "1", "metadata": {"window": "We're pleased with the growth and momentum across the business segments and the market \nfundamentals remain solid and support of the positive outlook we've outlined for fiscal 2024.  I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them. ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "847a56f33d362a30f7e282b65fda13fae0736278cdfaef83d04e25109ae01a54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95d17390-effd-473b-9f1c-ebc9af4667d3", "node_type": "1", "metadata": {"window": "We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "With that, Britt, I'll hand it over to you for additional insights.  \n "}, "hash": "3d1992eb31de455f6f80908bd8c76952454c19005871fcf44998265baf7f86a0", "class_name": "RelatedNodeInfo"}}, "text": "I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n", "start_char_idx": 3648, "end_char_idx": 3756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95d17390-effd-473b-9f1c-ebc9af4667d3": {"__data__": {"id_": "95d17390-effd-473b-9f1c-ebc9af4667d3", "embedding": null, "metadata": {"window": "We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "With that, Britt, I'll hand it over to you for additional insights.  \n ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61c1fba8-15ca-44b3-88b2-b8b16aacea38", "node_type": "1", "metadata": {"window": "I want to sincerely \nthank all of the McKesson employees.  We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbcceafe84f1e94518d4bd295b163ac87518d3d014cab03f6915e5837e9ddf92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc8649a8-c06b-400a-8c87-0ef33b316cae", "node_type": "1", "metadata": {"window": "What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "9d7e3db03250b6466d278a2deff8e06044ac795f28f78d05f917fbc4eda3cb48", "class_name": "RelatedNodeInfo"}}, "text": "With that, Britt, I'll hand it over to you for additional insights.  \n ", "start_char_idx": 3756, "end_char_idx": 3827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc8649a8-c06b-400a-8c87-0ef33b316cae": {"__data__": {"id_": "dc8649a8-c06b-400a-8c87-0ef33b316cae", "embedding": null, "metadata": {"window": "What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee34d6cf6706949ece5c16bcd29d0893525c42cfb76f026e869c48b3661c2496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95d17390-effd-473b-9f1c-ebc9af4667d3", "node_type": "1", "metadata": {"window": "We refer to them as Team McKesson.  What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "With that, Britt, I'll hand it over to you for additional insights.  \n ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "127162b4f7030493ae0f19c58d234ddfba18a75276ed1c929773b82510162b35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "344bb069-f82f-4295-991d-beb99ee52260", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range. ", "original_text": "McKesson Corp.  "}, "hash": "2b5803fd26bc2dd6397b787b7fedc0f1836dabc441fdb0cfebaffd7a6575d714", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 3827, "end_char_idx": 4187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "344bb069-f82f-4295-991d-beb99ee52260": {"__data__": {"id_": "344bb069-f82f-4295-991d-beb99ee52260", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc8649a8-c06b-400a-8c87-0ef33b316cae", "node_type": "1", "metadata": {"window": "What we have achieved would not \nbe possible without their dedication and the commitment of each and every one of them.  I'm tremendously proud \nto be your leade r and grateful for your contributions to advancing our vision.  \n \n With that, Britt, I'll hand it over to you for additional insights.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62a31960ec49e69840cf6898cc4fd0d82bb282bd873366b800e496e9cde9d182", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "498ac1b9-733d-49ce-a2b5-83c0f06da52e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n"}, "hash": "9e9c9f66b70869ff2fa6e7630a1d8c4788bf8109f4b0a828819c6cc40da52f3e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "498ac1b9-733d-49ce-a2b5-83c0f06da52e": {"__data__": {"id_": "498ac1b9-733d-49ce-a2b5-83c0f06da52e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "344bb069-f82f-4295-991d-beb99ee52260", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc98d4a446b48a77cd8a84d89a529f19ab42bb98d296585ab0bbc92bcef5b998", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "503b7818-6fef-4926-92b1-f0e589c92ad9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results. ", "original_text": "Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today. "}, "hash": "70b6046ab9838359ecdebd1b006f0926dc80f8835f71ff56dfff78008fcd3b93", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n", "start_char_idx": 16, "end_char_idx": 452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "503b7818-6fef-4926-92b1-f0e589c92ad9": {"__data__": {"id_": "503b7818-6fef-4926-92b1-f0e589c92ad9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results. ", "original_text": "Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "498ac1b9-733d-49ce-a2b5-83c0f06da52e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae1da8ad852f7e73fd7ea60d92a344144829eb59513e1c71d5dc1d1f7da6cdbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a786c40-f7e2-46ed-9b0f-f4e2c2c43310", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n", "original_text": "I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range. "}, "hash": "2b326f00a2b1f3a45e883adc1adf080f8a0bd8ca442c0fe19df491dee7d5238a", "class_name": "RelatedNodeInfo"}}, "text": "Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today. ", "start_char_idx": 452, "end_char_idx": 583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a786c40-f7e2-46ed-9b0f-f4e2c2c43310": {"__data__": {"id_": "4a786c40-f7e2-46ed-9b0f-f4e2c2c43310", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n", "original_text": "I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "503b7818-6fef-4926-92b1-f0e589c92ad9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results. ", "original_text": "Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25cff38bda5464a3df6d9df95289e0fabb67c261d00b5c17e28cc2685c80d907", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8536f6fa-5430-4c33-90a6-2ca05fd0f7a6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%. ", "original_text": "My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n"}, "hash": "4cdc609be2e88fe039eaf90ba8689abf6e2a85829c680610878f9ab3581c9a08", "class_name": "RelatedNodeInfo"}}, "text": "I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range. ", "start_char_idx": 583, "end_char_idx": 761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8536f6fa-5430-4c33-90a6-2ca05fd0f7a6": {"__data__": {"id_": "8536f6fa-5430-4c33-90a6-2ca05fd0f7a6", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%. ", "original_text": "My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a786c40-f7e2-46ed-9b0f-f4e2c2c43310", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n", "original_text": "I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75a3a1337f9563cd6479bbd7652bbdc6e60317d74b894b48e88e9bd11bbe38bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70fb7dcb-21bf-4ae3-9ab4-a84cf5a6c09c", "node_type": "1", "metadata": {"window": "Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S. ", "original_text": "Let me start with a review of our consolidated results. "}, "hash": "6569ffd9a652095392e446f55796ce29467d0b51f13bc8124946162292abc6e3", "class_name": "RelatedNodeInfo"}}, "text": "My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n", "start_char_idx": 761, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70fb7dcb-21bf-4ae3-9ab4-a84cf5a6c09c": {"__data__": {"id_": "70fb7dcb-21bf-4ae3-9ab4-a84cf5a6c09c", "embedding": null, "metadata": {"window": "Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S. ", "original_text": "Let me start with a review of our consolidated results. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8536f6fa-5430-4c33-90a6-2ca05fd0f7a6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%. ", "original_text": "My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41a88377d1444811a4e0a79ed9a437257f4b41a86aa4ffcf1dc2fdaeafec1665", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2489bc7-9b83-4ac3-b095-d99330fd7da1", "node_type": "1", "metadata": {"window": "I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n", "original_text": "Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n"}, "hash": "594a87828e2af17eeb3c9b54b4ffbdc905fae9c5ded625c5f89d637e750bd37f", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with a review of our consolidated results. ", "start_char_idx": 857, "end_char_idx": 913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2489bc7-9b83-4ac3-b095-d99330fd7da1": {"__data__": {"id_": "e2489bc7-9b83-4ac3-b095-d99330fd7da1", "embedding": null, "metadata": {"window": "I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n", "original_text": "Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70fb7dcb-21bf-4ae3-9ab4-a84cf5a6c09c", "node_type": "1", "metadata": {"window": "Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S. ", "original_text": "Let me start with a review of our consolidated results. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bddfca5a4722c6fdd60831203e44f3cdd7977a108f1a4ab40a16ddba6bc1fb24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2208d0cb-f893-45dc-9f50-70d203c97be4", "node_type": "1", "metadata": {"window": "My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter. ", "original_text": "When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%. "}, "hash": "91c181e0de3792a6e2ed89f1ddca66f81a573cca39a01c2bd740b1f22ec56c53", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n", "start_char_idx": 913, "end_char_idx": 1363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2208d0cb-f893-45dc-9f50-70d203c97be4": {"__data__": {"id_": "2208d0cb-f893-45dc-9f50-70d203c97be4", "embedding": null, "metadata": {"window": "My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter. ", "original_text": "When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2489bc7-9b83-4ac3-b095-d99330fd7da1", "node_type": "1", "metadata": {"window": "I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range.  My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n", "original_text": "Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3ad788d0314c7acf99136b1e0921f5c10525beca2c56e1093fa29da4069dfd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d995580b-3f11-497f-a287-9b53adec93e2", "node_type": "1", "metadata": {"window": "Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year. ", "original_text": "Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S. "}, "hash": "7ae6674eadb9c041ee7820d17b9243d08bb0899f00a80ae2d57d4213f3f4ce17", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%. ", "start_char_idx": 1363, "end_char_idx": 1485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d995580b-3f11-497f-a287-9b53adec93e2": {"__data__": {"id_": "d995580b-3f11-497f-a287-9b53adec93e2", "embedding": null, "metadata": {"window": "Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year. ", "original_text": "Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2208d0cb-f893-45dc-9f50-70d203c97be4", "node_type": "1", "metadata": {"window": "My comments today will refer to our \nfiscal 2024 adjusted results unless I state otherwise.  \n \n Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter. ", "original_text": "When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d128b3396e827885b2a5d95c390a0741d01a6a1a9b01d870039c22836355734f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c20bdb28-28e6-4021-8904-1664c20292e0", "node_type": "1", "metadata": {"window": "Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n", "original_text": "Pharmaceutical and Prescription Technology Solu tions segments.  \n \n"}, "hash": "0cedb31b0f8287c8245d31af67dc90a64312c155eb87e7ff96fd2acc98cf7118", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S. ", "start_char_idx": 1485, "end_char_idx": 1734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c20bdb28-28e6-4021-8904-1664c20292e0": {"__data__": {"id_": "c20bdb28-28e6-4021-8904-1664c20292e0", "embedding": null, "metadata": {"window": "Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n", "original_text": "Pharmaceutical and Prescription Technology Solu tions segments.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d995580b-3f11-497f-a287-9b53adec93e2", "node_type": "1", "metadata": {"window": "Let me start with a review of our consolidated results.  Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year. ", "original_text": "Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03e59f63e018f2d704216f65c9ee90e9e34eccfb5c1a5e1530ec96c98032c416", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3885fc8-16e9-4ddb-9ae7-e64c8bae811e", "node_type": "1", "metadata": {"window": "When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment. ", "original_text": "Operating expenses decreased 4% in the quarter. "}, "hash": "5e5f2aaa0c181d9dabb431d2d7742a0268ca395317c5805d23f9863ac60e8204", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Prescription Technology Solu tions segments.  \n \n", "start_char_idx": 1734, "end_char_idx": 1802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3885fc8-16e9-4ddb-9ae7-e64c8bae811e": {"__data__": {"id_": "c3885fc8-16e9-4ddb-9ae7-e64c8bae811e", "embedding": null, "metadata": {"window": "When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment. ", "original_text": "Operating expenses decreased 4% in the quarter. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c20bdb28-28e6-4021-8904-1664c20292e0", "node_type": "1", "metadata": {"window": "Consolidated revenues increased 11% to $74.5 billion \nwhich was led by growth in the U. S. Pharmaceutical segment, resulting from increased prescription volumes \nincluding higher volumes from retail national account customers, specialty products and weight loss or GLP -1 \ndrugs and they are partially offset by lower revenues in the International  segment, resulting from completed \ndivestitures within our European business during fiscal 2023.  \n \n When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n", "original_text": "Pharmaceutical and Prescription Technology Solu tions segments.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0592330c52f117016414b900290aeb08a64f9f559a783c48976b2c66d523da2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1f42793-9497-446d-adf6-e7afe3bf52c6", "node_type": "1", "metadata": {"window": "Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n", "original_text": "When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year. "}, "hash": "de8e56b6d13ebdb5b24f01903e551604410770308f19fa043df7c7b07d30703f", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses decreased 4% in the quarter. ", "start_char_idx": 1802, "end_char_idx": 1850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1f42793-9497-446d-adf6-e7afe3bf52c6": {"__data__": {"id_": "a1f42793-9497-446d-adf6-e7afe3bf52c6", "embedding": null, "metadata": {"window": "Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n", "original_text": "When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3885fc8-16e9-4ddb-9ae7-e64c8bae811e", "node_type": "1", "metadata": {"window": "When excluding the impact of our European Business Operations, including completed divestitures, revenues \nincreased 16%.  Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment. ", "original_text": "Operating expenses decreased 4% in the quarter. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57af21c7227af92eff497f1feb19e3bce6bb8f2978d52dbeb630cb4054b17298", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be479c44-2283-4830-8ff3-69b633a36a49", "node_type": "1", "metadata": {"window": "Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets. ", "original_text": "Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n"}, "hash": "2477cc20128660f59060ba70716ced81f4501528167c79e5227b2240ab907ed5", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year. ", "start_char_idx": 1850, "end_char_idx": 1996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be479c44-2283-4830-8ff3-69b633a36a49": {"__data__": {"id_": "be479c44-2283-4830-8ff3-69b633a36a49", "embedding": null, "metadata": {"window": "Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets. ", "original_text": "Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1f42793-9497-446d-adf6-e7afe3bf52c6", "node_type": "1", "metadata": {"window": "Gross profit was $2.9 billion for the  quarter a decrease of 2% and when excluding the impact of \nour European business operations and completed divestitures, gross profit increased 7% in the first quarter, \nprimarily a result of growth in the U.S.  Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n", "original_text": "When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c702828683104078e5e1911ecfd92e28d7225a62e560919407c771a85dee7ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dda5a64f-cd01-4429-bac6-e20387c258ac", "node_type": "1", "metadata": {"window": "Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n", "original_text": "First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment. "}, "hash": "c039c1fc5bfa2dcceef698e22d3293732b6a4a85f56d22b74929d9f66591e574", "class_name": "RelatedNodeInfo"}}, "text": "Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n", "start_char_idx": 1996, "end_char_idx": 2242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dda5a64f-cd01-4429-bac6-e20387c258ac": {"__data__": {"id_": "dda5a64f-cd01-4429-bac6-e20387c258ac", "embedding": null, "metadata": {"window": "Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n", "original_text": "First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be479c44-2283-4830-8ff3-69b633a36a49", "node_type": "1", "metadata": {"window": "Pharmaceutical and Prescription Technology Solu tions segments.  \n \n Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets. ", "original_text": "Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a34c00f6575835628a90817feeac9fb8661d4eb26008763a4ff183bf1ace6ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28436069-e16d-43b1-9ff0-cf1149931e52", "node_type": "1", "metadata": {"window": "When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks. ", "original_text": "When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n"}, "hash": "946b6f6f879ae63c4b85b4153853fea9b05ff6dfec2ca0c0098d582dca2a574b", "class_name": "RelatedNodeInfo"}}, "text": "First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment. ", "start_char_idx": 2242, "end_char_idx": 2495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28436069-e16d-43b1-9ff0-cf1149931e52": {"__data__": {"id_": "28436069-e16d-43b1-9ff0-cf1149931e52", "embedding": null, "metadata": {"window": "When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks. ", "original_text": "When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dda5a64f-cd01-4429-bac6-e20387c258ac", "node_type": "1", "metadata": {"window": "Operating expenses decreased 4% in the quarter.  When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n", "original_text": "First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ea1a6c060afd1123ed669fa9c6f3e259c83c76c37603a086717f6429811c9ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44028522-7cdc-4797-bcb7-0d6a8251d9ef", "node_type": "1", "metadata": {"window": "Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n", "original_text": "We're pleased with these strong operating results, which are above the long -range growth targets. "}, "hash": "058f9409444dfeeadcac4fc1efc5e12beac34ab5c989e2e0940b9bd87e9485b8", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n", "start_char_idx": 2495, "end_char_idx": 2707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44028522-7cdc-4797-bcb7-0d6a8251d9ef": {"__data__": {"id_": "44028522-7cdc-4797-bcb7-0d6a8251d9ef", "embedding": null, "metadata": {"window": "Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n", "original_text": "We're pleased with these strong operating results, which are above the long -range growth targets. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28436069-e16d-43b1-9ff0-cf1149931e52", "node_type": "1", "metadata": {"window": "When excluding the impact of our European Business \nOperations including completed divestitures, operating expenses increased 8% year -over-year.  Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks. ", "original_text": "When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbcbec39285ea1788d7c3025fbf122c8fa6eec6e2d9463e23a87607a7e0d7ba0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8b24d58-98a1-4ad8-9cd4-10fc0d59994d", "node_type": "1", "metadata": {"window": "First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance. ", "original_text": "We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n"}, "hash": "f4ec1b2723bfa4d4cc44fc4edb31baf166263d0389d36a65d562109b880a9849", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with these strong operating results, which are above the long -range growth targets. ", "start_char_idx": 2707, "end_char_idx": 2806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8b24d58-98a1-4ad8-9cd4-10fc0d59994d": {"__data__": {"id_": "f8b24d58-98a1-4ad8-9cd4-10fc0d59994d", "embedding": null, "metadata": {"window": "First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance. ", "original_text": "We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44028522-7cdc-4797-bcb7-0d6a8251d9ef", "node_type": "1", "metadata": {"window": "Operating \nexpenses during the quarter included integration costs related to our acquisition of Rx Savings Solutions, and a \njoint venture with Sarah Cannon Research Institute, both of which were completed in the second half of fiscal \n2023.  \n \n First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n", "original_text": "We're pleased with these strong operating results, which are above the long -range growth targets. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54526c5a0d4237a2414454d7f60a89a9b4a292463e5dfc1beff14ab58748635a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cb75e27-f463-4ea7-9645-6ecaa3dab75a", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n", "original_text": "Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks. "}, "hash": "030bd43c1cd4e3b2ad97eeea00b8c0e9c565e6faa118d4de59440cc7915cb700", "class_name": "RelatedNodeInfo"}}, "text": "We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n", "start_char_idx": 2806, "end_char_idx": 2926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cb75e27-f463-4ea7-9645-6ecaa3dab75a": {"__data__": {"id_": "5cb75e27-f463-4ea7-9645-6ecaa3dab75a", "embedding": null, "metadata": {"window": "When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n", "original_text": "Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8b24d58-98a1-4ad8-9cd4-10fc0d59994d", "node_type": "1", "metadata": {"window": "First quarter operating profit increased 3% to $1.2 billion, pr imarily driven by growth in our North American \nbusinesses, partially offset by the completed divestitures of our European Business Operations, which are within \nour International segment.  When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance. ", "original_text": "We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ddd705af160ce42a3acbe3acc8a7433ff4f41b592b48f3374177a80c5dc09e33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1e7869b-27f3-4e56-805f-b1ea46995a4f", "node_type": "1", "metadata": {"window": "We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year. ", "original_text": "The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n"}, "hash": "c39194037cfea5e6fe4869d7af6b4b96149f1c3d03cadb5449396bbeacf3733d", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks. ", "start_char_idx": 2926, "end_char_idx": 3112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1e7869b-27f3-4e56-805f-b1ea46995a4f": {"__data__": {"id_": "c1e7869b-27f3-4e56-805f-b1ea46995a4f", "embedding": null, "metadata": {"window": "We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year. ", "original_text": "The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cb75e27-f463-4ea7-9645-6ecaa3dab75a", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-related items in fiscal 2023, a nd losses \nassociated with McKesson Ventures equity investments, in fiscal 2023 and 2024, operating profit increased 9% in \nthe quarter.  \n \n We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n", "original_text": "Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54b3f25ff10888e0f5a8ba05a146ff817f592a7b1fc152d694c68ee07cf3b214", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb582c7d-ffe0-4495-ae08-76c478a81e52", "node_type": "1", "metadata": {"window": "We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year. ", "original_text": "As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance. "}, "hash": "dc3bd8d065d780b4f8ea6fd98c817c5300f72d4dbbef523a3d93d46318520291", "class_name": "RelatedNodeInfo"}}, "text": "The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n", "start_char_idx": 3112, "end_char_idx": 3404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb582c7d-ffe0-4495-ae08-76c478a81e52": {"__data__": {"id_": "eb582c7d-ffe0-4495-ae08-76c478a81e52", "embedding": null, "metadata": {"window": "We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year. ", "original_text": "As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1e7869b-27f3-4e56-805f-b1ea46995a4f", "node_type": "1", "metadata": {"window": "We're pleased with these strong operating results, which are above the long -range growth targets.  We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year. ", "original_text": "The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "abce0ed042e8b20d57ce9e740e2ba002dd6e1abd52a9342685c768d4d7c6e410", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cb8912a-834f-4a96-92cf-4b73fa8d211e", "node_type": "1", "metadata": {"window": "Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year.  Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "original_text": "Our effective tax rate guidance for the full year remains uncha nged.  \n \n"}, "hash": "75fdf592fd507858789aeff02e8d0514543971c091a10975929613dc181d35f1", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance. ", "start_char_idx": 3404, "end_char_idx": 3549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cb8912a-834f-4a96-92cf-4b73fa8d211e": {"__data__": {"id_": "5cb8912a-834f-4a96-92cf-4b73fa8d211e", "embedding": null, "metadata": {"window": "Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year.  Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "original_text": "Our effective tax rate guidance for the full year remains uncha nged.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb582c7d-ffe0-4495-ae08-76c478a81e52", "node_type": "1", "metadata": {"window": "We're \ndelivering durab le operating performance and sustained momentum and we're executing against our strategies.  \n \n Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year. ", "original_text": "As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1eb8c79bb3316c9ebb60dd96c1bc523f420230c2e58b41e86b209c8b6ba38a4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e6a975e-ceba-4b3a-a3fa-89f77bca0667", "node_type": "1", "metadata": {"window": "The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year.  Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "original_text": "First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year. "}, "hash": "7d36c3a7c28298649fbcfe34ec1e44ad93a0e122c358190d27816c6ac062280c", "class_name": "RelatedNodeInfo"}}, "text": "Our effective tax rate guidance for the full year remains uncha nged.  \n \n", "start_char_idx": 3549, "end_char_idx": 3623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e6a975e-ceba-4b3a-a3fa-89f77bca0667": {"__data__": {"id_": "6e6a975e-ceba-4b3a-a3fa-89f77bca0667", "embedding": null, "metadata": {"window": "The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year.  Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "original_text": "First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cb8912a-834f-4a96-92cf-4b73fa8d211e", "node_type": "1", "metadata": {"window": "Moving below the line, interest expense was $42 million a year -over-year decrease driven by transactions within \nour long -term debt portfolio, which I'll discuss la ter in my remarks.  The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year.  Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "original_text": "Our effective tax rate guidance for the full year remains uncha nged.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a018c244ac1c7de80cbdff4dee0444ad92423eb3466ea5954de332646569538", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d9ef24a-6f8c-471f-ba61-77acc1948741", "node_type": "1", "metadata": {"window": "As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year.  Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "original_text": "Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year. "}, "hash": "edfb5bae6c7d92b8d15892c7574d3e3a5c5dc8e189f45aa0782d4eca1839ec68", "class_name": "RelatedNodeInfo"}}, "text": "First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year. ", "start_char_idx": 3623, "end_char_idx": 3752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d9ef24a-6f8c-471f-ba61-77acc1948741": {"__data__": {"id_": "4d9ef24a-6f8c-471f-ba61-77acc1948741", "embedding": null, "metadata": {"window": "As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year.  Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "original_text": "Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e6a975e-ceba-4b3a-a3fa-89f77bca0667", "node_type": "1", "metadata": {"window": "The effective tax rate was 8.4% driven by the \nrecognition of a net discrete tax benefit of $147 million in the first quarter of fiscal 2024 related to the repatriation \nof certain intellectual property between wholly -owned legal entities that were based in different tax jurisdictions.  \n \n As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year.  Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "original_text": "First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "387eb017d5e925c945ba96a51bf9e5d830fbaccb19c6c66d2424d6e12895750d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45112e3a-03b0-4d75-bbd4-8ee3ecca29ef", "node_type": "1", "metadata": {"window": "Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year.  Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "original_text": "Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  "}, "hash": "b61da6c3222612886ae94df7d935a2a66951cf71c83ce42f1f9e776a2687d4bc", "class_name": "RelatedNodeInfo"}}, "text": "Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year. ", "start_char_idx": 3752, "end_char_idx": 3872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45112e3a-03b0-4d75-bbd4-8ee3ecca29ef": {"__data__": {"id_": "45112e3a-03b0-4d75-bbd4-8ee3ecca29ef", "embedding": null, "metadata": {"window": "Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year.  Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "original_text": "Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81beb269-f9f1-4b7d-9ef9-706128297398", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8519ecf6c334e849e218474ec35073cf35a18c554651337bc60be151502a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d9ef24a-6f8c-471f-ba61-77acc1948741", "node_type": "1", "metadata": {"window": "As a reminder, the timing of discrete tax items is difficult to predict and therefore, we do not provide quarterly \neffective tax rate guidance.  Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year.  Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "original_text": "Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year. ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fca58974c68b56322cf541dc193d87ede9da85dfe494a4986e8f6010b19f69e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e7328e8-0c3d-4c22-8b4b-7b510842deba", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations. ", "original_text": "McKesson Corp.  "}, "hash": "35078558681bbe5d9bb63b3d3ce7ba0014335ccbda95ef459b7b0f522794d2a2", "class_name": "RelatedNodeInfo"}}, "text": "Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "start_char_idx": 3872, "end_char_idx": 4101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e7328e8-0c3d-4c22-8b4b-7b510842deba": {"__data__": {"id_": "8e7328e8-0c3d-4c22-8b4b-7b510842deba", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45112e3a-03b0-4d75-bbd4-8ee3ecca29ef", "node_type": "1", "metadata": {"window": "Our effective tax rate guidance for the full year remains uncha nged.  \n \n First quarter diluted weighted -average shares outstanding was $136.6 million \u2013 136.6 million, a decrease of 6% \nyear-over-year.  Adding it all up, first quarter earnings per diluted share of $7.27 represents an increase of 25% \nover the prior year.  Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "original_text": "Whe n excluding COVID -19-related items in the first quarter of fiscal 2023, and losses within \nour McKesson Ventures portfolio in fiscal 2023 and 2024, first quarter earnings per diluted share was up 33% \nover the prior -year.  ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30034f61e6c61f7014f0f294137e28a60cd47b9c8e7ff1114a8b50ad429e2a1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4042a939-53cc-4446-b156-5470138cae8c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n"}, "hash": "50ddb7e75be5fe64e50a71d87e4daf1333bf87dcd274340ca2b123d5e90d8696", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4042a939-53cc-4446-b156-5470138cae8c": {"__data__": {"id_": "4042a939-53cc-4446-b156-5470138cae8c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e7328e8-0c3d-4c22-8b4b-7b510842deba", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33373970adf32a8f667f7b19a014092f5b32ada3dac28eca98259be0769ac682", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5409e8dd-53ef-42f8-af6a-d46fff81252c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs. ", "original_text": "Pharmaceutical. "}, "hash": "649e486cf6a0ecf48a25a2c11f64cb0c843acd4e7873deed75f2a2095a32a078", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n", "start_char_idx": 16, "end_char_idx": 299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5409e8dd-53ef-42f8-af6a-d46fff81252c": {"__data__": {"id_": "5409e8dd-53ef-42f8-af6a-d46fff81252c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs. ", "original_text": "Pharmaceutical. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4042a939-53cc-4446-b156-5470138cae8c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf3ca9fec924ba393bdcb2da19adc3f37005b9eaaa3ed9912d3a4741eca4c6e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcf0e9d0-cda9-44ae-a713-b5f5e8982934", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n", "original_text": "Revenue and operating profit results in the quarter exceeded our expectations. "}, "hash": "6b572010cffa650796ee6069742a40b6ae70d634f3f7ee0e0ceb31ec13a3b8a9", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical. ", "start_char_idx": 299, "end_char_idx": 315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcf0e9d0-cda9-44ae-a713-b5f5e8982934": {"__data__": {"id_": "dcf0e9d0-cda9-44ae-a713-b5f5e8982934", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n", "original_text": "Revenue and operating profit results in the quarter exceeded our expectations. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5409e8dd-53ef-42f8-af6a-d46fff81252c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs. ", "original_text": "Pharmaceutical. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50da05d8309f0b2fcbcf01461602df1db831e9022ef07461895fecf2c8684417", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "869e72ff-d78c-41a7-b009-fb212e98ab09", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter. ", "original_text": "First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year. "}, "hash": "a797be18e29dda3e4abfe955cb032040e4bbdd8ea386288e88c1ccf4b69b4468", "class_name": "RelatedNodeInfo"}}, "text": "Revenue and operating profit results in the quarter exceeded our expectations. ", "start_char_idx": 315, "end_char_idx": 394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "869e72ff-d78c-41a7-b009-fb212e98ab09": {"__data__": {"id_": "869e72ff-d78c-41a7-b009-fb212e98ab09", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter. ", "original_text": "First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcf0e9d0-cda9-44ae-a713-b5f5e8982934", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n", "original_text": "Revenue and operating profit results in the quarter exceeded our expectations. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9df3325b6f401cf4b679375f1b34ad2a51f310d466fa4dfab2853d3655699eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dab9e6aa-83ba-4839-b45a-711aadc49aaf", "node_type": "1", "metadata": {"window": "Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs. ", "original_text": "Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs. "}, "hash": "a1f58194181ebdedffecf0f9b311102954e52a005dc8d7b2c3deeacbe10b08a7", "class_name": "RelatedNodeInfo"}}, "text": "First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year. ", "start_char_idx": 394, "end_char_idx": 474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dab9e6aa-83ba-4839-b45a-711aadc49aaf": {"__data__": {"id_": "dab9e6aa-83ba-4839-b45a-711aadc49aaf", "embedding": null, "metadata": {"window": "Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs. ", "original_text": "Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "869e72ff-d78c-41a7-b009-fb212e98ab09", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter. ", "original_text": "First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0a53c4beadea80b9cf4434afc33930f9159d2ea99f2a3efeed11e9220ed71e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f302c4f-8f5a-4497-bade-d6ea4b36d06f", "node_type": "1", "metadata": {"window": "Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n", "original_text": "These increases were partially offset by branded to generic conversions.  \n \n"}, "hash": "73241266499438372e03f2c8e3ec69c7b60635fc988d88cc067d98df7165a82d", "class_name": "RelatedNodeInfo"}}, "text": "Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs. ", "start_char_idx": 474, "end_char_idx": 646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f302c4f-8f5a-4497-bade-d6ea4b36d06f": {"__data__": {"id_": "5f302c4f-8f5a-4497-bade-d6ea4b36d06f", "embedding": null, "metadata": {"window": "Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n", "original_text": "These increases were partially offset by branded to generic conversions.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dab9e6aa-83ba-4839-b45a-711aadc49aaf", "node_type": "1", "metadata": {"window": "Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs. ", "original_text": "Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e29bed5c6501a18cb8f93d8feefd163495f07298505b63c5cb45775f5b974ed6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "118cb664-9bed-4564-a773-18c84e3b5c34", "node_type": "1", "metadata": {"window": "First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy. ", "original_text": "The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter. "}, "hash": "aea8d350ff2eca24df17b5d72fecd088b2390ce3d7c1a5d18b2f9dbea7d1421b", "class_name": "RelatedNodeInfo"}}, "text": "These increases were partially offset by branded to generic conversions.  \n \n", "start_char_idx": 646, "end_char_idx": 723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "118cb664-9bed-4564-a773-18c84e3b5c34": {"__data__": {"id_": "118cb664-9bed-4564-a773-18c84e3b5c34", "embedding": null, "metadata": {"window": "First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy. ", "original_text": "The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f302c4f-8f5a-4497-bade-d6ea4b36d06f", "node_type": "1", "metadata": {"window": "Revenue and operating profit results in the quarter exceeded our expectations.  First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n", "original_text": "These increases were partially offset by branded to generic conversions.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5580c80a0dd6924a711526ca0774ed1cb6668e82497bf3894981856e19099a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70211729-306c-49fa-b345-336404636a27", "node_type": "1", "metadata": {"window": "Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets. ", "original_text": "We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs. "}, "hash": "a200dcf8405eb96ab2f6364fbbdd673f5c7749c0d4b28115a4e2167ef70fbe35", "class_name": "RelatedNodeInfo"}}, "text": "The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter. ", "start_char_idx": 723, "end_char_idx": 826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70211729-306c-49fa-b345-336404636a27": {"__data__": {"id_": "70211729-306c-49fa-b345-336404636a27", "embedding": null, "metadata": {"window": "Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets. ", "original_text": "We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "118cb664-9bed-4564-a773-18c84e3b5c34", "node_type": "1", "metadata": {"window": "First quarter \nrevenues were $67.2 billion, an increase of 18% year -over-year.  Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy. ", "original_text": "The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51d5d4030b4765e1bd63dede6ef21edbae240175b2d9edb236a180c5c301d379", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14481372-58f4-410e-b73a-a888c64045f7", "node_type": "1", "metadata": {"window": "These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n", "original_text": "The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n"}, "hash": "78f8bd54352becb3839297841ac5ff55a3146e7b4269ffb90a2e7d5dcfac0bf0", "class_name": "RelatedNodeInfo"}}, "text": "We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs. ", "start_char_idx": 826, "end_char_idx": 909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14481372-58f4-410e-b73a-a888c64045f7": {"__data__": {"id_": "14481372-58f4-410e-b73a-a888c64045f7", "embedding": null, "metadata": {"window": "These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n", "original_text": "The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70211729-306c-49fa-b345-336404636a27", "node_type": "1", "metadata": {"window": "Rev enue growth reflected increased prescription \ntransaction volumes including higher volumes from retail national account customers, specialty products and \nGLP-1 drugs.  These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets. ", "original_text": "We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd061deccb36448255ee27646c7219721ac84cc47495f20fd66fd1c5e52728d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1307c224-5d98-4f43-8315-bde30308a003", "node_type": "1", "metadata": {"window": "The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network. ", "original_text": "The first quarter also marked further progress against our oncology growth strategy. "}, "hash": "7817d4601e37f09ec1e5a8e64d045d19e197bb6218a1627a6a11d075d2eb376d", "class_name": "RelatedNodeInfo"}}, "text": "The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n", "start_char_idx": 909, "end_char_idx": 1141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1307c224-5d98-4f43-8315-bde30308a003": {"__data__": {"id_": "1307c224-5d98-4f43-8315-bde30308a003", "embedding": null, "metadata": {"window": "The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network. ", "original_text": "The first quarter also marked further progress against our oncology growth strategy. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14481372-58f4-410e-b73a-a888c64045f7", "node_type": "1", "metadata": {"window": "These increases were partially offset by branded to generic conversions.  \n \n The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n", "original_text": "The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "617ea11bcbfe5c71e066b203e2eddbecf3ecf3b1ec54832efde1b129409a9c96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f18310cf-3879-4f60-8971-ff3e3127f31e", "node_type": "1", "metadata": {"window": "We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year. ", "original_text": "We're pleased with the \ngrowth acros s all of our oncology assets. "}, "hash": "4490b2b0ff05f8952f9f4608a47500af9b3867c159581c32c916087653148877", "class_name": "RelatedNodeInfo"}}, "text": "The first quarter also marked further progress against our oncology growth strategy. ", "start_char_idx": 1141, "end_char_idx": 1226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f18310cf-3879-4f60-8971-ff3e3127f31e": {"__data__": {"id_": "f18310cf-3879-4f60-8971-ff3e3127f31e", "embedding": null, "metadata": {"window": "We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year. ", "original_text": "We're pleased with the \ngrowth acros s all of our oncology assets. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1307c224-5d98-4f43-8315-bde30308a003", "node_type": "1", "metadata": {"window": "The growth of th e weight loss or the GLP -1 drug category provided a revenue tailwind in the quarter.  We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network. ", "original_text": "The first quarter also marked further progress against our oncology growth strategy. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2c4829a35356df3799b476d1de3e3a047a5a76b3f8e5b754e954c518849d955", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2dfbb26-f060-44d4-a53f-5fd0a818c1ca", "node_type": "1", "metadata": {"window": "The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n", "original_text": "We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n"}, "hash": "a27fd7addf11fe24be6b145f269fd25ea519956386de4e50ba7c2493954e6d41", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with the \ngrowth acros s all of our oncology assets. ", "start_char_idx": 1226, "end_char_idx": 1293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2dfbb26-f060-44d4-a53f-5fd0a818c1ca": {"__data__": {"id_": "f2dfbb26-f060-44d4-a53f-5fd0a818c1ca", "embedding": null, "metadata": {"window": "The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n", "original_text": "We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f18310cf-3879-4f60-8971-ff3e3127f31e", "node_type": "1", "metadata": {"window": "We \ngenerally recognized lower -margin rates for the distribution of GLP -1 drugs.  The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year. ", "original_text": "We're pleased with the \ngrowth acros s all of our oncology assets. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af81f05f60678439a83ea2fd521cef2603abbdfb87dce0690a600a540f941f2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e660c48d-28f8-4780-86b1-7fb4f030816a", "node_type": "1", "metadata": {"window": "The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n", "original_text": "During the quarter, we delivered solid performance and contribution from the US Oncology Network. "}, "hash": "348ad781bd0f2eaff6cf03da7a2b9413734b006f34b364d8c62fd1800eadcabe", "class_name": "RelatedNodeInfo"}}, "text": "We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n", "start_char_idx": 1293, "end_char_idx": 1555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e660c48d-28f8-4780-86b1-7fb4f030816a": {"__data__": {"id_": "e660c48d-28f8-4780-86b1-7fb4f030816a", "embedding": null, "metadata": {"window": "The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n", "original_text": "During the quarter, we delivered solid performance and contribution from the US Oncology Network. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2dfbb26-f060-44d4-a53f-5fd0a818c1ca", "node_type": "1", "metadata": {"window": "The growth of these products, similar \nto other new brand launches, led to increased demand for our access and affordability support programs such as \nour prior authorization services, which are offered within our RxTS segment.  \n \n The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n", "original_text": "We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "837ad8168369fc9f19fc04c0992467a45652f7501f486f34f5d1a13794a8bc7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfbbdccc-8eeb-4a5d-beba-250fa9a84b31", "node_type": "1", "metadata": {"window": "We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S. ", "original_text": "First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year. "}, "hash": "32d3e244c28d4c0b5cd51aa817694524d59bdf97a2de4a16c4f9c49c493826b2", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we delivered solid performance and contribution from the US Oncology Network. ", "start_char_idx": 1555, "end_char_idx": 1653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfbbdccc-8eeb-4a5d-beba-250fa9a84b31": {"__data__": {"id_": "bfbbdccc-8eeb-4a5d-beba-250fa9a84b31", "embedding": null, "metadata": {"window": "We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S. ", "original_text": "First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e660c48d-28f8-4780-86b1-7fb4f030816a", "node_type": "1", "metadata": {"window": "The first quarter also marked further progress against our oncology growth strategy.  We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n", "original_text": "During the quarter, we delivered solid performance and contribution from the US Oncology Network. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cefbf88f183642fa615df986ef9e76c204e5969bd06003a9264381564f560a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43178e70-9803-4c6c-82a4-cbf7fe7cb1d8", "node_type": "1", "metadata": {"window": "We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter. ", "original_text": "The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n"}, "hash": "95d95bf836adc2acf13bb5bd1dd4305612e8069b7a904b53f5668a69cfe138f2", "class_name": "RelatedNodeInfo"}}, "text": "First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year. ", "start_char_idx": 1653, "end_char_idx": 1836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43178e70-9803-4c6c-82a4-cbf7fe7cb1d8": {"__data__": {"id_": "43178e70-9803-4c6c-82a4-cbf7fe7cb1d8", "embedding": null, "metadata": {"window": "We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter. ", "original_text": "The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfbbdccc-8eeb-4a5d-beba-250fa9a84b31", "node_type": "1", "metadata": {"window": "We're pleased with the \ngrowth acros s all of our oncology assets.  We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S. ", "original_text": "First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43f2f6bf4e84387cc655cb899e5537f9992bd038ad567adb9db979c872ee62bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c20d6a6e-aaf5-4f40-aea4-8e55cee6d421", "node_type": "1", "metadata": {"window": "During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S. ", "original_text": "These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n"}, "hash": "9c7514e106e015b43823cec8a3e56e39ab4528310652c534d1f137ba76bb0486", "class_name": "RelatedNodeInfo"}}, "text": "The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n", "start_char_idx": 1836, "end_char_idx": 2097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c20d6a6e-aaf5-4f40-aea4-8e55cee6d421": {"__data__": {"id_": "c20d6a6e-aaf5-4f40-aea4-8e55cee6d421", "embedding": null, "metadata": {"window": "During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S. ", "original_text": "These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43178e70-9803-4c6c-82a4-cbf7fe7cb1d8", "node_type": "1", "metadata": {"window": "We saw growth in the US Oncology Network, supported by the strength \nof our GPL capabilities, and as Brian mentioned, recently we added Cancer Center of Kansas to the US Oncology \nNetwork expanding the total number of providers in our network to over 2,400.  \n \n During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter. ", "original_text": "The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99e23dfa956505ced36f2e589a34105fb42d9a557fdd1be5e88c947b2813af93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "547a8aa2-c4d6-48ea-860e-ac981e46f27e", "node_type": "1", "metadata": {"window": "First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n", "original_text": "First quarter U.S. "}, "hash": "1e4b02dd3abce552ce046c91c5e3e7dc5224211d5512ba143953933a6de50521", "class_name": "RelatedNodeInfo"}}, "text": "These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n", "start_char_idx": 2097, "end_char_idx": 2290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "547a8aa2-c4d6-48ea-860e-ac981e46f27e": {"__data__": {"id_": "547a8aa2-c4d6-48ea-860e-ac981e46f27e", "embedding": null, "metadata": {"window": "First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n", "original_text": "First quarter U.S. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c20d6a6e-aaf5-4f40-aea4-8e55cee6d421", "node_type": "1", "metadata": {"window": "During the quarter, we delivered solid performance and contribution from the US Oncology Network.  First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S. ", "original_text": "These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "623e8e2601dadb2e129cddd31b53603d6bdd22fdf1c3d97447dab528905b1061", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faba1044-d1dd-4c87-9e6e-91ded01030ba", "node_type": "1", "metadata": {"window": "The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S. ", "original_text": "Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter. "}, "hash": "7a6ebdf58df8098a1ab8f22394c8e53fb60c6b00fe2935af7741d2ccf702532e", "class_name": "RelatedNodeInfo"}}, "text": "First quarter U.S. ", "start_char_idx": 2290, "end_char_idx": 2309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faba1044-d1dd-4c87-9e6e-91ded01030ba": {"__data__": {"id_": "faba1044-d1dd-4c87-9e6e-91ded01030ba", "embedding": null, "metadata": {"window": "The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S. ", "original_text": "Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "547a8aa2-c4d6-48ea-860e-ac981e46f27e", "node_type": "1", "metadata": {"window": "First quarter \nfiscal 2024 total patient visits were 19% above the prior -year and on the same practice basis, US oncology patient \nvisits grew approximately 7% above the prior year.  The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n", "original_text": "First quarter U.S. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "409bc9ad56a8700c500df61f8d69305140171c54df80be513f9bf1506a65a614", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3472a94a-0fec-4df4-9a9e-4923985e7805", "node_type": "1", "metadata": {"window": "These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n", "original_text": "When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S. "}, "hash": "11faf0c05d99a446c55755e537c5ac75da49d38045eafca4ae8051b155bf6509", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter. ", "start_char_idx": 2309, "end_char_idx": 2574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3472a94a-0fec-4df4-9a9e-4923985e7805": {"__data__": {"id_": "3472a94a-0fec-4df4-9a9e-4923985e7805", "embedding": null, "metadata": {"window": "These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n", "original_text": "When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faba1044-d1dd-4c87-9e6e-91ded01030ba", "node_type": "1", "metadata": {"window": "The joint venture with Sarah Cannon Research Institute is \nprogressing well, as we support the expansion and the advancement of clinical trials, and clinical trial research \nand we continued to inves t in and progress our data and insights business Ontada.  \n \n These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S. ", "original_text": "Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b374de59bfc87136c1f98f1c1705ff6718819dda6fec8e5d4d8157295b80ac91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f868f50a-00ae-4a8f-a9aa-4c9683fee3ba", "node_type": "1", "metadata": {"window": "First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions. ", "original_text": "Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n"}, "hash": "f5a1302c0607a4af48e9243992657d40dab1ddb0782f3441d50b8181c596a495", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S. ", "start_char_idx": 2574, "end_char_idx": 2681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f868f50a-00ae-4a8f-a9aa-4c9683fee3ba": {"__data__": {"id_": "f868f50a-00ae-4a8f-a9aa-4c9683fee3ba", "embedding": null, "metadata": {"window": "First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions. ", "original_text": "Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3472a94a-0fec-4df4-9a9e-4923985e7805", "node_type": "1", "metadata": {"window": "These oncology assets and capabilities are important pieces to the long -term development of this segment, and \nwe're excited about the growth and the continued progress that we're seeing.  \n \n First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n", "original_text": "When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33a14ab6d55e9f4472a02e089527997b9bca8ffdb9a2aa8edd556abca252983d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebc4d77e-c6f9-4e7f-a62b-35d3a252da44", "node_type": "1", "metadata": {"window": "Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes. ", "original_text": "U.S. "}, "hash": "52b9f3247ee5fb2b8cc9dde1377a2b1f5e852a2ce7989a7562034860c86edc22", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n", "start_char_idx": 2681, "end_char_idx": 2815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebc4d77e-c6f9-4e7f-a62b-35d3a252da44": {"__data__": {"id_": "ebc4d77e-c6f9-4e7f-a62b-35d3a252da44", "embedding": null, "metadata": {"window": "Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes. ", "original_text": "U.S. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f868f50a-00ae-4a8f-a9aa-4c9683fee3ba", "node_type": "1", "metadata": {"window": "First quarter U.S.  Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions. ", "original_text": "Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f41735b7dea1e8a9d4818dcd1557989e923d5467d8168e6c41fdff6eb69632d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a79def66-b7da-4220-9bda-a7a0a0546994", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions. ", "original_text": "Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n"}, "hash": "6b4936756085e4beaffa7f83a4fefc4e72e4ab3202ca8848bcc73c6f3a15d9a2", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 293, "end_char_idx": 298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a79def66-b7da-4220-9bda-a7a0a0546994": {"__data__": {"id_": "a79def66-b7da-4220-9bda-a7a0a0546994", "embedding": null, "metadata": {"window": "When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions. ", "original_text": "Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebc4d77e-c6f9-4e7f-a62b-35d3a252da44", "node_type": "1", "metadata": {"window": "Pharmaceutical operating profit increased 8% to $771 million driven by growth in the distribution \nof specialty products to providers in Health Systems and increased contributions from our generics programs, \nwhich included new product launches within the quarter.  When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes. ", "original_text": "U.S. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f5cec99a292fb175513060b43ea7644b1b99cb4071756146bf8a8c1759abc3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9635211e-a017-4700-bb6d-ce08042d5585", "node_type": "1", "metadata": {"window": "Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter. ", "original_text": "Let me move now to Prescription Technology Solutions. "}, "hash": "b8dd811fede5a4808a2af5508b40a834b022af5f9f2a3e6acc59c1b85191ae1b", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n", "start_char_idx": 2820, "end_char_idx": 3090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9635211e-a017-4700-bb6d-ce08042d5585": {"__data__": {"id_": "9635211e-a017-4700-bb6d-ce08042d5585", "embedding": null, "metadata": {"window": "Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter. ", "original_text": "Let me move now to Prescription Technology Solutions. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a79def66-b7da-4220-9bda-a7a0a0546994", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19 vaccine \ndistribution in the first quarter of fiscal 2023, the U.S.  Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions. ", "original_text": "Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c47aa742ba8fd1e41750d781eebe0ec5c4fb11429cd48907b613936072d46a0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "313e1abb-2d70-4831-9e4c-dcb19fcc80ad", "node_type": "1", "metadata": {"window": "U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n", "original_text": "First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes. "}, "hash": "f0a4e804421f639cbf7d17dbf6dfffb07dfe42989a00857024ae352d5f7e750e", "class_name": "RelatedNodeInfo"}}, "text": "Let me move now to Prescription Technology Solutions. ", "start_char_idx": 3090, "end_char_idx": 3144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "313e1abb-2d70-4831-9e4c-dcb19fcc80ad": {"__data__": {"id_": "313e1abb-2d70-4831-9e4c-dcb19fcc80ad", "embedding": null, "metadata": {"window": "U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n", "original_text": "First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9635211e-a017-4700-bb6d-ce08042d5585", "node_type": "1", "metadata": {"window": "Pharmaceutical segment delivered operating profit growth of \n14% year -over-year ahead of the segment's long -term growth target.  \n \n U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter. ", "original_text": "Let me move now to Prescription Technology Solutions. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af984b8509233968c0e01f9194502c407202aff1ecdded217d4dc0fd569e6fb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cc67925-606c-4d90-bca2-caec2a45c78d", "node_type": "1", "metadata": {"window": "Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n", "original_text": "Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions. "}, "hash": "add960d6e325fb4bfa3321d84b1c906a791d4f3eb1ac3cd8e56aac9ebc0dbf7b", "class_name": "RelatedNodeInfo"}}, "text": "First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes. ", "start_char_idx": 3144, "end_char_idx": 3345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cc67925-606c-4d90-bca2-caec2a45c78d": {"__data__": {"id_": "8cc67925-606c-4d90-bca2-caec2a45c78d", "embedding": null, "metadata": {"window": "Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n", "original_text": "Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "313e1abb-2d70-4831-9e4c-dcb19fcc80ad", "node_type": "1", "metadata": {"window": "U.S.  Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n", "original_text": "First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a5765f22e451ec3f2aa9db7c0e6ff01a4bbdefbdfc612c3274d6b9d1102779c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85fbe087-f27c-4290-a0bd-16892e6c60d7", "node_type": "1", "metadata": {"window": "Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends. ", "original_text": "As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter. "}, "hash": "614d36786022e9fd34be4beacd1741d15c18ece0d8d958df02e141bc459506b6", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions. ", "start_char_idx": 3345, "end_char_idx": 3476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85fbe087-f27c-4290-a0bd-16892e6c60d7": {"__data__": {"id_": "85fbe087-f27c-4290-a0bd-16892e6c60d7", "embedding": null, "metadata": {"window": "Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends. ", "original_text": "As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cc67925-606c-4d90-bca2-caec2a45c78d", "node_type": "1", "metadata": {"window": "Pharmaceutical operating profit growth reflects increased prescription volumes and the breadth of \ncapabilities that we provide, including solid generic volumes and sourcing contributions, operating discipline and \nthe continued momentum from our oncology platform.  \n \n Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n", "original_text": "Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd90f08fbed466022a8e113fe04fa2ba0d6fce87f702e897d3fc587b00cb6854", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3580dff-3b29-4e4d-aa68-95707b01a5cf", "node_type": "1", "metadata": {"window": "First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends.  Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "original_text": "The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n"}, "hash": "7e20f882a8527bf863ccef01be0a6a597ab55e450f6e98d2291fe159415b0dfd", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter. ", "start_char_idx": 3476, "end_char_idx": 3589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3580dff-3b29-4e4d-aa68-95707b01a5cf": {"__data__": {"id_": "d3580dff-3b29-4e4d-aa68-95707b01a5cf", "embedding": null, "metadata": {"window": "First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends.  Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "original_text": "The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85fbe087-f27c-4290-a0bd-16892e6c60d7", "node_type": "1", "metadata": {"window": "Let me move now to Prescription Technology Solutions.  First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends. ", "original_text": "As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c17853185ae062bbc04160e52b6123faa93bb19d81791b652813b25953389c7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a52085a1-f773-4800-a20b-fd2fb90ac7e9", "node_type": "1", "metadata": {"window": "Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends.  Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "original_text": "During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n"}, "hash": "3ee8e86efc3c50997e13f55896f432a3070f592de55540a963d64817d6c1892d", "class_name": "RelatedNodeInfo"}}, "text": "The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n", "start_char_idx": 3589, "end_char_idx": 3716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a52085a1-f773-4800-a20b-fd2fb90ac7e9": {"__data__": {"id_": "a52085a1-f773-4800-a20b-fd2fb90ac7e9", "embedding": null, "metadata": {"window": "Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends.  Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "original_text": "During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3580dff-3b29-4e4d-aa68-95707b01a5cf", "node_type": "1", "metadata": {"window": "First quarter revenues were $1.2 billion, an increase of \n17% year -over-year driven by growth in our third -party logistics and technology services businesses due to \nincreased prescription volu mes.  Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends.  Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "original_text": "The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc1909234aef7bbb78c55f42c51eedae0a5ab59e4f558f0820fd24c6615f2c21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3b49551-b09d-4788-bff8-cd7e4ba8e921", "node_type": "1", "metadata": {"window": "As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends.  Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "original_text": "The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends. "}, "hash": "657177eb07bb3f33c7c232d571b324e182d1cf730437958fc78a108c1090415d", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n", "start_char_idx": 3716, "end_char_idx": 3826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3b49551-b09d-4788-bff8-cd7e4ba8e921": {"__data__": {"id_": "b3b49551-b09d-4788-bff8-cd7e4ba8e921", "embedding": null, "metadata": {"window": "As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends.  Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "original_text": "The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a52085a1-f773-4800-a20b-fd2fb90ac7e9", "node_type": "1", "metadata": {"window": "Operating profit increased 35% to $223 million driven by increasing demand for \nour access, adherence and affordability solutions.  As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends.  Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "original_text": "During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c99cf6ea896c04f081b4c8dca54b1e78b1f861acfa00212ed34e653ca5a7d7c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "badee450-5035-42a9-8032-266c0f648e7b", "node_type": "1", "metadata": {"window": "The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends.  Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "original_text": "Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n "}, "hash": "2a21f68ee027288cfd12af22b9fe4727cde8573366a0c9b71357e523ae18e4da", "class_name": "RelatedNodeInfo"}}, "text": "The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends. ", "start_char_idx": 3826, "end_char_idx": 3991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "badee450-5035-42a9-8032-266c0f648e7b": {"__data__": {"id_": "badee450-5035-42a9-8032-266c0f648e7b", "embedding": null, "metadata": {"window": "The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends.  Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "original_text": "Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a45bd5bb673105f3e29b055675318de08cbd0b235b09273d0b7c26cea11227b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3b49551-b09d-4788-bff8-cd7e4ba8e921", "node_type": "1", "metadata": {"window": "As I mentioned earlier in my remarks, prescription transaction \nvolumes showed solid improvement in the quarter.  The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends.  Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "original_text": "The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends. ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f23d1fb4a1fb9bc6102ba50d40ebc94f2aa4e49517bff0ba885b5cdd6f5f1b53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "081cb9d3-b446-4102-964d-0e15bea0212b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "bd1f1cfc33c6157b8cddfedb128e24d5638cab8715747ba9f79be9eb185a6b3c", "class_name": "RelatedNodeInfo"}}, "text": "Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "start_char_idx": 3991, "end_char_idx": 4113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "081cb9d3-b446-4102-964d-0e15bea0212b": {"__data__": {"id_": "081cb9d3-b446-4102-964d-0e15bea0212b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "badee450-5035-42a9-8032-266c0f648e7b", "node_type": "1", "metadata": {"window": "The incre ased transaction volume drove higher demand for \nour access programs including our prior authorization products.  \n \n During the quarter, we noted strong new brand prescription volumes, which included the GLP -1 drug category. \n The strength of our program support ing access and affordability solutions positions us to capture the demand \ndriven by the strong prescription utilization trends.  Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "original_text": "Our products continue to receive positive feedback and \nrecognition for the value that they delivered to our partners.  \n ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfbebd9c7d15b9cc10b46115db1393759ab804863c720e7686d2ec48956380ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce409c7c-12d2-4379-a7a7-a387b1b8f011", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions. "}, "hash": "bd40f10034b0fbc8b8d68d0625379ee4220e665cda6fc2e24d7a0d859efb6164", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce409c7c-12d2-4379-a7a7-a387b1b8f011": {"__data__": {"id_": "ce409c7c-12d2-4379-a7a7-a387b1b8f011", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "081cb9d3-b446-4102-964d-0e15bea0212b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2eeb23bff2a34dfeaf31e74bbe165054c35272d47822dc529f5db8c81318e52d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4547e0d-238a-4e97-83d3-b7c68330ea74", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n", "original_text": "Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers. "}, "hash": "4c828baaa0c2521174eda21cddc3a804ae95ccbb97133a099056bdcf0468230e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions. ", "start_char_idx": 16, "end_char_idx": 258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4547e0d-238a-4e97-83d3-b7c68330ea74": {"__data__": {"id_": "f4547e0d-238a-4e97-83d3-b7c68330ea74", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n", "original_text": "Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce409c7c-12d2-4379-a7a7-a387b1b8f011", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fb8d8e204274db5d668ed4e274f9f50ece1f788dec1ff89c6bb6e0107c56149", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a9e56ce-399c-437e-9b34-1352df18d70b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations. ", "original_text": "Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n"}, "hash": "0602ab37730eeaf86fc40ebf937f217db2e71f54ca5c4af6f1eeeca1c6e0f9db", "class_name": "RelatedNodeInfo"}}, "text": "Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers. ", "start_char_idx": 258, "end_char_idx": 359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a9e56ce-399c-437e-9b34-1352df18d70b": {"__data__": {"id_": "6a9e56ce-399c-437e-9b34-1352df18d70b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations. ", "original_text": "Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4547e0d-238a-4e97-83d3-b7c68330ea74", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n", "original_text": "Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d5213b82354997d7138ba8895fa031532bab9007c9cbd7e46325f483db5e870", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a83d2a0-207f-411a-b4b4-5bec825aad7b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth. ", "original_text": "CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows. "}, "hash": "b89e7af8e0f717c9b6a5dcdc566d871de24569a218e34469e373e6b30392b5df", "class_name": "RelatedNodeInfo"}}, "text": "Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n", "start_char_idx": 359, "end_char_idx": 536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a83d2a0-207f-411a-b4b4-5bec825aad7b": {"__data__": {"id_": "3a83d2a0-207f-411a-b4b4-5bec825aad7b", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth. ", "original_text": "CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a9e56ce-399c-437e-9b34-1352df18d70b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations. ", "original_text": "Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7f762ff2d1770fd85ffc149d8b2bf886551cf578bc96dd97b3e5ae8faf94c25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b71ad006-aec7-42c4-9a20-e69a0159be33", "node_type": "1", "metadata": {"window": "Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%. ", "original_text": "First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n"}, "hash": "1942cfff0bbbe38fe9fdfdcc1be7c42d3219ff8fd4a013d50559a888f9a539da", "class_name": "RelatedNodeInfo"}}, "text": "CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows. ", "start_char_idx": 536, "end_char_idx": 822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b71ad006-aec7-42c4-9a20-e69a0159be33": {"__data__": {"id_": "b71ad006-aec7-42c4-9a20-e69a0159be33", "embedding": null, "metadata": {"window": "Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%. ", "original_text": "First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a83d2a0-207f-411a-b4b4-5bec825aad7b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth. ", "original_text": "CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "232b08fd2c9d4128e1a175593fa090c7a88db0cf45f57e59e21f94d676974725", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1268891f-bdd7-4d94-8a31-5440f28938cf", "node_type": "1", "metadata": {"window": "Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n", "original_text": "In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations. "}, "hash": "93a7993ffe809dfaca33aad05f793b40176f2a1c9065f5d13dc12595ea914c41", "class_name": "RelatedNodeInfo"}}, "text": "First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n", "start_char_idx": 822, "end_char_idx": 937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1268891f-bdd7-4d94-8a31-5440f28938cf": {"__data__": {"id_": "1268891f-bdd7-4d94-8a31-5440f28938cf", "embedding": null, "metadata": {"window": "Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n", "original_text": "In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b71ad006-aec7-42c4-9a20-e69a0159be33", "node_type": "1", "metadata": {"window": "Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%. ", "original_text": "First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67e420c29589b72a737b5cdf9bd321829594ea3de3e01260469b8123f73e3145", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a77a990-ee66-42db-ab3c-6cf29970be1e", "node_type": "1", "metadata": {"window": "CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products. ", "original_text": "Our core business \ndemonstrated revenue and operating profit growth. "}, "hash": "8949c166377ae51151bad0173697c5b07c82958bca6890b15c895db98aa29c1e", "class_name": "RelatedNodeInfo"}}, "text": "In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations. ", "start_char_idx": 937, "end_char_idx": 1036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a77a990-ee66-42db-ab3c-6cf29970be1e": {"__data__": {"id_": "0a77a990-ee66-42db-ab3c-6cf29970be1e", "embedding": null, "metadata": {"window": "CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products. ", "original_text": "Our core business \ndemonstrated revenue and operating profit growth. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1268891f-bdd7-4d94-8a31-5440f28938cf", "node_type": "1", "metadata": {"window": "Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n", "original_text": "In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1507fd6c5f68c2197f8c9c9647483d518e61c9e697c2922a4c69ee880e878018", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc4c0568-d9a9-4352-be98-ac4d82cf6fd6", "node_type": "1", "metadata": {"window": "First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n", "original_text": "Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%. "}, "hash": "b0ee8e01368eab26bdb760dad5a0388372bbdacd1f65e344852af1d123b9a35d", "class_name": "RelatedNodeInfo"}}, "text": "Our core business \ndemonstrated revenue and operating profit growth. ", "start_char_idx": 1036, "end_char_idx": 1105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc4c0568-d9a9-4352-be98-ac4d82cf6fd6": {"__data__": {"id_": "fc4c0568-d9a9-4352-be98-ac4d82cf6fd6", "embedding": null, "metadata": {"window": "First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n", "original_text": "Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a77a990-ee66-42db-ab3c-6cf29970be1e", "node_type": "1", "metadata": {"window": "CoverMyMeds is delivering value and returns for our partners, by increasing connectivity between pharmacies, \nproviders, payers and biopharma manufactures through next generat ion access, affordability and adherence \nsolutions that are automated and integrated into provider workflows.  First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products. ", "original_text": "Our core business \ndemonstrated revenue and operating profit growth. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20e8aa4892cf55f745acba2fd01eef232119f3a21e30c42d2b7b2fb1b2d7c8cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed3c1bdd-0cb2-4ef2-bfda-65ddc77ae0c9", "node_type": "1", "metadata": {"window": "In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals. ", "original_text": "First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n"}, "hash": "c188345e6a9b66515fb44b8d42ca58b176228ac8003d4647cc2b6aac501d877b", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%. ", "start_char_idx": 1105, "end_char_idx": 1241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed3c1bdd-0cb2-4ef2-bfda-65ddc77ae0c9": {"__data__": {"id_": "ed3c1bdd-0cb2-4ef2-bfda-65ddc77ae0c9", "embedding": null, "metadata": {"window": "In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals. ", "original_text": "First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc4c0568-d9a9-4352-be98-ac4d82cf6fd6", "node_type": "1", "metadata": {"window": "First quarter results exemplified the success \nof our broad range of technology programs and support services.  \n \n In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n", "original_text": "Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cf1c65f47a0124e21ba6278d1d5b27f6755c8de023d4fca9f69880f6a2858c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0024a5d9-4472-4c6b-b60e-cffb9144fe0a", "node_type": "1", "metadata": {"window": "Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements. ", "original_text": "As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products. "}, "hash": "3030cc16616c4919787080ab7ab3c56f91be5c602deaa07dee05e8a36d03c08a", "class_name": "RelatedNodeInfo"}}, "text": "First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n", "start_char_idx": 1241, "end_char_idx": 1536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0024a5d9-4472-4c6b-b60e-cffb9144fe0a": {"__data__": {"id_": "0024a5d9-4472-4c6b-b60e-cffb9144fe0a", "embedding": null, "metadata": {"window": "Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements. ", "original_text": "As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed3c1bdd-0cb2-4ef2-bfda-65ddc77ae0c9", "node_type": "1", "metadata": {"window": "In Medical -Surgical Solutions, our f irst quarter performance was in -line with our expectations.  Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals. ", "original_text": "First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a46ecd7e7673d19448447270578f63504b74e652a654ec423142570ff88777f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c46be7a3-81a4-4cad-986f-541bc4722222", "node_type": "1", "metadata": {"window": "Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n", "original_text": "When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n"}, "hash": "705f9314e0cfd712458ad7f0dabeff2c02944a44ceb874e1c75f9164584188f1", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products. ", "start_char_idx": 1536, "end_char_idx": 1693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c46be7a3-81a4-4cad-986f-541bc4722222": {"__data__": {"id_": "c46be7a3-81a4-4cad-986f-541bc4722222", "embedding": null, "metadata": {"window": "Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n", "original_text": "When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0024a5d9-4472-4c6b-b60e-cffb9144fe0a", "node_type": "1", "metadata": {"window": "Our core business \ndemonstrated revenue and operating profit growth.  Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements. ", "original_text": "As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95dd9e4d633fff71a1245515d929f481d5b2ae533b74db878b41afd39f044bdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9848bb70-5369-4f27-978e-226eb7a49de0", "node_type": "1", "metadata": {"window": "First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results. ", "original_text": "Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals. "}, "hash": "ec3ffc9f3861e33e57214ec041a1e90ac349246066b06c55cd900c046a7ba691", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n", "start_char_idx": 1693, "end_char_idx": 1965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9848bb70-5369-4f27-978e-226eb7a49de0": {"__data__": {"id_": "9848bb70-5369-4f27-978e-226eb7a49de0", "embedding": null, "metadata": {"window": "First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results. ", "original_text": "Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c46be7a3-81a4-4cad-986f-541bc4722222", "node_type": "1", "metadata": {"window": "Revenues were $2.6 billion in the quarter, an increase of 1% \nyear-over-year and operating profit was $235 million, a decrease of  12%.  First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n", "original_text": "When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c28e02c5c7b4d66402a2024d8513b7d007d07d4dbf2257693c31a8fba15b45e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e53dd68-f6e4-4dac-8840-1c52ce89f5be", "node_type": "1", "metadata": {"window": "As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%. ", "original_text": "In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements. "}, "hash": "70678b0b58dfbf8d1c4fc8f819e570a54cd813a0a9560ea5045ac54d0212d390", "class_name": "RelatedNodeInfo"}}, "text": "Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals. ", "start_char_idx": 1965, "end_char_idx": 2071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e53dd68-f6e4-4dac-8840-1c52ce89f5be": {"__data__": {"id_": "1e53dd68-f6e4-4dac-8840-1c52ce89f5be", "embedding": null, "metadata": {"window": "As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%. ", "original_text": "In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9848bb70-5369-4f27-978e-226eb7a49de0", "node_type": "1", "metadata": {"window": "First quarter results were impacted by \nanticipated lower contributions in the kitting, storage and distribution of ancillary supplies for the US Government's \nCOVID -19 vaccine program and lower illness season testing, including flu and COVID -19 tests,  when compared \nto the prior -year.  \n \n As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results. ", "original_text": "Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be3e862b6cdb5d35cf6ef15c91f9380a1f6927090e060370d4b627cbb83043cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "387e23e8-b0d3-4d92-8850-5a1495cadfc0", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%. ", "original_text": "We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n"}, "hash": "03f7856f891d3ec7bdac7d4c1f840fbe73e5b4e7ce15339c57ce64df79bb19af", "class_name": "RelatedNodeInfo"}}, "text": "In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements. ", "start_char_idx": 2071, "end_char_idx": 2205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "387e23e8-b0d3-4d92-8850-5a1495cadfc0": {"__data__": {"id_": "387e23e8-b0d3-4d92-8850-5a1495cadfc0", "embedding": null, "metadata": {"window": "When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%. ", "original_text": "We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e53dd68-f6e4-4dac-8840-1c52ce89f5be", "node_type": "1", "metadata": {"window": "As a reminder, the first quarter of fiscal 2023 saw an extension of the 2022 illness season driving higher -levels of \nillness testing and related products.  When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%. ", "original_text": "In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6968a0fa043f6627f5496a6c4b66383346744a7d8fdc9a0d45046a23fd3d322f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47fdb188-097e-4633-8f4e-8b629c17e189", "node_type": "1", "metadata": {"window": "Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n", "original_text": "Next, let me address our international results. "}, "hash": "2e528a52f25afcb7ffa319e1ccc28cc3e7f82165597db9438ce2636a496686aa", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n", "start_char_idx": 2205, "end_char_idx": 2428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47fdb188-097e-4633-8f4e-8b629c17e189": {"__data__": {"id_": "47fdb188-097e-4633-8f4e-8b629c17e189", "embedding": null, "metadata": {"window": "Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n", "original_text": "Next, let me address our international results. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "387e23e8-b0d3-4d92-8850-5a1495cadfc0", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-related items from the first  quarter \nof fiscal 2023, the segment delivered operating profit growth of 7% driven by growth in the extended and primary \ncare businesses, partially offset by a nonrecurring expense of $12 million.  \n \n Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%. ", "original_text": "We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1528e6683f533729c9544e5a27d9592d7e0289131e3e3e4b74edc06fac106b05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7848ab05-e927-41db-97f5-2976f0245d0a", "node_type": "1", "metadata": {"window": "In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review. ", "original_text": "Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%. "}, "hash": "75cf2aea73a86182345b9d6ef11dd6f3f24018aad75554abec09ce62d76f3a73", "class_name": "RelatedNodeInfo"}}, "text": "Next, let me address our international results. ", "start_char_idx": 2428, "end_char_idx": 2476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7848ab05-e927-41db-97f5-2976f0245d0a": {"__data__": {"id_": "7848ab05-e927-41db-97f5-2976f0245d0a", "embedding": null, "metadata": {"window": "In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review. ", "original_text": "Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47fdb188-097e-4633-8f4e-8b629c17e189", "node_type": "1", "metadata": {"window": "Within the primary care market, we saw growth in lab solu tions, equipment and specialty pharmaceuticals.  In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n", "original_text": "Next, let me address our international results. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1f9806d849c6202f4888354e9e7ee0a3ad765056f6580b6311d4d1d373bec9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "494fd32d-4c50-4008-b66a-c3aa6f0d5e3e", "node_type": "1", "metadata": {"window": "We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year. ", "original_text": "On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%. "}, "hash": "aca47009a8204b5d9b358399e1e64f566d2995258bbd9280e96bb66b985c5d8f", "class_name": "RelatedNodeInfo"}}, "text": "Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%. ", "start_char_idx": 2476, "end_char_idx": 2617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "494fd32d-4c50-4008-b66a-c3aa6f0d5e3e": {"__data__": {"id_": "494fd32d-4c50-4008-b66a-c3aa6f0d5e3e", "embedding": null, "metadata": {"window": "We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year. ", "original_text": "On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7848ab05-e927-41db-97f5-2976f0245d0a", "node_type": "1", "metadata": {"window": "In the \nextended care market, growth was led by sales to new customers, which included increased volumes of \nnutritional supplements.  We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review. ", "original_text": "Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7e943946ac6cb6f6c26274cbf9920913bea119cad7c1ab16fa40787f41f7c2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "747671b9-939f-4344-9923-f77e83dc3ffb", "node_type": "1", "metadata": {"window": "Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n", "original_text": "First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n"}, "hash": "478767f9c6a5b8903225106470e7d46a7fc037a16144491af43f96995492402b", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%. ", "start_char_idx": 2617, "end_char_idx": 2762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "747671b9-939f-4344-9923-f77e83dc3ffb": {"__data__": {"id_": "747671b9-939f-4344-9923-f77e83dc3ffb", "embedding": null, "metadata": {"window": "Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n", "original_text": "First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "494fd32d-4c50-4008-b66a-c3aa6f0d5e3e", "node_type": "1", "metadata": {"window": "We are pleased with the continued solid results, which are in line with our expectations, \nour leadership position combined with operating execution positions us for continued growth across the ultimate \nsites of care.  \n \n Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year. ", "original_text": "On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1871aab98c365b1013d0ce6ddd3674054254b7a21ebd7f07bb87dfc25118fea3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbe617d2-24e9-4c5e-ae9c-4d935c61ffc2", "node_type": "1", "metadata": {"window": "Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n", "original_text": "And let me wrap -up our segment review. "}, "hash": "1cba0df2ac52f2023b1aab7bca94ec857ffde234410ea315d7611130a29bccf3", "class_name": "RelatedNodeInfo"}}, "text": "First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n", "start_char_idx": 2762, "end_char_idx": 2888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbe617d2-24e9-4c5e-ae9c-4d935c61ffc2": {"__data__": {"id_": "fbe617d2-24e9-4c5e-ae9c-4d935c61ffc2", "embedding": null, "metadata": {"window": "Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n", "original_text": "And let me wrap -up our segment review. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "747671b9-939f-4344-9923-f77e83dc3ffb", "node_type": "1", "metadata": {"window": "Next, let me address our international results.  Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n", "original_text": "First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63a9e1126e8933af963dffe1d4be4a3a56dbf7570361b9de6aaa1c8b538a4d38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b167d256-b3e5-4dc6-a6d1-65f06e3b3c6a", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies. ", "original_text": "Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year. "}, "hash": "d7f86905204a52c94312531db9d88ef46294d54a68a2c213011c9b151873b629", "class_name": "RelatedNodeInfo"}}, "text": "And let me wrap -up our segment review. ", "start_char_idx": 2888, "end_char_idx": 2928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b167d256-b3e5-4dc6-a6d1-65f06e3b3c6a": {"__data__": {"id_": "b167d256-b3e5-4dc6-a6d1-65f06e3b3c6a", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies. ", "original_text": "Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbe617d2-24e9-4c5e-ae9c-4d935c61ffc2", "node_type": "1", "metadata": {"window": "Revenues in the first quarter were $3.5 billion, a decrease of 47%  \nyear-over-year and operating profit was $90 million, a decrease of 35%.  On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n", "original_text": "And let me wrap -up our segment review. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc86d96e97a5bdf886bf5e684b989b33b92886ae0c4ecb2a6f6f1d89b71b4b9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23a2a383-1d57-4902-8574-698e99ff81df", "node_type": "1", "metadata": {"window": "First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n", "original_text": "As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n"}, "hash": "deb6c6cee8664ca3399268439b7f1b92745079f1a1c762c740faabcf73516cb7", "class_name": "RelatedNodeInfo"}}, "text": "Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year. ", "start_char_idx": 2928, "end_char_idx": 3016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23a2a383-1d57-4902-8574-698e99ff81df": {"__data__": {"id_": "23a2a383-1d57-4902-8574-698e99ff81df", "embedding": null, "metadata": {"window": "First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n", "original_text": "As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b167d256-b3e5-4dc6-a6d1-65f06e3b3c6a", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, first quarter \nrevenues were $3.7 billion, a decrease of 44%, and operating profit was $95 million, a decrease of 31%.  First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies. ", "original_text": "Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01bea4cebf018e6f5d30cefad549be1ccf5fce90057d28f35a7f2c3dc81dc559", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ef21995-b87f-44a1-8c63-25339853d894", "node_type": "1", "metadata": {"window": "And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "original_text": "During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n"}, "hash": "9d8b0e79787be9ec9a61e973e3db55526d0947dd566a03255c6a99aebe4a3122", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n", "start_char_idx": 3016, "end_char_idx": 3225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ef21995-b87f-44a1-8c63-25339853d894": {"__data__": {"id_": "1ef21995-b87f-44a1-8c63-25339853d894", "embedding": null, "metadata": {"window": "And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "original_text": "During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23a2a383-1d57-4902-8574-698e99ff81df", "node_type": "1", "metadata": {"window": "First \nquarter results reflect the year -over-year effects from the combined divestitures within our European businesses.  \n \n And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n", "original_text": "As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6024367c4bda20fefb56ff1818a51d221188e8594f0e9eed65eab470ba2e80af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2604d4a-ee67-44db-90b2-704866438a4c", "node_type": "1", "metadata": {"window": "Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "original_text": "As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies. "}, "hash": "c41fe32166f45722e422130ac01fa8d6161e38230ecf358172a933b9097e4701", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n", "start_char_idx": 3225, "end_char_idx": 3473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2604d4a-ee67-44db-90b2-704866438a4c": {"__data__": {"id_": "a2604d4a-ee67-44db-90b2-704866438a4c", "embedding": null, "metadata": {"window": "Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "original_text": "As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ef21995-b87f-44a1-8c63-25339853d894", "node_type": "1", "metadata": {"window": "And let me wrap -up our segment review.  Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "original_text": "During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bb0a1b527f8eb2657b5bd83c0ea0465dc5134e49e2e9229e55b025da563e834", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61a83e01-7dae-40b6-8ac6-384705d0622a", "node_type": "1", "metadata": {"window": "As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "original_text": "We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n"}, "hash": "972b1c3afc799cb51635e6468b44024e69481614097e1e457aa85d04db6f643b", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies. ", "start_char_idx": 3473, "end_char_idx": 3608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61a83e01-7dae-40b6-8ac6-384705d0622a": {"__data__": {"id_": "61a83e01-7dae-40b6-8ac6-384705d0622a", "embedding": null, "metadata": {"window": "As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "original_text": "We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2604d4a-ee67-44db-90b2-704866438a4c", "node_type": "1", "metadata": {"window": "Corporate expenses were $149 million in the quarter, an increase of 3% \nyear-over-year.  As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "original_text": "As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies. ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30ea8c7211cd52b7cb327520b1955b4721f03e553f21e93db1ff58bb55125ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c93640b8-6072-438a-814d-f2e5a8da02ce", "node_type": "1", "metadata": {"window": "During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "original_text": "The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n "}, "hash": "50a676ea0b6440ecc69f3432f3330ea0b1c5f4d53c625326981cade4a21aa624", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n", "start_char_idx": 3608, "end_char_idx": 3704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c93640b8-6072-438a-814d-f2e5a8da02ce": {"__data__": {"id_": "c93640b8-6072-438a-814d-f2e5a8da02ce", "embedding": null, "metadata": {"window": "During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "original_text": "The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c70fbde30267efc70e597b0d85c1bd310792f5ba91c4101fdc4588a564d05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61a83e01-7dae-40b6-8ac6-384705d0622a", "node_type": "1", "metadata": {"window": "As a reminder, in the first quarter of fiscal 202 3, corporate expenses included the receipt of a \npayment relating to a prior tax receivable agreement and our previous joint venture with change health care. \n During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "original_text": "We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "185b9e5d76093741aa79b4409147f69d757d3410cd19d716f8b8c7eecf7deec2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25814a57-ec6c-45bb-b159-8f0578441fe2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "53604c6cc371c0f11f075f8a0268b7ca882e97aa296bef17b0f8c85c513b9521", "class_name": "RelatedNodeInfo"}}, "text": "The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "start_char_idx": 3704, "end_char_idx": 3975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25814a57-ec6c-45bb-b159-8f0578441fe2": {"__data__": {"id_": "25814a57-ec6c-45bb-b159-8f0578441fe2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c93640b8-6072-438a-814d-f2e5a8da02ce", "node_type": "1", "metadata": {"window": "During the quarter, we had losses of $7 million or $0.04 per share related to equity investments wi thin the \nMcKesson Ventures portfolio, compared to losses of approximately $22 million or $0.11 per share in the first \nquarter of fiscal 2023.  \n \n As a reminder the McKesson Ventures portfolio holds equity investments in several growth stage digital health \nand services companies.  We're pleased with the insights and the results that we've obtained through this portfolio.  \n \n The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "original_text": "The impacts on our consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter and as a resu lt, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  \n ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3208b0023fd353b8c5ed97a79e5e24321731d0a46d5ff76d5015d3a757643c5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1dc3eaa-932b-4d4b-8d8e-50b2cd440e7d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12. "}, "hash": "4f87186ba592e7f2e68f457e515e2c67953e2e3e33c1bc3dddf25abed0dc266a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1dc3eaa-932b-4d4b-8d8e-50b2cd440e7d": {"__data__": {"id_": "e1dc3eaa-932b-4d4b-8d8e-50b2cd440e7d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25814a57-ec6c-45bb-b159-8f0578441fe2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b75648930455837fa08979f1425972877d95e21d904dd88fd1f832fac5a2337", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2539d410-ea5b-40cc-977b-d4caca3cddf4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments. ", "original_text": "We ended the quarter with \n$2.6 billion in cash an d cash equivalents. "}, "hash": "0dbba5cfaa391f4de7864ad45c02c74949ff059a97f3a0dc2f56679fbe21d8dd", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12. ", "start_char_idx": 16, "end_char_idx": 264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2539d410-ea5b-40cc-977b-d4caca3cddf4": {"__data__": {"id_": "2539d410-ea5b-40cc-977b-d4caca3cddf4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments. ", "original_text": "We ended the quarter with \n$2.6 billion in cash an d cash equivalents. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1dc3eaa-932b-4d4b-8d8e-50b2cd440e7d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cb9179d8296856bce2ef3e79e823a7a2cf2758790c773d755db635ec394e24a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ccc4995-6b83-413a-a2bb-7a081b6364d6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors. ", "original_text": "We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n"}, "hash": "84f4dbc56acb7e59d7342f960ed15892d87850025183c9278ecb19d7c4a34c73", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with \n$2.6 billion in cash an d cash equivalents. ", "start_char_idx": 264, "end_char_idx": 335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ccc4995-6b83-413a-a2bb-7a081b6364d6": {"__data__": {"id_": "5ccc4995-6b83-413a-a2bb-7a081b6364d6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors. ", "original_text": "We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2539d410-ea5b-40cc-977b-d4caca3cddf4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments. ", "original_text": "We ended the quarter with \n$2.6 billion in cash an d cash equivalents. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9184be475a7e9e50c26e5f1ff02637abed8e7d39adf210b45376503db3b3c947", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a10e04d1-1aed-40c6-ae21-ceab48a1c682", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024. ", "original_text": "For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n"}, "hash": "9d6d6b2b79c52e1f8e94dc3ece68ff478743e34332757d3db045de71b2641e4d", "class_name": "RelatedNodeInfo"}}, "text": "We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n", "start_char_idx": 335, "end_char_idx": 548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a10e04d1-1aed-40c6-ae21-ceab48a1c682": {"__data__": {"id_": "a10e04d1-1aed-40c6-ae21-ceab48a1c682", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024. ", "original_text": "For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ccc4995-6b83-413a-a2bb-7a081b6364d6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors. ", "original_text": "We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe5cbfdec5e3f83ac458306dddfb41fd6add65d7a74e21f267827239bd6b19e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cd9719d-b368-4c78-932d-b4e003d5fc52", "node_type": "1", "metadata": {"window": "We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n", "original_text": "We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments. "}, "hash": "f37106978ca263582a4a1f97d2a1f4f424760457ec92ef550b3d882ec7a2560e", "class_name": "RelatedNodeInfo"}}, "text": "For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n", "start_char_idx": 548, "end_char_idx": 861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cd9719d-b368-4c78-932d-b4e003d5fc52": {"__data__": {"id_": "7cd9719d-b368-4c78-932d-b4e003d5fc52", "embedding": null, "metadata": {"window": "We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n", "original_text": "We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a10e04d1-1aed-40c6-ae21-ceab48a1c682", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024. ", "original_text": "For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "948878d71743b3fee1a68c3d9e5e8704727497243ddf76e1f26872b0ff12ffe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a575ea26-79c6-4340-a8e3-1b0ed1327327", "node_type": "1", "metadata": {"window": "We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July. ", "original_text": "During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors. "}, "hash": "4cfce4d2e0726c6922159c60a47b8dea75b4203a9980fc3eac984f225e3d793e", "class_name": "RelatedNodeInfo"}}, "text": "We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments. ", "start_char_idx": 861, "end_char_idx": 1000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a575ea26-79c6-4340-a8e3-1b0ed1327327": {"__data__": {"id_": "a575ea26-79c6-4340-a8e3-1b0ed1327327", "embedding": null, "metadata": {"window": "We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July. ", "original_text": "During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cd9719d-b368-4c78-932d-b4e003d5fc52", "node_type": "1", "metadata": {"window": "We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n", "original_text": "We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f27fd6b973c2def3db3dcfdd2ebbeee4d36a8d7296df814c5a07f4495500e4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6af93a8f-53f6-4b83-a156-6d5df1c43ac2", "node_type": "1", "metadata": {"window": "For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion. ", "original_text": "Concurrently, we retired approximately $900 million of notes that were due March of \n2024. "}, "hash": "b29ff2d93fb5f482d094a2b2f4bb8c73ad1f3069a9f42d6de96b74cf6f62aa37", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors. ", "start_char_idx": 1000, "end_char_idx": 1119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6af93a8f-53f6-4b83-a156-6d5df1c43ac2": {"__data__": {"id_": "6af93a8f-53f6-4b83-a156-6d5df1c43ac2", "embedding": null, "metadata": {"window": "For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion. ", "original_text": "Concurrently, we retired approximately $900 million of notes that were due March of \n2024. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a575ea26-79c6-4340-a8e3-1b0ed1327327", "node_type": "1", "metadata": {"window": "We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July. ", "original_text": "During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0e2fc982558ee9b81ea2671c98222c45f44da7c253e6af1afabc3187057637d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "092fa69a-620f-41ad-8f4a-943c789a12e2", "node_type": "1", "metadata": {"window": "We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n", "original_text": "These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n"}, "hash": "5aeae670e6d86392f39baf658b3e28a9dac59890a12857252b49e4045f3c07ec", "class_name": "RelatedNodeInfo"}}, "text": "Concurrently, we retired approximately $900 million of notes that were due March of \n2024. ", "start_char_idx": 1119, "end_char_idx": 1210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "092fa69a-620f-41ad-8f4a-943c789a12e2": {"__data__": {"id_": "092fa69a-620f-41ad-8f4a-943c789a12e2", "embedding": null, "metadata": {"window": "We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n", "original_text": "These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6af93a8f-53f6-4b83-a156-6d5df1c43ac2", "node_type": "1", "metadata": {"window": "For the first quarter, we had negative free cash flow of $1.2 billion and as a reminder, our cash position, our \nworking capital metrics and the resulting cash flows can each be impacted by timing, which includes the day of \nthe week that a quarter -ends on and therefore, can vary fro m quarter -to-quarter.  \n \n We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion. ", "original_text": "Concurrently, we retired approximately $900 million of notes that were due March of \n2024. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5abbb137758c9a5482ec7ec962c24559dd32399625ca6878a371b9a61936851a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "056cf365-e399-4698-af5a-8322286b2f50", "node_type": "1", "metadata": {"window": "During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook. ", "original_text": "Our board of directors approved two actions in July. "}, "hash": "9fe7438aa2b6e5e58ff0e7bf23f9828e9a0e5c35801774a7e1f4a49d03ddf262", "class_name": "RelatedNodeInfo"}}, "text": "These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n", "start_char_idx": 1210, "end_char_idx": 1368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "056cf365-e399-4698-af5a-8322286b2f50": {"__data__": {"id_": "056cf365-e399-4698-af5a-8322286b2f50", "embedding": null, "metadata": {"window": "During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook. ", "original_text": "Our board of directors approved two actions in July. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "092fa69a-620f-41ad-8f4a-943c789a12e2", "node_type": "1", "metadata": {"window": "We returned $770 million of cash to shareholders, which included $696 million of share repurchases, and $74 \nmillion in dividend payments.  During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n", "original_text": "These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d6eb4200ec160c287d977619e40609a112b3c34c3feacd6c6848fc129524d1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d0a8a59-8000-47d3-bbd7-741230fcff7a", "node_type": "1", "metadata": {"window": "Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024. ", "original_text": "First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion. "}, "hash": "ca195b0a974a47e30052d7aa102d9147147623ab5d9d2898a769c814d0138781", "class_name": "RelatedNodeInfo"}}, "text": "Our board of directors approved two actions in July. ", "start_char_idx": 1368, "end_char_idx": 1421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d0a8a59-8000-47d3-bbd7-741230fcff7a": {"__data__": {"id_": "3d0a8a59-8000-47d3-bbd7-741230fcff7a", "embedding": null, "metadata": {"window": "Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024. ", "original_text": "First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "056cf365-e399-4698-af5a-8322286b2f50", "node_type": "1", "metadata": {"window": "During the quarter, we successfully completed a public offering for $1 billion of notes \nwith 5 - and 10 -year tenors.  Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook. ", "original_text": "Our board of directors approved two actions in July. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0287a2e1863a0a45e650a824914eaf06894c26dcbbf2d556addf33d37b80ef1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24455dc9-c588-448e-8282-4c9016754c86", "node_type": "1", "metadata": {"window": "These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis. ", "original_text": "These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n"}, "hash": "7ecf3d5151350ec562be98f28a875c79ce44cfb8c2bf8d23b7d18ec182d0c009", "class_name": "RelatedNodeInfo"}}, "text": "First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion. ", "start_char_idx": 1421, "end_char_idx": 1670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24455dc9-c588-448e-8282-4c9016754c86": {"__data__": {"id_": "24455dc9-c588-448e-8282-4c9016754c86", "embedding": null, "metadata": {"window": "These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis. ", "original_text": "These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d0a8a59-8000-47d3-bbd7-741230fcff7a", "node_type": "1", "metadata": {"window": "Concurrently, we retired approximately $900 million of notes that were due March of \n2024.  These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024. ", "original_text": "First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "860571ab03c804427f9f18703196316333fd0978f19e121f90d26af09635accc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b94eb3c3-717b-470b-951c-003bb14be91d", "node_type": "1", "metadata": {"window": "Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n", "original_text": "Now, let me discuss our updated outlook. "}, "hash": "071d15bb233b720a21c4941ecc297d06d4c58b130d3e6489027b9f967134f1db", "class_name": "RelatedNodeInfo"}}, "text": "These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n", "start_char_idx": 1670, "end_char_idx": 1810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b94eb3c3-717b-470b-951c-003bb14be91d": {"__data__": {"id_": "b94eb3c3-717b-470b-951c-003bb14be91d", "embedding": null, "metadata": {"window": "Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n", "original_text": "Now, let me discuss our updated outlook. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24455dc9-c588-448e-8282-4c9016754c86", "node_type": "1", "metadata": {"window": "These transactions reduced our interest expense and they further supported our strong credit profile as \nevidenced by our recent credit rating upg rades.  \n \n Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis. ", "original_text": "These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a64a7f193f875b66b8ce73dfa802d8ee98d5b44b6452c809c9f82c25c2a58369", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e7c7f36-03a5-46af-bab9-d4e2d72a2536", "node_type": "1", "metadata": {"window": "First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation. ", "original_text": "The guidance I'm providing t oday relates to fiscal 2024. "}, "hash": "bd3e421553ef1c81723c11ce49be298446f04b2fb911bd55d27f971f2f1d1274", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me discuss our updated outlook. ", "start_char_idx": 1810, "end_char_idx": 1851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e7c7f36-03a5-46af-bab9-d4e2d72a2536": {"__data__": {"id_": "2e7c7f36-03a5-46af-bab9-d4e2d72a2536", "embedding": null, "metadata": {"window": "First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation. ", "original_text": "The guidance I'm providing t oday relates to fiscal 2024. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b94eb3c3-717b-470b-951c-003bb14be91d", "node_type": "1", "metadata": {"window": "Our board of directors approved two actions in July.  First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n", "original_text": "Now, let me discuss our updated outlook. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "705a991d761cfe7e1968dc1be967d5cb27f25f5ea338e9a2011c0e946cb692ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6993ce6f-c10d-4eb8-881b-5721bb1f1360", "node_type": "1", "metadata": {"window": "These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35. ", "original_text": "As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis. "}, "hash": "18374356ec3b896e8beb865924e22b5af9e2b5f55ec017106c82200439af1439", "class_name": "RelatedNodeInfo"}}, "text": "The guidance I'm providing t oday relates to fiscal 2024. ", "start_char_idx": 1851, "end_char_idx": 1909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6993ce6f-c10d-4eb8-881b-5721bb1f1360": {"__data__": {"id_": "6993ce6f-c10d-4eb8-881b-5721bb1f1360", "embedding": null, "metadata": {"window": "These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35. ", "original_text": "As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e7c7f36-03a5-46af-bab9-d4e2d72a2536", "node_type": "1", "metadata": {"window": "First, a 15% increase to our quarterly dividend to $0.62 per \nshare and second, the board approved an additional $6 billion of share repurchase authorization bringing the total \nremaining share rep urchase authorization to approximately $9 billion.  These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation. ", "original_text": "The guidance I'm providing t oday relates to fiscal 2024. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "339ce435ae1e59129abc23e8baa7a19c3167a590cb37248765977394604e8f42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59d8181f-b4e3-4b18-b545-e1fd16d34047", "node_type": "1", "metadata": {"window": "Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n", "original_text": "The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n"}, "hash": "16e5573cacbda29a710fb3c05fd5ac4162f1066479cef9b1f54965e45303fc31", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis. ", "start_char_idx": 1909, "end_char_idx": 1986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59d8181f-b4e3-4b18-b545-e1fd16d34047": {"__data__": {"id_": "59d8181f-b4e3-4b18-b545-e1fd16d34047", "embedding": null, "metadata": {"window": "Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n", "original_text": "The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6993ce6f-c10d-4eb8-881b-5721bb1f1360", "node_type": "1", "metadata": {"window": "These actions demonstrate the confidence \nthat the board of directors and management have in the execution of our strategic priorities.  \n \n Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35. ", "original_text": "As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dca67037c95279c6325a24a6058cd48d4e2b0c18da69e8d9d048bcb2f0bea34d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecf039d8-8f1a-4450-9de4-ec1e7153a2a5", "node_type": "1", "metadata": {"window": "The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S. ", "original_text": "I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation. "}, "hash": "6dc476948fa79c32a64ce5a199e690e6fbb0fea58dc3bea0bdcdc02b2512f38d", "class_name": "RelatedNodeInfo"}}, "text": "The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n", "start_char_idx": 1986, "end_char_idx": 2057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecf039d8-8f1a-4450-9de4-ec1e7153a2a5": {"__data__": {"id_": "ecf039d8-8f1a-4450-9de4-ec1e7153a2a5", "embedding": null, "metadata": {"window": "The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S. ", "original_text": "I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59d8181f-b4e3-4b18-b545-e1fd16d34047", "node_type": "1", "metadata": {"window": "Now, let me discuss our updated outlook.  The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n", "original_text": "The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ba4a855f49db6137bda1ea2f81f5c3946e83b0ad86e3b1465517f617d6c4190", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38b039da-2e70-472f-b793-18571ba92d7c", "node_type": "1", "metadata": {"window": "As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n", "original_text": "As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35. "}, "hash": "6fad0362e702c1f0990ae92fa7185d97622ee5f2b84446d59ce2f5e8060b5528", "class_name": "RelatedNodeInfo"}}, "text": "I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation. ", "start_char_idx": 2057, "end_char_idx": 2262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38b039da-2e70-472f-b793-18571ba92d7c": {"__data__": {"id_": "38b039da-2e70-472f-b793-18571ba92d7c", "embedding": null, "metadata": {"window": "As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n", "original_text": "As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecf039d8-8f1a-4450-9de4-ec1e7153a2a5", "node_type": "1", "metadata": {"window": "The guidance I'm providing t oday relates to fiscal 2024.  As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S. ", "original_text": "I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08ad2ea704b62e4c277e07c65e0017ad9f4a63eaa7d0a1112d9d0f4800bba01a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5047491-fb25-4062-bfb3-c9834bd6132a", "node_type": "1", "metadata": {"window": "The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year. ", "original_text": "As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n"}, "hash": "1b4c276d363fe04f989cb91544d1a2d75545a8318252e17dd7281110a82fc875", "class_name": "RelatedNodeInfo"}}, "text": "As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35. ", "start_char_idx": 2262, "end_char_idx": 2490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5047491-fb25-4062-bfb3-c9834bd6132a": {"__data__": {"id_": "b5047491-fb25-4062-bfb3-c9834bd6132a", "embedding": null, "metadata": {"window": "The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year. ", "original_text": "As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38b039da-2e70-472f-b793-18571ba92d7c", "node_type": "1", "metadata": {"window": "As a reminder, \nwe do not provide forward -looking guidance on a GAAP basis.  The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n", "original_text": "As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81b36432128e7e6786f6a9f82b250598ee7618d937a473649e610b7b7c6a9211", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c10aa366-a35c-4b22-961d-a7b74cfbff5a", "node_type": "1", "metadata": {"window": "I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year. ", "original_text": "As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S. "}, "hash": "335b22eddae6be7a36eb300cd1975ee068db3f55a3e41f712e4722be41933bb4", "class_name": "RelatedNodeInfo"}}, "text": "As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n", "start_char_idx": 2490, "end_char_idx": 2614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c10aa366-a35c-4b22-961d-a7b74cfbff5a": {"__data__": {"id_": "c10aa366-a35c-4b22-961d-a7b74cfbff5a", "embedding": null, "metadata": {"window": "I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year. ", "original_text": "As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5047491-fb25-4062-bfb3-c9834bd6132a", "node_type": "1", "metadata": {"window": "The following metrics are provided on an adjusted \nnon-GAAP basis.  \n \n I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year. ", "original_text": "As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8172e910f7bb12b897f7bffc9900c3708dc2e8566e531564ed9540298007b234", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42089d29-72db-428b-8d53-a0dd1a3097ef", "node_type": "1", "metadata": {"window": "As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n", "original_text": "Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n"}, "hash": "9658221de7571788ddbc073a678879dbbf147bba83ac74fbd61c81fd48198a94", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S. ", "start_char_idx": 2614, "end_char_idx": 2939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42089d29-72db-428b-8d53-a0dd1a3097ef": {"__data__": {"id_": "42089d29-72db-428b-8d53-a0dd1a3097ef", "embedding": null, "metadata": {"window": "As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n", "original_text": "Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c10aa366-a35c-4b22-961d-a7b74cfbff5a", "node_type": "1", "metadata": {"window": "I'll discuss the key items, beginning with additional details of our consolidated gui dance and a full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year. ", "original_text": "As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6fd26ab141123167352b70505c0d545d5be1cde6b6307d937bb4d86bf6c0c03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb564e63-83c0-426f-9202-e097b43dfc77", "node_type": "1", "metadata": {"window": "As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S. ", "original_text": "We anticipate operating profit will be flat to 4% decline compared to the prior year. "}, "hash": "746afd21537f16fcb07e92bfca3c1cb771144f04665a1d9ba7e37e59b9a9b622", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n", "start_char_idx": 2939, "end_char_idx": 3096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb564e63-83c0-426f-9202-e097b43dfc77": {"__data__": {"id_": "cb564e63-83c0-426f-9202-e097b43dfc77", "embedding": null, "metadata": {"window": "As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S. ", "original_text": "We anticipate operating profit will be flat to 4% decline compared to the prior year. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42089d29-72db-428b-8d53-a0dd1a3097ef", "node_type": "1", "metadata": {"window": "As we've talked about \nalready today, we are encouraged by the strong performance in the first quarter of fiscal 2024 and as a result, \nwe're increasing our earnings per diluted share outlook to a new range of $26.55 to $27.35.  As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n", "original_text": "Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5a5f5141edcc221a93c102c31fbddcd5151a9805bb97de008fa832ba1b8923c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd0a4056-c930-4846-b864-4156774e8349", "node_type": "1", "metadata": {"window": "As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers. ", "original_text": "When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year. "}, "hash": "79886b69936b7bbf1caa3deed0c3ffec77144c156eaad60d934c4cf1c866d084", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate operating profit will be flat to 4% decline compared to the prior year. ", "start_char_idx": 3096, "end_char_idx": 3182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd0a4056-c930-4846-b864-4156774e8349": {"__data__": {"id_": "fd0a4056-c930-4846-b864-4156774e8349", "embedding": null, "metadata": {"window": "As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers. ", "original_text": "When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb564e63-83c0-426f-9202-e097b43dfc77", "node_type": "1", "metadata": {"window": "As a result of this, we \nnow anticipate earnings per diluted share to increase 13% to 16% when excluding certain items.  \n \n As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S. ", "original_text": "We anticipate operating profit will be flat to 4% decline compared to the prior year. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6830f33fc7ff9e880f0a698603dc186d2caf839d133ff2263927765d5a596555", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55720998-aa7f-4a42-bde5-f6877a801b93", "node_type": "1", "metadata": {"window": "Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n", "original_text": "Let me discuss the outlook for our \nsegments.  \n \n"}, "hash": "521d8cf4ca8453cb3abbdf4b37847152c42db58c1ba4c61475cbcbeda0461f40", "class_name": "RelatedNodeInfo"}}, "text": "When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year. ", "start_char_idx": 3182, "end_char_idx": 3287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55720998-aa7f-4a42-bde5-f6877a801b93": {"__data__": {"id_": "55720998-aa7f-4a42-bde5-f6877a801b93", "embedding": null, "metadata": {"window": "Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n", "original_text": "Let me discuss the outlook for our \nsegments.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd0a4056-c930-4846-b864-4156774e8349", "node_type": "1", "metadata": {"window": "As a reminder, what the certain items include, n et gains and losses associated with McKesson Ventures equity \ninvestments in fiscal 2023 and 2024, a $0.65 benefit related to the early termination of a tax receivable agreement \nwith Change Healthcare in fiscal 2023, and $1.90 related to COVID -19-related it ems in our U.S.  Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers. ", "original_text": "When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b25bf1248d41dd359fd7daa486db1bcff18dc9189ca1f371249e7de0c72a459", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8062c598-6c2f-4747-a7d7-e0dca70be29c", "node_type": "1", "metadata": {"window": "We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs. ", "original_text": "Our core distribution business within the U.S. "}, "hash": "e90fef2914e8081b886c4127610166dc513fb2ccd53724462260d985aa00d43e", "class_name": "RelatedNodeInfo"}}, "text": "Let me discuss the outlook for our \nsegments.  \n \n", "start_char_idx": 3287, "end_char_idx": 3337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8062c598-6c2f-4747-a7d7-e0dca70be29c": {"__data__": {"id_": "8062c598-6c2f-4747-a7d7-e0dca70be29c", "embedding": null, "metadata": {"window": "We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs. ", "original_text": "Our core distribution business within the U.S. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55720998-aa7f-4a42-bde5-f6877a801b93", "node_type": "1", "metadata": {"window": "Pharmaceutical \nand Medical -Surgical segments in fiscal 2023, and we anticipate the impact of COVID -19-related items to be \nimmaterial to fiscal 2024.  \n \n We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n", "original_text": "Let me discuss the outlook for our \nsegments.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26d34affccc46ad78a1d21ddb229130486f394c6024f78d785c64714a301a9da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa189654-9b0e-426e-8f26-87c09ed437ab", "node_type": "1", "metadata": {"window": "When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs.  Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "original_text": "Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers. "}, "hash": "2dfb77c67b335c6271aa06a149643089fd6acaef10141bf977d6d299400341de", "class_name": "RelatedNodeInfo"}}, "text": "Our core distribution business within the U.S. ", "start_char_idx": 3337, "end_char_idx": 3384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa189654-9b0e-426e-8f26-87c09ed437ab": {"__data__": {"id_": "aa189654-9b0e-426e-8f26-87c09ed437ab", "embedding": null, "metadata": {"window": "When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs.  Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "original_text": "Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8062c598-6c2f-4747-a7d7-e0dca70be29c", "node_type": "1", "metadata": {"window": "We anticipate operating profit will be flat to 4% decline compared to the prior year.  When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs. ", "original_text": "Our core distribution business within the U.S. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5698a3832e71365bceb309f03b182c390903a4fcc3caa9989ca65f5368bd1239", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df237d5f-144a-458c-aa12-c67f718dedc8", "node_type": "1", "metadata": {"window": "Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs.  Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "original_text": "We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n"}, "hash": "826c300f6d6bb78e3d562c48278adcd7dee796b186b2b3a12e64fbee9bd15eac", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers. ", "start_char_idx": 3384, "end_char_idx": 3480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df237d5f-144a-458c-aa12-c67f718dedc8": {"__data__": {"id_": "df237d5f-144a-458c-aa12-c67f718dedc8", "embedding": null, "metadata": {"window": "Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs.  Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "original_text": "We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa189654-9b0e-426e-8f26-87c09ed437ab", "node_type": "1", "metadata": {"window": "When  excluding certain items, \nwe anticipate operating profit to increase by 6% to 10% year -over-year.  Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs.  Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "original_text": "Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e39aca750ef32a837ac8f1dda87d44d06839206d689d705715b35eaa7bed56a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "469985a7-f3b9-4f79-b7df-18be2a744d9d", "node_type": "1", "metadata": {"window": "Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs.  Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "original_text": "During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs. "}, "hash": "6d89a2c65efcf591071189fc34d1f9c53fa66226378d7808e611f3c350617163", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n", "start_char_idx": 3480, "end_char_idx": 3786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "469985a7-f3b9-4f79-b7df-18be2a744d9d": {"__data__": {"id_": "469985a7-f3b9-4f79-b7df-18be2a744d9d", "embedding": null, "metadata": {"window": "Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs.  Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "original_text": "During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df237d5f-144a-458c-aa12-c67f718dedc8", "node_type": "1", "metadata": {"window": "Let me discuss the outlook for our \nsegments.  \n \n Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs.  Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "original_text": "We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95aa228b2acf83c53bd40559c07e30990eb7120e64ee1f3989b11cf8f2eece9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9c15640-b808-4a43-8cf9-2ab78de286e0", "node_type": "1", "metadata": {"window": "Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs.  Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "original_text": "Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  "}, "hash": "a66e0eee125fbc1e089571ebb8c44ae0d9398f3798bd880ba421da908194e033", "class_name": "RelatedNodeInfo"}}, "text": "During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs. ", "start_char_idx": 3786, "end_char_idx": 3905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9c15640-b808-4a43-8cf9-2ab78de286e0": {"__data__": {"id_": "c9c15640-b808-4a43-8cf9-2ab78de286e0", "embedding": null, "metadata": {"window": "Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs.  Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "original_text": "Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994fd9a9c058a586c552fb0f987c047d602c916e0e12475592ab9d9597e0c10a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "469985a7-f3b9-4f79-b7df-18be2a744d9d", "node_type": "1", "metadata": {"window": "Our core distribution business within the U.S.  Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs.  Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "original_text": "During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs. ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b6794d87ec97af72e3ce37ea3d6f42fc9a93e3be0ecc735fd2f6cfbea1410e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84bfe11d-c7c9-434e-812b-4e37b5a7a6a5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile. ", "original_text": "McKesson Corp.  "}, "hash": "75e21239df2366e49b0139abef65a0032690f9c1c99bd6842de4121c4871b752", "class_name": "RelatedNodeInfo"}}, "text": "Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "start_char_idx": 3905, "end_char_idx": 4056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84bfe11d-c7c9-434e-812b-4e37b5a7a6a5": {"__data__": {"id_": "84bfe11d-c7c9-434e-812b-4e37b5a7a6a5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9c15640-b808-4a43-8cf9-2ab78de286e0", "node_type": "1", "metadata": {"window": "Pharmaceutical segment continues to demonstrate its strong value \nproposition to our customers.  We anticipate further growth in specialty distribution including our differentiated \nplasma and biologics business where our customers can access an expansive portfolio of plasma -derived \nproducts, biologics, oncology treatments  and other specialty drugs, at competitive prices from a single source.  \n \n During the first quarter, we experienced revenue tailwind from higher volumes related to weight loss or GLP -1 \ndrugs.  Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "original_text": "Our full year outlook assumes that volumes related to GLP -1 drugs will remain elevated compared to the \nprior year and may vary quarter -to-quarter.  ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "230906d32709619a9e6f32996a7c9a41b7a603b821752fc043d840d0e02f10ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ca74d9f-b615-4165-9e10-cecd956431eb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S. "}, "hash": "4a6a48be0957ed85039ec25fb783893240fdc5488ec799380c8c000a8cb6e982", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ca74d9f-b615-4165-9e10-cecd956431eb": {"__data__": {"id_": "4ca74d9f-b615-4165-9e10-cecd956431eb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84bfe11d-c7c9-434e-812b-4e37b5a7a6a5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e39802bf2cc2f3cedd2b699123cbaa01ba19141d5c4911b844c3abd6b8baca2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d22967b1-0bc3-4786-a7b2-9854ab6357ea", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n", "original_text": "Pharmaceutical as we support our \ncustomers through our distribution services. "}, "hash": "e7aa411c1c032f43d67815a23272c64480ebadfc09035d882eca2a26b21091b1", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S. ", "start_char_idx": 16, "end_char_idx": 265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d22967b1-0bc3-4786-a7b2-9854ab6357ea": {"__data__": {"id_": "d22967b1-0bc3-4786-a7b2-9854ab6357ea", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n", "original_text": "Pharmaceutical as we support our \ncustomers through our distribution services. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ca74d9f-b615-4165-9e10-cecd956431eb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc8f9b0e1da8d5e808e7f2984521037bedf672c1a997aa61b5fc13d9b30da553", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2c0a407-b3f6-4bbc-8f65-93a007f1c644", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%. ", "original_text": "As I discussed  earlier, these drugs have a lower distribution margin \nrate profile. "}, "hash": "2b0812b00e26e3349991b40c8054c07bafa93183865fb955682f93e46acd052d", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical as we support our \ncustomers through our distribution services. ", "start_char_idx": 265, "end_char_idx": 344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2c0a407-b3f6-4bbc-8f65-93a007f1c644": {"__data__": {"id_": "d2c0a407-b3f6-4bbc-8f65-93a007f1c644", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%. ", "original_text": "As I discussed  earlier, these drugs have a lower distribution margin \nrate profile. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d22967b1-0bc3-4786-a7b2-9854ab6357ea", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n", "original_text": "Pharmaceutical as we support our \ncustomers through our distribution services. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69b909b72c862e936b7c6ce1e4ebf1b1d0de2af9125fe797b8d7a746f943edba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bbc8298-fe7a-42fc-b1d1-2d970d40921a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n", "original_text": "For the full year, we now anticipate U.S. "}, "hash": "9c0a1096d8ccbfca01e5715a4c23099acf77fa268dd674586b8fcad0b3035a4a", "class_name": "RelatedNodeInfo"}}, "text": "As I discussed  earlier, these drugs have a lower distribution margin \nrate profile. ", "start_char_idx": 344, "end_char_idx": 429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bbc8298-fe7a-42fc-b1d1-2d970d40921a": {"__data__": {"id_": "8bbc8298-fe7a-42fc-b1d1-2d970d40921a", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n", "original_text": "For the full year, we now anticipate U.S. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2c0a407-b3f6-4bbc-8f65-93a007f1c644", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%. ", "original_text": "As I discussed  earlier, these drugs have a lower distribution margin \nrate profile. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "acb24dd353c95c6ea0f7e714a3e2c5bfceb34a22605ac73f3e74566f83083dfa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a1f66b3-66f0-4796-9fd3-ae542dc8373f", "node_type": "1", "metadata": {"window": "Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer. ", "original_text": "Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n"}, "hash": "41881b02a0ddcc16138f3db00909d5cd6a243c9752cc154d130c127a4aeed8d5", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, we now anticipate U.S. ", "start_char_idx": 429, "end_char_idx": 471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a1f66b3-66f0-4796-9fd3-ae542dc8373f": {"__data__": {"id_": "1a1f66b3-66f0-4796-9fd3-ae542dc8373f", "embedding": null, "metadata": {"window": "Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer. ", "original_text": "Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bbc8298-fe7a-42fc-b1d1-2d970d40921a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n", "original_text": "For the full year, we now anticipate U.S. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aaa938571482229fa9c98c159bbb2209ce4724fc46416d095383945f723e7344", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64867703-8412-4d8e-ae28-7da104c26454", "node_type": "1", "metadata": {"window": "As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n", "original_text": "Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%. "}, "hash": "5a4ca6a345e4318f41f2a436d06891f05b4d5bce417a1debd4f1b1044aab6cfa", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n", "start_char_idx": 471, "end_char_idx": 582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64867703-8412-4d8e-ae28-7da104c26454": {"__data__": {"id_": "64867703-8412-4d8e-ae28-7da104c26454", "embedding": null, "metadata": {"window": "As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n", "original_text": "Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a1f66b3-66f0-4796-9fd3-ae542dc8373f", "node_type": "1", "metadata": {"window": "Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer. ", "original_text": "Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54e2cc522d9b2cc145d5f57cd2f6bfbd0fd995ad8377a7024ada58af2d24e225", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00100d14-7154-40ef-8449-ea5cc38788f7", "node_type": "1", "metadata": {"window": "For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%. ", "original_text": "The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n"}, "hash": "294f086a88f33c8c2583d9eaee2973d067761cba88440459dce499dc430e626a", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%. ", "start_char_idx": 582, "end_char_idx": 709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00100d14-7154-40ef-8449-ea5cc38788f7": {"__data__": {"id_": "00100d14-7154-40ef-8449-ea5cc38788f7", "embedding": null, "metadata": {"window": "For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%. ", "original_text": "The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64867703-8412-4d8e-ae28-7da104c26454", "node_type": "1", "metadata": {"window": "As I discussed  earlier, these drugs have a lower distribution margin \nrate profile.  For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n", "original_text": "Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39100c0626a074b2bb19137ff58dfcc8ba469d17fe3e6f49fbc7773446a6afb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89a3a931-4803-42fb-b0e4-458cda89ae80", "node_type": "1", "metadata": {"window": "Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results. ", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer. "}, "hash": "ad86b22df63d56afbb09794cab58d8af5290c05300eba76672c056862ac92b40", "class_name": "RelatedNodeInfo"}}, "text": "The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n", "start_char_idx": 709, "end_char_idx": 864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89a3a931-4803-42fb-b0e4-458cda89ae80": {"__data__": {"id_": "89a3a931-4803-42fb-b0e4-458cda89ae80", "embedding": null, "metadata": {"window": "Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results. ", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00100d14-7154-40ef-8449-ea5cc38788f7", "node_type": "1", "metadata": {"window": "For the full year, we now anticipate U.S.  Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%. ", "original_text": "The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a504c53d4811b625ac3d82502076cb42478ef345cbefc2f3d723ff00394313bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62b33ef7-ef38-445c-8f31-208120f09672", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n", "original_text": "We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n"}, "hash": "86430cbce0f2adb9e7b506ab2e69055b2c5e9bd776cbef4a7e22c7259dcc02ec", "class_name": "RelatedNodeInfo"}}, "text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer. ", "start_char_idx": 864, "end_char_idx": 1215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62b33ef7-ef38-445c-8f31-208120f09672": {"__data__": {"id_": "62b33ef7-ef38-445c-8f31-208120f09672", "embedding": null, "metadata": {"window": "Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n", "original_text": "We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89a3a931-4803-42fb-b0e4-458cda89ae80", "node_type": "1", "metadata": {"window": "Pharmaceutical revenues to increase 13% to 15% and \noperating profit to increase 3% to 5% year -over-year.  \n \n Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results. ", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4345e53512236749f8607b628939d3742c82b2c52c828a91cfbaa386c6b8632", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "406f0a3e-b4e1-4292-8f03-d5efec7a5656", "node_type": "1", "metadata": {"window": "The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%. ", "original_text": "In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%. "}, "hash": "c446677cbd5534f30a1d1f9f12170c86f1accb0dea6b0962b92c0ca4af8735e5", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n", "start_char_idx": 1215, "end_char_idx": 1508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "406f0a3e-b4e1-4292-8f03-d5efec7a5656": {"__data__": {"id_": "406f0a3e-b4e1-4292-8f03-d5efec7a5656", "embedding": null, "metadata": {"window": "The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%. ", "original_text": "In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62b33ef7-ef38-445c-8f31-208120f09672", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID -19 vaccin e distribution in fiscal 2023, we anticipate operating profit to increase 8% \nto 11%.  The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n", "original_text": "We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b05352b9756dea344b678d15057d771a61575444a6f4a7386b82702842333705", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aed76bf9-61cf-40e7-9e7a-8bf7b8a6d674", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n", "original_text": "For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results. "}, "hash": "b445c1c6cfa1c912f5d034e363e392869f808fc21a91e3bf3365944b9ce0236c", "class_name": "RelatedNodeInfo"}}, "text": "In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%. ", "start_char_idx": 1508, "end_char_idx": 1662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aed76bf9-61cf-40e7-9e7a-8bf7b8a6d674": {"__data__": {"id_": "aed76bf9-61cf-40e7-9e7a-8bf7b8a6d674", "embedding": null, "metadata": {"window": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n", "original_text": "For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "406f0a3e-b4e1-4292-8f03-d5efec7a5656", "node_type": "1", "metadata": {"window": "The full year performance includes continued investment in our oncology platform and increased \ntechnology spend to support the growth of the segment.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%. ", "original_text": "In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eee06af08a6670d664491c3b041f98d55a044f5240fe840e13ea3f4ec9f751a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bfa1b02-f2c0-4419-9b8e-db7bc42ec14c", "node_type": "1", "metadata": {"window": "We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures. ", "original_text": "Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n"}, "hash": "b6646fac0c418d360d82633baff477571c0b0e68e679cce0647bc69aea49ff8e", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results. ", "start_char_idx": 1662, "end_char_idx": 1866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bfa1b02-f2c0-4419-9b8e-db7bc42ec14c": {"__data__": {"id_": "8bfa1b02-f2c0-4419-9b8e-db7bc42ec14c", "embedding": null, "metadata": {"window": "We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures. ", "original_text": "Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aed76bf9-61cf-40e7-9e7a-8bf7b8a6d674", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 15% to 19% which reflects increased utilization and new brand prescription transaction volumes, \nincluding the GLP -1 drugs, and strong demand for the acce ss, adherence, and affordability products and \nprograms that we offer.  We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n", "original_text": "For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6080fda9d708548c6911fea5fed79b74521e642b362cd7cbf6c7d244febdf962", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b463ab99-4175-4559-a6a3-79d4efa6270d", "node_type": "1", "metadata": {"window": "In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n", "original_text": "And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%. "}, "hash": "2f25d201e0c3e905a6841d325e1804bf2b79d0958dcafe0eb9c6356432edf353", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n", "start_char_idx": 1866, "end_char_idx": 2017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b463ab99-4175-4559-a6a3-79d4efa6270d": {"__data__": {"id_": "b463ab99-4175-4559-a6a3-79d4efa6270d", "embedding": null, "metadata": {"window": "In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n", "original_text": "And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bfa1b02-f2c0-4419-9b8e-db7bc42ec14c", "node_type": "1", "metadata": {"window": "We anticipate that we may continue to see quarter -to-quarter variability in this segment \ndriven by transaction volumes, the pace and trajectory of new product drug launches and the annua l verification \nprograms that we provide for our customers that occur in our fiscal fourth quarter.  \n \n In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures. ", "original_text": "Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78ca8d034609d764e036540f244821db5bdb904888203774871c43fb54c6df06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc03d0b4-17a5-47c1-9473-7053b78676b6", "node_type": "1", "metadata": {"window": "For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line. ", "original_text": "This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n"}, "hash": "5a469203aa885d0ff7c6eb13181e185b4c4c28e0c5032ff0139d62d133802aa3", "class_name": "RelatedNodeInfo"}}, "text": "And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%. ", "start_char_idx": 2017, "end_char_idx": 2155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc03d0b4-17a5-47c1-9473-7053b78676b6": {"__data__": {"id_": "bc03d0b4-17a5-47c1-9473-7053b78676b6", "embedding": null, "metadata": {"window": "For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line. ", "original_text": "This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b463ab99-4175-4559-a6a3-79d4efa6270d", "node_type": "1", "metadata": {"window": "In Medical -Surgical Solutions segment, we anticipate revenues to be approximately a 1% decline to 3% growth \nand operating profit to decrease 5% to 11%.  For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n", "original_text": "And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e762b2dd167fb1529f90a115b56a01ff48fcece9f0c33875827c9407107d4e42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a721984d-cc61-4753-89a6-972b4c5a7ec3", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n", "original_text": "As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures. "}, "hash": "379169345b0b32033a8fefa050ffb064291752ee203cfb7eb49da030d953a951", "class_name": "RelatedNodeInfo"}}, "text": "This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n", "start_char_idx": 2155, "end_char_idx": 2317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a721984d-cc61-4753-89a6-972b4c5a7ec3": {"__data__": {"id_": "a721984d-cc61-4753-89a6-972b4c5a7ec3", "embedding": null, "metadata": {"window": "Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n", "original_text": "As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc03d0b4-17a5-47c1-9473-7053b78676b6", "node_type": "1", "metadata": {"window": "For the full year, we anticipate volumes of COVID -19 tests to \ncontinue to decline compared to fiscal 2023 and the impact from the COVID -19-related items will remain \nimmaterial to fiscal 2024 results.  Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line. ", "original_text": "This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20ec79ed2162595143c4f19169505c4193859ddee3fb1a5ac3f7b2652bc0fba6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83e1dfc7-5949-41af-8894-ccaaf3a84750", "node_type": "1", "metadata": {"window": "And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment. ", "original_text": "In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n"}, "hash": "5a2cb0725eb500ee3c15f2d51b370ab2e96e10475110ecf42a62dfddf173b8ca", "class_name": "RelatedNodeInfo"}}, "text": "As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures. ", "start_char_idx": 2317, "end_char_idx": 2467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83e1dfc7-5949-41af-8894-ccaaf3a84750": {"__data__": {"id_": "83e1dfc7-5949-41af-8894-ccaaf3a84750", "embedding": null, "metadata": {"window": "And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment. ", "original_text": "In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a721984d-cc61-4753-89a6-972b4c5a7ec3", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID -19-related items from fiscal 2 023 results, we \nanticipate operating profit to increase 11% to 15% year -over-year.  \n \n And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n", "original_text": "As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87be5b7ff47692bc11d3e983272bef93fea96d6c6030604a684233633f42d3eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36442eb9-e1fa-4505-b842-c3c3e5b14068", "node_type": "1", "metadata": {"window": "This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense. ", "original_text": "Now, moving below the line. "}, "hash": "d9d008892ec10404ddf3223649fcb04c2304110cbda8f78b9468c87d1740c0cd", "class_name": "RelatedNodeInfo"}}, "text": "In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n", "start_char_idx": 2467, "end_char_idx": 2756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36442eb9-e1fa-4505-b842-c3c3e5b14068": {"__data__": {"id_": "36442eb9-e1fa-4505-b842-c3c3e5b14068", "embedding": null, "metadata": {"window": "This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense. ", "original_text": "Now, moving below the line. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83e1dfc7-5949-41af-8894-ccaaf3a84750", "node_type": "1", "metadata": {"window": "And finally in the International segment, we anticipate revenues to decline by 30% to 34% and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment. ", "original_text": "In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b01ec0d748dac59b0bc0f0452d90d52d11c13792c7dd40eeb7769ed51f55e274", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f63297d-946c-4634-b04a-89b792e58d09", "node_type": "1", "metadata": {"window": "As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares. ", "original_text": "As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n"}, "hash": "bbda53faf2d1ba37aca3bc9052e9c14b62e084f7e877f55b0cd617acd9a88908", "class_name": "RelatedNodeInfo"}}, "text": "Now, moving below the line. ", "start_char_idx": 2756, "end_char_idx": 2784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f63297d-946c-4634-b04a-89b792e58d09": {"__data__": {"id_": "2f63297d-946c-4634-b04a-89b792e58d09", "embedding": null, "metadata": {"window": "As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares. ", "original_text": "As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36442eb9-e1fa-4505-b842-c3c3e5b14068", "node_type": "1", "metadata": {"window": "This year -over-year decrease includ es a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  \n \n As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense. ", "original_text": "Now, moving below the line. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "000e84674cdbac3fd86e0daaf1f0864ee59c6d0e49b5755612be8279415821a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12ecb74e-3435-4f90-8c2e-656c463be044", "node_type": "1", "metadata": {"window": "In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n", "original_text": "Let me now turn to cash flow and capital deployment. "}, "hash": "b24f33cf4a2602adaa252102c21f4d45ec0ef8e8130bf0d0e67fec947f5a70a0", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n", "start_char_idx": 2784, "end_char_idx": 2949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12ecb74e-3435-4f90-8c2e-656c463be044": {"__data__": {"id_": "12ecb74e-3435-4f90-8c2e-656c463be044", "embedding": null, "metadata": {"window": "In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n", "original_text": "Let me now turn to cash flow and capital deployment. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f63297d-946c-4634-b04a-89b792e58d09", "node_type": "1", "metadata": {"window": "As I've previously discussed, we intend to deploy capital through share repurchases to offset the dilution resulting \nfrom the European divestitures.  In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares. ", "original_text": "As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06cb3a343b872e7d3ec7ea47ef767da09c2a8a8e76cf66608e41b93c9eddc71f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0639cb23-8eb4-4e9f-8c4d-94ad8b0983f7", "node_type": "1", "metadata": {"window": "Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow. ", "original_text": "We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense. "}, "hash": "ae16606b21e598539e42a67e99ad1c6fd505c93c2a400bee5ddc9f77129faf52", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to cash flow and capital deployment. ", "start_char_idx": 2949, "end_char_idx": 3002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0639cb23-8eb4-4e9f-8c4d-94ad8b0983f7": {"__data__": {"id_": "0639cb23-8eb4-4e9f-8c4d-94ad8b0983f7", "embedding": null, "metadata": {"window": "Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow. ", "original_text": "We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12ecb74e-3435-4f90-8c2e-656c463be044", "node_type": "1", "metadata": {"window": "In the Corporate segment, we anticipate expenses to be in the range of $580 \nmillion to $640 million which includes losses associated with McKesson Ventures equity investments recorded in \nthe first quarter as well as elevated technology spend to support the growth of our businesses.  \n \n Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n", "original_text": "Let me now turn to cash flow and capital deployment. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8210dbba890931469625a21cc5ea97779cb2e7a0199c40a6ddcac494ee7967f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b42f99d-58e6-4daa-a049-17b723489f5e", "node_type": "1", "metadata": {"window": "As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n", "original_text": "Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares. "}, "hash": "c5b46f9a78579a531b42a37b508fdedc045670a745f3c459e001e3aaf00e7a69", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense. ", "start_char_idx": 3002, "end_char_idx": 3143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b42f99d-58e6-4daa-a049-17b723489f5e": {"__data__": {"id_": "0b42f99d-58e6-4daa-a049-17b723489f5e", "embedding": null, "metadata": {"window": "As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n", "original_text": "Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0639cb23-8eb4-4e9f-8c4d-94ad8b0983f7", "node_type": "1", "metadata": {"window": "Now, moving below the line.  As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow. ", "original_text": "We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad35c65a4ca252988a6ac0e2a9e3b5f4c2b8f77ac1b1aefeb03aceac3239e6d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48b7e6ae-b9e6-41e4-8e17-641f5eb32fe8", "node_type": "1", "metadata": {"window": "Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35. ", "original_text": "As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n"}, "hash": "1bc7e8f7639d0727f7fb8fe39de6fea1e10d408842b3d503170989a7a7859390", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares. ", "start_char_idx": 3143, "end_char_idx": 3227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48b7e6ae-b9e6-41e4-8e17-641f5eb32fe8": {"__data__": {"id_": "48b7e6ae-b9e6-41e4-8e17-641f5eb32fe8", "embedding": null, "metadata": {"window": "Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35. ", "original_text": "As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b42f99d-58e6-4daa-a049-17b723489f5e", "node_type": "1", "metadata": {"window": "As a result of the debt transactions that I discussed earlier in my remarks, we \nanticipate lower interest expense in the range of $205 million to $225 million.  \n \n Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n", "original_text": "Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52f598e7cfc274d69f63c3d00f7368b5494e48ccab5dbdda2c01980c77906820", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8decb527-369d-4b30-97cb-7014fe4d67e8", "node_type": "1", "metadata": {"window": "We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35.  Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "original_text": "Our portfolio continues to generate strong free cash flow. "}, "hash": "363a3b81f496f3d699c466e08abe3fb00ac214a32775484fda922a3c1f73850f", "class_name": "RelatedNodeInfo"}}, "text": "As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n", "start_char_idx": 3227, "end_char_idx": 3400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8decb527-369d-4b30-97cb-7014fe4d67e8": {"__data__": {"id_": "8decb527-369d-4b30-97cb-7014fe4d67e8", "embedding": null, "metadata": {"window": "We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35.  Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "original_text": "Our portfolio continues to generate strong free cash flow. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48b7e6ae-b9e6-41e4-8e17-641f5eb32fe8", "node_type": "1", "metadata": {"window": "Let me now turn to cash flow and capital deployment.  We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35. ", "original_text": "As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50fb1d36a3a33eb3becdc179e943ac5acdf8b1fa924ab84b3542f6b221aba923", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85827c5b-874c-4a4b-b874-7a27e0b16a4a", "node_type": "1", "metadata": {"window": "Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35.  Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "original_text": "We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n"}, "hash": "be4d4355424a363555dc6073bc67a26d62da4b2dd9c2735387bb8880723c18de", "class_name": "RelatedNodeInfo"}}, "text": "Our portfolio continues to generate strong free cash flow. ", "start_char_idx": 3400, "end_char_idx": 3459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85827c5b-874c-4a4b-b874-7a27e0b16a4a": {"__data__": {"id_": "85827c5b-874c-4a4b-b874-7a27e0b16a4a", "embedding": null, "metadata": {"window": "Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35.  Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "original_text": "We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8decb527-369d-4b30-97cb-7014fe4d67e8", "node_type": "1", "metadata": {"window": "We anticipate free cash flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions, and capitalized software expense.  Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35.  Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "original_text": "Our portfolio continues to generate strong free cash flow. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65d27d6cbbbc412328d7755d01e8d9df662644689c95b0fbfaa7b25001c05919", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2431a75-d2b5-4330-8e34-bd7d554cf368", "node_type": "1", "metadata": {"window": "As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35.  Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "original_text": "In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35. "}, "hash": "49b3c48075563cf2f457a587e61a4eda7d9510955b71461c0f699168244111a3", "class_name": "RelatedNodeInfo"}}, "text": "We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n", "start_char_idx": 3459, "end_char_idx": 3640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2431a75-d2b5-4330-8e34-bd7d554cf368": {"__data__": {"id_": "b2431a75-d2b5-4330-8e34-bd7d554cf368", "embedding": null, "metadata": {"window": "As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35.  Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "original_text": "In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85827c5b-874c-4a4b-b874-7a27e0b16a4a", "node_type": "1", "metadata": {"window": "Our outlook incorporates plans to \nrepurchase approximately $3.5 billion of shares.  As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35.  Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "original_text": "We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5e43215e1a36b0d2d02784c07dfb3db509d21a1a10b86e07bfd2533c2b83ba2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a697180-fa49-46fe-9c37-f9526bda6140", "node_type": "1", "metadata": {"window": "Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35.  Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "original_text": "Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  "}, "hash": "126a017c433ed3fecd5e55876ad6b3734d192d18cb77acf63041b9701b6f97bd", "class_name": "RelatedNodeInfo"}}, "text": "In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35. ", "start_char_idx": 3640, "end_char_idx": 3829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a697180-fa49-46fe-9c37-f9526bda6140": {"__data__": {"id_": "9a697180-fa49-46fe-9c37-f9526bda6140", "embedding": null, "metadata": {"window": "Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35.  Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "original_text": "Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68e87f72-df25-4aba-89e0-510d1d52d088", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870a17abe95329ce8dfc6837d7d20fcebf8d7c5dcaf6b2738adc66802323ecd7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2431a75-d2b5-4330-8e34-bd7d554cf368", "node_type": "1", "metadata": {"window": "As a  result of the share repurchase activity, we estimate \nweighted -average diluted shares outstanding to be in the range of approximately 133 million to 134 million.  \n \n Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35.  Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "original_text": "In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35. ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b84b0ab529aa65a787d89d7d457402fe2d954a92fc7c527daf515c8515ba8e92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4eb62ee7-6d5f-4d86-b553-95fc82375a51", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year. ", "original_text": "McKesson Corp.  "}, "hash": "7ced37ded2a8616a6000aacd0c51431648ceee0d675a5affc17c2c677b2efbb6", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "start_char_idx": 3829, "end_char_idx": 3999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4eb62ee7-6d5f-4d86-b553-95fc82375a51": {"__data__": {"id_": "4eb62ee7-6d5f-4d86-b553-95fc82375a51", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a697180-fa49-46fe-9c37-f9526bda6140", "node_type": "1", "metadata": {"window": "Our portfolio continues to generate strong free cash flow.  We remain committed to operating p rofit growth and \nefficient capital deployment, and our 24% return -on-invested capital illustrates our focus on shareholder value \ncreation.  \n \n In summary, our strong start to fiscal 2024 and our outlook for the remainder of the year results in an increase to \nadjusted earnings per diluted share to a new range of $26.55 to $27.35.  Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "original_text": "Excluding the impact of certain items and \nthe contribution from our European operations, we anticipate earnings per diluted share growth of 16% to 20% in \nfiscal 2024.  ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de0a8476aea4e8772779b5ba87ba56fcc694a022556a69e12fc201e9163d7a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9ae5792-85b4-41aa-b987-1ded19854def", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously. "}, "hash": "50774cee7016f15b73fb51c9af447a5c6d809eb2a10b83d3a1d8a8701c6f9a43", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9ae5792-85b4-41aa-b987-1ded19854def": {"__data__": {"id_": "c9ae5792-85b4-41aa-b987-1ded19854def", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4eb62ee7-6d5f-4d86-b553-95fc82375a51", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d478139f867c37c22253a6966e4a3ed5d444c9f3495a1fdda93b00059dc81939", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7be35870-7f6d-4e38-98b4-6506e1f0b1e0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n", "original_text": "We \ncontinue to be focused on sustainable growth and efficient deployment of capital. "}, "hash": "4abaa1ebae979a1c3def2ea1dcff8a0ddddedbe2bafbfe198fe2eb821f7f1ee9", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously. ", "start_char_idx": 16, "end_char_idx": 291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7be35870-7f6d-4e38-98b4-6506e1f0b1e0": {"__data__": {"id_": "7be35870-7f6d-4e38-98b4-6506e1f0b1e0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n", "original_text": "We \ncontinue to be focused on sustainable growth and efficient deployment of capital. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9ae5792-85b4-41aa-b987-1ded19854def", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ad16d2ae603f7231493d8d27cf6b6d967d107411d32704e8970cb71e2b2ccd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd8f8396-d5ad-406a-aa50-7bea1d8810f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies. ", "original_text": "We're pleased with the strong \nstart to the fiscal year. "}, "hash": "4fc5f053116cd8ef0d6338e1e4306b4a1769db66cd4d08744e00af990cae40ee", "class_name": "RelatedNodeInfo"}}, "text": "We \ncontinue to be focused on sustainable growth and efficient deployment of capital. ", "start_char_idx": 291, "end_char_idx": 377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd8f8396-d5ad-406a-aa50-7bea1d8810f3": {"__data__": {"id_": "bd8f8396-d5ad-406a-aa50-7bea1d8810f3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies. ", "original_text": "We're pleased with the strong \nstart to the fiscal year. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7be35870-7f6d-4e38-98b4-6506e1f0b1e0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n", "original_text": "We \ncontinue to be focused on sustainable growth and efficient deployment of capital. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4c2c1a821f9e1be89a0ab1081a02f20e0d56bb5d0dc20897f185bc8b7af8048", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9e2b909-4f1c-493a-ae67-9c47d1b54f5f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care. ", "original_text": "Our 50,000 Team McKesson  associates continued to deliver exceptional performance. "}, "hash": "a148c58c735b047c54054209f8e559a121b1642e7a5129929296bade5eabac44", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with the strong \nstart to the fiscal year. ", "start_char_idx": 377, "end_char_idx": 434, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9e2b909-4f1c-493a-ae67-9c47d1b54f5f": {"__data__": {"id_": "f9e2b909-4f1c-493a-ae67-9c47d1b54f5f", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care. ", "original_text": "Our 50,000 Team McKesson  associates continued to deliver exceptional performance. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd8f8396-d5ad-406a-aa50-7bea1d8810f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies. ", "original_text": "We're pleased with the strong \nstart to the fiscal year. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1f2b0e1c315eb1143f662769e049d6b37bf0d737af12e8fb62d5becda702384", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e91bcad6-220f-4fc3-9fb0-65b08a7f1586", "node_type": "1", "metadata": {"window": "We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n", "original_text": "Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n"}, "hash": "5eafd39fa338530b0b3827fcd8cca43f0aad57ef1b2eb59f3499f2bcca9d13cf", "class_name": "RelatedNodeInfo"}}, "text": "Our 50,000 Team McKesson  associates continued to deliver exceptional performance. ", "start_char_idx": 434, "end_char_idx": 517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e91bcad6-220f-4fc3-9fb0-65b08a7f1586": {"__data__": {"id_": "e91bcad6-220f-4fc3-9fb0-65b08a7f1586", "embedding": null, "metadata": {"window": "We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n", "original_text": "Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9e2b909-4f1c-493a-ae67-9c47d1b54f5f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care. ", "original_text": "Our 50,000 Team McKesson  associates continued to deliver exceptional performance. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "326e3b99851e3ace948b92519abbaacbc619f7d1653fe36c3df5d64659c36203", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f68320a-395f-44f5-9cd9-8da90486a8ad", "node_type": "1", "metadata": {"window": "We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n ", "original_text": "Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies. "}, "hash": "c889f4f7585af30ea160b8b31bb7f5459be5ce285c272252c5c0089aac249e89", "class_name": "RelatedNodeInfo"}}, "text": "Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n", "start_char_idx": 517, "end_char_idx": 631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f68320a-395f-44f5-9cd9-8da90486a8ad": {"__data__": {"id_": "8f68320a-395f-44f5-9cd9-8da90486a8ad", "embedding": null, "metadata": {"window": "We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n ", "original_text": "Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e91bcad6-220f-4fc3-9fb0-65b08a7f1586", "node_type": "1", "metadata": {"window": "We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n", "original_text": "Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fc6c05a1689479fa075c0e512b0c3446995178b7c00e4be45a58aebc6984796", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5541cea-64d0-43ae-88e7-f5196cd59fe7", "node_type": "1", "metadata": {"window": "Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care. "}, "hash": "70db16c3ea1d75da49f7114634c2b3d96249f2d690c136296a0fbf1dc233776d", "class_name": "RelatedNodeInfo"}}, "text": "Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies. ", "start_char_idx": 631, "end_char_idx": 908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5541cea-64d0-43ae-88e7-f5196cd59fe7": {"__data__": {"id_": "e5541cea-64d0-43ae-88e7-f5196cd59fe7", "embedding": null, "metadata": {"window": "Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f68320a-395f-44f5-9cd9-8da90486a8ad", "node_type": "1", "metadata": {"window": "We're pleased with the strong \nstart to the fiscal year.  Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n ", "original_text": "Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ac518ab63443bd0349c72631bd7ee33afeb01e4632952bc73fd560376077582", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "880635ba-5ce0-4cc2-876e-4413b6ea5fd7", "node_type": "1", "metadata": {"window": "Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n", "original_text": "With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n"}, "hash": "a725f53c194f8486b15044048e115b2d4f4b870d6b31a7f74b9f31615e677937", "class_name": "RelatedNodeInfo"}}, "text": "Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care. ", "start_char_idx": 908, "end_char_idx": 1045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "880635ba-5ce0-4cc2-876e-4413b6ea5fd7": {"__data__": {"id_": "880635ba-5ce0-4cc2-876e-4413b6ea5fd7", "embedding": null, "metadata": {"window": "Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n", "original_text": "With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5541cea-64d0-43ae-88e7-f5196cd59fe7", "node_type": "1", "metadata": {"window": "Our 50,000 Team McKesson  associates continued to deliver exceptional performance.  Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1e25f3e691be344e8d7e155b988f0f3c8dc1bed94ed65c68427b275dcc1ed99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4c17f8f-95f0-4abd-9b2b-d1e1a3bd315c", "node_type": "1", "metadata": {"window": "Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n ", "original_text": "With that, let me turn it back over to the operator for your questions.  \n "}, "hash": "dfe8f2cf9adb9adc1bab7a1fedb6fac8ec48b746911af61748a72149b5473e58", "class_name": "RelatedNodeInfo"}}, "text": "With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n", "start_char_idx": 1045, "end_char_idx": 1297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4c17f8f-95f0-4abd-9b2b-d1e1a3bd315c": {"__data__": {"id_": "b4c17f8f-95f0-4abd-9b2b-d1e1a3bd315c", "embedding": null, "metadata": {"window": "Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n ", "original_text": "With that, let me turn it back over to the operator for your questions.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "880635ba-5ce0-4cc2-876e-4413b6ea5fd7", "node_type": "1", "metadata": {"window": "Our \nfirst quarter financial performance reflects their dedication, as well as the strength of our portfolio.  \n \n Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n", "original_text": "With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc11c734bfceef6a6d9f3a2e0938ad9c5fb645d5c6a5e67552ecd4cd5534ed96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd55dbd6-02d3-413e-ba6f-9d783ee7960c", "node_type": "1", "metadata": {"window": "Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "6317ff55872a6565ed11672853d37e08202325c7dea004f14dea040050eb2d2c", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it back over to the operator for your questions.  \n ", "start_char_idx": 1297, "end_char_idx": 1372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd55dbd6-02d3-413e-ba6f-9d783ee7960c": {"__data__": {"id_": "fd55dbd6-02d3-413e-ba6f-9d783ee7960c", "embedding": null, "metadata": {"window": "Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4c17f8f-95f0-4abd-9b2b-d1e1a3bd315c", "node_type": "1", "metadata": {"window": "Through our expansive oncology and biopharma platforms, we're supporting customers and p atients by \nadvancing health outcomes for all, we're delivering faster time to therapy for patients, and we're accelerating the \ndiscovery, development and manufacturing of new therapies.  Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n ", "original_text": "With that, let me turn it back over to the operator for your questions.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce42bf3e01ff46863e728b935bec576c7930e5a1f08ae6f5c2d382790c9f1aca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "564c3fca-68af-40dc-b1b3-f9586fcdc276", "node_type": "1", "metadata": {"window": "With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details. ", "original_text": "[Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n"}, "hash": "e6ef7a8e96bfb1802422b1861de28ddd5720638071d50ee71329d155d33d01c3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 1372, "end_char_idx": 1701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "564c3fca-68af-40dc-b1b3-f9586fcdc276": {"__data__": {"id_": "564c3fca-68af-40dc-b1b3-f9586fcdc276", "embedding": null, "metadata": {"window": "With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details. ", "original_text": "[Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd55dbd6-02d3-413e-ba6f-9d783ee7960c", "node_type": "1", "metadata": {"window": "Our services and solutions are at the forefront of \nimproving patient o utcomes, and ensuring more patients have access to quality care.  With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcfcda43a1fc5a4ef865212a94439380275a85df5e46aa15348580606d00981a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d93624e3-07ec-4533-8db0-815d1cbcab66", "node_type": "1", "metadata": {"window": "With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1. ", "original_text": "Please go ahead.  \n "}, "hash": "36c85745e6ebe54fe5bd33ec138403c0df4cff197ae75e274548b5d4f410374e", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n", "start_char_idx": 1701, "end_char_idx": 1790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d93624e3-07ec-4533-8db0-815d1cbcab66": {"__data__": {"id_": "d93624e3-07ec-4533-8db0-815d1cbcab66", "embedding": null, "metadata": {"window": "With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1. ", "original_text": "Please go ahead.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "564c3fca-68af-40dc-b1b3-f9586fcdc276", "node_type": "1", "metadata": {"window": "With our strong underlying \nmomentum from the first quarter of fiscal 2024, and our aligned focus on our growth strategies, we remain \nconfident that we'll continue to deliver long -term sustain able growth and value creation for our shareholders.  \n \n With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details. ", "original_text": "[Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a60bc30deb8cb6222998858f4e443618c8eb7470065d3a1a07127a8a4d191305", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d9a048c-2401-41ae-9ca0-26f43fe844ec", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon. "}, "hash": "f418f52706b96a546cc9fb584ec522b35acf56c4a3abb046e4c4db4a128a55ed", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1790, "end_char_idx": 1810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d9a048c-2401-41ae-9ca0-26f43fe844ec": {"__data__": {"id_": "2d9a048c-2401-41ae-9ca0-26f43fe844ec", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d93624e3-07ec-4533-8db0-815d1cbcab66", "node_type": "1", "metadata": {"window": "With that, let me turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1. ", "original_text": "Please go ahead.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1eda4a90ae6484f24d758fc4a72d92edd05c5d256128399dade550c54ac67b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b29243d8-b392-4abc-82d5-cf866b1f9932", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n", "original_text": "Thank you for all the details. "}, "hash": "cbf72acf896d57be11712668c5621f8472fa2b93a3f2e263e7deeeb569032584", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon. ", "start_char_idx": 1810, "end_char_idx": 2171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b29243d8-b392-4abc-82d5-cf866b1f9932": {"__data__": {"id_": "b29243d8-b392-4abc-82d5-cf866b1f9932", "embedding": null, "metadata": {"window": "[Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n", "original_text": "Thank you for all the details. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d9a048c-2401-41ae-9ca0-26f43fe844ec", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ce258b368123fe91405c7b4cbc865418ce317fdea3a0d37143d29123d89e054", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57edf449-2a82-46a3-914c-c8cb3b9d9e51", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now. ", "original_text": "I just want to go back and just better \nunderstand a few things around GLP -1. "}, "hash": "3307b2470a4a110e6ad55bc006c72ce8215bfa45327a9d5896cc629d249a356f", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for all the details. ", "start_char_idx": 2171, "end_char_idx": 2202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57edf449-2a82-46a3-914c-c8cb3b9d9e51": {"__data__": {"id_": "57edf449-2a82-46a3-914c-c8cb3b9d9e51", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now. ", "original_text": "I just want to go back and just better \nunderstand a few things around GLP -1. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b29243d8-b392-4abc-82d5-cf866b1f9932", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question will come from Lisa Gill with  JPMorgan. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n", "original_text": "Thank you for all the details. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f367fcdc717ce55cda12ba10db3721be9c7db6f0e69bc17f9e4decdba50d9f8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94a0f273-c020-4cbe-9ff4-47c0516e7e3d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n", "original_text": "So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n"}, "hash": "93a754a156023deea637942f261ef4ad2600a14e88dfe23381f5829626886996", "class_name": "RelatedNodeInfo"}}, "text": "I just want to go back and just better \nunderstand a few things around GLP -1. ", "start_char_idx": 2202, "end_char_idx": 2281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94a0f273-c020-4cbe-9ff4-47c0516e7e3d": {"__data__": {"id_": "94a0f273-c020-4cbe-9ff4-47c0516e7e3d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n", "original_text": "So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57edf449-2a82-46a3-914c-c8cb3b9d9e51", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now. ", "original_text": "I just want to go back and just better \nunderstand a few things around GLP -1. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffcd23623299ce5db50a494f80e8275c4692b508bd475caf1cccb64983403fda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48330d5f-b16f-485d-afba-666826461e9a", "node_type": "1", "metadata": {"window": "Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n ", "original_text": "And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n"}, "hash": "8542c1a6c35d8a911bf72d8751ea8f1065e27706caf4548eefc2c77c1a060d48", "class_name": "RelatedNodeInfo"}}, "text": "So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n", "start_char_idx": 2281, "end_char_idx": 2464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48330d5f-b16f-485d-afba-666826461e9a": {"__data__": {"id_": "48330d5f-b16f-485d-afba-666826461e9a", "embedding": null, "metadata": {"window": "Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n ", "original_text": "And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94a0f273-c020-4cbe-9ff4-47c0516e7e3d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good afternoon.  Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n", "original_text": "So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c493e471cd13b5d95c3c0b6dbc31a993ee7af65c40016163a8a821e85e2c1bca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2cc864a-054c-4731-89be-b6d8277ad0cb", "node_type": "1", "metadata": {"window": "I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We're hearing stabilization and generic pricing right now. "}, "hash": "71be4e4b3ebea7f16d8a60591ada99456291885cfbd79ea897e70dd4d6c76163", "class_name": "RelatedNodeInfo"}}, "text": "And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n", "start_char_idx": 2464, "end_char_idx": 2661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2cc864a-054c-4731-89be-b6d8277ad0cb": {"__data__": {"id_": "c2cc864a-054c-4731-89be-b6d8277ad0cb", "embedding": null, "metadata": {"window": "I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We're hearing stabilization and generic pricing right now. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48330d5f-b16f-485d-afba-666826461e9a", "node_type": "1", "metadata": {"window": "Thank you for all the details.  I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n ", "original_text": "And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66e06254d407da1b126eeb201b98b7ef4e0d71135cc2fbda1623f2f356971cc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "017c5c63-f51a-41d3-9dd9-61ad4ca534a7", "node_type": "1", "metadata": {"window": "So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions. ", "original_text": "You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n"}, "hash": "3a2452b11809ef18a3285a6ecefb56a39d91d9af00f5353a96530ae7d1d981b1", "class_name": "RelatedNodeInfo"}}, "text": "We're hearing stabilization and generic pricing right now. ", "start_char_idx": 2661, "end_char_idx": 2720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "017c5c63-f51a-41d3-9dd9-61ad4ca534a7": {"__data__": {"id_": "017c5c63-f51a-41d3-9dd9-61ad4ca534a7", "embedding": null, "metadata": {"window": "So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions. ", "original_text": "You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2cc864a-054c-4731-89be-b6d8277ad0cb", "node_type": "1", "metadata": {"window": "I just want to go back and just better \nunderstand a few things around GLP -1.  So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We're hearing stabilization and generic pricing right now. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09793d8d832fce1be6d0d632ee956ae6c57d060cb94ab447c27effbd71850f50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "917acb11-1421-4ad4-8dce-5dd967d25b8d", "node_type": "1", "metadata": {"window": "And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there. ", "original_text": "One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n "}, "hash": "7e0987405d08cdb596b6bc2d609719d3e81d79accff7068259362c3e7efc1ead", "class_name": "RelatedNodeInfo"}}, "text": "You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n", "start_char_idx": 2720, "end_char_idx": 2929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "917acb11-1421-4ad4-8dce-5dd967d25b8d": {"__data__": {"id_": "917acb11-1421-4ad4-8dce-5dd967d25b8d", "embedding": null, "metadata": {"window": "And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there. ", "original_text": "One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "017c5c63-f51a-41d3-9dd9-61ad4ca534a7", "node_type": "1", "metadata": {"window": "So Britt, you gave us a lot of data but when I think about the increase in \nthe revenue from 9% to 11% to 13% to 15%, can you talk about specifically how much is coming from GLP -1? \n And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions. ", "original_text": "You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eaf439606846a122b245806d2daac611e0e3ae90dde68ef7b975a51c0a094257", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7033f752-add3-4194-9ad4-2b7a6372e764", "node_type": "1", "metadata": {"window": "We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "b79aa9d756f87c0eaee0dc13b0ab7121710da466f649e9297efee08c416aba76", "class_name": "RelatedNodeInfo"}}, "text": "One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n ", "start_char_idx": 2929, "end_char_idx": 3195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7033f752-add3-4194-9ad4-2b7a6372e764": {"__data__": {"id_": "7033f752-add3-4194-9ad4-2b7a6372e764", "embedding": null, "metadata": {"window": "We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "917acb11-1421-4ad4-8dce-5dd967d25b8d", "node_type": "1", "metadata": {"window": "And then I understand that between cold chain and some other things that the gross profit is less on GLP -1, but \nhow do I think about some of the other areas that potentially can offset this?  \n \n We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there. ", "original_text": "One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f714b140c6fa3481491b6a622c00c3c5e5cc396f626542954f72db1084531777", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c49cb09c-f691-455c-a866-d0efc541c6e7", "node_type": "1", "metadata": {"window": "You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S. ", "original_text": "A \nWell, thanks, Lisa, for the questions. "}, "hash": "88a70ebe382c49c7d43131d616720252b537ba5f6aa9aff0a51cc4627da09a4b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 3195, "end_char_idx": 3555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c49cb09c-f691-455c-a866-d0efc541c6e7": {"__data__": {"id_": "c49cb09c-f691-455c-a866-d0efc541c6e7", "embedding": null, "metadata": {"window": "You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S. ", "original_text": "A \nWell, thanks, Lisa, for the questions. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7033f752-add3-4194-9ad4-2b7a6372e764", "node_type": "1", "metadata": {"window": "We're hearing stabilization and generic pricing right now.  You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f976b775b91ec360e29bcf18981d6d17666362c24b4093116c981e7bf06d1d90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bb50d7a-f395-4c53-9fa0-2453ce3afebd", "node_type": "1", "metadata": {"window": "One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma. ", "original_text": "There's a lot to unpack there. "}, "hash": "eff101a7e7d746799b9311d55b150dd55fe457d8a9ece05f6dac71676a0d9a7a", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, thanks, Lisa, for the questions. ", "start_char_idx": 3555, "end_char_idx": 3597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bb50d7a-f395-4c53-9fa0-2453ce3afebd": {"__data__": {"id_": "2bb50d7a-f395-4c53-9fa0-2453ce3afebd", "embedding": null, "metadata": {"window": "One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma. ", "original_text": "There's a lot to unpack there. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c49cb09c-f691-455c-a866-d0efc541c6e7", "node_type": "1", "metadata": {"window": "You talked about growth in specialty, which I also think \nis generally lower margin, but some of the other areas,  you've talked about procurement opportunities so I just \nwanted to understand two things.  \n \n One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S. ", "original_text": "A \nWell, thanks, Lisa, for the questions. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd2043dfbc61583170218d19dddcefba15ab7ef1865fbaade4715e745a218bf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df77c3c7-1b9c-490c-a060-4c729609871c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind. ", "original_text": "Let me see if I can try to answer some of those \nquestions for you. "}, "hash": "59ef5b0428aad9537358c1dc9087ee0201b4cb4e94e84ff81f783c22e8b21cb5", "class_name": "RelatedNodeInfo"}}, "text": "There's a lot to unpack there. ", "start_char_idx": 3597, "end_char_idx": 3628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df77c3c7-1b9c-490c-a060-4c729609871c": {"__data__": {"id_": "df77c3c7-1b9c-490c-a060-4c729609871c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind. ", "original_text": "Let me see if I can try to answer some of those \nquestions for you. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bb50d7a-f395-4c53-9fa0-2453ce3afebd", "node_type": "1", "metadata": {"window": "One, when we think about GLP -1s and think about the contribution to the revenue side, and then secondly, how \ndo we try to bifurcate some of these things on the margi n side so we can have an idea of how to think about really \nmodeling the margin going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma. ", "original_text": "There's a lot to unpack there. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd40bb048cb48633d6e4e85d0f4b296c33ef0ed675e1e7042cca041a047cb719", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b744ddd4-9af2-44c6-aa56-ac1c22de6d5d", "node_type": "1", "metadata": {"window": "A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n", "original_text": "As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S. "}, "hash": "48023efb65c41472f24ac634fffb11372fc3b1dfed8f7c9bb58056878f5fb8c8", "class_name": "RelatedNodeInfo"}}, "text": "Let me see if I can try to answer some of those \nquestions for you. ", "start_char_idx": 3628, "end_char_idx": 3696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b744ddd4-9af2-44c6-aa56-ac1c22de6d5d": {"__data__": {"id_": "b744ddd4-9af2-44c6-aa56-ac1c22de6d5d", "embedding": null, "metadata": {"window": "A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n", "original_text": "As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df77c3c7-1b9c-490c-a060-4c729609871c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind. ", "original_text": "Let me see if I can try to answer some of those \nquestions for you. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a36deae2623e1f4e39799fed587463522fc66a25ca229ad911ed9a9c95b2b59f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e9f6703-bec5-4f7e-9016-586bf00a0679", "node_type": "1", "metadata": {"window": "There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "original_text": "Pharma. "}, "hash": "eff1f3cca19a9428bbdfd012ea3e84d0fa20fc1ded6990b9350562cba550192d", "class_name": "RelatedNodeInfo"}}, "text": "As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S. ", "start_char_idx": 3696, "end_char_idx": 3808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e9f6703-bec5-4f7e-9016-586bf00a0679": {"__data__": {"id_": "7e9f6703-bec5-4f7e-9016-586bf00a0679", "embedding": null, "metadata": {"window": "There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "original_text": "Pharma. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b744ddd4-9af2-44c6-aa56-ac1c22de6d5d", "node_type": "1", "metadata": {"window": "A \nWell, thanks, Lisa, for the questions.  There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n", "original_text": "As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a86c404a61825fb39e0ff86b867a2afa9a65e2aa58bc735173c408d59e092780", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52bbe08f-05a8-41d2-9aee-c63eb21b57dd", "node_type": "1", "metadata": {"window": "Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "original_text": "Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind. "}, "hash": "d75fa73294804c50c1b63ec4987b1ef20414981ae0921c9fcb461b6bd77cf0d7", "class_name": "RelatedNodeInfo"}}, "text": "Pharma. ", "start_char_idx": 3808, "end_char_idx": 3816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52bbe08f-05a8-41d2-9aee-c63eb21b57dd": {"__data__": {"id_": "52bbe08f-05a8-41d2-9aee-c63eb21b57dd", "embedding": null, "metadata": {"window": "Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "original_text": "Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e9f6703-bec5-4f7e-9016-586bf00a0679", "node_type": "1", "metadata": {"window": "There's a lot to unpack there.  Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "original_text": "Pharma. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bda3a3d4dcf4b2aedf609a3220d17d96bd20259eea9d7f7cd1ef6ac0455e9f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0320b8c8-ad72-4227-939f-01a3bd19a057", "node_type": "1", "metadata": {"window": "As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "original_text": "Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n"}, "hash": "08fa2e10bbd230882b5c057f86d8c31ebcfa0b0de31c03f302d871f86436eb88", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind. ", "start_char_idx": 3816, "end_char_idx": 3965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0320b8c8-ad72-4227-939f-01a3bd19a057": {"__data__": {"id_": "0320b8c8-ad72-4227-939f-01a3bd19a057", "embedding": null, "metadata": {"window": "As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "original_text": "Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52bbe08f-05a8-41d2-9aee-c63eb21b57dd", "node_type": "1", "metadata": {"window": "Let me see if I can try to answer some of those \nquestions for you.  As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "original_text": "Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind. ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88f78680e7b2c7e83a9b3af121380daf9c2f77edb1bdd933f6a1a66f28683f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f62f072a-a8d0-4725-bbc8-0e173c6c3efb", "node_type": "1", "metadata": {"window": "Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "original_text": "We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions "}, "hash": "2da2c6035989a210e4f996256b2345f4b4eb21539227ef421f25479f58aae799", "class_name": "RelatedNodeInfo"}}, "text": "Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n", "start_char_idx": 3965, "end_char_idx": 4067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f62f072a-a8d0-4725-bbc8-0e173c6c3efb": {"__data__": {"id_": "f62f072a-a8d0-4725-bbc8-0e173c6c3efb", "embedding": null, "metadata": {"window": "Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "original_text": "We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "208ff8ea-f627-4d33-a125-f63b872b3558", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c2f571b241f947399eac77eaa4fcd9ff1313a218537c2220f0c71c79bfa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0320b8c8-ad72-4227-939f-01a3bd19a057", "node_type": "1", "metadata": {"window": "As we talked about, the revenue growth was very broad -based across the company but in \nparticular, within U.S.  Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "original_text": "Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49e025d837b4a907761a1bed37b9152a264bf962eb58eb861f549d307de4b072", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a98a1ee1-58b9-4bf3-b11f-9d25841ff767", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "f0e219409bc6d9108cc44a9cb655dc9c01b7154d401b375b2e8aec7554fb2e9d", "class_name": "RelatedNodeInfo"}}, "text": "We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "start_char_idx": 4067, "end_char_idx": 4299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a98a1ee1-58b9-4bf3-b11f-9d25841ff767": {"__data__": {"id_": "a98a1ee1-58b9-4bf3-b11f-9d25841ff767", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f62f072a-a8d0-4725-bbc8-0e173c6c3efb", "node_type": "1", "metadata": {"window": "Pharma.  Certainly, we're benefiting from stronger utilization trends overall an d that does \ninclude GLP -1s and as I mentioned, they do provide a tailwind.  Just generally speaking, though, utilization trends \ncontinue to be solid growth and improvement.  \n \n We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "original_text": "We're certainly as I mentioned from a margin rate profile, GLP -1 have a lower distr ibution margin rate profile but \nalso, as I mentioned, the breadth of the portfolio that we have, we also offer affordability and access solutions ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2583246bf5661232fa0282d5aa5ecc3ebcb107a06123952b0f31af127cd63717", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b697d28c-ef28-46cb-a47d-a5ded9a054d0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received. "}, "hash": "b0c5dcb5a6cb7e786b749e7ea94a453a96197933d000a7f5131f1cd948a8bcc1", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b697d28c-ef28-46cb-a47d-a5ded9a054d0": {"__data__": {"id_": "b697d28c-ef28-46cb-a47d-a5ded9a054d0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a98a1ee1-58b9-4bf3-b11f-9d25841ff767", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "330b5acf2ee5e4e69991b0e8a344381d0f7f2da521952c4dcd53fd75a95b8ecd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4279805e-5a4d-414d-b48d-b7ac26c00023", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable. ", "original_text": "They'r e \nproviding a lot of value to our customers. "}, "hash": "281f494a8d724b4d257f8ba0d76cda06f42c9e0c012814265e1e63ac9075173d", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received. ", "start_char_idx": 16, "end_char_idx": 286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4279805e-5a4d-414d-b48d-b7ac26c00023": {"__data__": {"id_": "4279805e-5a4d-414d-b48d-b7ac26c00023", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable. ", "original_text": "They'r e \nproviding a lot of value to our customers. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b697d28c-ef28-46cb-a47d-a5ded9a054d0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "679bcf028af5c271bb136494f650c76eba8b62b6a4143a745e5e8f2c7fdc0dc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1723b70b-938d-4699-838d-9e3362564684", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n ", "original_text": "And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n"}, "hash": "8dbaa97be0a10e6e2f80dbf52ed83c384d330f600a6da04b728ca4b3c0937bb8", "class_name": "RelatedNodeInfo"}}, "text": "They'r e \nproviding a lot of value to our customers. ", "start_char_idx": 286, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1723b70b-938d-4699-838d-9e3362564684": {"__data__": {"id_": "1723b70b-938d-4699-838d-9e3362564684", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n ", "original_text": "And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4279805e-5a4d-414d-b48d-b7ac26c00023", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable. ", "original_text": "They'r e \nproviding a lot of value to our customers. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61f74f7c920cf7d5877d63a64670394412de06de36edf9aa89eb3dde5be44d34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ee12911-2ce7-4566-90ef-9e18a868c586", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "So just generally speaking I think that the utilization environment has been continued to be solid. "}, "hash": "17a0f36536da369fdc5cc9683867e142ccd247bc6919d9f0f0bb961683498a0c", "class_name": "RelatedNodeInfo"}}, "text": "And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n", "start_char_idx": 339, "end_char_idx": 439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ee12911-2ce7-4566-90ef-9e18a868c586": {"__data__": {"id_": "7ee12911-2ce7-4566-90ef-9e18a868c586", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "So just generally speaking I think that the utilization environment has been continued to be solid. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1723b70b-938d-4699-838d-9e3362564684", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n ", "original_text": "And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca388641834ec9b90a51db7f87a0758edeb66b3a9d6e00e78dd0c9e99a55f1b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48500160-ac7f-45d5-ad01-e9d97e50fd89", "node_type": "1", "metadata": {"window": "They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "The pricing \nenvironment continues to be competitive but stable. "}, "hash": "7bc5c5834b875e8a3fedf610a1d645d422d01dcc6e1c978e01371fe90c1de053", "class_name": "RelatedNodeInfo"}}, "text": "So just generally speaking I think that the utilization environment has been continued to be solid. ", "start_char_idx": 439, "end_char_idx": 539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48500160-ac7f-45d5-ad01-e9d97e50fd89": {"__data__": {"id_": "48500160-ac7f-45d5-ad01-e9d97e50fd89", "embedding": null, "metadata": {"window": "They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "The pricing \nenvironment continues to be competitive but stable. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ee12911-2ce7-4566-90ef-9e18a868c586", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "So just generally speaking I think that the utilization environment has been continued to be solid. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72872c28fd3a1e027877b369e2316f3a826c00298f75c2c12c8dea8d5e4608de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "683e9671-98c9-4dd0-b1a4-e3f2c3a7287e", "node_type": "1", "metadata": {"window": "And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America. ", "original_text": "Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n "}, "hash": "6947d0a4e6999588ab02e0e67240392205dda10dac9df36d375b00de757abe5e", "class_name": "RelatedNodeInfo"}}, "text": "The pricing \nenvironment continues to be competitive but stable. ", "start_char_idx": 539, "end_char_idx": 604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "683e9671-98c9-4dd0-b1a4-e3f2c3a7287e": {"__data__": {"id_": "683e9671-98c9-4dd0-b1a4-e3f2c3a7287e", "embedding": null, "metadata": {"window": "And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America. ", "original_text": "Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48500160-ac7f-45d5-ad01-e9d97e50fd89", "node_type": "1", "metadata": {"window": "They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "The pricing \nenvironment continues to be competitive but stable. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16ff3394c0b02bf640973459325f9538ce63c3fc2532f793547e6dce31ac7301", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04a921cf-9a49-447f-b1e4-e50d10765d5a", "node_type": "1", "metadata": {"window": "So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "5b223d7589864ff5674f7bcfcaa14e43600568cdc8866bb2939115ef24248f39", "class_name": "RelatedNodeInfo"}}, "text": "Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n ", "start_char_idx": 604, "end_char_idx": 810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04a921cf-9a49-447f-b1e4-e50d10765d5a": {"__data__": {"id_": "04a921cf-9a49-447f-b1e4-e50d10765d5a", "embedding": null, "metadata": {"window": "So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "683e9671-98c9-4dd0-b1a4-e3f2c3a7287e", "node_type": "1", "metadata": {"window": "And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America. ", "original_text": "Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "373ab042345d00ccd41c7df3901d2a3fbd2c89c233b6db936ccf612ddc39c05c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef3f422f-be5f-4d64-8b1e-0de691604811", "node_type": "1", "metadata": {"window": "The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question, please?  \n "}, "hash": "a5e6a58b67d5fd31497266178b06b47dc2b2cc4c187bb80fd9cc17e0f9f69636", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 810, "end_char_idx": 1155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef3f422f-be5f-4d64-8b1e-0de691604811": {"__data__": {"id_": "ef3f422f-be5f-4d64-8b1e-0de691604811", "embedding": null, "metadata": {"window": "The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04a921cf-9a49-447f-b1e4-e50d10765d5a", "node_type": "1", "metadata": {"window": "So just generally speaking I think that the utilization environment has been continued to be solid.  The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dff7598933d1c9eb00d275557dee24fe2a4660b42ce147956ecf64cb5747aa6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dc7ab97-b29a-443a-b3d0-c6c1d9dadcac", "node_type": "1", "metadata": {"window": "Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America. "}, "hash": "6a91de70402b9a10828f9b250e96a8b3b96f3579490822da0b01fed3b8d11c71", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 1155, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dc7ab97-b29a-443a-b3d0-c6c1d9dadcac": {"__data__": {"id_": "1dc7ab97-b29a-443a-b3d0-c6c1d9dadcac", "embedding": null, "metadata": {"window": "Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef3f422f-be5f-4d64-8b1e-0de691604811", "node_type": "1", "metadata": {"window": "The pricing \nenvironment continues to be competitive but stable.  Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1c3bdef1c00b72526d55b678a3befad88223a6ac3d6a52aaa040f0019281305", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "666f3216-9c7f-44cc-a4e5-c045826b0e7d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year. ", "original_text": "Please go ahead.  \n "}, "hash": "94cf07b071c9c9b21d7154e9f81cc883107a5c1ef6613c6ea0b778faf16a2cac", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America. ", "start_char_idx": 1184, "end_char_idx": 1542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "666f3216-9c7f-44cc-a4e5-c045826b0e7d": {"__data__": {"id_": "666f3216-9c7f-44cc-a4e5-c045826b0e7d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year. ", "original_text": "Please go ahead.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dc7ab97-b29a-443a-b3d0-c6c1d9dadcac", "node_type": "1", "metadata": {"window": "Our generic programs continue to perform quite well, \nparticularly our sourcing programs, and we're benefiting from just broad -based performance across all of the \nchannels that we provide services to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "122f8778adda363e63baa6bd0b7b8a568584d5d5b54367c0dc6d17625c848c89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e05e3961-0cce-426c-8682-6f3b0babfe52", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "9a0d05562f9112090831094f67444797fd2347cb7e3628196982d06445439f53", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1542, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e05e3961-0cce-426c-8682-6f3b0babfe52": {"__data__": {"id_": "e05e3961-0cce-426c-8682-6f3b0babfe52", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "666f3216-9c7f-44cc-a4e5-c045826b0e7d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year. ", "original_text": "Please go ahead.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d82c208cf1b056a52c10d9b951336dd719790be09a90a98bb2fa53da80e67df0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecaf62a5-4702-48e3-9d95-b7660adbfb1c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business? ", "original_text": "Q \nGood a fternoon, and thanks so much for taking the question. "}, "hash": "26e3c62cb1536ba54f25329209aa04084412a60bab8c8c9071d6dc4317d6628b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 1562, "end_char_idx": 1883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecaf62a5-4702-48e3-9d95-b7660adbfb1c": {"__data__": {"id_": "ecaf62a5-4702-48e3-9d95-b7660adbfb1c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business? ", "original_text": "Q \nGood a fternoon, and thanks so much for taking the question. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e05e3961-0cce-426c-8682-6f3b0babfe52", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "621c10a6d9fa8924fc6717f4c055849e8740cc96425b1c800ac258aefd045c21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e4dc653-4aa7-4910-a9f5-a4d27f34f480", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n ", "original_text": "Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year. "}, "hash": "6664f1be0d014063c6164cbd291a6c61344c826b4395d00204eb535555beff86", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood a fternoon, and thanks so much for taking the question. ", "start_char_idx": 1883, "end_char_idx": 1947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e4dc653-4aa7-4910-a9f5-a4d27f34f480": {"__data__": {"id_": "4e4dc653-4aa7-4910-a9f5-a4d27f34f480", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n ", "original_text": "Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecaf62a5-4702-48e3-9d95-b7660adbfb1c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : We will take our next question from Michael Cherny with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business? ", "original_text": "Q \nGood a fternoon, and thanks so much for taking the question. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f77c0b58a38c854ec0253d1eac9419b78fae3357125113c3d1f0975a34d9e2fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26e227b9-7c7c-4e65-b39e-9a4fcd64761a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations. "}, "hash": "5fd880b9843f27cca6356e799203391a409f97c1d9d218478b2138f5be162048", "class_name": "RelatedNodeInfo"}}, "text": "Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year. ", "start_char_idx": 1947, "end_char_idx": 2105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26e227b9-7c7c-4e65-b39e-9a4fcd64761a": {"__data__": {"id_": "26e227b9-7c7c-4e65-b39e-9a4fcd64761a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e4dc653-4aa7-4910-a9f5-a4d27f34f480", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n ", "original_text": "Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14a4a986dba1194ab301a25d2f240ece57e16dad77cb9ccfc342b88297e82ca4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6410cd4-d6f7-425a-b8be-994ca76460cb", "node_type": "1", "metadata": {"window": "Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael. ", "original_text": "Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business? "}, "hash": "49f60f9b1c3b6a3abac807fd93297d8b4a828e60c581093c07027f7b34f573db", "class_name": "RelatedNodeInfo"}}, "text": "This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations. ", "start_char_idx": 2105, "end_char_idx": 2240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6410cd4-d6f7-425a-b8be-994ca76460cb": {"__data__": {"id_": "a6410cd4-d6f7-425a-b8be-994ca76460cb", "embedding": null, "metadata": {"window": "Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael. ", "original_text": "Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business? ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26e227b9-7c7c-4e65-b39e-9a4fcd64761a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc5332d228109459d553545d158da3ff5425416ae5ee92f585a0fa838d7ad035", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05889b7e-8ce4-4dc9-9c11-2662a959e978", "node_type": "1", "metadata": {"window": "Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit. ", "original_text": "And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n "}, "hash": "bff4b0d6566cf51189e05cb8f2182db4392ec2afdcfa0b01cfaecd69cad5fa1e", "class_name": "RelatedNodeInfo"}}, "text": "Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business? ", "start_char_idx": 2240, "end_char_idx": 2436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05889b7e-8ce4-4dc9-9c11-2662a959e978": {"__data__": {"id_": "05889b7e-8ce4-4dc9-9c11-2662a959e978", "embedding": null, "metadata": {"window": "Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit. ", "original_text": "And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6410cd4-d6f7-425a-b8be-994ca76460cb", "node_type": "1", "metadata": {"window": "Q \nGood a fternoon, and thanks so much for taking the question.  Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael. ", "original_text": "Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business? ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4499a7d758df4f9271cca88426f7d97c462e9599229b520d921f32424f915cad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83e9feb0-b9c1-4f0d-9906-338eeea99da7", "node_type": "1", "metadata": {"window": "This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "9fd2585bc2c939b9d22527fd1996e5b53579ea973c4b615c3c232e892bcb9bd2", "class_name": "RelatedNodeInfo"}}, "text": "And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n ", "start_char_idx": 2436, "end_char_idx": 2656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83e9feb0-b9c1-4f0d-9906-338eeea99da7": {"__data__": {"id_": "83e9feb0-b9c1-4f0d-9906-338eeea99da7", "embedding": null, "metadata": {"window": "This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05889b7e-8ce4-4dc9-9c11-2662a959e978", "node_type": "1", "metadata": {"window": "Maybe if I can spend a little time on RxTS, last year \nis almost like a discovery year in terms of the moving pieces that we saw over the course of the year.  This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit. ", "original_text": "And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd5850f4c053d2c5eda507ceff4e5032e2e8c9135bc15a5c3badc18e62ba62b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba24dc12-9532-486a-be31-ae926c75856f", "node_type": "1", "metadata": {"window": "Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n", "original_text": "A \nThanks, Michael. "}, "hash": "9a71733546a9cda14bf45adff1d0d703437c4fc570766e7e3e6f1b6aa03584a6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2656, "end_char_idx": 3000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba24dc12-9532-486a-be31-ae926c75856f": {"__data__": {"id_": "ba24dc12-9532-486a-be31-ae926c75856f", "embedding": null, "metadata": {"window": "Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n", "original_text": "A \nThanks, Michael. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83e9feb0-b9c1-4f0d-9906-338eeea99da7", "node_type": "1", "metadata": {"window": "This year \nreally coming out of the gate stron g in terms of profit growth and I know you mentioned some of the prior \nauthorizations.  Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c0500d7b74f693ded4aa3e64c1e071b6fbd782a35e2b347d70200674c3af21e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "553cd0ce-52db-477d-8ce4-117ccfb6ca57", "node_type": "1", "metadata": {"window": "And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n", "original_text": "I'll start and talk about the RxTS business a little bit. "}, "hash": "0888f0a5946bfd2b619ccce5c3919c60f97a083b66fad2092b65d374538a5654", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks, Michael. ", "start_char_idx": 3000, "end_char_idx": 3020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "553cd0ce-52db-477d-8ce4-117ccfb6ca57": {"__data__": {"id_": "553cd0ce-52db-477d-8ce4-117ccfb6ca57", "embedding": null, "metadata": {"window": "And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n", "original_text": "I'll start and talk about the RxTS business a little bit. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba24dc12-9532-486a-be31-ae926c75856f", "node_type": "1", "metadata": {"window": "Given the noise and moving pieces we had in prior authorizations broadly, against the backdrop of \nGLP-1s and other areas, is that the biggest driver of growth that you s ee in the RxTS business?  And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n", "original_text": "A \nThanks, Michael. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02b1235ad0a7aaf66c5b1a26351ceb7b56fd46e44ead9f155b68f0fe7fe382e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b02055c9-dafd-470c-9eb1-9c2bc783305c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business. ", "original_text": "We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have. "}, "hash": "c5ff8f643535253b6f82c9ca569d10282d108508e9bc8d7dc6ccf0afee959815", "class_name": "RelatedNodeInfo"}}, "text": "I'll start and talk about the RxTS business a little bit. ", "start_char_idx": 3020, "end_char_idx": 3078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b02055c9-dafd-470c-9eb1-9c2bc783305c": {"__data__": {"id_": "b02055c9-dafd-470c-9eb1-9c2bc783305c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business. ", "original_text": "We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "553cd0ce-52db-477d-8ce4-117ccfb6ca57", "node_type": "1", "metadata": {"window": "And how should \nwe think about the lumpiness or lack thereof that we could see over the course of this year relative to the fact that \nlast year was a little bit more volatile than I think we would have all expected?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n", "original_text": "I'll start and talk about the RxTS business a little bit. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81ff2e37e781f4aa1522b3476db1c734d468be6e75fe524d44371c78bd305b3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c43a071-de2b-4243-b610-11025703d4a2", "node_type": "1", "metadata": {"window": "A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will. ", "original_text": "And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n"}, "hash": "148551b4f1c248dabba053a80caa9612a23831f75b0c0244f70c0171ad48a768", "class_name": "RelatedNodeInfo"}}, "text": "We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have. ", "start_char_idx": 3078, "end_char_idx": 3312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c43a071-de2b-4243-b610-11025703d4a2": {"__data__": {"id_": "8c43a071-de2b-4243-b610-11025703d4a2", "embedding": null, "metadata": {"window": "A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will. ", "original_text": "And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b02055c9-dafd-470c-9eb1-9c2bc783305c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Ty ler \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business. ", "original_text": "We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "910b23bb044b0b281bf743029a4b13e1720dea23d466f68cbf05f292feb457e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea49a3ae-a435-45f8-bf2a-3b6939262383", "node_type": "1", "metadata": {"window": "I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n", "original_text": "I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n"}, "hash": "7120d960e7f0bbcbd7ea4917cc6d4f6d46b4cea23ed308f930684aa12c0dab00", "class_name": "RelatedNodeInfo"}}, "text": "And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n", "start_char_idx": 3312, "end_char_idx": 3442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea49a3ae-a435-45f8-bf2a-3b6939262383": {"__data__": {"id_": "ea49a3ae-a435-45f8-bf2a-3b6939262383", "embedding": null, "metadata": {"window": "I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n", "original_text": "I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c43a071-de2b-4243-b610-11025703d4a2", "node_type": "1", "metadata": {"window": "A \nThanks, Michael.  I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will. ", "original_text": "And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbb781f5416923fd77330f462a18bf37528f33b8e8f9061a0ff82d8e5d857e73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50ab4bbc-3f99-4a21-8441-7a6036c4aeab", "node_type": "1", "metadata": {"window": "We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n ", "original_text": "And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business. "}, "hash": "d05b60a7e3c87269ca7987cfbdb5319d9b337bc73e1e0bf6981427a61153ecdf", "class_name": "RelatedNodeInfo"}}, "text": "I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n", "start_char_idx": 3442, "end_char_idx": 3562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50ab4bbc-3f99-4a21-8441-7a6036c4aeab": {"__data__": {"id_": "50ab4bbc-3f99-4a21-8441-7a6036c4aeab", "embedding": null, "metadata": {"window": "We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n ", "original_text": "And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea49a3ae-a435-45f8-bf2a-3b6939262383", "node_type": "1", "metadata": {"window": "I'll start and talk about the RxTS business a little bit.  We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n", "original_text": "I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "572f7d959542301ab1fc6fcf30eba33a084e3ad52db9f0bd93dbdf925dc17403", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2974cddd-e6bc-44dc-8ea0-e449ad6a4800", "node_type": "1", "metadata": {"window": "And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.  ", "original_text": "We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will. "}, "hash": "bd83b268eaa0b3ccc0d54348cef614daaff369bdba4e2d36288f657fd4c9c4c9", "class_name": "RelatedNodeInfo"}}, "text": "And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business. ", "start_char_idx": 3562, "end_char_idx": 3694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2974cddd-e6bc-44dc-8ea0-e449ad6a4800": {"__data__": {"id_": "2974cddd-e6bc-44dc-8ea0-e449ad6a4800", "embedding": null, "metadata": {"window": "And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.  ", "original_text": "We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50ab4bbc-3f99-4a21-8441-7a6036c4aeab", "node_type": "1", "metadata": {"window": "We've talked in the past about the \nimportance of mix in this business that the different financial profiles of the 3PL business, which had good growth \nin the quarter versus the more technologically -oriented solutions that we have.  And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n ", "original_text": "And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfaadce33de17297aeffaf3a096302643e5b9373561c336631197c7dc5a34e4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ced1c62-c512-4216-8b56-053683f9e2e4", "node_type": "1", "metadata": {"window": "I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment. ", "original_text": "We're going to \nbenefit from those kinds of volume -related things over time.  \n \n"}, "hash": "def8d660a47f87557bc75367190f59d467b09e2898719d4045ad6c7721eb590c", "class_name": "RelatedNodeInfo"}}, "text": "We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will. ", "start_char_idx": 3694, "end_char_idx": 3893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ced1c62-c512-4216-8b56-053683f9e2e4": {"__data__": {"id_": "6ced1c62-c512-4216-8b56-053683f9e2e4", "embedding": null, "metadata": {"window": "I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment. ", "original_text": "We're going to \nbenefit from those kinds of volume -related things over time.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2974cddd-e6bc-44dc-8ea0-e449ad6a4800", "node_type": "1", "metadata": {"window": "And so that mix will always be \nimportant and did introduce some fluctuations quarter -to-quarter over our prior fiscal year.  \n \n I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.  ", "original_text": "We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d0d19fd9a574e90e9ccd4c6efeea7f2c8ae1e787d81f2ac350a45d7ddd1db0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0b1f557-1aa8-4356-a7bd-f3fda876f214", "node_type": "1", "metadata": {"window": "And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends. ", "original_text": "Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n "}, "hash": "8a6a9182dae5630ce3733661a383721e84128de9628e987a6aee8ee0cc5d7bb1", "class_name": "RelatedNodeInfo"}}, "text": "We're going to \nbenefit from those kinds of volume -related things over time.  \n \n", "start_char_idx": 3893, "end_char_idx": 3975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0b1f557-1aa8-4356-a7bd-f3fda876f214": {"__data__": {"id_": "b0b1f557-1aa8-4356-a7bd-f3fda876f214", "embedding": null, "metadata": {"window": "And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends. ", "original_text": "Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ced1c62-c512-4216-8b56-053683f9e2e4", "node_type": "1", "metadata": {"window": "I would say in gene ral though, this business is going to benefit from the utilization trends that Britt talked about. \n And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment. ", "original_text": "We're going to \nbenefit from those kinds of volume -related things over time.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a0664a527e746311f1f202d657f7a7430b8418f7271142a55f4afdb1c3a1057", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47fa2038-6dfa-4237-bff0-a29a2751c1d8", "node_type": "1", "metadata": {"window": "We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends.  We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.  "}, "hash": "dbd76265b616bcfe3c52d18f66850bf4d62524a2a861975ae927caed30bb189c", "class_name": "RelatedNodeInfo"}}, "text": "Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n ", "start_char_idx": 3975, "end_char_idx": 4170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47fa2038-6dfa-4237-bff0-a29a2751c1d8": {"__data__": {"id_": "47fa2038-6dfa-4237-bff0-a29a2751c1d8", "embedding": null, "metadata": {"window": "We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends.  We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0b1f557-1aa8-4356-a7bd-f3fda876f214", "node_type": "1", "metadata": {"window": "And specifically, as prescription volumes go up, as the need for prior authorization services go up, that's help for \nour business.  We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends. ", "original_text": "Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ef938a9452a6394fd37112cb66402f21c7e981aa5c92f93bbcd0bf1fdbff908", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ebafc20-db0b-4acc-8a94-2deadbbb5fe3", "node_type": "1", "metadata": {"window": "We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends.  We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "original_text": "A \nMike, maybe just one other thing that I would add as we've continued to develop this segment. "}, "hash": "ce7c0b73be315cddbddda2e323695e28583bb35c9a9032b1a687313a976eb301", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.  ", "start_char_idx": 4170, "end_char_idx": 4531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ebafc20-db0b-4acc-8a94-2deadbbb5fe3": {"__data__": {"id_": "2ebafc20-db0b-4acc-8a94-2deadbbb5fe3", "embedding": null, "metadata": {"window": "We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends.  We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "original_text": "A \nMike, maybe just one other thing that I would add as we've continued to develop this segment. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47fa2038-6dfa-4237-bff0-a29a2751c1d8", "node_type": "1", "metadata": {"window": "We're going to win by winn ing more of these manufacturer relationships, extending our relationships \nin the places where we have them today, [indiscernible] (00:39:17) more penetration if you will.  We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends.  We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "876b63d21e16461f904cd20e2739e9d0497d3ee54da3b970dcf6baa9a0ba0889", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "106c9c15-8215-431c-b0aa-256cf6c26851", "node_type": "1", "metadata": {"window": "Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends.  We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "original_text": "One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends. "}, "hash": "afed21a4f3819f64f9ad52793ed5750e92c4d6aab4427f1d7bce1c7ed69d687e", "class_name": "RelatedNodeInfo"}}, "text": "A \nMike, maybe just one other thing that I would add as we've continued to develop this segment. ", "start_char_idx": 4531, "end_char_idx": 4628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "106c9c15-8215-431c-b0aa-256cf6c26851": {"__data__": {"id_": "106c9c15-8215-431c-b0aa-256cf6c26851", "embedding": null, "metadata": {"window": "Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends.  We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "original_text": "One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ebafc20-db0b-4acc-8a94-2deadbbb5fe3", "node_type": "1", "metadata": {"window": "We're going to \nbenefit from those kinds of volume -related things over time.  \n \n Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends.  We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "original_text": "A \nMike, maybe just one other thing that I would add as we've continued to develop this segment. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a4bf8006bae402cd8618e28c208bfcc55be5968d05333b8ecd0fb8fee4c5295", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ac8bb8e-2e21-491f-9f3d-b7b9793428ed", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends.  We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "original_text": "We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what "}, "hash": "73be4cc83883d10e69ff1f834f0cd2ddfb74439cf31366e657e8ff3a2c3ca31a", "class_name": "RelatedNodeInfo"}}, "text": "One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends. ", "start_char_idx": 4628, "end_char_idx": 4836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ac8bb8e-2e21-491f-9f3d-b7b9793428ed": {"__data__": {"id_": "1ac8bb8e-2e21-491f-9f3d-b7b9793428ed", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends.  We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "original_text": "We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "535e8124-c88a-461c-a64c-475f3d854179", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37910ce943cadf2448c561671141fda906fe36ad96b87413e44cbf88cd0d7762", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "106c9c15-8215-431c-b0aa-256cf6c26851", "node_type": "1", "metadata": {"window": "Now, as new drugs launch, as they go through their lifecycles, there can be some variation into the demands and \nneeds of the services we offer and that's just a natural part of the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends.  We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "original_text": "One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends. ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "426721180156d1fd5a747072ef29bcfc44a8204a0febdcb23c2a56a68eea7a84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84e14511-18ed-45c3-815a-57561996c153", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n ", "original_text": "McKesson Corp.  "}, "hash": "fc6b8721dd6fed2fda65039fc7ab89f34f56a4946d3ce0596fc31e3135838b3d", "class_name": "RelatedNodeInfo"}}, "text": "We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "start_char_idx": 4836, "end_char_idx": 4990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84e14511-18ed-45c3-815a-57561996c153": {"__data__": {"id_": "84e14511-18ed-45c3-815a-57561996c153", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ac8bb8e-2e21-491f-9f3d-b7b9793428ed", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, M cKesson Corp.   A \nMike, maybe just one other thing that I would add as we've continued to develop this segment.  One of the things \nthat we're doing is continuing to add capabilities and programs within it, so as time goes on we're offering more \nservices, whi ch is certainly taking advantage of the utilization trends.  We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "original_text": "We added Rx Savings Solutions last year, \nso another capability with a whole another set of economics available to us, and our customers, so I think what ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3d0e1703274f680dba71b5fbf3e3c3aefd0a4db06b3f9108fba24acc7306b92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28af7c38-820c-427b-be09-9f92fc51e3ea", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n "}, "hash": "23f76b763f6e4576ba344f84b0186b927a9f2fda37c8ec123a2866708ffaf1c1", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28af7c38-820c-427b-be09-9f92fc51e3ea": {"__data__": {"id_": "28af7c38-820c-427b-be09-9f92fc51e3ea", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84e14511-18ed-45c3-815a-57561996c153", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3a55df0861ba64a3bfb4c9acb77a8f2c1180741871a991bc11a2e039e5f1fbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b790a42f-48d7-47aa-8f74-db1279441395", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "437775a2c6205fc1edcd8ae49f4fb1f4dabee33ffdc9b28dc4e957ef7c9d44ef", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n ", "start_char_idx": 16, "end_char_idx": 451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b790a42f-48d7-47aa-8f74-db1279441395": {"__data__": {"id_": "b790a42f-48d7-47aa-8f74-db1279441395", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28af7c38-820c-427b-be09-9f92fc51e3ea", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bd3b43803a5933689b28966d6cb26da554e3e6b9b86ff720d0f3b243ff3df69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53e20382-39a3-4b88-890b-668b6143726b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird. ", "original_text": "A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n "}, "hash": "ba0fd9986dddc76054ed233497c4708e995e49ad971bb7a114ce42bf9201416e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 451, "end_char_idx": 795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53e20382-39a3-4b88-890b-668b6143726b": {"__data__": {"id_": "53e20382-39a3-4b88-890b-668b6143726b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird. ", "original_text": "A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b790a42f-48d7-47aa-8f74-db1279441395", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c28caf42456ea77fdebb5e260c21f513296cef302b2a41fdbd6b5d931ed08d96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e031ce21-f0cf-43da-976d-bf049e0c662b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "5ba112dd8fa435ed660b2082c6fc7cbf854da27756047ee157529b289e7f4a5d", "class_name": "RelatedNodeInfo"}}, "text": "A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n ", "start_char_idx": 795, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e031ce21-f0cf-43da-976d-bf049e0c662b": {"__data__": {"id_": "e031ce21-f0cf-43da-976d-bf049e0c662b", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53e20382-39a3-4b88-890b-668b6143726b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird. ", "original_text": "A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47c7ae934294e113f4c762a91e5aebce4628b2d3478b63d64bff6b23f3b69200", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12b63ca2-37cf-4199-bf24-f0798a1928ea", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nNext question, please?  \n "}, "hash": "f2a304213ea46c95a69a4112e6b76187d44b081d26a2edcf27303f97e6e33834", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 914, "end_char_idx": 1259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12b63ca2-37cf-4199-bf24-f0798a1928ea": {"__data__": {"id_": "12b63ca2-37cf-4199-bf24-f0798a1928ea", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e031ce21-f0cf-43da-976d-bf049e0c662b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56564415c8a62eed20b412ba86b2274df0eea6f38dea51e4244d725308815708", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa24bcd6-6e9f-4c9b-9e94-6756578bfe77", "node_type": "1", "metadata": {"window": "A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird. "}, "hash": "ef233952fe0007e75e89a00ed75050ffa00ce30339fa1e447ea9b97b927b6a7a", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 1259, "end_char_idx": 1288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa24bcd6-6e9f-4c9b-9e94-6756578bfe77": {"__data__": {"id_": "fa24bcd6-6e9f-4c9b-9e94-6756578bfe77", "embedding": null, "metadata": {"window": "A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12b63ca2-37cf-4199-bf24-f0798a1928ea", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86e9cbd5c2081784b7b1a86188d4563be67ddee1130c255894758e2190f3e902", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9a5cbb7-0d34-4b4b-b932-fcfaff41c967", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much. ", "original_text": "Please go ahead.  \n "}, "hash": "5066b1b9f5f1bd9a278e9775cafad617bb6e239f01b1da3ad72e99b26cdcb623", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird. ", "start_char_idx": 1288, "end_char_idx": 1616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9a5cbb7-0d34-4b4b-b932-fcfaff41c967": {"__data__": {"id_": "a9a5cbb7-0d34-4b4b-b932-fcfaff41c967", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much. ", "original_text": "Please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa24bcd6-6e9f-4c9b-9e94-6756578bfe77", "node_type": "1", "metadata": {"window": "A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ddfc428b637103542de6926485c8ab20d6654cdfc0bb03874d54fde916e0c49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd4cb021-a161-4e62-8bde-e4af3a3f48c0", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  Congrats on a nice report. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "6fca1aad83d34b581211bdbb95179d4cdb16e6ae7da3a88eb022a4e3a0a4242c", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1616, "end_char_idx": 1636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd4cb021-a161-4e62-8bde-e4af3a3f48c0": {"__data__": {"id_": "dd4cb021-a161-4e62-8bde-e4af3a3f48c0", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  Congrats on a nice report. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9a5cbb7-0d34-4b4b-b932-fcfaff41c967", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much. ", "original_text": "Please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3338f5eb93fda0769356befc07f983cb215f623a795b4e1f2c0a1ff8d085222d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3315d8e0-894d-48be-890b-13e55e22cd2e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort? ", "original_text": "Q \nHey. "}, "hash": "fe48a24def4459a1d35388a82c3d34a21155dcf4eda0150c3d2de52381712d0c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 1636, "end_char_idx": 1968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3315d8e0-894d-48be-890b-13e55e22cd2e": {"__data__": {"id_": "3315d8e0-894d-48be-890b-13e55e22cd2e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort? ", "original_text": "Q \nHey. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd4cb021-a161-4e62-8bde-e4af3a3f48c0", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  Congrats on a nice report. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee1e5b437498a769422acd3a17aa7b30467515222547c4739d5dabc031d7f691", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f3c86dc-9f06-4804-9728-cea7d8b6ac2a", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items? ", "original_text": "Thanks very much. "}, "hash": "eabd477c3b26b0bffddac3446ac0c9d7b8184b900c97a864be9c2170847be192", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHey. ", "start_char_idx": 1968, "end_char_idx": 1976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f3c86dc-9f06-4804-9728-cea7d8b6ac2a": {"__data__": {"id_": "8f3c86dc-9f06-4804-9728-cea7d8b6ac2a", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items? ", "original_text": "Thanks very much. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3315d8e0-894d-48be-890b-13e55e22cd2e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort? ", "original_text": "Q \nHey. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b0ac6e5917ca5c5bea72076c1227f6337bb4b068af765ff2b06047c1baf4839", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "534561ae-2758-4649-abc7-6d357b87f413", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges? ", "original_text": "Congrats on a nice report. "}, "hash": "62f36eec48376f26b12cb272672b337442095944bd2417838a6f0722d33dbf47", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much. ", "start_char_idx": 1976, "end_char_idx": 1994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "534561ae-2758-4649-abc7-6d357b87f413": {"__data__": {"id_": "534561ae-2758-4649-abc7-6d357b87f413", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges? ", "original_text": "Congrats on a nice report. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f3c86dc-9f06-4804-9728-cea7d8b6ac2a", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items? ", "original_text": "Thanks very much. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab810d2d3808c41b66e6bc2cdccc5980f6032f57db1a6ff69997d2c33074d90f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb0c494f-850e-4b86-8e36-21dbf1e6c84f", "node_type": "1", "metadata": {"window": "Q \nHey.  Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n ", "original_text": "So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort? "}, "hash": "65360bac9760f9a2d9ed732ec67abad6b47ee676cfba7b45abc5d8eecb7c4889", "class_name": "RelatedNodeInfo"}}, "text": "Congrats on a nice report. ", "start_char_idx": 1994, "end_char_idx": 2021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb0c494f-850e-4b86-8e36-21dbf1e6c84f": {"__data__": {"id_": "fb0c494f-850e-4b86-8e36-21dbf1e6c84f", "embedding": null, "metadata": {"window": "Q \nHey.  Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n ", "original_text": "So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort? ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "534561ae-2758-4649-abc7-6d357b87f413", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges? ", "original_text": "Congrats on a nice report. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c82ef0081b6a21f2925a2a45fa70f9e157476632269e767e43144e35df038c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6951472e-d9aa-4678-9672-db5bdc0ac0cd", "node_type": "1", "metadata": {"window": "Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items? "}, "hash": "cc4bbd7c6a04577beb3dd497c7ec04d4abe67243ed27eb0db27553cd0ca7afad", "class_name": "RelatedNodeInfo"}}, "text": "So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort? ", "start_char_idx": 2021, "end_char_idx": 2403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6951472e-d9aa-4678-9672-db5bdc0ac0cd": {"__data__": {"id_": "6951472e-d9aa-4678-9672-db5bdc0ac0cd", "embedding": null, "metadata": {"window": "Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items? ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb0c494f-850e-4b86-8e36-21dbf1e6c84f", "node_type": "1", "metadata": {"window": "Q \nHey.  Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n ", "original_text": "So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort? ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7227187df190db98545be2454ebc6b68919df9ffa013a295508a931b6712a8f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99fbff5f-4cbd-41d8-aaf3-44ea2e9ba34f", "node_type": "1", "metadata": {"window": "Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric. ", "original_text": "Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges? "}, "hash": "3e1d954a4f325129668ce9f0b93a599e29b6934bcbaada11195aaeb227f830f5", "class_name": "RelatedNodeInfo"}}, "text": "And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items? ", "start_char_idx": 2403, "end_char_idx": 2575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99fbff5f-4cbd-41d8-aaf3-44ea2e9ba34f": {"__data__": {"id_": "99fbff5f-4cbd-41d8-aaf3-44ea2e9ba34f", "embedding": null, "metadata": {"window": "Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric. ", "original_text": "Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges? ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6951472e-d9aa-4678-9672-db5bdc0ac0cd", "node_type": "1", "metadata": {"window": "Thanks very much.  Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items? ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "753f093d690412202644d17f2eb472172054018be9858cf1e89c02256143cf6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9e7ff88-cf6c-491d-99ed-3c3a7ccf139e", "node_type": "1", "metadata": {"window": "So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers. ", "original_text": "Thank you very much.  \n "}, "hash": "791b3263a72ae0ddd28bf425fff6d3b65a23a87e5c1838db7d2f86571ab0fbfa", "class_name": "RelatedNodeInfo"}}, "text": "Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges? ", "start_char_idx": 2575, "end_char_idx": 2707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9e7ff88-cf6c-491d-99ed-3c3a7ccf139e": {"__data__": {"id_": "c9e7ff88-cf6c-491d-99ed-3c3a7ccf139e", "embedding": null, "metadata": {"window": "So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers. ", "original_text": "Thank you very much.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99fbff5f-4cbd-41d8-aaf3-44ea2e9ba34f", "node_type": "1", "metadata": {"window": "Congrats on a nice report.  So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric. ", "original_text": "Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges? ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beff49de07c6b5537b9653485f7426128f473331df0879176c515f084c66f0b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e1e5318-30a6-4dcd-8749-58a7161d1827", "node_type": "1", "metadata": {"window": "And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "2be4d11021c7a560a622ff17f5a3d16834ad40cb09872a6f72f8a8288859ef6c", "class_name": "RelatedNodeInfo"}}, "text": "Thank you very much.  \n ", "start_char_idx": 2707, "end_char_idx": 2731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e1e5318-30a6-4dcd-8749-58a7161d1827": {"__data__": {"id_": "3e1e5318-30a6-4dcd-8749-58a7161d1827", "embedding": null, "metadata": {"window": "And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9e7ff88-cf6c-491d-99ed-3c3a7ccf139e", "node_type": "1", "metadata": {"window": "So during the quarter, the health of one of your known \ncustomers, I'll leave the name out, was very much in debate, and I'm just larger bigger picture here, curious if you \ncould talk about in general, when you see possible challenges at an account, what kind of protections do you put \nin place whether it be just -in-time invent ories, collection practices, things of that sort?  And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers. ", "original_text": "Thank you very much.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27413303682b1760ac8cc10d9240ea0812370f4d93f9c5335d7f333f7af3cf2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7981b5fd-e5bd-4cd5-957e-e2527fd0ab07", "node_type": "1", "metadata": {"window": "Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective. ", "original_text": "A \nHey, Eric. "}, "hash": "04aae9e12007afa3db556b9f3c9cb01bbe9eafc1c8fa8403d307ca422fd4b57c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2731, "end_char_idx": 3091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7981b5fd-e5bd-4cd5-957e-e2527fd0ab07": {"__data__": {"id_": "7981b5fd-e5bd-4cd5-957e-e2527fd0ab07", "embedding": null, "metadata": {"window": "Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective. ", "original_text": "A \nHey, Eric. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e1e5318-30a6-4dcd-8749-58a7161d1827", "node_type": "1", "metadata": {"window": "And also, if a formal \nrestructuring were to occur, such as a Chapter 11, what protections do you have then in terms of things like \ncritical vendor status or other items?  Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a067493f7f33bf31d12e796d01b1c1371f87b20dac10acdb7e463ef88e513b4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddb7ced3-8ea8-4413-a091-6d67db136b6d", "node_type": "1", "metadata": {"window": "Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n", "original_text": "Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers. "}, "hash": "4d837f0f7c4e137da42c0ba8968fbe0569e58bdb4cd7a25624be8a5223d1986d", "class_name": "RelatedNodeInfo"}}, "text": "A \nHey, Eric. ", "start_char_idx": 3091, "end_char_idx": 3105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddb7ced3-8ea8-4413-a091-6d67db136b6d": {"__data__": {"id_": "ddb7ced3-8ea8-4413-a091-6d67db136b6d", "embedding": null, "metadata": {"window": "Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n", "original_text": "Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7981b5fd-e5bd-4cd5-957e-e2527fd0ab07", "node_type": "1", "metadata": {"window": "Just a lot of debate from the invest or base in terms of what actually happens \nif a larger account has more pronounced challenges?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective. ", "original_text": "A \nHey, Eric. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2b8750efea9c84c0335b5c00f735ce3b1a0ba10c52f69408754f7805b47405b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7107c50-cdeb-4806-8f0e-64de66258cdc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer. ", "original_text": "We do stay very close to \nour customers. "}, "hash": "897c292555f5c1301d76b17420fcfcb0c786b2316b68659c02dd139d14183f46", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers. ", "start_char_idx": 3105, "end_char_idx": 3292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7107c50-cdeb-4806-8f0e-64de66258cdc": {"__data__": {"id_": "d7107c50-cdeb-4806-8f0e-64de66258cdc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer. ", "original_text": "We do stay very close to \nour customers. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddb7ced3-8ea8-4413-a091-6d67db136b6d", "node_type": "1", "metadata": {"window": "Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n", "original_text": "Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79d27ecec19e769c77080f5c5115120afb9aab984649fdaf12dcd54c979e1f48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d51503f-af6c-450e-b8c7-291f9a63f3f5", "node_type": "1", "metadata": {"window": "A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n ", "original_text": "We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective. "}, "hash": "b42c5f6c1a33ada0c915f2aca20c665122a507116a08da9bc6b0ee64243a69f2", "class_name": "RelatedNodeInfo"}}, "text": "We do stay very close to \nour customers. ", "start_char_idx": 3292, "end_char_idx": 3333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d51503f-af6c-450e-b8c7-291f9a63f3f5": {"__data__": {"id_": "5d51503f-af6c-450e-b8c7-291f9a63f3f5", "embedding": null, "metadata": {"window": "A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n ", "original_text": "We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7107c50-cdeb-4806-8f0e-64de66258cdc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer. ", "original_text": "We do stay very close to \nour customers. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a289ad7c1f5d03ace74bceaa33632e3fec90ef1600dea29b857f9b72f88a5b93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f729d1b8-d907-4629-a1a1-0deac2ea2435", "node_type": "1", "metadata": {"window": "Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.  ", "original_text": "And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n"}, "hash": "ab6fd135ebc703ed93585da3bcd094fcc9eeba6d181e40f0e13aa82a988c5fd6", "class_name": "RelatedNodeInfo"}}, "text": "We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective. ", "start_char_idx": 3333, "end_char_idx": 3606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f729d1b8-d907-4629-a1a1-0deac2ea2435": {"__data__": {"id_": "f729d1b8-d907-4629-a1a1-0deac2ea2435", "embedding": null, "metadata": {"window": "Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.  ", "original_text": "And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d51503f-af6c-450e-b8c7-291f9a63f3f5", "node_type": "1", "metadata": {"window": "A \nHey, Eric.  Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n ", "original_text": "We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "340ed4820aa825a795bc42d8df0fb8d9ba323508b379eea517d4da075680351a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f3d2cab-3cd5-4978-9922-7893781d2d18", "node_type": "1", "metadata": {"window": "We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "Beyond that, I really can't get into the specifics of our contracts that we have with each customer. "}, "hash": "8d7b384cecbb25a06f1501823b9a3e57e34b596fd1aa144a5f111ce817baa75c", "class_name": "RelatedNodeInfo"}}, "text": "And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n", "start_char_idx": 3606, "end_char_idx": 3754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f3d2cab-3cd5-4978-9922-7893781d2d18": {"__data__": {"id_": "6f3d2cab-3cd5-4978-9922-7893781d2d18", "embedding": null, "metadata": {"window": "We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "Beyond that, I really can't get into the specifics of our contracts that we have with each customer. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f729d1b8-d907-4629-a1a1-0deac2ea2435", "node_type": "1", "metadata": {"window": "Thanks for the question and I appreciate  where you're coming from on this, for probably obvious \nreasons we don't get into the health or the economics or the situation of our customers.  We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.  ", "original_text": "And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5b458e7b411c97712ecde44d6c924a23c8a595e706411a7747253e254e722d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18023cbf-e69f-4a9d-8433-968c2f67ee33", "node_type": "1", "metadata": {"window": "We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "original_text": "Hopefully, you \ncan understand that.  \n "}, "hash": "d99177b8cd4104bbdf336cd759600621cae3e5c14655dbac829b9f3e9147be2d", "class_name": "RelatedNodeInfo"}}, "text": "Beyond that, I really can't get into the specifics of our contracts that we have with each customer. ", "start_char_idx": 3754, "end_char_idx": 3855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18023cbf-e69f-4a9d-8433-968c2f67ee33": {"__data__": {"id_": "18023cbf-e69f-4a9d-8433-968c2f67ee33", "embedding": null, "metadata": {"window": "We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "original_text": "Hopefully, you \ncan understand that.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f3d2cab-3cd5-4978-9922-7893781d2d18", "node_type": "1", "metadata": {"window": "We do stay very close to \nour customers.  We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "Beyond that, I really can't get into the specifics of our contracts that we have with each customer. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ca04d43f520752d8a98cb1dbde357d485d12035f35268e5f0597eb94a327f83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a639ecff-4e09-48a7-8f08-042ae2af7609", "node_type": "1", "metadata": {"window": "And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.  "}, "hash": "5a55579918bcd0b1038cbac76ec11b2bd95dad7f2d5a89426fd05dbd2ae459c8", "class_name": "RelatedNodeInfo"}}, "text": "Hopefully, you \ncan understand that.  \n ", "start_char_idx": 3855, "end_char_idx": 3895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a639ecff-4e09-48a7-8f08-042ae2af7609": {"__data__": {"id_": "a639ecff-4e09-48a7-8f08-042ae2af7609", "embedding": null, "metadata": {"window": "And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18023cbf-e69f-4a9d-8433-968c2f67ee33", "node_type": "1", "metadata": {"window": "We're always trying to find ways to help them to grow and find addition al services and capabilities \nfor them, so I feel good about the customer contacts that we have and our ability to understand their strategies \nand what they're trying to do from a growth perspective.  And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "original_text": "Hopefully, you \ncan understand that.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ef3ee3c84e9423455f5a023e447cc99664cb40b235388bc468c539939cdf674", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd952959-baa4-42d6-932c-e5f0782251ef", "node_type": "1", "metadata": {"window": "Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "original_text": "A \nNext question, please?  \n "}, "hash": "987503fc97fe90c4f9ea8a7c9f822fc8104a98b156be0a12a7e6fb8be6a43455", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.  ", "start_char_idx": 3895, "end_char_idx": 4241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd952959-baa4-42d6-932c-e5f0782251ef": {"__data__": {"id_": "fd952959-baa4-42d6-932c-e5f0782251ef", "embedding": null, "metadata": {"window": "Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "original_text": "A \nNext question, please?  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a639ecff-4e09-48a7-8f08-042ae2af7609", "node_type": "1", "metadata": {"window": "And I think the broad base set of customers that we have \nacross each of our segments, I feel comfortable with how we manage our relationships.  \n \n Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a1141bb920b8fe1c81922c233d6d48698d8810295351efe55432558ac0d641d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46a793ab-0b7b-4aa8-8ddb-3c84cf3b841c", "node_type": "1", "metadata": {"window": "Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. "}, "hash": "03d3ff37800725d22abf11cf297980084e7e2029016efca1365fd50b8d887bc2", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 1259, "end_char_idx": 1288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46a793ab-0b7b-4aa8-8ddb-3c84cf3b841c": {"__data__": {"id_": "46a793ab-0b7b-4aa8-8ddb-3c84cf3b841c", "embedding": null, "metadata": {"window": "Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd952959-baa4-42d6-932c-e5f0782251ef", "node_type": "1", "metadata": {"window": "Beyond that, I really can't get into the specifics of our contracts that we have with each customer.  Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "original_text": "A \nNext question, please?  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "831a98b34a49cc6969f7ce2b201ef3af5015b69f459c9b21aedbcb39337dac81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aba50923-a485-49a8-924b-606596942162", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "original_text": "Please go ahead.  \n "}, "hash": "4448d36d3ffdf32b681d47d24db85f43c368506490fe4cad2bd3fe222ddd541a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "start_char_idx": 4270, "end_char_idx": 4597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aba50923-a485-49a8-924b-606596942162": {"__data__": {"id_": "aba50923-a485-49a8-924b-606596942162", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "original_text": "Please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46a793ab-0b7b-4aa8-8ddb-3c84cf3b841c", "node_type": "1", "metadata": {"window": "Hopefully, you \ncan understand that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0145a0362ae04281d49bdaadce648c5eb5f2271cbab9b2491b8460f231ec556c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4913b27-4b2f-4801-9181-d486d6fe920a", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. "}, "hash": "2596e273115851dd1baf73da72372cb415c28c583f09b0413dce9df08d72e5b5", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1616, "end_char_idx": 1636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4913b27-4b2f-4801-9181-d486d6fe920a": {"__data__": {"id_": "d4913b27-4b2f-4801-9181-d486d6fe920a", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aba50923-a485-49a8-924b-606596942162", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presiden t of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "original_text": "Please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00e8942b4adb9aaa8023a109f28754ce038a57b9abee745a502ddf0f7c4d0927", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a877cb2-16f6-47b7-a66d-7fca81c8c4b4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "original_text": "Thanks for taking my question. "}, "hash": "5a3bbebbf6a5d8aab60313916d11f09599d050e07b70225f7f299a0158cab72a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "start_char_idx": 4617, "end_char_idx": 4942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a877cb2-16f6-47b7-a66d-7fca81c8c4b4": {"__data__": {"id_": "5a877cb2-16f6-47b7-a66d-7fca81c8c4b4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "original_text": "Thanks for taking my question. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4913b27-4b2f-4801-9181-d486d6fe920a", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4776f9f5850f4e10c541fe5b33a036e9fe82e01ccb8b510563cb3707bc48e5e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c47f6e7b-6f0d-4eb3-84ec-19d9f707e5f7", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "original_text": "I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a "}, "hash": "1fa6970c46274fa319a53621925d46848875862ff3903183f3c73c017e711cad", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my question. ", "start_char_idx": 4942, "end_char_idx": 4973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c47f6e7b-6f0d-4eb3-84ec-19d9f707e5f7": {"__data__": {"id_": "c47f6e7b-6f0d-4eb3-84ec-19d9f707e5f7", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "original_text": "I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "204daa18-f611-4af9-b386-642ea97a1e42", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2c14d584b2a10d8b7f78723f8fe108f92933cd597c51d79123e8a8ec590135f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a877cb2-16f6-47b7-a66d-7fca81c8c4b4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "original_text": "Thanks for taking my question. ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36b97a7ebad906a192b9a403ba6d4292233b2f20befc117f164f20ac82533747", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b7520e2-48b8-4fa8-8ede-f3ed56981886", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n ", "original_text": "McKesson Corp.  "}, "hash": "4c08e5cb9722f985f14613e51977d115927d480f7b32f6acc3ee5da98b9d55d1", "class_name": "RelatedNodeInfo"}}, "text": "I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "start_char_idx": 4973, "end_char_idx": 5163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b7520e2-48b8-4fa8-8ede-f3ed56981886": {"__data__": {"id_": "4b7520e2-48b8-4fa8-8ede-f3ed56981886", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c47f6e7b-6f0d-4eb3-84ec-19d9f707e5f7", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "original_text": "I guess on the GLP -1s, I have to ask just because it's obviously such a big \ndriver, but do you think that your share of the market corresponds to your typical share within a category or a ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2764b05e35fdc138fc1d6c4e8c3acb95f2df546745a283283bfca9442a57ec8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "226d34b0-b831-48f2-90bd-1059683b9667", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug? "}, "hash": "46d7c91109b9072c2db37e39720656ceaf694c4c6ee06fb43492e804e256c69b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "226d34b0-b831-48f2-90bd-1059683b9667": {"__data__": {"id_": "226d34b0-b831-48f2-90bd-1059683b9667", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug? ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b7520e2-48b8-4fa8-8ede-f3ed56981886", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52bc62baa9949e1b3468f938fb06d4fa7b2640cdc123eac783fe635b4a1e2017", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bc7d83b-8250-4e47-a4be-f93aa1d8255c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall. ", "original_text": "Meaning have you been able to secure more supply or do you have any means? "}, "hash": "e64c3247107580987291e7dea811401fc9a5d7b6add50a7e8b8ec431de1af7ef", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug? ", "start_char_idx": 16, "end_char_idx": 187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bc7d83b-8250-4e47-a4be-f93aa1d8255c": {"__data__": {"id_": "5bc7d83b-8250-4e47-a4be-f93aa1d8255c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall. ", "original_text": "Meaning have you been able to secure more supply or do you have any means? ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "226d34b0-b831-48f2-90bd-1059683b9667", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug? ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6fccf3c5355d6cc41efc5a44dc89ff2f9c17cf9eded7cd7314d18fe433ca1b7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "516e7170-65b8-479c-b5e6-c2b624609118", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts. ", "original_text": "Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n "}, "hash": "1a36c8e46ab1a5f54cf118c156a805d27dd2a896cfca8f7ea1bd27be56d12cfa", "class_name": "RelatedNodeInfo"}}, "text": "Meaning have you been able to secure more supply or do you have any means? ", "start_char_idx": 187, "end_char_idx": 262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "516e7170-65b8-479c-b5e6-c2b624609118": {"__data__": {"id_": "516e7170-65b8-479c-b5e6-c2b624609118", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts. ", "original_text": "Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bc7d83b-8250-4e47-a4be-f93aa1d8255c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall. ", "original_text": "Meaning have you been able to secure more supply or do you have any means? ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64e97b6c0b0ced0ea52ab17b994da45b030676bcf94319aa68c01b0d88ba1fc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54c44b5e-4169-4582-be1f-3c23ea0a0e80", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "9f1658cfd0b1b9ef0d56a2af1fb6ef762517086911858a230c502efb2b0f2fe6", "class_name": "RelatedNodeInfo"}}, "text": "Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n ", "start_char_idx": 262, "end_char_idx": 463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54c44b5e-4169-4582-be1f-3c23ea0a0e80": {"__data__": {"id_": "54c44b5e-4169-4582-be1f-3c23ea0a0e80", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "516e7170-65b8-479c-b5e6-c2b624609118", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts. ", "original_text": "Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e27d8ac702d7feaf1edc8c2f752c00a44e9dddbf68b55aab4cc2ecb9dbbf15a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "596f5e9a-9ff2-4cab-a564-68c417250aac", "node_type": "1", "metadata": {"window": "Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n ", "original_text": "A \nI would  think that our mix would be fairly representative of our business mix overall. "}, "hash": "56ec294b2e9b1870e4de7d29db6e231df8bbd43f9eee1570764e5201dc3a5df3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 463, "end_char_idx": 807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "596f5e9a-9ff2-4cab-a564-68c417250aac": {"__data__": {"id_": "596f5e9a-9ff2-4cab-a564-68c417250aac", "embedding": null, "metadata": {"window": "Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n ", "original_text": "A \nI would  think that our mix would be fairly representative of our business mix overall. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54c44b5e-4169-4582-be1f-3c23ea0a0e80", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c6bf729c2100954b8bc67777812755a14ccba2a4220420ac9a34b592e418c35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c68548ee-bc92-4c45-b943-02ef6f38544f", "node_type": "1", "metadata": {"window": "Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts. "}, "hash": "0afb86a275fb36511611bf50439b9df8d1acb963bc8e7442a770d98b772a58a9", "class_name": "RelatedNodeInfo"}}, "text": "A \nI would  think that our mix would be fairly representative of our business mix overall. ", "start_char_idx": 807, "end_char_idx": 898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c68548ee-bc92-4c45-b943-02ef6f38544f": {"__data__": {"id_": "c68548ee-bc92-4c45-b943-02ef6f38544f", "embedding": null, "metadata": {"window": "Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "596f5e9a-9ff2-4cab-a564-68c417250aac", "node_type": "1", "metadata": {"window": "Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n ", "original_text": "A \nI would  think that our mix would be fairly representative of our business mix overall. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45238ff2275cff167b0e21127c9df8666b31eec4278ddf359c2ecd3d7105de80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3581b95c-e23d-4f25-8ee7-087cb3b767db", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based. ", "original_text": "There have been poin ts in time where supply has been less than demand. "}, "hash": "62f0fee2e86739de1ce98045fa6d653910b690ede078378ae40352812c5b12fa", "class_name": "RelatedNodeInfo"}}, "text": "They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts. ", "start_char_idx": 898, "end_char_idx": 1056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3581b95c-e23d-4f25-8ee7-087cb3b767db": {"__data__": {"id_": "3581b95c-e23d-4f25-8ee7-087cb3b767db", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based. ", "original_text": "There have been poin ts in time where supply has been less than demand. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c68548ee-bc92-4c45-b943-02ef6f38544f", "node_type": "1", "metadata": {"window": "Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8aa69e0a175bde31a2334d961be9f585f82dfb22c6293affb6d57820879d2cda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "739ee451-e1bb-4bcb-b561-83358e60b070", "node_type": "1", "metadata": {"window": "A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends. ", "original_text": "We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n "}, "hash": "3dd58a13a0132bafd1bcfdcca4d38f7bb38335d1fe2f89af7067d8469d291928", "class_name": "RelatedNodeInfo"}}, "text": "There have been poin ts in time where supply has been less than demand. ", "start_char_idx": 1056, "end_char_idx": 1128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "739ee451-e1bb-4bcb-b561-83358e60b070": {"__data__": {"id_": "739ee451-e1bb-4bcb-b561-83358e60b070", "embedding": null, "metadata": {"window": "A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends. ", "original_text": "We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3581b95c-e23d-4f25-8ee7-087cb3b767db", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based. ", "original_text": "There have been poin ts in time where supply has been less than demand. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44fe9e9696427dd35ac948ce577eb68b33ee1765838b1832c11b80fcb1a7f7bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c04148b2-d67b-41f1-9b47-3493494ad6fe", "node_type": "1", "metadata": {"window": "They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "3cbe80d89946f13dc446ac62e34d24c0684150aa08e11ebf04ab57f15e9812ee", "class_name": "RelatedNodeInfo"}}, "text": "We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n ", "start_char_idx": 1128, "end_char_idx": 1373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c04148b2-d67b-41f1-9b47-3493494ad6fe": {"__data__": {"id_": "c04148b2-d67b-41f1-9b47-3493494ad6fe", "embedding": null, "metadata": {"window": "They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "739ee451-e1bb-4bcb-b561-83358e60b070", "node_type": "1", "metadata": {"window": "A \nI would  think that our mix would be fairly representative of our business mix overall.  They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends. ", "original_text": "We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc2e98ad2c67e85e27a7e3a6280c7475c44e7b6715120dd8568c14d083f37891", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65c5bd94-0a7f-4f90-ae30-5c25d728bfa0", "node_type": "1", "metadata": {"window": "There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n ", "original_text": "A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based. "}, "hash": "4413a41d11c27c6abd179515f54b4ab00faee13cf708fc9b601ab992092d9738", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1373, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65c5bd94-0a7f-4f90-ae30-5c25d728bfa0": {"__data__": {"id_": "65c5bd94-0a7f-4f90-ae30-5c25d728bfa0", "embedding": null, "metadata": {"window": "There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n ", "original_text": "A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c04148b2-d67b-41f1-9b47-3493494ad6fe", "node_type": "1", "metadata": {"window": "They probably have our \nappropriate share in Health Systems, our appropriate share in independence, our appropriate share in large retail \nnational accounts.  There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b751c8299c9386f455a3ed9f1cb83866cc3f5246a58d38d100678dd972f7a10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fcb084b-b7a1-494c-9661-bb389171f824", "node_type": "1", "metadata": {"window": "We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends. "}, "hash": "1b1fdf79fb27b31cb6abe5c1fe1d21c3547324edfca897c53600860988b1f852", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based. ", "start_char_idx": 1733, "end_char_idx": 1954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fcb084b-b7a1-494c-9661-bb389171f824": {"__data__": {"id_": "0fcb084b-b7a1-494c-9661-bb389171f824", "embedding": null, "metadata": {"window": "We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65c5bd94-0a7f-4f90-ae30-5c25d728bfa0", "node_type": "1", "metadata": {"window": "There have been poin ts in time where supply has been less than demand.  We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n ", "original_text": "A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73eaafc6fba848c523243c143d6c6c4172c186729a0218b04c5c14b0904d03fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0084350b-01be-406a-ad53-61a1473f3973", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n "}, "hash": "81410969f1cd10aead1daa095a04f2c254a0549bb113032611da60fce3d59572", "class_name": "RelatedNodeInfo"}}, "text": "It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends. ", "start_char_idx": 1954, "end_char_idx": 2130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0084350b-01be-406a-ad53-61a1473f3973": {"__data__": {"id_": "0084350b-01be-406a-ad53-61a1473f3973", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fcb084b-b7a1-494c-9661-bb389171f824", "node_type": "1", "metadata": {"window": "We work closely \nwith all of our vendors to make sure we get our representative in fair share and that we can coordinate with them \nand communicate effectively with our customers, but overall, I'd say we wou ld have the mix you would expect.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47fb8799ccfdb506ac67ed24d47db9c8411645de203cfadab28ddd1e7d858afb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa18f7ed-078c-46aa-9ee3-c3ab114924f7", "node_type": "1", "metadata": {"window": "A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n "}, "hash": "fda1bde1b51fe7885d97a22b3daeedf2da5befbc8cf1b39c7bea1fec914fb389", "class_name": "RelatedNodeInfo"}}, "text": "I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n ", "start_char_idx": 2130, "end_char_idx": 2396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa18f7ed-078c-46aa-9ee3-c3ab114924f7": {"__data__": {"id_": "aa18f7ed-078c-46aa-9ee3-c3ab114924f7", "embedding": null, "metadata": {"window": "A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0084350b-01be-406a-ad53-61a1473f3973", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e04ac2e3f2a491d5ea6da70589d4f6233bb71c318bc2890788ebdc88657f2ec2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "294d3db0-3eb1-44e0-a96d-5ec68a17ca22", "node_type": "1", "metadata": {"window": "It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "b253946d5aada59e40267c70db63717abbd5ab661343383f7998e42d4ea9bd71", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n ", "start_char_idx": 2396, "end_char_idx": 2731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "294d3db0-3eb1-44e0-a96d-5ec68a17ca22": {"__data__": {"id_": "294d3db0-3eb1-44e0-a96d-5ec68a17ca22", "embedding": null, "metadata": {"window": "It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa18f7ed-078c-46aa-9ee3-c3ab114924f7", "node_type": "1", "metadata": {"window": "A \nAnd I would say that it's a fair question, and as we talked about GLP -1s did provide revenue tailwind for our \ndistribution business,  but I would just remind you that the growth in the segment was very broad -based.  It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18093de18c390626a215ad22a28c8eb6c0ab2ec9ea24bdc635aa06780a63e8c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9f4229e-e5d9-4614-9a29-4f35c2a4b14c", "node_type": "1", "metadata": {"window": "I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "A \nNext question, please?  \n "}, "hash": "3cd6d71dfcf4af0590bf476dc7a3fb6f8e8fa4e48d8bc51afb5ff98641975a33", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 2731, "end_char_idx": 3076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9f4229e-e5d9-4614-9a29-4f35c2a4b14c": {"__data__": {"id_": "c9f4229e-e5d9-4614-9a29-4f35c2a4b14c", "embedding": null, "metadata": {"window": "I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "A \nNext question, please?  \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "294d3db0-3eb1-44e0-a96d-5ec68a17ca22", "node_type": "1", "metadata": {"window": "It was \nacross specialty products, it was across our generics business, it was really across each of the segments outside \nof GLP -1s and that reflects the utilization trends.  I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edb1e52b6afb94ae7869f4ade72b945ee734616b00fd4734a6bb9c31000edd2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "926bde06-fe04-4777-98f8-3421139740cd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. "}, "hash": "750eea8b565fc57560aa120d526c302c4d2b0ac5d3b5eb7a300a40e6f04f7d99", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 3076, "end_char_idx": 3105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "926bde06-fe04-4777-98f8-3421139740cd": {"__data__": {"id_": "926bde06-fe04-4777-98f8-3421139740cd", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9f4229e-e5d9-4614-9a29-4f35c2a4b14c", "node_type": "1", "metadata": {"window": "I t also reflects the services and capabilities that we have that we \nprovide to our broad customer base, so certainly GLP -1s are topical and have provided a tailwind but the \nbusiness is performing quite well across really all categories and our customer base . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "A \nNext question, please?  \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c1cb504b212d73d04c28cb9716fc77fa1f43564f57ccf675369a9b408919ee2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5acbe72b-7b14-46e2-ab18-a9d5085c31e5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Please go ahead.  \n "}, "hash": "bc99d556fde68c67df21d4b5f5b26a1899c60431d346676aecb80bb0132ec5ab", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "start_char_idx": 3105, "end_char_idx": 3443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5acbe72b-7b14-46e2-ab18-a9d5085c31e5": {"__data__": {"id_": "5acbe72b-7b14-46e2-ab18-a9d5085c31e5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Please go ahead.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "926bde06-fe04-4777-98f8-3421139740cd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "febf1b0c18d1fadba4e3de99bb0bec5279f87d4f8c60a07165cc3143311f6e1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31396a9c-c1d5-4589-8de3-b6f0da24ebba", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. "}, "hash": "9d03264118fa7b794d744a17346f19befb113f2cdf03e25f1491ccc5c4d317d7", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 3443, "end_char_idx": 3463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31396a9c-c1d5-4589-8de3-b6f0da24ebba": {"__data__": {"id_": "31396a9c-c1d5-4589-8de3-b6f0da24ebba", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5acbe72b-7b14-46e2-ab18-a9d5085c31e5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Please go ahead.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "719cad41ea2d496363dcf34de9994e18b0c342da7d34fd3b34bbec420eb52246", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5132822b-52b2-48f4-a9b4-018b2877355b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class. ", "original_text": "I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n "}, "hash": "acb538ef699107e62cdecaa105c1015c7d6b945ae38eb1edddbb461d85296e00", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "start_char_idx": 3463, "end_char_idx": 3795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5132822b-52b2-48f4-a9b4-018b2877355b": {"__data__": {"id_": "5132822b-52b2-48f4-a9b4-018b2877355b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class. ", "original_text": "I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31396a9c-c1d5-4589-8de3-b6f0da24ebba", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e7fb8b115784626a2a7df0bbc45df3d9c2d032e1871c7c060dff58f4281f16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a8bcd2f-67b6-478e-bc6b-45a6c7bf7965", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "0e60d62a560f62ee4dbdcd8af9bf9b0e993704c47a22d3061d4ac04bd243e03d", "class_name": "RelatedNodeInfo"}}, "text": "I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n ", "start_char_idx": 3795, "end_char_idx": 4076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a8bcd2f-67b6-478e-bc6b-45a6c7bf7965": {"__data__": {"id_": "1a8bcd2f-67b6-478e-bc6b-45a6c7bf7965", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5132822b-52b2-48f4-a9b4-018b2877355b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class. ", "original_text": "I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e83f568f2dfdfb5bd2dbfb843acf77f1b5cd78e5bd843625f768f8246caa560d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49a8269b-9061-41bb-913d-d367d1f94f28", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "original_text": "A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle. "}, "hash": "ccbb5c70ce85e3b0ba88cf9e94f9502af51dda04a0990f6a5416c4e0d1f283ed", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 463, "end_char_idx": 807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49a8269b-9061-41bb-913d-d367d1f94f28": {"__data__": {"id_": "49a8269b-9061-41bb-913d-d367d1f94f28", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "original_text": "A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a8bcd2f-67b6-478e-bc6b-45a6c7bf7965", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74820b2b1824d2d4d70d9b06a9e62bc613c1e28a4f07c617960a53eb1218e60a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9511f79b-1489-4056-bf5d-b2ac09ba1f40", "node_type": "1", "metadata": {"window": "I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "original_text": "Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class. "}, "hash": "834f2a0867f278d4d8fc24a5a9e194d6ec046a30f88e127a7ae89990a6a47b92", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle. ", "start_char_idx": 4420, "end_char_idx": 4540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9511f79b-1489-4056-bf5d-b2ac09ba1f40": {"__data__": {"id_": "9511f79b-1489-4056-bf5d-b2ac09ba1f40", "embedding": null, "metadata": {"window": "I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "original_text": "Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49a8269b-9061-41bb-913d-d367d1f94f28", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "original_text": "A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6df80cb302e79a1ba5d3edb99ba87ffbea688d852ff630d1a6f5be10a582f7f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e36b966-a831-4bbb-9f02-0c16f8a5653e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "original_text": "We like to try to think about supporting the products over the course of their \nlifetime.  \n \n"}, "hash": "1384879b5b079a52ea543acaaeb0a3a8aa822eda80adad551aa3ccfcb6abb494", "class_name": "RelatedNodeInfo"}}, "text": "Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class. ", "start_char_idx": 4540, "end_char_idx": 4688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e36b966-a831-4bbb-9f02-0c16f8a5653e": {"__data__": {"id_": "7e36b966-a831-4bbb-9f02-0c16f8a5653e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "original_text": "We like to try to think about supporting the products over the course of their \nlifetime.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9511f79b-1489-4056-bf5d-b2ac09ba1f40", "node_type": "1", "metadata": {"window": "I want to ask a RxTS question that is somewhat GLP -1-related, which is as you see products go from \ntightly managed to more open access, how does RxTS's offering change and have you seen success moving \nfrom early  restricted access assistance to adherence or other offerings?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "original_text": "Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class. ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9245834ee0df3ce65453ab951a79bb65cd8ca00cc349e4757398d9b7b69c7486", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dc2d2af-0900-4666-b86c-e538bcfdff88", "node_type": "1", "metadata": {"window": "A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "original_text": "Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can "}, "hash": "dd40bcaa91512fbfb723b8cf485dab8a136a28db61e9a2fafa551f69a0e7ed6b", "class_name": "RelatedNodeInfo"}}, "text": "We like to try to think about supporting the products over the course of their \nlifetime.  \n \n", "start_char_idx": 4688, "end_char_idx": 4782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dc2d2af-0900-4666-b86c-e538bcfdff88": {"__data__": {"id_": "3dc2d2af-0900-4666-b86c-e538bcfdff88", "embedding": null, "metadata": {"window": "A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "original_text": "Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3799385-e838-4303-8560-c424e27f15f4", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28045e7d0add673b01084dc6965c4f1d0d5d869064f320c3cdd55c743fdc9f4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e36b966-a831-4bbb-9f02-0c16f8a5653e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "original_text": "We like to try to think about supporting the products over the course of their \nlifetime.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cd54a6ca709fd10243c313528f327b56728986ba72ab46ab7b3f4cfd4b2b178", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb2d947f-93b5-4901-9728-a6ac37e9ceb6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  "}, "hash": "a30b74dcd5b313d4887d17b8ccc542bcaa74c88563922a37b9ee33e1593e1472", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "start_char_idx": 4782, "end_char_idx": 5009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb2d947f-93b5-4901-9728-a6ac37e9ceb6": {"__data__": {"id_": "cb2d947f-93b5-4901-9728-a6ac37e9ceb6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dc2d2af-0900-4666-b86c-e538bcfdff88", "node_type": "1", "metadata": {"window": "A \nWell, I mean, the nature of what we offer to support a drug is often different at different points in its lifecycle.  Wh at \nyou might want at launch will be a lot different than what you are at maturity and can depend on how other \ncompetitors come into the class.  We like to try to think about supporting the products over the course of their \nlifetime.  \n \n Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "original_text": "Obviously, their payer and employer decisions around how they want to treat certain classes of drugs can dictate \nthe services that we might offer and as these drugs are relatively new to market, speaking as an employer, I can ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c49d960add4f51105249ec4e7becf512ab9cb7585f9d78926f24aaebbf88f1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6d1e569-24dc-430f-95eb-290f9822b01e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please? ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them. "}, "hash": "dd6c3825fe612ab085369c663795562ffcbcea3f1cbe7a2cab94900b3bc9cbb2", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6d1e569-24dc-430f-95eb-290f9822b01e": {"__data__": {"id_": "d6d1e569-24dc-430f-95eb-290f9822b01e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please? ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb2d947f-93b5-4901-9728-a6ac37e9ceb6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "355be342485ce30306647a92268b8938d1e1670a03c1db95f5340b85a1ffce81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbb3ac72-c242-42be-a53f-b0c520f89f37", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n ", "original_text": "That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n "}, "hash": "b7b57f185f3bab1ab78da5a8caa3bee65015fb75889e9a0d3ae558e2c624dc40", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them. ", "start_char_idx": 16, "end_char_idx": 260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbb3ac72-c242-42be-a53f-b0c520f89f37": {"__data__": {"id_": "cbb3ac72-c242-42be-a53f-b0c520f89f37", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n ", "original_text": "That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6d1e569-24dc-430f-95eb-290f9822b01e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please? ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c998091b7fea89cf382b7facdd73b0afeea07e4ecb466eed217e53afb944fc08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18d6a387-e9a9-468b-a0fc-8b758ed321c4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "96393b43d0330c9a81ceb76973958e8b4fc1f5bfb018a133f0dd9e8a8d19f329", "class_name": "RelatedNodeInfo"}}, "text": "That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n ", "start_char_idx": 260, "end_char_idx": 381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18d6a387-e9a9-468b-a0fc-8b758ed321c4": {"__data__": {"id_": "18d6a387-e9a9-468b-a0fc-8b758ed321c4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbb3ac72-c242-42be-a53f-b0c520f89f37", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n ", "original_text": "That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9a33e3a7b22694d984ad3806e3462a8bfbed8b7b235a3956beb655051ff9218", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b7b66c4-a638-4821-a0b9-31a1a096735d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse. ", "original_text": "A \nNext question, please? "}, "hash": "27f9c056aa12be69b2b3c6a66d61c984a6fd84fa3c82d307ab0b742c352ee823", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 381, "end_char_idx": 726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b7b66c4-a638-4821-a0b9-31a1a096735d": {"__data__": {"id_": "0b7b66c4-a638-4821-a0b9-31a1a096735d", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse. ", "original_text": "A \nNext question, please? ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18d6a387-e9a9-468b-a0fc-8b758ed321c4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1b6f380f85f97bf636fd64a127b329af7785f8ed4eb0d78cb3c3f93162aab44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1baef5f8-eb70-4f0f-a346-63c2ca3842ed", "node_type": "1", "metadata": {"window": "That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n ", "original_text": "Operator, next question, please?  \n "}, "hash": "bef97a3afdfc65b4ff1a1ca1ab7375380fed671cdbd41434cb92c2839fc70e5f", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please? ", "start_char_idx": 726, "end_char_idx": 752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1baef5f8-eb70-4f0f-a346-63c2ca3842ed": {"__data__": {"id_": "1baef5f8-eb70-4f0f-a346-63c2ca3842ed", "embedding": null, "metadata": {"window": "That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n ", "original_text": "Operator, next question, please?  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b7b66c4-a638-4821-a0b9-31a1a096735d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse. ", "original_text": "A \nNext question, please? ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eaadfee61eb5aeaf8897f9859d596a73847a8d13eab00d04e6b7a158926b101a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f1ec978-0cf5-4ff6-a858-411b34c2cdeb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J. "}, "hash": "f04e21c091c59ebe163872e4afe3c189bde042fb66e4bfd1681159fb2de7d90c", "class_name": "RelatedNodeInfo"}}, "text": "Operator, next question, please?  \n ", "start_char_idx": 752, "end_char_idx": 788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f1ec978-0cf5-4ff6-a858-411b34c2cdeb": {"__data__": {"id_": "3f1ec978-0cf5-4ff6-a858-411b34c2cdeb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1baef5f8-eb70-4f0f-a346-63c2ca3842ed", "node_type": "1", "metadata": {"window": "That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n ", "original_text": "Operator, next question, please?  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5909241a280802549f0f7454b9d2cca080f9d26891d39da97ea515096186245e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "814cd7ec-a158-43bd-a4ba-4a9e330d70dc", "node_type": "1", "metadata": {"window": "A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n ", "original_text": "Rice with Credit Suisse. "}, "hash": "2b2622228e7b703147e0b61a001fb8916f227f305274120fd68a598d3048ce54", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J. ", "start_char_idx": 788, "end_char_idx": 1095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "814cd7ec-a158-43bd-a4ba-4a9e330d70dc": {"__data__": {"id_": "814cd7ec-a158-43bd-a4ba-4a9e330d70dc", "embedding": null, "metadata": {"window": "A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n ", "original_text": "Rice with Credit Suisse. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f1ec978-0cf5-4ff6-a858-411b34c2cdeb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e455a368851dec579c0a5b5aad54849dc93e45a5ea96617fd00f5d2f69823ba9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a482791-5899-4df3-a2d2-e8fa3a65df90", "node_type": "1", "metadata": {"window": "Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. ", "original_text": "Please go ahead.  \n "}, "hash": "8b9277aa948535b28b503e736bb745aac49737a5a06dc847be9f5f2209fea928", "class_name": "RelatedNodeInfo"}}, "text": "Rice with Credit Suisse. ", "start_char_idx": 1095, "end_char_idx": 1120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a482791-5899-4df3-a2d2-e8fa3a65df90": {"__data__": {"id_": "6a482791-5899-4df3-a2d2-e8fa3a65df90", "embedding": null, "metadata": {"window": "Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "814cd7ec-a158-43bd-a4ba-4a9e330d70dc", "node_type": "1", "metadata": {"window": "A \nNext question, please?  Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n ", "original_text": "Rice with Credit Suisse. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2ce5948252204d4ba74554111821a94c4296deee7398d3ebcd313b549983c92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b03afb18-1da9-437a-b741-348f3ae658c9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "2d812f7e77aa067a7f165a01601e8438b60c9f6eb127ea90e6ca9c9cf74bcc8d", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1120, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b03afb18-1da9-437a-b741-348f3ae658c9": {"__data__": {"id_": "b03afb18-1da9-437a-b741-348f3ae658c9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a482791-5899-4df3-a2d2-e8fa3a65df90", "node_type": "1", "metadata": {"window": "Operator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4792e4844d5eddab9f57fb134ea8a5e1050d463f2a33b6f035142d6aa4b2b17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "570bc289-5a95-4dc5-b03c-df2acff19a63", "node_type": "1", "metadata": {"window": "Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n ", "original_text": "A \nA.J.?  \n "}, "hash": "d7096cb643781f626f94541689ce15ce60e2b107b24f1ffdea96de68225604b1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 381, "end_char_idx": 726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "570bc289-5a95-4dc5-b03c-df2acff19a63": {"__data__": {"id_": "570bc289-5a95-4dc5-b03c-df2acff19a63", "embedding": null, "metadata": {"window": "Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n ", "original_text": "A \nA.J.?  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b03afb18-1da9-437a-b741-348f3ae658c9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be A.J.  Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44c8d81652776e81ab137fdc59c1104f89ac98b9396b4adc88e17d18ff459cb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23d2a0f8-a595-4a06-88b2-4cfe97ff1268", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. "}, "hash": "bd553f961a36c336bc7e99d150e124634bce43428db52b61590a11dd247e2cfa", "class_name": "RelatedNodeInfo"}}, "text": "A \nA.J.?  \n ", "start_char_idx": 1485, "end_char_idx": 1497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23d2a0f8-a595-4a06-88b2-4cfe97ff1268": {"__data__": {"id_": "23d2a0f8-a595-4a06-88b2-4cfe97ff1268", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "570bc289-5a95-4dc5-b03c-df2acff19a63", "node_type": "1", "metadata": {"window": "Rice with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n ", "original_text": "A \nA.J.?  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f445e49356e4964830ab00da54039de2809e6c07f599278965aaca6a7ee4fce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3163f572-9720-48dc-a8ae-f8348162ac5b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry. ", "original_text": "Rice, are you on the line? "}, "hash": "24bc61f5e59bc9da014fc9705c16e25023c681334e0219880229b367263f90c7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. ", "start_char_idx": 1497, "end_char_idx": 1786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3163f572-9720-48dc-a8ae-f8348162ac5b": {"__data__": {"id_": "3163f572-9720-48dc-a8ae-f8348162ac5b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry. ", "original_text": "Rice, are you on the line? ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23d2a0f8-a595-4a06-88b2-4cfe97ff1268", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "330cea9789fafff95bf65903a44ec22baf68c04b1f12591571ef73730a58e0c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ca54a56-bc0d-4a3d-9656-e6c33d98aedf", "node_type": "1", "metadata": {"window": "A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody. ", "original_text": "Please check your mute button.  \n "}, "hash": "ddcc5c29c7be6d8d8f6f00ca414857ce125afb2e318b2a47bb8b9b1cdc5da1b2", "class_name": "RelatedNodeInfo"}}, "text": "Rice, are you on the line? ", "start_char_idx": 1786, "end_char_idx": 1813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ca54a56-bc0d-4a3d-9656-e6c33d98aedf": {"__data__": {"id_": "2ca54a56-bc0d-4a3d-9656-e6c33d98aedf", "embedding": null, "metadata": {"window": "A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody. ", "original_text": "Please check your mute button.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3163f572-9720-48dc-a8ae-f8348162ac5b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry. ", "original_text": "Rice, are you on the line? ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc5056c95d6a3d26f63fc66bb27de5bca0c3d8f02bc025b832a055e554c3f38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1d901bc-ea8c-4a32-857f-75f35e050759", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J. "}, "hash": "015d6b79b5f23ce393876357d2c20571b908c18e739ecc1c5b0f5c0db7184d88", "class_name": "RelatedNodeInfo"}}, "text": "Please check your mute button.  \n ", "start_char_idx": 1813, "end_char_idx": 1847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1d901bc-ea8c-4a32-857f-75f35e050759": {"__data__": {"id_": "a1d901bc-ea8c-4a32-857f-75f35e050759", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ca54a56-bc0d-4a3d-9656-e6c33d98aedf", "node_type": "1", "metadata": {"window": "A \nA.J.?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody. ", "original_text": "Please check your mute button.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdd2c2cacfa79cee70973dd8bfcc895d3e8c1764ae97e1484d95baca83318cdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bccf37ae-1549-47b6-b065-462b00763b8f", "node_type": "1", "metadata": {"window": "Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode. ", "original_text": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry. "}, "hash": "b9ea130c6771b30b234f48418148b16661d878176a2f5fedd5d787fad208e89f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J. ", "start_char_idx": 1847, "end_char_idx": 2124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bccf37ae-1549-47b6-b065-462b00763b8f": {"__data__": {"id_": "bccf37ae-1549-47b6-b065-462b00763b8f", "embedding": null, "metadata": {"window": "Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode. ", "original_text": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1d901bc-ea8c-4a32-857f-75f35e050759", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3410cea9af9ad8c440b32a0b0c1acc419c7e1d794310711bef9c687199cefb42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63e461ff-fd5b-4482-a2f4-650b838300c8", "node_type": "1", "metadata": {"window": "Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year? ", "original_text": "Hi, everybody. "}, "hash": "5e80ea3c7f57a355e17b66a291bef61e6de507457cf591844ba8080444f8858d", "class_name": "RelatedNodeInfo"}}, "text": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry. ", "start_char_idx": 2124, "end_char_idx": 2192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63e461ff-fd5b-4482-a2f4-650b838300c8": {"__data__": {"id_": "63e461ff-fd5b-4482-a2f4-650b838300c8", "embedding": null, "metadata": {"window": "Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year? ", "original_text": "Hi, everybody. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bccf37ae-1549-47b6-b065-462b00763b8f", "node_type": "1", "metadata": {"window": "Rice, are you on the line?  Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode. ", "original_text": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b04ec15125221f70a8d3a7f31870e1ef7716693363937d2e7dd69b154112e25f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e26718eb-dea8-4a82-87d1-df125d56728f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n ", "original_text": "I just wanted to delve a little bit into the oncology ecosystem. "}, "hash": "8a37c408f62ed8a92efdf075e538b169dfec3b8e878a8cae5ca5ddca6b06e4ad", "class_name": "RelatedNodeInfo"}}, "text": "Hi, everybody. ", "start_char_idx": 2192, "end_char_idx": 2207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e26718eb-dea8-4a82-87d1-df125d56728f": {"__data__": {"id_": "e26718eb-dea8-4a82-87d1-df125d56728f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n ", "original_text": "I just wanted to delve a little bit into the oncology ecosystem. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63e461ff-fd5b-4482-a2f4-650b838300c8", "node_type": "1", "metadata": {"window": "Please check your mute button.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year? ", "original_text": "Hi, everybody. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40ef60fab7604dbb0e0f8d7b01221f4ff8a087787cf5ebc945b283a715061b55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd44311c-3c23-4f11-8298-f6d964f44b3a", "node_type": "1", "metadata": {"window": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I think Sarah Cannon \nand Ontada are still in an investment mode. "}, "hash": "86308e989b6f278397a06a071c9d61515bb07284c5b4166a99e72a17bf99df1f", "class_name": "RelatedNodeInfo"}}, "text": "I just wanted to delve a little bit into the oncology ecosystem. ", "start_char_idx": 2207, "end_char_idx": 2272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd44311c-3c23-4f11-8298-f6d964f44b3a": {"__data__": {"id_": "fd44311c-3c23-4f11-8298-f6d964f44b3a", "embedding": null, "metadata": {"window": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I think Sarah Cannon \nand Ontada are still in an investment mode. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e26718eb-dea8-4a82-87d1-df125d56728f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA.J.  Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n ", "original_text": "I just wanted to delve a little bit into the oncology ecosystem. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87b47f7ffd0cdbcabf516f68c4aa97a578bdbc7e7a7f963bc965953e92d063ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0775a6d-4cac-4063-8611-980219a59b5a", "node_type": "1", "metadata": {"window": "Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J. ", "original_text": "Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year? "}, "hash": "c39fc26e319acfc7552fe50c6b002e57e7806bcd4029e715c00f19a482ad388d", "class_name": "RelatedNodeInfo"}}, "text": "I think Sarah Cannon \nand Ontada are still in an investment mode. ", "start_char_idx": 2272, "end_char_idx": 2338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0775a6d-4cac-4063-8611-980219a59b5a": {"__data__": {"id_": "c0775a6d-4cac-4063-8611-980219a59b5a", "embedding": null, "metadata": {"window": "Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J. ", "original_text": "Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year? ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd44311c-3c23-4f11-8298-f6d964f44b3a", "node_type": "1", "metadata": {"window": "Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, sorry.  Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I think Sarah Cannon \nand Ontada are still in an investment mode. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ce5ce64f9d75f982f3a9faa8c6b966509858f8e9a2eaa69104f13dec92997ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c29fb5e-5a36-45b4-8462-0015dbbba449", "node_type": "1", "metadata": {"window": "I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question. ", "original_text": "And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n "}, "hash": "bfed99d95a1f21d4419931777b70b3b2a2d289f8b58e25c781e655e815f97af9", "class_name": "RelatedNodeInfo"}}, "text": "Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year? ", "start_char_idx": 2338, "end_char_idx": 2504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c29fb5e-5a36-45b4-8462-0015dbbba449": {"__data__": {"id_": "9c29fb5e-5a36-45b4-8462-0015dbbba449", "embedding": null, "metadata": {"window": "I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question. ", "original_text": "And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0775a6d-4cac-4063-8611-980219a59b5a", "node_type": "1", "metadata": {"window": "Hi, everybody.  I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J. ", "original_text": "Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year? ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45b2d6d333f2378fbcd9c7495958ffa431c3fcd3ec2092adddcd65b64afb1870", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01d4dac7-408f-4291-907d-c6817416238c", "node_type": "1", "metadata": {"window": "I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "ca127842c97ecb73c16f69d9444bfc495d1ecd1759fae5df5063fb7a527a1ff7", "class_name": "RelatedNodeInfo"}}, "text": "And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n ", "start_char_idx": 2504, "end_char_idx": 2767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01d4dac7-408f-4291-907d-c6817416238c": {"__data__": {"id_": "01d4dac7-408f-4291-907d-c6817416238c", "embedding": null, "metadata": {"window": "I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c29fb5e-5a36-45b4-8462-0015dbbba449", "node_type": "1", "metadata": {"window": "I just wanted to delve a little bit into the oncology ecosystem.  I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question. ", "original_text": "And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcf5747f231fd8754976d19bd6499b6e0eea146b42e15dae31eda49e5facc377", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "feeaa33e-8b67-41d2-8255-19e052a76268", "node_type": "1", "metadata": {"window": "Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on. ", "original_text": "A \nHey, A.J. "}, "hash": "32453470dbe0d81ddad8a5eb233ab260092332ecec8866f27fbecf3835c84b63", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2767, "end_char_idx": 3127, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "feeaa33e-8b67-41d2-8255-19e052a76268": {"__data__": {"id_": "feeaa33e-8b67-41d2-8255-19e052a76268", "embedding": null, "metadata": {"window": "Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on. ", "original_text": "A \nHey, A.J. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01d4dac7-408f-4291-907d-c6817416238c", "node_type": "1", "metadata": {"window": "I think Sarah Cannon \nand Ontada are still in an investment mode.  Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "330d15480056f98cb9c3a08702d505d46e2685fec59636a2b351145e0f1762ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "121b7b5e-698e-428a-86d7-87fc56ba58cd", "node_type": "1", "metadata": {"window": "And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights. ", "original_text": "Thanks for the question. "}, "hash": "f8f3184326cc05f1d318d606828ff2d3f89f03d258cf5208b78a3f2b20d798ad", "class_name": "RelatedNodeInfo"}}, "text": "A \nHey, A.J. ", "start_char_idx": 3127, "end_char_idx": 3140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "121b7b5e-698e-428a-86d7-87fc56ba58cd": {"__data__": {"id_": "121b7b5e-698e-428a-86d7-87fc56ba58cd", "embedding": null, "metadata": {"window": "And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights. ", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "feeaa33e-8b67-41d2-8255-19e052a76268", "node_type": "1", "metadata": {"window": "Is that meaningfully different from quarter -to-quarter as you layout \nthis year's numbers and is it meaningfully different than the investment level from last year?  And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on. ", "original_text": "A \nHey, A.J. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5bf8179cc22d5ffdfb7dbeb8dcce805ec709b13dc1cb23936beb8d8444e3eba4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73afa61d-b9f6-425c-96fa-3e634b8ae132", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis. ", "original_text": "Let  me try to answer that for you. "}, "hash": "06cf4782d69a8a8101dd93e7159032332d1810e365fd1e7230de1f17e693f8a8", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 3140, "end_char_idx": 3165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73afa61d-b9f6-425c-96fa-3e634b8ae132": {"__data__": {"id_": "73afa61d-b9f6-425c-96fa-3e634b8ae132", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis. ", "original_text": "Let  me try to answer that for you. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "121b7b5e-698e-428a-86d7-87fc56ba58cd", "node_type": "1", "metadata": {"window": "And obviously as \nyou're putting this in place, you're expecting it to have a benefit on its own but I wondered if you could comm ent \non the sort of flywheel benefit to the rest of the businesses from making this push in oncology that you expect to \nrealize.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights. ", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c61c64ad23f4851827dca52156090cb847ca69ac79d99abead8c36441f2e1c3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "790c6dc2-42d5-44be-abd7-fde5705104ae", "node_type": "1", "metadata": {"window": "A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant. ", "original_text": "I'll start and Brian can add on. "}, "hash": "c8c2f982fb6bfeb134f1fda642416b3be7014e3730590afba4dc60f53cb1610f", "class_name": "RelatedNodeInfo"}}, "text": "Let  me try to answer that for you. ", "start_char_idx": 3165, "end_char_idx": 3201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "790c6dc2-42d5-44be-abd7-fde5705104ae": {"__data__": {"id_": "790c6dc2-42d5-44be-abd7-fde5705104ae", "embedding": null, "metadata": {"window": "A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant. ", "original_text": "I'll start and Brian can add on. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73afa61d-b9f6-425c-96fa-3e634b8ae132", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis. ", "original_text": "Let  me try to answer that for you. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "407818a73883cef02a7c0f6efed3b67310e5d9d823cfe0339d9a98ff3bebf7e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13e74cc9-f1e3-40f2-a7d1-dc444cced94e", "node_type": "1", "metadata": {"window": "Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n ", "original_text": "We have been \ninvesting principally in our Ontada business where we're developing data and insights. "}, "hash": "7d97b9bce59e15527547e9713c0eecbc289249e492cb10dbdf3181ba8b41c526", "class_name": "RelatedNodeInfo"}}, "text": "I'll start and Brian can add on. ", "start_char_idx": 3201, "end_char_idx": 3234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13e74cc9-f1e3-40f2-a7d1-dc444cced94e": {"__data__": {"id_": "13e74cc9-f1e3-40f2-a7d1-dc444cced94e", "embedding": null, "metadata": {"window": "Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n ", "original_text": "We have been \ninvesting principally in our Ontada business where we're developing data and insights. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "790c6dc2-42d5-44be-abd7-fde5705104ae", "node_type": "1", "metadata": {"window": "A \nHey, A.J.  Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant. ", "original_text": "I'll start and Brian can add on. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a688c44f440932c9b6ab722bf0999470ef9edf08a864f2a49fd52b01cdeec096", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ce09066-e7cf-4ba1-bebb-885d680cf593", "node_type": "1", "metadata": {"window": "Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis. "}, "hash": "b0e2ff12b806fdebed85cf61f267a55da2cd56bb7b78cff21124048c2f3bf552", "class_name": "RelatedNodeInfo"}}, "text": "We have been \ninvesting principally in our Ontada business where we're developing data and insights. ", "start_char_idx": 3234, "end_char_idx": 3335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ce09066-e7cf-4ba1-bebb-885d680cf593": {"__data__": {"id_": "5ce09066-e7cf-4ba1-bebb-885d680cf593", "embedding": null, "metadata": {"window": "Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13e74cc9-f1e3-40f2-a7d1-dc444cced94e", "node_type": "1", "metadata": {"window": "Thanks for the question.  Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n ", "original_text": "We have been \ninvesting principally in our Ontada business where we're developing data and insights. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7b96f8fb569bef7bb2e7698b9d5272dbb980acb887a2e2b6c61f975a2daa42c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56aa5f67-7e5d-4b50-949e-87d7bc4425a5", "node_type": "1", "metadata": {"window": "I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant. "}, "hash": "22aabf68afce58d8b49a6bc29f58a6f104079290fd65a654ca9747bac8fbdc21", "class_name": "RelatedNodeInfo"}}, "text": "And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis. ", "start_char_idx": 3335, "end_char_idx": 3462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56aa5f67-7e5d-4b50-949e-87d7bc4425a5": {"__data__": {"id_": "56aa5f67-7e5d-4b50-949e-87d7bc4425a5", "embedding": null, "metadata": {"window": "I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ce09066-e7cf-4ba1-bebb-885d680cf593", "node_type": "1", "metadata": {"window": "Let  me try to answer that for you.  I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d493f25c5c114115780dea190724155dff0c27024736a9fa325b1525853bb68a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a9b2959-dd87-4205-abf4-c7669e422900", "node_type": "1", "metadata": {"window": "We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi. ", "original_text": "And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n "}, "hash": "18aa2e3ae7ae47155ea05c3c03fe3809ecf076f61502f4bde525dec20aec1a8b", "class_name": "RelatedNodeInfo"}}, "text": "Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant. ", "start_char_idx": 3462, "end_char_idx": 3582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a9b2959-dd87-4205-abf4-c7669e422900": {"__data__": {"id_": "9a9b2959-dd87-4205-abf4-c7669e422900", "embedding": null, "metadata": {"window": "We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi. ", "original_text": "And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56aa5f67-7e5d-4b50-949e-87d7bc4425a5", "node_type": "1", "metadata": {"window": "I'll start and Brian can add on.  We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb70dc059cf1bd2c8cf1da8f2f885965bd9bc823ccb96fd7a20e807bb5140091", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c8c88d1-0c3c-4a67-8741-60a0e92b3df7", "node_type": "1", "metadata": {"window": "And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "d8c1b7e6df99dc9a8fe3f945319eee47bdc5d50c7cda6f75861d0c048f5642aa", "class_name": "RelatedNodeInfo"}}, "text": "And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n ", "start_char_idx": 3582, "end_char_idx": 3956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c8c88d1-0c3c-4a67-8741-60a0e92b3df7": {"__data__": {"id_": "2c8c88d1-0c3c-4a67-8741-60a0e92b3df7", "embedding": null, "metadata": {"window": "And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a9b2959-dd87-4205-abf4-c7669e422900", "node_type": "1", "metadata": {"window": "We have been \ninvesting principally in our Ontada business where we're developing data and insights.  And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi. ", "original_text": "And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdb86d887067596d944bdc5f5a95f009d780e96f03485ab3cba09fe6e9609a4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f086c620-9a1c-4edd-ac8f-2abf57c1e051", "node_type": "1", "metadata": {"window": "Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "A \nNext question, please?  \n "}, "hash": "58bf853d6bb2e93e1b4e279f5746d2dcbfd3be68869edf4bc500b2f65f431f13", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 381, "end_char_idx": 726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f086c620-9a1c-4edd-ac8f-2abf57c1e051": {"__data__": {"id_": "f086c620-9a1c-4edd-ac8f-2abf57c1e051", "embedding": null, "metadata": {"window": "Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c8c88d1-0c3c-4a67-8741-60a0e92b3df7", "node_type": "1", "metadata": {"window": "And I would say that on a \nyear-to-year basis, the overall investment is probably not vary t oo much on a year -to-year basis.  Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1b7ca158c2e42f5d78aa8715964b787be388741cbe77fa14fdcab8ab85967", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a23078b-c802-4ab4-ad11-0e823cb1ef29", "node_type": "1", "metadata": {"window": "And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi. "}, "hash": "00cceeeeb35647d9916cf3dd0f8d8232b62ebb44f72b2a02a283b8735ea6d200", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 4301, "end_char_idx": 4330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a23078b-c802-4ab4-ad11-0e823cb1ef29": {"__data__": {"id_": "0a23078b-c802-4ab4-ad11-0e823cb1ef29", "embedding": null, "metadata": {"window": "And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f086c620-9a1c-4edd-ac8f-2abf57c1e051", "node_type": "1", "metadata": {"window": "Now quarter -to-\nquarter that can certainly vary, but on a year -to-year basis our investment has been pretty constant.  And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd98f30415a3860ce92abd9c2e347c795359713bed1acedd9096865ab29ca5d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da675109-3f0e-4875-bb7d-b8092f70ba55", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question. ", "original_text": "Please go ahead.  \n "}, "hash": "bc4dc4447509e95a21548ab95f853b5b952a48d299e60903a9230572b07acbd1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi. ", "start_char_idx": 4330, "end_char_idx": 4661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da675109-3f0e-4875-bb7d-b8092f70ba55": {"__data__": {"id_": "da675109-3f0e-4875-bb7d-b8092f70ba55", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question. ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a23078b-c802-4ab4-ad11-0e823cb1ef29", "node_type": "1", "metadata": {"window": "And as Sarah \nCannon Research is really in the integration phase and I talked about some of the integration  costs for both the \nSarah Cannon and the acquisition of Rx Savings Solutions but the investment that we principally have been \nmaking to develop our Ontada business on an annual basis has been pretty constant year -over-year, quarter -to-\nquarter it would vary . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44fad9f51947251cbbbcd32fc652c5bb7136fb2bf95d87deb43935957054bece", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5220c6b5-453d-4d5d-abda-3178999bf891", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  "}, "hash": "8f548d3de3d59227f58c294b97e04bccd80e576e0008d51b0b1dff0e8d1cd7c7", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1120, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5220c6b5-453d-4d5d-abda-3178999bf891": {"__data__": {"id_": "5220c6b5-453d-4d5d-abda-3178999bf891", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da675109-3f0e-4875-bb7d-b8092f70ba55", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question. ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1ff1d7a58b6f75b1d6efd9d7cc1d2091d465c9e814e36766b8f28bd32ace7a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "312f0a92-b9b2-4759-a2bb-2f05687476cf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind. ", "original_text": "Q \nHi. "}, "hash": "59c66ed99b3021bd44d998cdc8a4c73cfd577b671d7e2ab669bfcb6a14ff81c6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "start_char_idx": 4681, "end_char_idx": 5014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "312f0a92-b9b2-4759-a2bb-2f05687476cf": {"__data__": {"id_": "312f0a92-b9b2-4759-a2bb-2f05687476cf", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind. ", "original_text": "Q \nHi. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5220c6b5-453d-4d5d-abda-3178999bf891", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "533913f4cff3d39d28b8655db9e1ed27c13c0436c014d5f815b4f9725db5325c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "172c8689-8a13-4697-9742-b7fca115af25", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind.  If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "original_text": "Thanks for taking the question. "}, "hash": "12e9adbfb20358b909d1de45175f960137fd90baeb9c4abba453e1b4c404b4a3", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHi. ", "start_char_idx": 5014, "end_char_idx": 5021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "172c8689-8a13-4697-9742-b7fca115af25": {"__data__": {"id_": "172c8689-8a13-4697-9742-b7fca115af25", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind.  If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "original_text": "Thanks for taking the question. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "312f0a92-b9b2-4759-a2bb-2f05687476cf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind. ", "original_text": "Q \nHi. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "372f6bc2f16df6d1c9562eba63bdb175bc28521aaf94b92dbd2adec32e4cfe6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97022488-253d-4e31-b934-282419554e25", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind.  If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "original_text": "Want to go back to the generics environment. "}, "hash": "9558327333705d1a126598296191eb77111f06b61f88f6cf81cab4251841d419", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 5021, "end_char_idx": 5053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97022488-253d-4e31-b934-282419554e25": {"__data__": {"id_": "97022488-253d-4e31-b934-282419554e25", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind.  If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "original_text": "Want to go back to the generics environment. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "172c8689-8a13-4697-9742-b7fca115af25", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind.  If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "original_text": "Thanks for taking the question. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3a14159034f8c2b3bd30c29c05f20043800506d6e0fd24b2336a34f3f848961", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d11d8dde-c900-43cc-9f2c-ad3e30c5db15", "node_type": "1", "metadata": {"window": "Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind.  If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "original_text": "You mentioned this a few times \nas a tailwind. "}, "hash": "aaf089c62824136e0307211ca8aee6c583872602d857112795d08d06190bb1bd", "class_name": "RelatedNodeInfo"}}, "text": "Want to go back to the generics environment. ", "start_char_idx": 5053, "end_char_idx": 5098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d11d8dde-c900-43cc-9f2c-ad3e30c5db15": {"__data__": {"id_": "d11d8dde-c900-43cc-9f2c-ad3e30c5db15", "embedding": null, "metadata": {"window": "Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind.  If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "original_text": "You mentioned this a few times \nas a tailwind. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97022488-253d-4e31-b934-282419554e25", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind.  If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "original_text": "Want to go back to the generics environment. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13cf59ccc02be2bd2ba95ad27a4954f336dc0a1523937f7b51c762cccfd0f43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0cb8a60-2983-4365-b1fc-7d4c3874d69e", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind.  If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "original_text": "If you look at third -party data, it seems to point to a much more benign generic pricing environment. "}, "hash": "67196ba6bb869288bd420249ab93a856ce606520161247cb90ee4df29293ef00", "class_name": "RelatedNodeInfo"}}, "text": "You mentioned this a few times \nas a tailwind. ", "start_char_idx": 5098, "end_char_idx": 5145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0cb8a60-2983-4365-b1fc-7d4c3874d69e": {"__data__": {"id_": "d0cb8a60-2983-4365-b1fc-7d4c3874d69e", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind.  If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "original_text": "If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e562867-5be9-412b-93c5-b17ff20af4b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd475248dd79b48791038d2746e3e0a70f89e1b7eb0928bf69067df2bf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d11d8dde-c900-43cc-9f2c-ad3e30c5db15", "node_type": "1", "metadata": {"window": "Q \nHi.  Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind.  If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "original_text": "You mentioned this a few times \nas a tailwind. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c298148c3be8379280b0788f15688cc44160a22e9242be49cbb0bcbd4801f44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b50509ba-7557-4587-ac96-080733d318b3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n ", "original_text": "McKesson Corp.  "}, "hash": "30012f1be742b14210fb2670bbb022d0e737f39d8ddf6a7275c1e16891006f34", "class_name": "RelatedNodeInfo"}}, "text": "If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "start_char_idx": 5145, "end_char_idx": 5248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b50509ba-7557-4587-ac96-080733d318b3": {"__data__": {"id_": "b50509ba-7557-4587-ac96-080733d318b3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0cb8a60-2983-4365-b1fc-7d4c3874d69e", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Want to go back to the generics environment.  You mentioned this a few times \nas a tailwind.  If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "original_text": "If you look at third -party data, it seems to point to a much more benign generic pricing environment. ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2573b70f01becc5bfe7071be7795cddeb65bb413b5ea888853df20c15317fa67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a750f0e3-9fe1-428f-b5d6-a9c4cca42bc3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment? "}, "hash": "5a68f793c70cb33393a079feddb7d477b6be9e1e8d39090708c8b154bcf28dcc", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a750f0e3-9fe1-428f-b5d6-a9c4cca42bc3": {"__data__": {"id_": "a750f0e3-9fe1-428f-b5d6-a9c4cca42bc3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment? ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b50509ba-7557-4587-ac96-080733d318b3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b26b7144fa86828165aec1b0acb2b929597185f8707fcbdfcf041874a9b95435", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74684cf7-2e74-4fc0-94bf-db7f54d8904c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question. ", "original_text": "How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently? "}, "hash": "4981d84bee06a0a9b0196ce569edb7451f9e6ea93442be78645e7c3631fee179", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment? ", "start_char_idx": 16, "end_char_idx": 264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74684cf7-2e74-4fc0-94bf-db7f54d8904c": {"__data__": {"id_": "74684cf7-2e74-4fc0-94bf-db7f54d8904c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question. ", "original_text": "How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently? ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a750f0e3-9fe1-428f-b5d6-a9c4cca42bc3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment? ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc2f46e1feee1dbaa3b21310b2116a5ec16e7d8c6fea93248207cc3c76b9823c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f42aab92-12f9-4a17-9d38-22b1173bda47", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say. ", "original_text": "And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n "}, "hash": "7edc5725a8ff924eb76ce3e7d471482740da35b0faf522f57cf891dee03a9241", "class_name": "RelatedNodeInfo"}}, "text": "How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently? ", "start_char_idx": 264, "end_char_idx": 360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f42aab92-12f9-4a17-9d38-22b1173bda47": {"__data__": {"id_": "f42aab92-12f9-4a17-9d38-22b1173bda47", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say. ", "original_text": "And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74684cf7-2e74-4fc0-94bf-db7f54d8904c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question. ", "original_text": "How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently? ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b82360875ad693e275919af77aea3f4735e7e691fc28e52228c037122ed61b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3fa2b68-b3ca-4171-af8d-f295b8715e38", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "ac44ecb24b41650bfde505136c6fd4fc0ab42a524c73e23196ede3d54dac6546", "class_name": "RelatedNodeInfo"}}, "text": "And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n ", "start_char_idx": 360, "end_char_idx": 498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3fa2b68-b3ca-4171-af8d-f295b8715e38": {"__data__": {"id_": "f3fa2b68-b3ca-4171-af8d-f295b8715e38", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f42aab92-12f9-4a17-9d38-22b1173bda47", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say. ", "original_text": "And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2aa0c5c3e7cb3993b6d5a06c652baf79896eab22e60a9ccfa0283e28db5a8a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57e15ac2-07e0-4373-bfa2-8c44e9f9d22e", "node_type": "1", "metadata": {"window": "How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from. ", "original_text": "A \nYeah, thanks for the question. "}, "hash": "0934eb9ca9dd2de010499218ca97110185f98ede15a17a590412c3400fb12883", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 498, "end_char_idx": 858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57e15ac2-07e0-4373-bfa2-8c44e9f9d22e": {"__data__": {"id_": "57e15ac2-07e0-4373-bfa2-8c44e9f9d22e", "embedding": null, "metadata": {"window": "How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from. ", "original_text": "A \nYeah, thanks for the question. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3fa2b68-b3ca-4171-af8d-f295b8715e38", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b979461bb8e3f0449e400a53a20547ce1639a077f2337998e3fa2e3fd3ce8f80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df628668-1760-4f43-8bf7-143dc06a20e8", "node_type": "1", "metadata": {"window": "And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply. ", "original_text": "Here is what I would say. "}, "hash": "bf912d8263ea9211be2dc7ae9029b35452d0f6b928b538cdec5f50fef047bff4", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, thanks for the question. ", "start_char_idx": 858, "end_char_idx": 892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df628668-1760-4f43-8bf7-143dc06a20e8": {"__data__": {"id_": "df628668-1760-4f43-8bf7-143dc06a20e8", "embedding": null, "metadata": {"window": "And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply. ", "original_text": "Here is what I would say. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57e15ac2-07e0-4373-bfa2-8c44e9f9d22e", "node_type": "1", "metadata": {"window": "How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from. ", "original_text": "A \nYeah, thanks for the question. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b648deeb744eca24d6951df4acb38d860658615b790d4ad22bb6dcab340c63e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fabe5232-b631-4156-8948-333d786a8ded", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company. ", "original_text": "In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n"}, "hash": "10b28ad37e0cf9973f8bb471967822c48015c3ec455647d953d258f9520508ad", "class_name": "RelatedNodeInfo"}}, "text": "Here is what I would say. ", "start_char_idx": 892, "end_char_idx": 918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fabe5232-b631-4156-8948-333d786a8ded": {"__data__": {"id_": "fabe5232-b631-4156-8948-333d786a8ded", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company. ", "original_text": "In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df628668-1760-4f43-8bf7-143dc06a20e8", "node_type": "1", "metadata": {"window": "And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply. ", "original_text": "Here is what I would say. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27e0515e8e20c93ad45920e17f7ba6a212d093aa805e7b4d36102779bf74b266", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a00fac8a-c47a-4e71-b1a4-738b7a72514a", "node_type": "1", "metadata": {"window": "A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n", "original_text": "Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from. "}, "hash": "9720fed3bccacf67f91ef5b5bc08f4868332ded02291babc1843171814d25712", "class_name": "RelatedNodeInfo"}}, "text": "In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n", "start_char_idx": 918, "end_char_idx": 1249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a00fac8a-c47a-4e71-b1a4-738b7a72514a": {"__data__": {"id_": "a00fac8a-c47a-4e71-b1a4-738b7a72514a", "embedding": null, "metadata": {"window": "A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n", "original_text": "Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fabe5232-b631-4156-8948-333d786a8ded", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company. ", "original_text": "In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15ad59c102cb3d6e34fe5c67e8d985eefac9bb029369acd0bb0fcf9ea42ff04b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd9726a2-1c61-4520-abff-799bb502a75c", "node_type": "1", "metadata": {"window": "Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged. ", "original_text": "So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply. "}, "hash": "b0f7bb26180683a86d10b0dfacc3e4bf9d1bbe08552ee96b486e4941fc71e582", "class_name": "RelatedNodeInfo"}}, "text": "Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from. ", "start_char_idx": 1249, "end_char_idx": 1450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd9726a2-1c61-4520-abff-799bb502a75c": {"__data__": {"id_": "cd9726a2-1c61-4520-abff-799bb502a75c", "embedding": null, "metadata": {"window": "Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged. ", "original_text": "So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a00fac8a-c47a-4e71-b1a4-738b7a72514a", "node_type": "1", "metadata": {"window": "A \nYeah, thanks for the question.  Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n", "original_text": "Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8d787e2e8a4bf6abf372b0c0bb66963d3ad23a73f8e93e967b2149dea3b2123", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2fd5cc8-718c-4ef3-8a32-c29d2aba11b9", "node_type": "1", "metadata": {"window": "In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well. ", "original_text": "And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company. "}, "hash": "a99cf0d1e297b0f3311e649d7682ac2f1dececeedc1916884599ffb50ef15a5a", "class_name": "RelatedNodeInfo"}}, "text": "So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply. ", "start_char_idx": 1450, "end_char_idx": 1696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2fd5cc8-718c-4ef3-8a32-c29d2aba11b9": {"__data__": {"id_": "e2fd5cc8-718c-4ef3-8a32-c29d2aba11b9", "embedding": null, "metadata": {"window": "In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well. ", "original_text": "And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd9726a2-1c61-4520-abff-799bb502a75c", "node_type": "1", "metadata": {"window": "Here is what I would say.  In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged. ", "original_text": "So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ed4c33f017d63f0a47b15f442e74073d68be8d5ebc8e87361ed48bec5157128", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f10cccd7-855e-4aff-9a9b-e8d1d2d9c37a", "node_type": "1", "metadata": {"window": "Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n ", "original_text": "F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n"}, "hash": "e227eb59642a5815376170b4bd066fc3e8240357418d9f5d359d685515fa49a2", "class_name": "RelatedNodeInfo"}}, "text": "And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company. ", "start_char_idx": 1696, "end_char_idx": 1796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f10cccd7-855e-4aff-9a9b-e8d1d2d9c37a": {"__data__": {"id_": "f10cccd7-855e-4aff-9a9b-e8d1d2d9c37a", "embedding": null, "metadata": {"window": "Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n ", "original_text": "F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2fd5cc8-718c-4ef3-8a32-c29d2aba11b9", "node_type": "1", "metadata": {"window": "In terms of our generics program, it is a combination of \nthe sourcing activities that we have whi ch really reflects the relationships that we have across hundreds of \nmanufacturing partners, and then it reflects the discipline that we have on the sell -side, and the combination of \nthat has led to some really good results.  \n \n Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well. ", "original_text": "And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e1ad9def181d70eaadb114b04e3fb65a59f341f89ecd0740dede10daca4b19f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c5329ea-c1a2-4eff-ba9a-e663537d60a6", "node_type": "1", "metadata": {"window": "So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged. "}, "hash": "fd20ece85f461e6cbe172d59c55ebdba69105fdae73abeb6a672265e4c9f57e2", "class_name": "RelatedNodeInfo"}}, "text": "F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n", "start_char_idx": 1796, "end_char_idx": 1934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c5329ea-c1a2-4eff-ba9a-e663537d60a6": {"__data__": {"id_": "1c5329ea-c1a2-4eff-ba9a-e663537d60a6", "embedding": null, "metadata": {"window": "So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f10cccd7-855e-4aff-9a9b-e8d1d2d9c37a", "node_type": "1", "metadata": {"window": "Now we've also had some new br and or I should say some new generic launches and we certainly participate in \nthose new generic launches as well and we had a few in the quarter that we benefited from.  So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n ", "original_text": "F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7b0ab7020418b7ab8ede19b04b6ef1e51373540c4fbd0808650ab514d81b63b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c2cec5f-43ee-4600-a379-c0304f8f3651", "node_type": "1", "metadata": {"window": "And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well. "}, "hash": "be00182f5dd8a1f835f90845f9bc17e816478e1b7d92fc59ac7611783fa5438c", "class_name": "RelatedNodeInfo"}}, "text": "Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged. ", "start_char_idx": 1934, "end_char_idx": 2170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c2cec5f-43ee-4600-a379-c0304f8f3651": {"__data__": {"id_": "8c2cec5f-43ee-4600-a379-c0304f8f3651", "embedding": null, "metadata": {"window": "And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c5329ea-c1a2-4eff-ba9a-e663537d60a6", "node_type": "1", "metadata": {"window": "So the combination \nof our sourcing operations, the stability that we're seeing in a com petitive marketplace has provided us the ability \nto create spread at the same time is providing competitive pricing for our customers with a stable supply.  And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8edbd6b3400e9d37b8ddf9067138dc95648bffc30c3b35d252408473a683bd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abfd454f-4353-41a2-9155-3fdccd399538", "node_type": "1", "metadata": {"window": "F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank. ", "original_text": "And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n "}, "hash": "b34ea491523abbcdd8c1dd92bb3467629ab348b63aa9285d907c1812a35d77f9", "class_name": "RelatedNodeInfo"}}, "text": "But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well. ", "start_char_idx": 2170, "end_char_idx": 2284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abfd454f-4353-41a2-9155-3fdccd399538": {"__data__": {"id_": "abfd454f-4353-41a2-9155-3fdccd399538", "embedding": null, "metadata": {"window": "F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank. ", "original_text": "And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c2cec5f-43ee-4600-a379-c0304f8f3651", "node_type": "1", "metadata": {"window": "And you \nmentioned shortages, and we have seen shortages for as long as I've been with the company.  F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8d158a713fec0e6cb01405638793e0d60c78081f89cdd79b8f9ab96271f0c64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07c81dd9-a138-44c5-acf3-bee29ae2cbef", "node_type": "1", "metadata": {"window": "Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "4b544a90be8fc1a122e7a6d45842462cdaef69f1d1a70530091abcf0ff867e67", "class_name": "RelatedNodeInfo"}}, "text": "And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n ", "start_char_idx": 2284, "end_char_idx": 2456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07c81dd9-a138-44c5-acf3-bee29ae2cbef": {"__data__": {"id_": "07c81dd9-a138-44c5-acf3-bee29ae2cbef", "embedding": null, "metadata": {"window": "Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abfd454f-4353-41a2-9155-3fdccd399538", "node_type": "1", "metadata": {"window": "F rom time -to-time, \nthey will spike up like we had with some of the cold and flu products or the illness season products last year.  \n \n Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank. ", "original_text": "And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029ac189fa5cf4f0b92bc161b2a64d1c52969b079fe8c2833b88600380ea334a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b9e141f-ed09-4630-9d61-ebda6e0eef61", "node_type": "1", "metadata": {"window": "But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "A \nNext question, please?  \n "}, "hash": "990147d713e0a33cc0bf11d383884aa16045970f402284527a79764b241885b9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 2456, "end_char_idx": 2801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b9e141f-ed09-4630-9d61-ebda6e0eef61": {"__data__": {"id_": "8b9e141f-ed09-4630-9d61-ebda6e0eef61", "embedding": null, "metadata": {"window": "But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07c81dd9-a138-44c5-acf3-bee29ae2cbef", "node_type": "1", "metadata": {"window": "Generally speaking, I would think that \u2013 I would say that the \u2013 what we're seeing now from a supply perspective is \nmore in line with what we've seen historically, every now and then you'll have a product that will be more \nchallenged.  But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d456740648bd733108ee8f78de6ad31887012fa09b94fb55057cf6d8302665e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02d06e93-0d56-4e6b-b4db-e4165b84b048", "node_type": "1", "metadata": {"window": "And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank. "}, "hash": "44e0729ab54958ffb4a9ea9661ff8d24b9f302533da7d72001fb55391e0c1677", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 2801, "end_char_idx": 2830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02d06e93-0d56-4e6b-b4db-e4165b84b048": {"__data__": {"id_": "02d06e93-0d56-4e6b-b4db-e4165b84b048", "embedding": null, "metadata": {"window": "And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b9e141f-ed09-4630-9d61-ebda6e0eef61", "node_type": "1", "metadata": {"window": "But the broad base of partners that we have in our sourcing program allows us to manage through \nthat quite well.  And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5f876c748214ec2360794fe361dc550ebbfa6d4063a72d651b73666eb757164", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e0efcfd-b5c7-45f8-8c7c-e95f701fd46b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology. ", "original_text": "Please go ahead.  \n "}, "hash": "f56bc8f9b50dfce1dc20ccfceeb0212f9cd5ee2c1a934d7b8bc38b2143777fcf", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank. ", "start_char_idx": 2830, "end_char_idx": 3165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e0efcfd-b5c7-45f8-8c7c-e95f701fd46b": {"__data__": {"id_": "3e0efcfd-b5c7-45f8-8c7c-e95f701fd46b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology. ", "original_text": "Please go ahead.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02d06e93-0d56-4e6b-b4db-e4165b84b048", "node_type": "1", "metadata": {"window": "And the performance that we're s eeing in the first quarter which is continued momentum from last \nyear, that's included in the guidance that we have for the full year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "265bc32e94f36318f4194313f24041501cbb976ecbb7ab085a8d9348e082ff7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "787f2e5f-e559-4020-a578-b6e6b98381c4", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "2cf5ab807c6411162ecb050ca98770dbc9acedd9b77e1753c006d92b7e208c88", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 3165, "end_char_idx": 3185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "787f2e5f-e559-4020-a578-b6e6b98381c4": {"__data__": {"id_": "787f2e5f-e559-4020-a578-b6e6b98381c4", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e0efcfd-b5c7-45f8-8c7c-e95f701fd46b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology. ", "original_text": "Please go ahead.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f97ca64c8458093907a57a4b92e38df999ab97d9b76e9a514f4279c0d44be90f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9634ea32-e42b-426c-a995-65777d409418", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter. ", "original_text": "Q \nYeah, good morning, guys. "}, "hash": "f5b9374a57474feb1da2909d10f7e62071db9aa3fb3136d361733bc3a5409e40", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 3185, "end_char_idx": 3512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9634ea32-e42b-426c-a995-65777d409418": {"__data__": {"id_": "9634ea32-e42b-426c-a995-65777d409418", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter. ", "original_text": "Q \nYeah, good morning, guys. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "787f2e5f-e559-4020-a578-b6e6b98381c4", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "12106a569af8760ee2e34134e99374b016d7bc6d415eaae5fb9cdb27110c93ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b05684d6-671b-4e7d-a683-a05ff7fef3fd", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO? ", "original_text": "Britt, I want to come back to oncology as well and talk about US oncology. "}, "hash": "31396f29cd423ec078cfd54da073d881c5574eb833a55238a45ddc4376899c9c", "class_name": "RelatedNodeInfo"}}, "text": "Q \nYeah, good morning, guys. ", "start_char_idx": 3512, "end_char_idx": 3541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b05684d6-671b-4e7d-a683-a05ff7fef3fd": {"__data__": {"id_": "b05684d6-671b-4e7d-a683-a05ff7fef3fd", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO? ", "original_text": "Britt, I want to come back to oncology as well and talk about US oncology. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9634ea32-e42b-426c-a995-65777d409418", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next w ill be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter. ", "original_text": "Q \nYeah, good morning, guys. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ddb89b745d3ad0c139f29828e9afa7d56c4d7837579548e5d2da90bd34446433", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9db8992d-9945-4023-a3c7-007b36e7d237", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure? ", "original_text": "You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive. "}, "hash": "1d79098677d6a90d1b825b85a3041793116c4b5e9c4089ef2647bc6a84df5391", "class_name": "RelatedNodeInfo"}}, "text": "Britt, I want to come back to oncology as well and talk about US oncology. ", "start_char_idx": 3541, "end_char_idx": 3616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9db8992d-9945-4023-a3c7-007b36e7d237": {"__data__": {"id_": "9db8992d-9945-4023-a3c7-007b36e7d237", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure? ", "original_text": "You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b05684d6-671b-4e7d-a683-a05ff7fef3fd", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO? ", "original_text": "Britt, I want to come back to oncology as well and talk about US oncology. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2dab052e32158eb5172a5cfb1cbfb4964365985c48b11759d3556ddb8fc8198a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4afa49f3-515d-428f-9624-bd95c4231c92", "node_type": "1", "metadata": {"window": "Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n ", "original_text": "So we're talking like \n20% growth in US oncology in the quarter. "}, "hash": "27430f7216239b5553fcc6a6e83d21abc7517bbb8ec8e91fc6aa92683ce15358", "class_name": "RelatedNodeInfo"}}, "text": "You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive. ", "start_char_idx": 3616, "end_char_idx": 3717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4afa49f3-515d-428f-9624-bd95c4231c92": {"__data__": {"id_": "4afa49f3-515d-428f-9624-bd95c4231c92", "embedding": null, "metadata": {"window": "Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n ", "original_text": "So we're talking like \n20% growth in US oncology in the quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9db8992d-9945-4023-a3c7-007b36e7d237", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure? ", "original_text": "You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03a05605b69b1edfd1d36e6c14df42cf3f5b1c6a3d1d9f98698f2943cc5857bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f25e772c-3a52-4bdb-967e-56f4c5f416fc", "node_type": "1", "metadata": {"window": "Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO? "}, "hash": "80fd75a818eaa0d776b7ec9dc23f0fdab0347dcde3768090c8573ab7f2a5eac8", "class_name": "RelatedNodeInfo"}}, "text": "So we're talking like \n20% growth in US oncology in the quarter. ", "start_char_idx": 3717, "end_char_idx": 3782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f25e772c-3a52-4bdb-967e-56f4c5f416fc": {"__data__": {"id_": "f25e772c-3a52-4bdb-967e-56f4c5f416fc", "embedding": null, "metadata": {"window": "Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO? ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4afa49f3-515d-428f-9624-bd95c4231c92", "node_type": "1", "metadata": {"window": "Q \nYeah, good morning, guys.  Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n ", "original_text": "So we're talking like \n20% growth in US oncology in the quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d165155f1f4f0783664cdd4b7c07bf3858cd9cf94575f15e9e299c686a1d74a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bc36d4c-151e-4ecb-826f-f2b36d06d501", "node_type": "1", "metadata": {"window": "You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George. ", "original_text": "And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure? "}, "hash": "59e15b0175cc803d75b82f5f52f67043bcd3dfedc41376793c66fe134d733d9a", "class_name": "RelatedNodeInfo"}}, "text": "I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO? ", "start_char_idx": 3782, "end_char_idx": 3938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bc36d4c-151e-4ecb-826f-f2b36d06d501": {"__data__": {"id_": "4bc36d4c-151e-4ecb-826f-f2b36d06d501", "embedding": null, "metadata": {"window": "You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George. ", "original_text": "And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure? ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f25e772c-3a52-4bdb-967e-56f4c5f416fc", "node_type": "1", "metadata": {"window": "Britt, I want to come back to oncology as well and talk about US oncology.  You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO? ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7883f7cd1031e2000dd003157d539d7c5d2c03747673d41ce661fa91a05991d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72bb7f4d-88b2-4fb2-8ada-80893825a84d", "node_type": "1", "metadata": {"window": "So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question. ", "original_text": "Thank you.  \n "}, "hash": "f944f33303d7f1e22f9d00aa5a179e38dbf373d8de280c65a2bb17883a8fffb4", "class_name": "RelatedNodeInfo"}}, "text": "And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure? ", "start_char_idx": 3938, "end_char_idx": 4063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72bb7f4d-88b2-4fb2-8ada-80893825a84d": {"__data__": {"id_": "72bb7f4d-88b2-4fb2-8ada-80893825a84d", "embedding": null, "metadata": {"window": "So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question. ", "original_text": "Thank you.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bc36d4c-151e-4ecb-826f-f2b36d06d501", "node_type": "1", "metadata": {"window": "You said \nvisits were up 19% in total, same -store was up 7%, I'll assume drug pricing was positive.  So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George. ", "original_text": "And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure? ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49489c4019012820af195ada1d63c18126f3bec852a2f4e18ff796aaf3436614", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de7d3e59-96e9-4df2-9dbd-9e621cd9653b", "node_type": "1", "metadata": {"window": "I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question.  Let me be clear on what I provided. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "3afa10f2d58715e055037cb3e476721c7b54cc6b1684d87fa16bd0ad71f76f6e", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 4063, "end_char_idx": 4077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de7d3e59-96e9-4df2-9dbd-9e621cd9653b": {"__data__": {"id_": "de7d3e59-96e9-4df2-9dbd-9e621cd9653b", "embedding": null, "metadata": {"window": "I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question.  Let me be clear on what I provided. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72bb7f4d-88b2-4fb2-8ada-80893825a84d", "node_type": "1", "metadata": {"window": "So we're talking like \n20% growth in US oncology in the quarter.  I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question. ", "original_text": "Thank you.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ccd53186b4ac8134e663afb2349ca832f1be538959ba59695a37b92497b6343", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51375f5a-2acd-483f-b96e-1a7f96d6c378", "node_type": "1", "metadata": {"window": "And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful. ", "original_text": "A \nHi, George. "}, "hash": "2954e639e2d97e0a15c2cfa7751f3065bb61c280b2f0d5ce41a409360016ac39", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 498, "end_char_idx": 858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51375f5a-2acd-483f-b96e-1a7f96d6c378": {"__data__": {"id_": "51375f5a-2acd-483f-b96e-1a7f96d6c378", "embedding": null, "metadata": {"window": "And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful. ", "original_text": "A \nHi, George. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de7d3e59-96e9-4df2-9dbd-9e621cd9653b", "node_type": "1", "metadata": {"window": "I guess could you give us a little bit more detail on McKesson's kind of \nexposure to oncology kind of like the practices versus the dru gs versus the GPO?  And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question.  Let me be clear on what I provided. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3f7a09f59f46b5c6ef0045857610bd748f4281bd9d35b631e6525bbeb42e2a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "894c5bed-c081-44ee-a6ac-0246ac69ad67", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis. ", "original_text": "Thanks for the question. "}, "hash": "a67794693f3fd9659b4543089c89e89127a361cd228b5dbea9c82563813b14da", "class_name": "RelatedNodeInfo"}}, "text": "A \nHi, George. ", "start_char_idx": 4437, "end_char_idx": 4452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "894c5bed-c081-44ee-a6ac-0246ac69ad67": {"__data__": {"id_": "894c5bed-c081-44ee-a6ac-0246ac69ad67", "embedding": null, "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis. ", "original_text": "Thanks for the question. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51375f5a-2acd-483f-b96e-1a7f96d6c378", "node_type": "1", "metadata": {"window": "And is that type of growth \nprofile kind of in -line with what we're seeing in all segments of McKesson's oncology exposure?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful. ", "original_text": "A \nHi, George. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1cb66f9601b56cd6911ba6899dbe042f9b8c293994955b9b359c00e03df9aff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "684a8daa-aaeb-4f19-8f53-78c56f476fa3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year. ", "original_text": "Let me be clear on what I provided. "}, "hash": "354726c0bda9643e217ed6ce36743d026a685b10658b393500909b78b2c16a33", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 4452, "end_char_idx": 4477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "684a8daa-aaeb-4f19-8f53-78c56f476fa3": {"__data__": {"id_": "684a8daa-aaeb-4f19-8f53-78c56f476fa3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year. ", "original_text": "Let me be clear on what I provided. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "894c5bed-c081-44ee-a6ac-0246ac69ad67", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis. ", "original_text": "Thanks for the question. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21ab3962e91c81bb68e1d9ec84ad5f63e4307ae3c26af674cb86a4b75d37fac7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e518cb38-a1ee-41f3-8c06-2914ffd087bc", "node_type": "1", "metadata": {"window": "A \nHi, George.  Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that. ", "original_text": "I provided some insight into patient visits \nmetrics, and I thought that would be insightful. "}, "hash": "b100a6d8447c80aec63ab9997264e7474249da43c496c55137bd4723940ea252", "class_name": "RelatedNodeInfo"}}, "text": "Let me be clear on what I provided. ", "start_char_idx": 4477, "end_char_idx": 4513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e518cb38-a1ee-41f3-8c06-2914ffd087bc": {"__data__": {"id_": "e518cb38-a1ee-41f3-8c06-2914ffd087bc", "embedding": null, "metadata": {"window": "A \nHi, George.  Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that. ", "original_text": "I provided some insight into patient visits \nmetrics, and I thought that would be insightful. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "684a8daa-aaeb-4f19-8f53-78c56f476fa3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHi, George.  Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year. ", "original_text": "Let me be clear on what I provided. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "460e2dab2c3e1a3c0ecc6a0ea5b47d4dbb1b10ce5a5ab53709ca4d9cf08e7862", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2acc7557-d478-41fa-9e8b-38d0faaf4689", "node_type": "1", "metadata": {"window": "Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n ", "original_text": "We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis. "}, "hash": "2805ddd905c5335fcde752eb80b74b5ed7d51c3546d29c62d9f91f5378f31236", "class_name": "RelatedNodeInfo"}}, "text": "I provided some insight into patient visits \nmetrics, and I thought that would be insightful. ", "start_char_idx": 4513, "end_char_idx": 4607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2acc7557-d478-41fa-9e8b-38d0faaf4689": {"__data__": {"id_": "2acc7557-d478-41fa-9e8b-38d0faaf4689", "embedding": null, "metadata": {"window": "Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n ", "original_text": "We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e518cb38-a1ee-41f3-8c06-2914ffd087bc", "node_type": "1", "metadata": {"window": "A \nHi, George.  Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that. ", "original_text": "I provided some insight into patient visits \nmetrics, and I thought that would be insightful. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e56ad972ddee7347574962bc4e2df41100524e40b0623bab8f7a26e77f412f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "136e97ff-cb5a-4dcd-bf22-5ce24ba7246d", "node_type": "1", "metadata": {"window": "Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year. "}, "hash": "4226a058ddc0ffb50bf05ce8c5093e8a044ab9b8555334766178d010710f9e5a", "class_name": "RelatedNodeInfo"}}, "text": "We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis. ", "start_char_idx": 4607, "end_char_idx": 4701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "136e97ff-cb5a-4dcd-bf22-5ce24ba7246d": {"__data__": {"id_": "136e97ff-cb5a-4dcd-bf22-5ce24ba7246d", "embedding": null, "metadata": {"window": "Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2acc7557-d478-41fa-9e8b-38d0faaf4689", "node_type": "1", "metadata": {"window": "Thanks for the question.  Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n ", "original_text": "We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52020021a9253aabb151bfa44b1881542daaaa6c2c00434b69b0801f52103d3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb495716-8d81-46aa-a72e-fb0a64e3794c", "node_type": "1", "metadata": {"window": "I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that. "}, "hash": "8ac37811d1e4922002c1065bf8e2f7346d59d7c32c69b0d9caec5f60dc4ba742", "class_name": "RelatedNodeInfo"}}, "text": "I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year. ", "start_char_idx": 4701, "end_char_idx": 4866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb495716-8d81-46aa-a72e-fb0a64e3794c": {"__data__": {"id_": "eb495716-8d81-46aa-a72e-fb0a64e3794c", "embedding": null, "metadata": {"window": "I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "136e97ff-cb5a-4dcd-bf22-5ce24ba7246d", "node_type": "1", "metadata": {"window": "Let me be clear on what I provided.  I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "276e95cfadfe770bc891c519f25a5ee2a6563b214563e72fe40da50feaed0bbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ccb6a39-b3bb-4eac-9e07-123ea733f67e", "node_type": "1", "metadata": {"window": "We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I don't know, Brian, if you want to \ncomment on the other?  \n "}, "hash": "e68c7614544e343a2b7a44c39b057aa2f8e32671e8a04cad89971c3156a1b0a5", "class_name": "RelatedNodeInfo"}}, "text": "So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that. ", "start_char_idx": 4866, "end_char_idx": 4991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ccb6a39-b3bb-4eac-9e07-123ea733f67e": {"__data__": {"id_": "9ccb6a39-b3bb-4eac-9e07-123ea733f67e", "embedding": null, "metadata": {"window": "We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I don't know, Brian, if you want to \ncomment on the other?  \n ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb495716-8d81-46aa-a72e-fb0a64e3794c", "node_type": "1", "metadata": {"window": "I provided some insight into patient visits \nmetrics, and I thought that would be insightful.  We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that. ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e436644835e7299005273ed5c66afd6abae85fdbd76e03f96cbdd0d7ecdb6f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e38cc2b3-e09b-4186-800d-cf0f4a5afa4c", "node_type": "1", "metadata": {"window": "I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "bdf8d6c6c18d0217cb272d592dc580d81bee97b02c4a17776d319af15ff772ab", "class_name": "RelatedNodeInfo"}}, "text": "I don't know, Brian, if you want to \ncomment on the other?  \n ", "start_char_idx": 4991, "end_char_idx": 5053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e38cc2b3-e09b-4186-800d-cf0f4a5afa4c": {"__data__": {"id_": "e38cc2b3-e09b-4186-800d-cf0f4a5afa4c", "embedding": null, "metadata": {"window": "I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88527800055d05ef9de1c1f053380d4caba62b870ef5c989b3f1faeb5e3a61e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ccb6a39-b3bb-4eac-9e07-123ea733f67e", "node_type": "1", "metadata": {"window": "We had 19% increase year -over-year in total patient visits and 7% \non a same practice basis.  I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I don't know, Brian, if you want to \ncomment on the other?  \n ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "927b4b3bfe9c26575befc3bfcca93e85903656f31591cb84b6be2c5d1aee5632", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43fe314e-3350-4a79-9b3f-b8a82eedacbf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively. ", "original_text": "McKesson Corp.  "}, "hash": "30a0915fd7a6cb6fa82543778d8d79a78e555f500070635bc579568d4acf9827", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 498, "end_char_idx": 769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43fe314e-3350-4a79-9b3f-b8a82eedacbf": {"__data__": {"id_": "43fe314e-3350-4a79-9b3f-b8a82eedacbf", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e38cc2b3-e09b-4186-800d-cf0f4a5afa4c", "node_type": "1", "metadata": {"window": "I thought that would be insightful and it also reflects some of the acquisitions that we've \ndone, or some of the new practices that we've added over the last year.  So again, the numbers that I provided \nyou were patient visit metrics only and I didn't indicate anythi ng else beside that.  I don't know, Brian, if you want to \ncomment on the other?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d90a59d49103ee5f427296073579e169275b87fc1f3cfd6ddb971e8abe3a4c2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e01fe9d1-5c25-4f4f-9012-2e3d79caa05a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "e1a90c897d2dba86c193325ff72ee59893ce59c1592cf52786a8935988d719a9", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e01fe9d1-5c25-4f4f-9012-2e3d79caa05a": {"__data__": {"id_": "e01fe9d1-5c25-4f4f-9012-2e3d79caa05a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43fe314e-3350-4a79-9b3f-b8a82eedacbf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40784802f7337d7b6065cfbde1da82d2476ba40709f1b6c575b1e13d8d0f7611", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f059f14-bedb-4edb-8e2c-b7501dacb3d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n", "original_text": "A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management. "}, "hash": "e65265d03f71ca29259b20675a77b2cb6a116dd57ff12af683e8cbb2b54365a0", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f059f14-bedb-4edb-8e2c-b7501dacb3d1": {"__data__": {"id_": "1f059f14-bedb-4edb-8e2c-b7501dacb3d1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n", "original_text": "A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e01fe9d1-5c25-4f4f-9012-2e3d79caa05a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon. ", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f419b224e12756a5e08eaa1e2230d549282b6116a7cea1b7d57a1fd44cd9ba8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ccf2a2d-d758-439e-aeab-7b18434a24c9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n ", "original_text": "It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively. "}, "hash": "ef1d001c65ff3b9c2f3fc0ee4269ef78635126da8228954566a316cf408e1b13", "class_name": "RelatedNodeInfo"}}, "text": "A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management. ", "start_char_idx": 253, "end_char_idx": 470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ccf2a2d-d758-439e-aeab-7b18434a24c9": {"__data__": {"id_": "7ccf2a2d-d758-439e-aeab-7b18434a24c9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n ", "original_text": "It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f059f14-bedb-4edb-8e2c-b7501dacb3d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n", "original_text": "A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3d0481b93086249f0ed4ab16c8b71e74adea247d71e9ba159dbcb7c4fc5039e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f4c77a8-22c9-45bb-bc87-854d5d806e44", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon. "}, "hash": "cc8e855ffdfb70318aa3ec7fe54717760b4a03dbbcd61607271d86192b5da167", "class_name": "RelatedNodeInfo"}}, "text": "It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively. ", "start_char_idx": 470, "end_char_idx": 662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f4c77a8-22c9-45bb-bc87-854d5d806e44": {"__data__": {"id_": "2f4c77a8-22c9-45bb-bc87-854d5d806e44", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ccf2a2d-d758-439e-aeab-7b18434a24c9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n ", "original_text": "It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ac8945410c0100f1db87b857ef3af65ca6d05ae84e975ef0ca9cb531520423e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9be9c4bf-7e29-4ef1-af53-f358f53863c9", "node_type": "1", "metadata": {"window": "A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question. ", "original_text": "And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n"}, "hash": "059fcac4673279eaf8d6b6928a1046ac7a09e5419310e2855716dda6393bca3c", "class_name": "RelatedNodeInfo"}}, "text": "We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon. ", "start_char_idx": 662, "end_char_idx": 793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9be9c4bf-7e29-4ef1-af53-f358f53863c9": {"__data__": {"id_": "9be9c4bf-7e29-4ef1-af53-f358f53863c9", "embedding": null, "metadata": {"window": "A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question. ", "original_text": "And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f4c77a8-22c9-45bb-bc87-854d5d806e44", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7228e5485a9e4fa30e23ce474698bb382638c2fc63f512ff9c4dcc4d0d32843", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71a9899c-f7b5-4237-bb5d-cf653be96d6a", "node_type": "1", "metadata": {"window": "It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n ", "original_text": "I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n "}, "hash": "1aee43d94cc01293d241dc46b08871fa10dd242c3e64ebeb91dfafb522948ddd", "class_name": "RelatedNodeInfo"}}, "text": "And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n", "start_char_idx": 793, "end_char_idx": 1059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71a9899c-f7b5-4237-bb5d-cf653be96d6a": {"__data__": {"id_": "71a9899c-f7b5-4237-bb5d-cf653be96d6a", "embedding": null, "metadata": {"window": "It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n ", "original_text": "I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9be9c4bf-7e29-4ef1-af53-f358f53863c9", "node_type": "1", "metadata": {"window": "A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question. ", "original_text": "And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b8cf8d67730e37209de764c23a256059bb0bce79fba4dbca2f900aa01e9e283", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5bd00d7-5035-4ee2-91db-e5120ae8bd79", "node_type": "1", "metadata": {"window": "We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "64422f8ebf01432fb3376acc15bef9d6bc1ce6e087d6fd0afb47dfc4b96f2ca1", "class_name": "RelatedNodeInfo"}}, "text": "I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n ", "start_char_idx": 1059, "end_char_idx": 1294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5bd00d7-5035-4ee2-91db-e5120ae8bd79": {"__data__": {"id_": "c5bd00d7-5035-4ee2-91db-e5120ae8bd79", "embedding": null, "metadata": {"window": "We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71a9899c-f7b5-4237-bb5d-cf653be96d6a", "node_type": "1", "metadata": {"window": "It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively.  We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n ", "original_text": "I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89e432257f0eb092256b68b820e9b5272c5f3a4c8fc9b235bb9f4e020909ac0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75d53e53-83f8-4620-bf1e-475367c86b98", "node_type": "1", "metadata": {"window": "And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n ", "original_text": "A \nAnd we have time for one more question. "}, "hash": "677f6bc335ba5de5c7f09772e4109eeda192aeb92f23bb542d8467784699a4a5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 1294, "end_char_idx": 1639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75d53e53-83f8-4620-bf1e-475367c86b98": {"__data__": {"id_": "75d53e53-83f8-4620-bf1e-475367c86b98", "embedding": null, "metadata": {"window": "And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n ", "original_text": "A \nAnd we have time for one more question. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5bd00d7-5035-4ee2-91db-e5120ae8bd79", "node_type": "1", "metadata": {"window": "We've complemented that in recent years with \nOntada, the data analytics insight business and our joint venture with Sarah Cannon.  And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b5878505db402f818520e8707b88b8b5209c18d6c001784c2fa79d690952776", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d29b8bc7-1dc5-4f35-91a4-d589b9ecc1b7", "node_type": "1", "metadata": {"window": "I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "original_text": "So last question, please?  \n "}, "hash": "f287c3e74960f2bdc0768aadd1fe1ceb3a8bedc060cd7a0ad66fb0aa56eb2dd3", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd we have time for one more question. ", "start_char_idx": 1639, "end_char_idx": 1682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d29b8bc7-1dc5-4f35-91a4-d589b9ecc1b7": {"__data__": {"id_": "d29b8bc7-1dc5-4f35-91a4-d589b9ecc1b7", "embedding": null, "metadata": {"window": "I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "original_text": "So last question, please?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75d53e53-83f8-4620-bf1e-475367c86b98", "node_type": "1", "metadata": {"window": "And I think \u2013 then there's \nthe distribution business, so I think when you put those all together that's why we call it an ecosystem because we \nthink in many ways they self -reinforce and you've seen in the last several years pretty good growth in the network.  \n \n I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n ", "original_text": "A \nAnd we have time for one more question. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93f28b9deaa36253f905b329642a0e2bf15fbc4a0d6164d474b4640fd1247dc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a75277aa-c271-4188-bb95-c38c8b07b59a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. "}, "hash": "a88b3f70f6b8d6aca45de43335cc759299519bcdf5b50faa502169386708babf", "class_name": "RelatedNodeInfo"}}, "text": "So last question, please?  \n ", "start_char_idx": 1682, "end_char_idx": 1711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a75277aa-c271-4188-bb95-c38c8b07b59a": {"__data__": {"id_": "a75277aa-c271-4188-bb95-c38c8b07b59a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d29b8bc7-1dc5-4f35-91a4-d589b9ecc1b7", "node_type": "1", "metadata": {"window": "I think that's in part to that expansive value proposition and attractiveness we  represent to these practices as a \npartner to help them both provide the best patient care possible and to manage their business as well as they \ncan. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "original_text": "So last question, please?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0da7dbbe5e894e7bca3e0cf28c725b0ac732727ce98bb79685a160686490604", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c91798b0-3ef2-4414-9bb1-e75fbf7f6d67", "node_type": "1", "metadata": {"window": "A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business? ", "original_text": "That question will come from Elizabeth Anderson with Evercore ISI.  \n "}, "hash": "410db2986a6e30375b09e1203d9cc660acbc593feba070ae2069bb064b642698", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "start_char_idx": 1711, "end_char_idx": 2007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c91798b0-3ef2-4414-9bb1-e75fbf7f6d67": {"__data__": {"id_": "c91798b0-3ef2-4414-9bb1-e75fbf7f6d67", "embedding": null, "metadata": {"window": "A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business? ", "original_text": "That question will come from Elizabeth Anderson with Evercore ISI.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a75277aa-c271-4188-bb95-c38c8b07b59a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4fb929025a6919ceab16f19ee53455b3cdd0c3954b12533ddca6a6bef9ba99cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c478b514-77b1-4052-980b-b12898d28464", "node_type": "1", "metadata": {"window": "So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. "}, "hash": "e514e944bdb19b27271c859d24434dff29271e1b1d483d6602583b3d82462441", "class_name": "RelatedNodeInfo"}}, "text": "That question will come from Elizabeth Anderson with Evercore ISI.  \n ", "start_char_idx": 2007, "end_char_idx": 2077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c478b514-77b1-4052-980b-b12898d28464": {"__data__": {"id_": "c478b514-77b1-4052-980b-b12898d28464", "embedding": null, "metadata": {"window": "So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c91798b0-3ef2-4414-9bb1-e75fbf7f6d67", "node_type": "1", "metadata": {"window": "A \nAnd we have time for one more question.  So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business? ", "original_text": "That question will come from Elizabeth Anderson with Evercore ISI.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb476c8147c70bd9881eec5ff037afca0fb7358d1b9713b854487d719ab4b56d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "878e536b-9354-4d3f-ad40-da7a95aa3a6f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there? ", "original_text": "Thanks so much for the question. "}, "hash": "843a0b644c2482e0c076c25fcd22234c776a06cc937a93838ef44c4dbbc71d01", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "start_char_idx": 2077, "end_char_idx": 2406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "878e536b-9354-4d3f-ad40-da7a95aa3a6f": {"__data__": {"id_": "878e536b-9354-4d3f-ad40-da7a95aa3a6f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there? ", "original_text": "Thanks so much for the question. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c478b514-77b1-4052-980b-b12898d28464", "node_type": "1", "metadata": {"window": "So last question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0acd17195ac5f145f00b17057de41ab023616fd5ec00fda20592e66fe42080c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "427d5b3e-83bc-4aec-9c8b-2d9e0fdfc826", "node_type": "1", "metadata": {"window": "That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n ", "original_text": "I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business? "}, "hash": "65f548de689f604ea326040b2b0e44a30495745535b415547e5005c71dc95ee0", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question. ", "start_char_idx": 2406, "end_char_idx": 2439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "427d5b3e-83bc-4aec-9c8b-2d9e0fdfc826": {"__data__": {"id_": "427d5b3e-83bc-4aec-9c8b-2d9e0fdfc826", "embedding": null, "metadata": {"window": "That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n ", "original_text": "I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business? ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "878e536b-9354-4d3f-ad40-da7a95aa3a6f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there? ", "original_text": "Thanks so much for the question. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a812342330c29b892cdad0b15113d404f32ba88667efe6e3c1d67f5ac427b94e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a3f3f9c-987e-4869-b8e8-71c1dd92b817", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Is that \nsomething that sort of helps? "}, "hash": "4b20c68ad95bd1ee9bb39b2ac2afb879f1550050715bb7c62583bbaffbd54374", "class_name": "RelatedNodeInfo"}}, "text": "I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business? ", "start_char_idx": 2439, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a3f3f9c-987e-4869-b8e8-71c1dd92b817": {"__data__": {"id_": "3a3f3f9c-987e-4869-b8e8-71c1dd92b817", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Is that \nsomething that sort of helps? ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "427d5b3e-83bc-4aec-9c8b-2d9e0fdfc826", "node_type": "1", "metadata": {"window": "That question will come from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n ", "original_text": "I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business? ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bc6eae6b6a63740bc5791bca869234739559561436e9fa96a15289d5f5b3c26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29a40640-a0c4-46d3-b6d0-f204b24bb3bc", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business. ", "original_text": "Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there? "}, "hash": "9af4d22cf5349a887f1d362814143eee0be8de3c2d76c5d77848d83754fa1bef", "class_name": "RelatedNodeInfo"}}, "text": "Is that \nsomething that sort of helps? ", "start_char_idx": 2605, "end_char_idx": 2644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29a40640-a0c4-46d3-b6d0-f204b24bb3bc": {"__data__": {"id_": "29a40640-a0c4-46d3-b6d0-f204b24bb3bc", "embedding": null, "metadata": {"window": "Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business. ", "original_text": "Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there? ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a3f3f9c-987e-4869-b8e8-71c1dd92b817", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Is that \nsomething that sort of helps? ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd6486897be58b3b67e4b6a18c60b6d62dc65b123b3159f9c6e309434a8a20ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c0fcf51-81d0-4c33-9677-27a3cc007d79", "node_type": "1", "metadata": {"window": "I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out. ", "original_text": "Thank you.  \n "}, "hash": "ea0fa7abd722ce845bfdec76477ec37f8547e88e39b7c974b29552d55e5e90b6", "class_name": "RelatedNodeInfo"}}, "text": "Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there? ", "start_char_idx": 2644, "end_char_idx": 2903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c0fcf51-81d0-4c33-9677-27a3cc007d79": {"__data__": {"id_": "0c0fcf51-81d0-4c33-9677-27a3cc007d79", "embedding": null, "metadata": {"window": "I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out. ", "original_text": "Thank you.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29a40640-a0c4-46d3-b6d0-f204b24bb3bc", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business. ", "original_text": "Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there? ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "057cbd497fa0fd3d2b0e9915e93e0c57c768cc9dbb6680e2acbc5e3198ff1c27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "841ed584-2656-4e16-84b1-3d9c6618da03", "node_type": "1", "metadata": {"window": "Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "4f1c8538fcadf4ddf97b5521a2911305bafb675abc0af629a657e35c19932b49", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 2903, "end_char_idx": 2917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "841ed584-2656-4e16-84b1-3d9c6618da03": {"__data__": {"id_": "841ed584-2656-4e16-84b1-3d9c6618da03", "embedding": null, "metadata": {"window": "Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c0fcf51-81d0-4c33-9677-27a3cc007d79", "node_type": "1", "metadata": {"window": "I know this doesn't impact you from a re imbursement perspective, but \nI was wondering if you could speak to 340B and the impact on potentially on your PTS business?  Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out. ", "original_text": "Thank you.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a99b9b1bb038a20c506a6a1276517968306ed41402b8fa3c9f3d45c52418576", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f0e59e8-07dd-4430-8261-138bad539216", "node_type": "1", "metadata": {"window": "Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "A \nSo I thin k you asked 340B relative to our Prescription Technology Business. "}, "hash": "cb0bc5e13bcd4d395664a7557950824a4cbb7235b8eab5d3c64e4a0e39b0b1fe", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2917, "end_char_idx": 3261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f0e59e8-07dd-4430-8261-138bad539216": {"__data__": {"id_": "4f0e59e8-07dd-4430-8261-138bad539216", "embedding": null, "metadata": {"window": "Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "A \nSo I thin k you asked 340B relative to our Prescription Technology Business. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "841ed584-2656-4e16-84b1-3d9c6618da03", "node_type": "1", "metadata": {"window": "Is that \nsomething that sort of helps?  Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a01591a327e2e7a847a120b6fb522010638beb3dae151ee591171d89c47fc57d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25cbe986-7530-41e9-947e-1551f2abd53d", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "And I would say, I would characterize \n340B as not a particular driver of that business, just flat out. "}, "hash": "c03808ac6fa483a838eb5080ae0942d5022dee99571251df682d5c54d4e23817", "class_name": "RelatedNodeInfo"}}, "text": "A \nSo I thin k you asked 340B relative to our Prescription Technology Business. ", "start_char_idx": 3261, "end_char_idx": 3341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25cbe986-7530-41e9-947e-1551f2abd53d": {"__data__": {"id_": "25cbe986-7530-41e9-947e-1551f2abd53d", "embedding": null, "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "And I would say, I would characterize \n340B as not a particular driver of that business, just flat out. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f0e59e8-07dd-4430-8261-138bad539216", "node_type": "1", "metadata": {"window": "Does it have a volume fluctuation part in it or is it just something that as we kind of \nget fe wer of these 340B prescriptions potentially as the market changes that could have a modest impact but is \nunlikely to really have a real \u2013 be a real driver there?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "A \nSo I thin k you asked 340B relative to our Prescription Technology Business. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a6517fd4ca6b850de4f0300a92436e53de51c4af3de89be4f8b145effc528c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f097a8c9-adbc-4cd7-b998-5b6a355ce583", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody. ", "original_text": "I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n "}, "hash": "31d631c74b8b04aecbe2c96a01a4f61e7517f8acb8108d40569381936248756b", "class_name": "RelatedNodeInfo"}}, "text": "And I would say, I would characterize \n340B as not a particular driver of that business, just flat out. ", "start_char_idx": 3341, "end_char_idx": 3445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f097a8c9-adbc-4cd7-b998-5b6a355ce583": {"__data__": {"id_": "f097a8c9-adbc-4cd7-b998-5b6a355ce583", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody. ", "original_text": "I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25cbe986-7530-41e9-947e-1551f2abd53d", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "And I would say, I would characterize \n340B as not a particular driver of that business, just flat out. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "caa0e44fa192c89ac669bf979cd09a788f4c6a63c08f3a877611043ec21885f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e308182-5efc-446c-b887-626f74659005", "node_type": "1", "metadata": {"window": "A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  Thank you for joining the call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "9da7f741e014818b7bd073c40ee2f79d5a540696ca38574a4173fcaccf3bea0d", "class_name": "RelatedNodeInfo"}}, "text": "I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n ", "start_char_idx": 3445, "end_char_idx": 3807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e308182-5efc-446c-b887-626f74659005": {"__data__": {"id_": "2e308182-5efc-446c-b887-626f74659005", "embedding": null, "metadata": {"window": "A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  Thank you for joining the call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f097a8c9-adbc-4cd7-b998-5b6a355ce583", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody. ", "original_text": "I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2857aaeca14caf0491d17ba975d9ac88b27c20f46ea4ca06d8ff7f985f221ff3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ebbb803-64e7-4a8a-80ad-b453e554e8cf", "node_type": "1", "metadata": {"window": "And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson. ", "original_text": "Okay. "}, "hash": "60bc26679e3387a07184b293090681b833b125b4d2bb262d5e9b1583db58d8e6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 3807, "end_char_idx": 4152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ebbb803-64e7-4a8a-80ad-b453e554e8cf": {"__data__": {"id_": "2ebbb803-64e7-4a8a-80ad-b453e554e8cf", "embedding": null, "metadata": {"window": "And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson. ", "original_text": "Okay. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e308182-5efc-446c-b887-626f74659005", "node_type": "1", "metadata": {"window": "A \nSo I thin k you asked 340B relative to our Prescription Technology Business.  And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  Thank you for joining the call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e5daa51047d3a7f69c720a7517ac988d80b3179fab7dd521eb9b2dc00e0962e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41c687e4-6dca-472c-9400-b5942f3f2679", "node_type": "1", "metadata": {"window": "I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n", "original_text": "Well, thank you, everybody. "}, "hash": "807f0e2bb74f9530c8e33b85d435cf931b36f7a9fa7e9eb48125e5797dea0808", "class_name": "RelatedNodeInfo"}}, "text": "Okay. ", "start_char_idx": 4152, "end_char_idx": 4158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41c687e4-6dca-472c-9400-b5942f3f2679": {"__data__": {"id_": "41c687e4-6dca-472c-9400-b5942f3f2679", "embedding": null, "metadata": {"window": "I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n", "original_text": "Well, thank you, everybody. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ebbb803-64e7-4a8a-80ad-b453e554e8cf", "node_type": "1", "metadata": {"window": "And I would say, I would characterize \n340B as not a particular driver of that business, just flat out.  I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson. ", "original_text": "Okay. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4433034b0a89d19abfdb86050d2ff55d1737344df0c88811a1006a72cce2f37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcd8b5dd-d4c9-4d54-b947-87d3548ea3b5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results. ", "original_text": "Thank you for joining the call. "}, "hash": "8aeebb980b3a98d5a98dc0b5dfd15cb3446f61d02e2588c174db7803b299ccff", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, everybody. ", "start_char_idx": 4158, "end_char_idx": 4186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcd8b5dd-d4c9-4d54-b947-87d3548ea3b5": {"__data__": {"id_": "dcd8b5dd-d4c9-4d54-b947-87d3548ea3b5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results. ", "original_text": "Thank you for joining the call. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41c687e4-6dca-472c-9400-b5942f3f2679", "node_type": "1", "metadata": {"window": "I'd say the impacts of 340B would much more be in \nour resident pharmaceutical distribu tion business and obviously, we've talked a lot over the past quarters about \nevolutions in 340B, whether those be regulatory or commercial actions and reactions, and our best view of all that \nis reflected in the guidance that Britt and I have provided this  afternoon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n", "original_text": "Well, thank you, everybody. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1429dace9095808f8c97ba32188c480e51c4e2c0f9d7f3d3443eafd0ea1907c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d954a197-ed10-49a8-8616-40e5a4f02625", "node_type": "1", "metadata": {"window": "Okay.  Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany. ", "original_text": "Appreciate the thoughtful questions and your \ninterest in McKesson. "}, "hash": "97a18834afa38488c7893057c5f66da6487e4e9b87d383d6d22a27a6b66e116c", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for joining the call. ", "start_char_idx": 4186, "end_char_idx": 4218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d954a197-ed10-49a8-8616-40e5a4f02625": {"__data__": {"id_": "d954a197-ed10-49a8-8616-40e5a4f02625", "embedding": null, "metadata": {"window": "Okay.  Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany. ", "original_text": "Appreciate the thoughtful questions and your \ninterest in McKesson. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcd8b5dd-d4c9-4d54-b947-87d3548ea3b5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results. ", "original_text": "Thank you for joining the call. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7eb33fc542bbf67e18b9160b1b06822eb3be8221bb2b5c6378102d041c6f51a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3addae53-4ce2-4473-aeac-1ded1842df2a", "node_type": "1", "metadata": {"window": "Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany.  We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "original_text": "Thank you, Cynthia, for facilitating the call.  \n \n"}, "hash": "51e6ba96997166bdfb838b332e0a396d3f66f2493756a0ac02e7048c6c225daf", "class_name": "RelatedNodeInfo"}}, "text": "Appreciate the thoughtful questions and your \ninterest in McKesson. ", "start_char_idx": 4218, "end_char_idx": 4286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3addae53-4ce2-4473-aeac-1ded1842df2a": {"__data__": {"id_": "3addae53-4ce2-4473-aeac-1ded1842df2a", "embedding": null, "metadata": {"window": "Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany.  We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "original_text": "Thank you, Cynthia, for facilitating the call.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d954a197-ed10-49a8-8616-40e5a4f02625", "node_type": "1", "metadata": {"window": "Okay.  Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany. ", "original_text": "Appreciate the thoughtful questions and your \ninterest in McKesson. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9c56bd11d17018280beb9c0a911252cb94e5cdc3fafba48bdbbe5f03426199a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a07267f-f32f-49f5-9bb2-5c13ff84e042", "node_type": "1", "metadata": {"window": "Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany.  We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "original_text": "I'll just wrap up by saying McKesson delivered strong first quarter results. "}, "hash": "21bd7e5857a35d8d704e5b760c7b7bf4aef584e7dd76baba12f62ca5786c82a5", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Cynthia, for facilitating the call.  \n \n", "start_char_idx": 4286, "end_char_idx": 4337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a07267f-f32f-49f5-9bb2-5c13ff84e042": {"__data__": {"id_": "4a07267f-f32f-49f5-9bb2-5c13ff84e042", "embedding": null, "metadata": {"window": "Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany.  We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "original_text": "I'll just wrap up by saying McKesson delivered strong first quarter results. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3addae53-4ce2-4473-aeac-1ded1842df2a", "node_type": "1", "metadata": {"window": "Well, thank you, everybody.  Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany.  We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "original_text": "Thank you, Cynthia, for facilitating the call.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc6c27a8285720637a38bef050b9dd8c2ba34ebc3370653b20fc5c94520e87c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ceacbe01-12a6-4bdd-815e-7d69676e812a", "node_type": "1", "metadata": {"window": "Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany.  We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "original_text": "Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany. "}, "hash": "38db7583257c7e9f40dc5748efe923a0a4760a3060d600e25a37886fba6d19f2", "class_name": "RelatedNodeInfo"}}, "text": "I'll just wrap up by saying McKesson delivered strong first quarter results. ", "start_char_idx": 4337, "end_char_idx": 4414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ceacbe01-12a6-4bdd-815e-7d69676e812a": {"__data__": {"id_": "ceacbe01-12a6-4bdd-815e-7d69676e812a", "embedding": null, "metadata": {"window": "Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany.  We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "original_text": "Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a07267f-f32f-49f5-9bb2-5c13ff84e042", "node_type": "1", "metadata": {"window": "Thank you for joining the call.  Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany.  We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "original_text": "I'll just wrap up by saying McKesson delivered strong first quarter results. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "602829f4e1d6896bc2aea9bd400499fff6233e9424efeb2cbb77ba4c98fb2988", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a4d51d3-1468-4611-a0fc-5fb5e2c9bc44", "node_type": "1", "metadata": {"window": "Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany.  We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "original_text": "We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n "}, "hash": "af4a6e9d0e121e2660c1716e3984167eda9bce9720766de326f369794fa2a39d", "class_name": "RelatedNodeInfo"}}, "text": "Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany. ", "start_char_idx": 4414, "end_char_idx": 4569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a4d51d3-1468-4611-a0fc-5fb5e2c9bc44": {"__data__": {"id_": "6a4d51d3-1468-4611-a0fc-5fb5e2c9bc44", "embedding": null, "metadata": {"window": "Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany.  We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "original_text": "We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d516fb4c382ab217c9b47a8205fc2131dbd7729b8cb109a609f773d8c263a59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ceacbe01-12a6-4bdd-815e-7d69676e812a", "node_type": "1", "metadata": {"window": "Appreciate the thoughtful questions and your \ninterest in McKesson.  Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany.  We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "original_text": "Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany. ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85784bdc432f0d98fb765ba5bb46d0930ff5647a0d32fbe5e698d25496fa6bf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12862eaf-9d55-4deb-bbcf-58d436177422", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "McKesson Corp.  "}, "hash": "e6d7ae90eb506ddeec983813bf89e64d717af7590012e9b633b7386aaeb167c7", "class_name": "RelatedNodeInfo"}}, "text": "We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "start_char_idx": 4569, "end_char_idx": 4707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12862eaf-9d55-4deb-bbcf-58d436177422": {"__data__": {"id_": "12862eaf-9d55-4deb-bbcf-58d436177422", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a4d51d3-1468-4611-a0fc-5fb5e2c9bc44", "node_type": "1", "metadata": {"window": "Thank you, Cynthia, for facilitating the call.  \n \n I'll just wrap up by saying McKesson delivered strong first quarter results.  Our financial strength is really a \ntestament to the significant progress we've made in advancing McKesson as a diversified health care services \ncompany.  We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "original_text": "We're confident  in our differentiated market position and our ability to execute and continue to create \nlong-term shareholder value.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c61e5a63670b0f9a0f25e4b6b156400672da76d87fba365129541839280976f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75695894-f22e-414e-a24b-21011ded1e5c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us. "}, "hash": "b85d141b748af9981d1d9caed16ab85166ffa52b458fb18016940e9b3da50a13", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75695894-f22e-414e-a24b-21011ded1e5c": {"__data__": {"id_": "75695894-f22e-414e-a24b-21011ded1e5c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12862eaf-9d55-4deb-bbcf-58d436177422", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62eb2a3736c66418ce1625e6b8af934ed75621f0e50a32056ba55fc932ab0923", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba78996c-083b-49c9-9d4d-93b2a071f4cb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "I hope you all have a terrific evening.  \n "}, "hash": "a8ea0d61c19357f42ea0d6dd1813052147c49e081ad08a240fa5383c1c32ecd4", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us. ", "start_char_idx": 16, "end_char_idx": 210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba78996c-083b-49c9-9d4d-93b2a071f4cb": {"__data__": {"id_": "ba78996c-083b-49c9-9d4d-93b2a071f4cb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "I hope you all have a terrific evening.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75695894-f22e-414e-a24b-21011ded1e5c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b0a2c56e96b8fd6a855cdb7b2390dd6ada0a2db32dda43cb6f7b251e0046f2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb44492b-c0a9-4b9c-ab8c-2a848b8fc9a4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. "}, "hash": "cecfd362b4f123bdf90ba2d6bd4d460d507d6b890147db1f0d8d8a045424b4d7", "class_name": "RelatedNodeInfo"}}, "text": "I hope you all have a terrific evening.  \n ", "start_char_idx": 210, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb44492b-c0a9-4b9c-ab8c-2a848b8fc9a4": {"__data__": {"id_": "eb44492b-c0a9-4b9c-ab8c-2a848b8fc9a4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba78996c-083b-49c9-9d4d-93b2a071f4cb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "I hope you all have a terrific evening.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2dc7672b79bf71136accab2d3c991287eaee4a131d0c1df015c82962d94323c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4da320e1-1a60-4578-83d9-f0e219e70914", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information. ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n"}, "hash": "ee4227fe2e5aaa6ed2042549c1b642bbb83300b36760fcf7d25eb65c7a41998d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 253, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4da320e1-1a60-4578-83d9-f0e219e70914": {"__data__": {"id_": "4da320e1-1a60-4578-83d9-f0e219e70914", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information. ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb44492b-c0a9-4b9c-ab8c-2a848b8fc9a4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9992b43cb60f13ef81e7800cd9a4766a0d6cd84ab920dffdbdbb5b55abf94553", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72a88d9b-9fff-4f81-9294-c67b4005f33a", "node_type": "1", "metadata": {"window": "I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n"}, "hash": "065c4983a7b8459f5ec1d4e4b396c1af0a223848680bfe51e6fca32f5a41f52e", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "start_char_idx": 585, "end_char_idx": 654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72a88d9b-9fff-4f81-9294-c67b4005f33a": {"__data__": {"id_": "72a88d9b-9fff-4f81-9294-c67b4005f33a", "embedding": null, "metadata": {"window": "I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4da320e1-1a60-4578-83d9-f0e219e70914", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information. ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d761549f68abb1c35044e0a453bae871e113ab0dc036c1dbdcdd2448524ccdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff8e15dc-c537-4198-bc93-bb899abe8240", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "d73aca7c07f478744dae28a7c8f9e8fac17111dbe20d0f4a864257901e8a90f2", "class_name": "RelatedNodeInfo"}}, "text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "start_char_idx": 654, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff8e15dc-c537-4198-bc93-bb899abe8240": {"__data__": {"id_": "ff8e15dc-c537-4198-bc93-bb899abe8240", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72a88d9b-9fff-4f81-9294-c67b4005f33a", "node_type": "1", "metadata": {"window": "I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88f6e4bbf78a350520142edc7074527e011c6cde8c593480151e43b2d7bacc66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adc3a371-fc55-48d0-ae6a-ae3836c15611", "node_type": "1", "metadata": {"window": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information. "}, "hash": "38bee5cca3f2aaad0462c1fa562678ec7da4679695981cf88f05eb8bbdf13c6b", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 863, "end_char_idx": 985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adc3a371-fc55-48d0-ae6a-ae3836c15611": {"__data__": {"id_": "adc3a371-fc55-48d0-ae6a-ae3836c15611", "embedding": null, "metadata": {"window": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff8e15dc-c537-4198-bc93-bb899abe8240", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50f34d81d276d1a842c89a168c6332ce86eb4aeb66553204a06820f33cc1159e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e96b6c1-2b5b-469b-b99d-49c6f5e4cda5", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basi s \nof investment decisions. "}, "hash": "377a2736847bb856fe5c023a3d6cbc9a0545ac28a77e435184ab1d9f11521bc4", "class_name": "RelatedNodeInfo"}}, "text": "You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information. ", "start_char_idx": 985, "end_char_idx": 1186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e96b6c1-2b5b-469b-b99d-49c6f5e4cda5": {"__data__": {"id_": "9e96b6c1-2b5b-469b-b99d-49c6f5e4cda5", "embedding": null, "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basi s \nof investment decisions. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adc3a371-fc55-48d0-ae6a-ae3836c15611", "node_type": "1", "metadata": {"window": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b3f3284a03db7237c5003294f638d3e15dc5201e3dd907ecc7f70286252f0ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6838784-3c69-412f-9052-194c88aff515", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. "}, "hash": "73bd7d8822fe5b90ef8e2e4a3d4fcf1675a6b11c85daa266aa2f8516d1971e6f", "class_name": "RelatedNodeInfo"}}, "text": "This information is not intended to be used as the primary basi s \nof investment decisions. ", "start_char_idx": 1186, "end_char_idx": 1278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6838784-3c69-412f-9052-194c88aff515": {"__data__": {"id_": "d6838784-3c69-412f-9052-194c88aff515", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e96b6c1-2b5b-469b-b99d-49c6f5e4cda5", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basi s \nof investment decisions. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f64a05880d15f780de60cf6887cd61e7ca5fba57768dae1a1a1af4bffc68d853", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67fd1653-9aad-46cf-ae64-27803165951e", "node_type": "1", "metadata": {"window": "You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT. ", "original_text": "A ny \ninformation expressed herein on this date is subject to change without notice. "}, "hash": "fe0b3902097aa953cae05803e46d0c0f75112d14e18175b7be4b0f4133f9b13e", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "start_char_idx": 1278, "end_char_idx": 1640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67fd1653-9aad-46cf-ae64-27803165951e": {"__data__": {"id_": "67fd1653-9aad-46cf-ae64-27803165951e", "embedding": null, "metadata": {"window": "You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT. ", "original_text": "A ny \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6838784-3c69-412f-9052-194c88aff515", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c91b038a7c88f4af730c0869a71987aa5b431d986749cfb4ae5fc021df10071", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a57fa331-23ef-4633-be51-66b7f301f31c", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. "}, "hash": "11d2150bd3e7ad04a3ed37232dc707f65241df0abed4577a66c64dd1ef503963", "class_name": "RelatedNodeInfo"}}, "text": "A ny \ninformation expressed herein on this date is subject to change without notice. ", "start_char_idx": 1640, "end_char_idx": 1725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a57fa331-23ef-4633-be51-66b7f301f31c": {"__data__": {"id_": "a57fa331-23ef-4633-be51-66b7f301f31c", "embedding": null, "metadata": {"window": "This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67fd1653-9aad-46cf-ae64-27803165951e", "node_type": "1", "metadata": {"window": "You mu st evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accu racy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT. ", "original_text": "A ny \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20e37121401ec2de5c0f7971e96e822644fead3858840c7d891a214e6f2733c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "309590dd-f043-4e0d-b4bb-b5351fc65892", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n"}, "hash": "9c9765b9092ed545c996a65d3a0768aff8608c7d95909ea15afbb532fce71e2d", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 1725, "end_char_idx": 1853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "309590dd-f043-4e0d-b4bb-b5351fc65892": {"__data__": {"id_": "309590dd-f043-4e0d-b4bb-b5351fc65892", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a57fa331-23ef-4633-be51-66b7f301f31c", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the primary basi s \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "faa3db40bfdc70eed38c6ab639f83afc7fea858334b77c0e888a53147fe0fdac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f3d822a-238d-4716-a5be-01beb3cd987a", "node_type": "1", "metadata": {"window": "A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT. "}, "hash": "17be2130d595a742e53cc07ac04428b2ee70e75a954fc1c42c46358de9958d67", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "start_char_idx": 1853, "end_char_idx": 2016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f3d822a-238d-4716-a5be-01beb3cd987a": {"__data__": {"id_": "8f3d822a-238d-4716-a5be-01beb3cd987a", "embedding": null, "metadata": {"window": "A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "309590dd-f043-4e0d-b4bb-b5351fc65892", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f56445f80bc9d38797328a0b46ccc5181fad9a61376da1c593e9f0597bff080", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0b7157b-75b8-4614-ae79-7c615510c69b", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n"}, "hash": "94b7009b22313edaedf9690e8c62e0b9425b06090341dcbdecd7a563d32eb3c4", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT. ", "start_char_idx": 2016, "end_char_idx": 2452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0b7157b-75b8-4614-ae79-7c615510c69b": {"__data__": {"id_": "b0b7157b-75b8-4614-ae79-7c615510c69b", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f3d822a-238d-4716-a5be-01beb3cd987a", "node_type": "1", "metadata": {"window": "A ny \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f5329563f6fb97652e321ee01ce32d7b65e7910e154ebbf72604301c0b505e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f95b820-9574-4208-80a9-4cfa41f3eafa", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "c5025dcbcf3a4c15b00c716466f0a14a7e8431157aad77216d4fe9f68eac77ae", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "start_char_idx": 2452, "end_char_idx": 3131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f95b820-9574-4208-80a9-4cfa41f3eafa": {"__data__": {"id_": "6f95b820-9574-4208-80a9-4cfa41f3eafa", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0b7157b-75b8-4614-ae79-7c615510c69b", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0fa7017f0e25cfcc4790d82017463ff7b26e1665c9a7d62ae39bb9972d501a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36cc7327-3700-4b92-96d0-5e3bceaa7837", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "39bdb58fab676b4c9eeef21788f4eaad3a19e6f89afbc5b4c84bb0fba41ea898", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 3131, "end_char_idx": 3321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36cc7327-3700-4b92-96d0-5e3bceaa7837": {"__data__": {"id_": "36cc7327-3700-4b92-96d0-5e3bceaa7837", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f95b820-9574-4208-80a9-4cfa41f3eafa", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its e mployees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35d3a8ea3949aeed5afbcb1254e7d21ffec94f047782e9369b6c5eaa7a4df2dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6270448b-c2b6-4707-a7f1-3d8be4bc2168", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "e3daf5ba1805bef407acaff90276b52553248378451114a38a0638ce5e4153cc", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 3321, "end_char_idx": 3399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6270448b-c2b6-4707-a7f1-3d8be4bc2168": {"__data__": {"id_": "6270448b-c2b6-4707-a7f1-3d8be4bc2168", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01429f9bd0e4e46d897240bed91301020e534321b0b59fc6f8597cde5be7e942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36cc7327-3700-4b92-96d0-5e3bceaa7837", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND  ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETE NESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENT AL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMA GES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallS treet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6de2ff503ab829d038347db49938abb633f0f4bb8ea074047a2d7608c42fc7f8", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 3399, "end_char_idx": 3421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"1ec9f0f6-ddfb-4773-8c5b-9608fcb4639c": {"doc_hash": "c30c6654867ba408bbe11f2906cdedb94f63501e798ade8c64c3fd7cc502ade6", "ref_doc_id": "7f1a04c9-62a9-4615-bcb1-4492e1bcee63"}, "c4e052e2-2bde-4d36-87b0-ebd8dd84eab5": {"doc_hash": "16361d61a68e08e1ab9fba5989d2bba56559fcb81ac02949ed885919f7404d38", "ref_doc_id": "7f1a04c9-62a9-4615-bcb1-4492e1bcee63"}, "37f0b981-a739-4f4f-a0a2-4e4c7c3855ac": {"doc_hash": "e738a82087d481454557742925922da7b33505d92b6f1eff93000a2cb6defd66", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "767f484d-0e88-436b-8d0b-31c0f551f972": {"doc_hash": "4b2e7c3bb5b3e8d99c2e8d3ea2635feb46ca27b9c3a0d927dc65d3625abb6ea2", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "ceb9e48e-ae8d-4c0e-a214-7f9f703c045c": {"doc_hash": "1a43bd57c137416e9b811edc41b37e4fe717394067dd5a1ef3a8f9c1726bda09", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "03427b1f-5b9e-47cb-8f63-ef1061960587": {"doc_hash": "f97ecbd44474e0e0489256f73c353d712b66a0df078e4460c5999f1048b819a0", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "452a77cd-46f4-432a-863c-55ee682bc998": {"doc_hash": "88e42a2d52da27394ed2d245c308132ccc789874047403b1f1a084edd3318bf9", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "4f0072f1-57aa-4883-ae57-5d6ee9790961": {"doc_hash": "cac5376e9adbca474651546aeb85c66ad2cad8bf5fcb4e69d2d5b259d0423e03", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "5d73c376-9867-41a9-af43-d573f6520e98": {"doc_hash": "53f83a60dad1b4c9e9b68865ab62839029d20e9302ff17a143cffa04602da66e", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "b3a5d367-5036-4fd8-ac0b-79ed13607aef": {"doc_hash": "d1555ee963ee022c74bebfb0f17ed75bfa65f2f23c2760dc92504cb9181b25b7", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "4489f470-6222-468c-b9b2-4b13f096175c": {"doc_hash": "354faad6889f543fbf68040aa4123890cf558ce0528a1f8dea42f0aff5f331a3", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "004d145e-61f6-4210-830a-2d8c6e5a7342": {"doc_hash": "16cf0d5da072d69084105dcf511e8e06b7cf57565cdfcd8121ffb1beddcb7749", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "4204660c-9a85-4c3d-8471-38a8b2882200": {"doc_hash": "b13f3c5897b9c80f8e84ebb13ee4ff006d517e3993e6126060273344a14c09bc", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "43016a68-8cb0-4f94-a247-e274775219ed": {"doc_hash": "10d99c7c96ca6c7aae04ba167df512ae1f3adb43ac73a007d52f633766c674f7", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "489115f9-e3fa-40f7-aa73-982f729a742d": {"doc_hash": "99f4309ec8d82dab02aa244ca7b0f9869c2565b65fb280555338c4f71bf92bd3", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "2381de58-fc90-41ab-b6d8-72563f04b20d": {"doc_hash": "512b72f64964e0210739c3f006c02a29307e0c02dc88f1367f7140793321401d", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "dbb8d283-9428-400f-ab22-bb5065cd27d6": {"doc_hash": "79fa88f8c8c3a9829821b620e8ecce6fe0a248bd67c9f00913affc97f420fdb5", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "d7dfe3ce-80e1-4408-a81f-7ecd425997db": {"doc_hash": "298faf0f0e7ab1f079bac21e7bc276dfab7c4c4765b74ee8a8220682400b68ad", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "214f1ff4-e754-4102-8b7a-71d5a8ff81e0": {"doc_hash": "f59ec4dfb7c4f0783596dcc6ce6b5052139d86fa47c21d4d74c80f2b7307039a", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "562be26f-69b1-4a3a-bf93-ee728d91faaf": {"doc_hash": "839404e1777a07e4ebfdac4df8627cd0c4c14ba8e5ee9a2c21b23b0cf78b0f06", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "a3e57ff7-4a27-472c-b71e-26f7d7736d47": {"doc_hash": "360569da81ace6ecd9bab9e7fc8e68eb789bb8b720b9d365b8b32ca04da09e0e", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "68b0fa61-126a-4545-b51e-7e0d71ba3c2a": {"doc_hash": "44aaf61b7ef5844f85b01906c77d1981e5cda97c477551a79b5b94fd72a4aa54", "ref_doc_id": "ce84f197-3760-4cf2-86ad-93434da74016"}, "dd3ffb9b-2b55-44e0-b69c-2e36414c3dd1": {"doc_hash": "4da3e2557f486ea0924ddc2fae16a43d1357be8d40ceb0065607c793f6d0cd8e", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "94356b8f-c1e4-4510-9b95-681950125b4c": {"doc_hash": "560f1e2c26cbeac66d47853b259f6829ae9e99f884379e219f0c2316a27c4810", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "7e02e8d1-4228-43a8-a524-e9f414db46b7": {"doc_hash": "ff899463c369c7eb04695e1ca8eb17fa4e44d95223dc7de73dc3c83d3526f78b", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "0850248f-6f87-4b26-9586-444fd93b8403": {"doc_hash": "9c7e03dd577668863cdbf8a16733998f36c831bd2b0e0071f872679ec9067c4d", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "8823ca9d-82ff-4bdd-93e4-d4fcdca4d591": {"doc_hash": "f7ca9aec111b113338c1f30384fb4306794e4186143b6d4bda82ccf04ee1ab9f", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "7e3f3fe8-cf28-4d13-948b-ed67c19848c4": {"doc_hash": "8b63e2bd5f709a11fb70c226f74e59d6c78644e4d5b83df7724e6154ffa175e0", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "3c5cfd06-28c0-425a-bd0c-1f05c18dcad8": {"doc_hash": "d07bdab6c5a5a09051db09c9a3fe90c28feff0a96087541e6aba0c453393a49a", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "47d23fee-5c97-48c3-9e8f-eeaf7789ecdf": {"doc_hash": "40c5c189276180110daa3f127db10e2e4705839c241748c55c2ea79d9de15dfc", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "0b12ae4d-890f-4cf9-9848-6308534917fa": {"doc_hash": "942edf4022fef1a003cf3073c1465f4e6f1c7ca12a898e17b818eb498bd2a4aa", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "62805d47-3eef-4909-8940-a643268b2b4a": {"doc_hash": "c707dd440f1f4eeb2a098df2aa5cdf56fad50d85254da0979654ef53cd423c0f", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "5603e1b4-d0e5-40b2-8fe8-55540e6b0825": {"doc_hash": "700f3d15fdaaa5132a6cb66b0533112558361db522e6be9ef645da2c4d92863c", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "6cc20f45-0920-40f7-8961-96c54cdb94ec": {"doc_hash": "60b2d30dab2fd63c9fe729072da62b2c171ea5b478a9602961b3309ee9db4b94", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "53de1a3d-d2cb-4b16-8604-7ce5a26bf8d4": {"doc_hash": "bd591745034ca5c9ef328d7497d77d1146042496e05e743a50776f6028d04988", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "b96d8fab-ce28-4698-bcd4-53e4fc750479": {"doc_hash": "d4c26a0b38c0dfe77a9b10badbb0e9243458f96235d6904b282869f192eab92d", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "5ddfaf67-7d5f-40a0-848c-4a1aaab48cb8": {"doc_hash": "57cf4ad6f06e633329913099a2b2dd4a9cf81992ae99bf65abc40464b41ea210", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "b4f714c4-5ed4-4202-b28f-ddfdffe10a46": {"doc_hash": "b1a8d0719be6e923d23d81dd52ee540c6e143966978260a718170709f3a04f52", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "1183fa0b-3e23-4f63-9825-0e4148550dd0": {"doc_hash": "303f30cb8b663188a18fe51d323753d583bc566113fdf44b923095d6da1e1ee7", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "efadd836-07dd-4d38-b1c0-c4ff31a876d9": {"doc_hash": "d3841af6e3cf55d96fbe2e8556364e876542f7d6c0e971792aea6b781d288451", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "b3094e7b-3023-4ff4-8cce-f1810b4d8a97": {"doc_hash": "d7e8da3098776c9ff3ae4bbb25b667a5181a725c565e63d94e9a27433b8909e7", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "2a164599-b19f-436a-bc4d-cefdead83dfc": {"doc_hash": "77badbbc696e5776ff71406a4dacc760976e74ac36f6850275c1de646facbb04", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "74f6f97d-687d-429b-9845-a6977cb9a5cc": {"doc_hash": "a8e2747ec9108b3d179d220e95c93991a6888d8253d011185c65bcbf7b07b93d", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "768a9e8c-71aa-466f-bbb2-e3ffde772077": {"doc_hash": "2164c0a3171d175e1fbff7862cc731e96cc469b1b82694cfa98b2d33f4ced0b3", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "a0753336-3aff-48f1-99e5-7668777bc474": {"doc_hash": "9eb6f87dc8a7136494c0f0555b039a3bbc3114b1cba6de6405fc5f111a329f5f", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "1b2bcba6-b682-493d-87c3-783eafd82f30": {"doc_hash": "8c3b6ef068277123ea62a70b76063e245a35f870d88c01bad90c9edea6d53b63", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "268768c1-0610-4272-8d00-96f47f4e90f4": {"doc_hash": "50b73148b9f5e5ea10a663cf6215fc3a7eaa8c13a28f4ce92e5f7bd42cb37eca", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "fb9fabf6-7a73-4a75-942b-8c15df8f6dfb": {"doc_hash": "1529d675e969282ef9fa29253a1bafa56cb3e75abb4fe7bd30b6bb4fe09e8720", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "ad8f501a-a61c-49ef-bdb6-643bbd9a2a74": {"doc_hash": "442e47dbe976c48ee7c6b2a3ff5da7112603b700b3589f0190abab62656d8595", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "26cd9cf4-788d-432c-aa2b-e8d3484d701b": {"doc_hash": "c1a048dd843ea81bfb208315025e08ad4ad7401c2a413f61e944ec122a3fa8aa", "ref_doc_id": "30e42cd6-369e-40f3-9804-be6c6e3c8c60"}, "ab77c1b5-1ae4-4346-ac4b-070efee2f110": {"doc_hash": "ce363afe34f492094a9c46d986f618eae1fddbe842e3c6373fabd804f081cf77", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "c0fe4375-9202-49a9-83d2-0bc5d96619d1": {"doc_hash": "9629685b627c688e505f5f996ecd7acf118ba0ce7d3cb3e1f8a9b5522e1d776d", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "f279f272-842a-4ac1-93b5-a172cc3553d4": {"doc_hash": "b45f5df723b60faf7e62a4f56c5a2611861796302bcfdb0bf2d2f6330cc9f6f2", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "dbd86fe3-794c-4cb8-9cd5-a5cce384cc7f": {"doc_hash": "9122f24db04aa539a7e1814ac2b94656f20798bf295d91072298a977bcb4b768", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "a2afda1b-24ce-4f2f-908d-4973ac0d1b13": {"doc_hash": "1a450bf67cd7b57b8bb92bd4582b551e52212c9a629bb3c05f4d1ed94b37d41a", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "b4cb1d27-9236-451f-902e-b8c07709a0ae": {"doc_hash": "080760c1ca556bc3b8e47e38b77e581e07c901f9bef0d8907ed5b8692f4cbb67", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "e6f522ac-4300-46ea-ada4-e52ec0a4da3e": {"doc_hash": "4f353efbb33db0370177a2472525b140867f0c62d24b78499a06081c714c10b1", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "ba43908a-dc03-4de9-bdaf-00441d642097": {"doc_hash": "c04c339d5397c78cff397f25fca9bb5fb153cc22e64a0b85bfd126a23238ab92", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "141343ca-8286-4e09-b542-c8dc4bf9fdd9": {"doc_hash": "0fe4c0bd56eae4216e96f01996fcdc725583d19dd1611aec4d4059ef9673a0e3", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "f55035d3-72ee-4adf-9b16-b138990ddf09": {"doc_hash": "adb71da079010e1423ed90843382b463d40bb07622e219f453bbb6ab2f8a91cc", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "d32db43b-07a9-4ce0-8f83-9efec3792a2b": {"doc_hash": "d0605a4cb3ce6681df1d85984088dfb139b1fd1f131077f46ac5cd609fb3cd22", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "9f50d233-fae8-41bb-b4bb-a16962c03113": {"doc_hash": "a30716ee8fb08d0174d35ecc40105c263e0839889502b619983d86f9ce177104", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "ea0febec-c1a2-4d22-a012-4416d0be1fd0": {"doc_hash": "25bce646dfa906642cbdd602ff5cdd514cf47a36656eac549060897745c4b4a1", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "f7948fa0-84ad-4533-bb70-d25feeaf3b80": {"doc_hash": "8da0288255933c76267bf00c2bad64ab1ac766b5cff6201ab718def5372ee6bd", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "494371e0-8d8c-4d89-b6ea-4a3f82a7c3d3": {"doc_hash": "dc43c48236a6a76bf5c0197667acb6630d25a7e6d61cbcc2cd4e9084e398deca", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "1ae6e2af-8ec1-411e-a480-4c636660d70f": {"doc_hash": "38396367b4fa2cad2f34e789d902ab471649a971243d74935ebf96e1acfaf827", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "a1e70a96-2411-4739-b14b-57c66333a7ce": {"doc_hash": "4722bc803530c12f9e7552449300006e9b4788e821fe7edab22a8a024fd89b9e", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "62e9fd2d-2bb8-476b-954b-656cd55c6af2": {"doc_hash": "54431d40bd25ca742236e5d041209aed10aba58f82bdeec1a455f9ce86f065cb", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "9a050a31-ddde-4519-bccb-f45244be9364": {"doc_hash": "28ef5c8062ce30af6e0eb2d16021e58df1b35c28b4d929f66483027891b8cb7a", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "fa6fe6ce-66f1-4f8b-b0be-ff5507e1b09d": {"doc_hash": "3cbbb2982278a993b11bcac7afc31065a5675fac10aa75dd3d96fcb8f01af2aa", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "e9aeef17-fb1e-44c4-b551-adbaf029e369": {"doc_hash": "5cb8d86b35d89dbffdb5f86365eb408cacb3490c1809fbe6009f3695f256d168", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "a0b93953-044e-4195-b2fe-148e87f62d7e": {"doc_hash": "f6aafd51d89f0e2d878946620f1eec6e2e54969625b9c95cc59a1e4e86d3baf5", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "a742ed1b-9d14-4199-858e-66684f9d00fe": {"doc_hash": "f51cc5ff67439ab42f0acc38d6a30d736ccbf8d9bb97fdd41821c76926e20508", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "31d39711-f0dd-4acc-aa49-94918a227756": {"doc_hash": "c348c7bc849a5338fd2e8cc930b3fea721b220922833433b91d793b6bfc8a285", "ref_doc_id": "2d7274c5-67fe-4463-87fd-a9dd5be49633"}, "08d44b30-e3d0-4abe-8664-10397fdd43de": {"doc_hash": "1e4c363eb1c4c3806405f00e5247aa23a3d5f1211befaa099d72cf5cff0fd9eb", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "149c365f-be9c-4bd8-a199-1a87bf41933b": {"doc_hash": "0dc3f91126d6597ac89e5862523b9a7580154a57fc5b4ea03b81984af3937137", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "d6f7b39a-f5f1-45a9-ae33-25f8fa326c4a": {"doc_hash": "5b6d6c7ab5e5461b782e525493b6785a75ebc8e36793fb433a1e8bbd40771ae1", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "9208d2bf-fc66-4d32-9228-dd73be87cfa2": {"doc_hash": "c3b2f20a1ba6b256dc5047d7eba105fb9f1d64fc9c8febd61a83a0bdb85f0892", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "6e55c7b6-d80b-49c6-b374-8e6cc2e0bc5f": {"doc_hash": "f90472a9cdbeab88b2b57ae5b31ba99180014b8acf8e51b42d559decfa96df9f", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "8804b8cc-9143-489c-add1-7d7f5e392a5f": {"doc_hash": "07d47836ad4b471954e8836ae963f396f29b31ac28d43f986237848a975b1428", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "f592919e-849a-42b1-a49c-977946233075": {"doc_hash": "135f6f777e99e629cb51a15a833b6e9a8d6e5a252e6b8f7a43cd13877a711a84", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "d8fae14b-75bc-4b89-a90b-ffb1d3c57103": {"doc_hash": "b19c9e2ec53fbbbdd5e461ffdb025a6f93d80c0cdbccf1f6dbe5623bb5d2c042", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "c02d7f6f-ef8d-4e51-9ec4-628562f94478": {"doc_hash": "f95e665fad3e5eb218f75fd1d2bd42b92156f9dcd40d6178481c0897440bbcbd", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "06db4685-fba9-46fa-8fb2-72ca57ef9eea": {"doc_hash": "97ca23c9c18b0f2fbdf34bb265ef753041fe21c975381d6f7ec892bc74a18d2b", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "e66e1387-78e6-49e7-aa60-146bb4d541a4": {"doc_hash": "5687855ac4771c6ee8783e342c5234b7d3d5932a5ef54caf96cec8d87cfbabe7", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "bc924b69-fc69-4624-ae9c-81ca33e6ebca": {"doc_hash": "ab5b270d65e6ba2a004050fafdbef94e342e57cbb98a133e89c683e4e6b54393", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "9ead7b87-486b-40df-8b22-9f7bfa44ac33": {"doc_hash": "f6a859a90c72c01932c1f19ebb9a8c3afe234638b2d3b7ce74030c67c6c5e752", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "36627a81-bf43-427f-8a99-00781914d105": {"doc_hash": "f1b1dbf96186160f361d47e34113bf439dc6efdbfcf9d02e628ddafee5c1a9c3", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "bec63223-c37b-4753-9747-c989dfa46d01": {"doc_hash": "9876357582ec09fd952c5644b9fee293b75b26db4577cfe6e3835453f9210ef2", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "a51e6ff2-973a-477a-8634-931fb488aa6b": {"doc_hash": "37bf3f544d7cd3d58fd6df52681b9aaab757a1db42df608b23acbd62a21f474d", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "3cf0c175-c12d-4ddf-86b8-93f92f6f0419": {"doc_hash": "6f465f25fd826677d3d7b72458d1446adb037e5a02f768f1ec7e77d68c0cdcd1", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "e15da4ca-2600-4156-b247-72716b729aac": {"doc_hash": "ead323f5d22a0a9114eb4219936be578eb039f3a9c1b45b03ff1a0d69147770f", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "21bda11e-5417-40cd-898d-d797a4de0ad7": {"doc_hash": "8e8cd0e9fd79eab08f6dff3497ab296ce3ecb38d34a0129569dffc396d1cde2f", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "76f05b66-37f7-45f8-99c6-420af9cf8245": {"doc_hash": "621bdf4722b14c986d8c9343e1b228e06aff42d5a8890fb2217b9c450cd9bcd6", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "ecf4f618-27c6-4b1f-8cf7-a1a295ae15a8": {"doc_hash": "8ac63a2a63bd147043fa4477c374bb2451ae9313060bb5b3c5f55c0abcccf40f", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "60168cfe-8ab2-4c72-b007-88174a7ec8af": {"doc_hash": "63546529dbdf8aa92b9cc69338c6b74b7abe79b2a58175acc217dca584b52929", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "ddc6f3f2-1b35-4b9f-a7c3-82dab78c18c8": {"doc_hash": "6ca1bd5af1733db25cf319994a886400799c292eacf31013363596a90f1ae638", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "50c78d4c-255c-4cea-99ec-1634d6ac210e": {"doc_hash": "847a56f33d362a30f7e282b65fda13fae0736278cdfaef83d04e25109ae01a54", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "61c1fba8-15ca-44b3-88b2-b8b16aacea38": {"doc_hash": "dbcceafe84f1e94518d4bd295b163ac87518d3d014cab03f6915e5837e9ddf92", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "95d17390-effd-473b-9f1c-ebc9af4667d3": {"doc_hash": "127162b4f7030493ae0f19c58d234ddfba18a75276ed1c929773b82510162b35", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "dc8649a8-c06b-400a-8c87-0ef33b316cae": {"doc_hash": "62a31960ec49e69840cf6898cc4fd0d82bb282bd873366b800e496e9cde9d182", "ref_doc_id": "dc60f063-61b7-4464-aba0-74d1fa2101d3"}, "344bb069-f82f-4295-991d-beb99ee52260": {"doc_hash": "dc98d4a446b48a77cd8a84d89a529f19ab42bb98d296585ab0bbc92bcef5b998", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "498ac1b9-733d-49ce-a2b5-83c0f06da52e": {"doc_hash": "ae1da8ad852f7e73fd7ea60d92a344144829eb59513e1c71d5dc1d1f7da6cdbc", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "503b7818-6fef-4926-92b1-f0e589c92ad9": {"doc_hash": "25cff38bda5464a3df6d9df95289e0fabb67c261d00b5c17e28cc2685c80d907", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "4a786c40-f7e2-46ed-9b0f-f4e2c2c43310": {"doc_hash": "75a3a1337f9563cd6479bbd7652bbdc6e60317d74b894b48e88e9bd11bbe38bf", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "8536f6fa-5430-4c33-90a6-2ca05fd0f7a6": {"doc_hash": "41a88377d1444811a4e0a79ed9a437257f4b41a86aa4ffcf1dc2fdaeafec1665", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "70fb7dcb-21bf-4ae3-9ab4-a84cf5a6c09c": {"doc_hash": "bddfca5a4722c6fdd60831203e44f3cdd7977a108f1a4ab40a16ddba6bc1fb24", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "e2489bc7-9b83-4ac3-b095-d99330fd7da1": {"doc_hash": "b3ad788d0314c7acf99136b1e0921f5c10525beca2c56e1093fa29da4069dfd3", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "2208d0cb-f893-45dc-9f50-70d203c97be4": {"doc_hash": "d128b3396e827885b2a5d95c390a0741d01a6a1a9b01d870039c22836355734f", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "d995580b-3f11-497f-a287-9b53adec93e2": {"doc_hash": "03e59f63e018f2d704216f65c9ee90e9e34eccfb5c1a5e1530ec96c98032c416", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "c20bdb28-28e6-4021-8904-1664c20292e0": {"doc_hash": "f0592330c52f117016414b900290aeb08a64f9f559a783c48976b2c66d523da2", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "c3885fc8-16e9-4ddb-9ae7-e64c8bae811e": {"doc_hash": "57af21c7227af92eff497f1feb19e3bce6bb8f2978d52dbeb630cb4054b17298", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "a1f42793-9497-446d-adf6-e7afe3bf52c6": {"doc_hash": "7c702828683104078e5e1911ecfd92e28d7225a62e560919407c771a85dee7ac", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "be479c44-2283-4830-8ff3-69b633a36a49": {"doc_hash": "2a34c00f6575835628a90817feeac9fb8661d4eb26008763a4ff183bf1ace6ec", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "dda5a64f-cd01-4429-bac6-e20387c258ac": {"doc_hash": "9ea1a6c060afd1123ed669fa9c6f3e259c83c76c37603a086717f6429811c9ed", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "28436069-e16d-43b1-9ff0-cf1149931e52": {"doc_hash": "dbcbec39285ea1788d7c3025fbf122c8fa6eec6e2d9463e23a87607a7e0d7ba0", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "44028522-7cdc-4797-bcb7-0d6a8251d9ef": {"doc_hash": "54526c5a0d4237a2414454d7f60a89a9b4a292463e5dfc1beff14ab58748635a", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "f8b24d58-98a1-4ad8-9cd4-10fc0d59994d": {"doc_hash": "ddd705af160ce42a3acbe3acc8a7433ff4f41b592b48f3374177a80c5dc09e33", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "5cb75e27-f463-4ea7-9645-6ecaa3dab75a": {"doc_hash": "54b3f25ff10888e0f5a8ba05a146ff817f592a7b1fc152d694c68ee07cf3b214", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "c1e7869b-27f3-4e56-805f-b1ea46995a4f": {"doc_hash": "abce0ed042e8b20d57ce9e740e2ba002dd6e1abd52a9342685c768d4d7c6e410", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "eb582c7d-ffe0-4495-ae08-76c478a81e52": {"doc_hash": "1eb8c79bb3316c9ebb60dd96c1bc523f420230c2e58b41e86b209c8b6ba38a4f", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "5cb8912a-834f-4a96-92cf-4b73fa8d211e": {"doc_hash": "8a018c244ac1c7de80cbdff4dee0444ad92423eb3466ea5954de332646569538", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "6e6a975e-ceba-4b3a-a3fa-89f77bca0667": {"doc_hash": "387eb017d5e925c945ba96a51bf9e5d830fbaccb19c6c66d2424d6e12895750d", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "4d9ef24a-6f8c-471f-ba61-77acc1948741": {"doc_hash": "fca58974c68b56322cf541dc193d87ede9da85dfe494a4986e8f6010b19f69e6", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "45112e3a-03b0-4d75-bbd4-8ee3ecca29ef": {"doc_hash": "30034f61e6c61f7014f0f294137e28a60cd47b9c8e7ff1114a8b50ad429e2a1f", "ref_doc_id": "81beb269-f9f1-4b7d-9ef9-706128297398"}, "8e7328e8-0c3d-4c22-8b4b-7b510842deba": {"doc_hash": "33373970adf32a8f667f7b19a014092f5b32ada3dac28eca98259be0769ac682", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "4042a939-53cc-4446-b156-5470138cae8c": {"doc_hash": "bf3ca9fec924ba393bdcb2da19adc3f37005b9eaaa3ed9912d3a4741eca4c6e3", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "5409e8dd-53ef-42f8-af6a-d46fff81252c": {"doc_hash": "50da05d8309f0b2fcbcf01461602df1db831e9022ef07461895fecf2c8684417", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "dcf0e9d0-cda9-44ae-a713-b5f5e8982934": {"doc_hash": "b9df3325b6f401cf4b679375f1b34ad2a51f310d466fa4dfab2853d3655699eb", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "869e72ff-d78c-41a7-b009-fb212e98ab09": {"doc_hash": "c0a53c4beadea80b9cf4434afc33930f9159d2ea99f2a3efeed11e9220ed71e0", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "dab9e6aa-83ba-4839-b45a-711aadc49aaf": {"doc_hash": "e29bed5c6501a18cb8f93d8feefd163495f07298505b63c5cb45775f5b974ed6", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "5f302c4f-8f5a-4497-bade-d6ea4b36d06f": {"doc_hash": "e5580c80a0dd6924a711526ca0774ed1cb6668e82497bf3894981856e19099a6", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "118cb664-9bed-4564-a773-18c84e3b5c34": {"doc_hash": "51d5d4030b4765e1bd63dede6ef21edbae240175b2d9edb236a180c5c301d379", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "70211729-306c-49fa-b345-336404636a27": {"doc_hash": "dd061deccb36448255ee27646c7219721ac84cc47495f20fd66fd1c5e52728d8", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "14481372-58f4-410e-b73a-a888c64045f7": {"doc_hash": "617ea11bcbfe5c71e066b203e2eddbecf3ecf3b1ec54832efde1b129409a9c96", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "1307c224-5d98-4f43-8315-bde30308a003": {"doc_hash": "f2c4829a35356df3799b476d1de3e3a047a5a76b3f8e5b754e954c518849d955", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "f18310cf-3879-4f60-8971-ff3e3127f31e": {"doc_hash": "af81f05f60678439a83ea2fd521cef2603abbdfb87dce0690a600a540f941f2c", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "f2dfbb26-f060-44d4-a53f-5fd0a818c1ca": {"doc_hash": "837ad8168369fc9f19fc04c0992467a45652f7501f486f34f5d1a13794a8bc7d", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "e660c48d-28f8-4780-86b1-7fb4f030816a": {"doc_hash": "7cefbf88f183642fa615df986ef9e76c204e5969bd06003a9264381564f560a9", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "bfbbdccc-8eeb-4a5d-beba-250fa9a84b31": {"doc_hash": "43f2f6bf4e84387cc655cb899e5537f9992bd038ad567adb9db979c872ee62bc", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "43178e70-9803-4c6c-82a4-cbf7fe7cb1d8": {"doc_hash": "99e23dfa956505ced36f2e589a34105fb42d9a557fdd1be5e88c947b2813af93", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "c20d6a6e-aaf5-4f40-aea4-8e55cee6d421": {"doc_hash": "623e8e2601dadb2e129cddd31b53603d6bdd22fdf1c3d97447dab528905b1061", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "547a8aa2-c4d6-48ea-860e-ac981e46f27e": {"doc_hash": "409bc9ad56a8700c500df61f8d69305140171c54df80be513f9bf1506a65a614", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "faba1044-d1dd-4c87-9e6e-91ded01030ba": {"doc_hash": "b374de59bfc87136c1f98f1c1705ff6718819dda6fec8e5d4d8157295b80ac91", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "3472a94a-0fec-4df4-9a9e-4923985e7805": {"doc_hash": "33a14ab6d55e9f4472a02e089527997b9bca8ffdb9a2aa8edd556abca252983d", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "f868f50a-00ae-4a8f-a9aa-4c9683fee3ba": {"doc_hash": "5f41735b7dea1e8a9d4818dcd1557989e923d5467d8168e6c41fdff6eb69632d", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "ebc4d77e-c6f9-4e7f-a62b-35d3a252da44": {"doc_hash": "6f5cec99a292fb175513060b43ea7644b1b99cb4071756146bf8a8c1759abc3b", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "a79def66-b7da-4220-9bda-a7a0a0546994": {"doc_hash": "c47aa742ba8fd1e41750d781eebe0ec5c4fb11429cd48907b613936072d46a0e", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "9635211e-a017-4700-bb6d-ce08042d5585": {"doc_hash": "af984b8509233968c0e01f9194502c407202aff1ecdded217d4dc0fd569e6fb6", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "313e1abb-2d70-4831-9e4c-dcb19fcc80ad": {"doc_hash": "8a5765f22e451ec3f2aa9db7c0e6ff01a4bbdefbdfc612c3274d6b9d1102779c", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "8cc67925-606c-4d90-bca2-caec2a45c78d": {"doc_hash": "dd90f08fbed466022a8e113fe04fa2ba0d6fce87f702e897d3fc587b00cb6854", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "85fbe087-f27c-4290-a0bd-16892e6c60d7": {"doc_hash": "c17853185ae062bbc04160e52b6123faa93bb19d81791b652813b25953389c7c", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "d3580dff-3b29-4e4d-aa68-95707b01a5cf": {"doc_hash": "cc1909234aef7bbb78c55f42c51eedae0a5ab59e4f558f0820fd24c6615f2c21", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "a52085a1-f773-4800-a20b-fd2fb90ac7e9": {"doc_hash": "c99cf6ea896c04f081b4c8dca54b1e78b1f861acfa00212ed34e653ca5a7d7c4", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "b3b49551-b09d-4788-bff8-cd7e4ba8e921": {"doc_hash": "f23d1fb4a1fb9bc6102ba50d40ebc94f2aa4e49517bff0ba885b5cdd6f5f1b53", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "badee450-5035-42a9-8032-266c0f648e7b": {"doc_hash": "cfbebd9c7d15b9cc10b46115db1393759ab804863c720e7686d2ec48956380ab", "ref_doc_id": "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923"}, "081cb9d3-b446-4102-964d-0e15bea0212b": {"doc_hash": "2eeb23bff2a34dfeaf31e74bbe165054c35272d47822dc529f5db8c81318e52d", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "ce409c7c-12d2-4379-a7a7-a387b1b8f011": {"doc_hash": "2fb8d8e204274db5d668ed4e274f9f50ece1f788dec1ff89c6bb6e0107c56149", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "f4547e0d-238a-4e97-83d3-b7c68330ea74": {"doc_hash": "2d5213b82354997d7138ba8895fa031532bab9007c9cbd7e46325f483db5e870", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "6a9e56ce-399c-437e-9b34-1352df18d70b": {"doc_hash": "d7f762ff2d1770fd85ffc149d8b2bf886551cf578bc96dd97b3e5ae8faf94c25", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "3a83d2a0-207f-411a-b4b4-5bec825aad7b": {"doc_hash": "232b08fd2c9d4128e1a175593fa090c7a88db0cf45f57e59e21f94d676974725", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "b71ad006-aec7-42c4-9a20-e69a0159be33": {"doc_hash": "67e420c29589b72a737b5cdf9bd321829594ea3de3e01260469b8123f73e3145", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "1268891f-bdd7-4d94-8a31-5440f28938cf": {"doc_hash": "1507fd6c5f68c2197f8c9c9647483d518e61c9e697c2922a4c69ee880e878018", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "0a77a990-ee66-42db-ab3c-6cf29970be1e": {"doc_hash": "20e8aa4892cf55f745acba2fd01eef232119f3a21e30c42d2b7b2fb1b2d7c8cc", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "fc4c0568-d9a9-4352-be98-ac4d82cf6fd6": {"doc_hash": "5cf1c65f47a0124e21ba6278d1d5b27f6755c8de023d4fca9f69880f6a2858c1", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "ed3c1bdd-0cb2-4ef2-bfda-65ddc77ae0c9": {"doc_hash": "a46ecd7e7673d19448447270578f63504b74e652a654ec423142570ff88777f3", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "0024a5d9-4472-4c6b-b60e-cffb9144fe0a": {"doc_hash": "95dd9e4d633fff71a1245515d929f481d5b2ae533b74db878b41afd39f044bdd", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "c46be7a3-81a4-4cad-986f-541bc4722222": {"doc_hash": "c28e02c5c7b4d66402a2024d8513b7d007d07d4dbf2257693c31a8fba15b45e2", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "9848bb70-5369-4f27-978e-226eb7a49de0": {"doc_hash": "be3e862b6cdb5d35cf6ef15c91f9380a1f6927090e060370d4b627cbb83043cf", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "1e53dd68-f6e4-4dac-8840-1c52ce89f5be": {"doc_hash": "6968a0fa043f6627f5496a6c4b66383346744a7d8fdc9a0d45046a23fd3d322f", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "387e23e8-b0d3-4d92-8850-5a1495cadfc0": {"doc_hash": "1528e6683f533729c9544e5a27d9592d7e0289131e3e3e4b74edc06fac106b05", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "47fdb188-097e-4633-8f4e-8b629c17e189": {"doc_hash": "f1f9806d849c6202f4888354e9e7ee0a3ad765056f6580b6311d4d1d373bec9b", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "7848ab05-e927-41db-97f5-2976f0245d0a": {"doc_hash": "f7e943946ac6cb6f6c26274cbf9920913bea119cad7c1ab16fa40787f41f7c2d", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "494fd32d-4c50-4008-b66a-c3aa6f0d5e3e": {"doc_hash": "1871aab98c365b1013d0ce6ddd3674054254b7a21ebd7f07bb87dfc25118fea3", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "747671b9-939f-4344-9923-f77e83dc3ffb": {"doc_hash": "63a9e1126e8933af963dffe1d4be4a3a56dbf7570361b9de6aaa1c8b538a4d38", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "fbe617d2-24e9-4c5e-ae9c-4d935c61ffc2": {"doc_hash": "fc86d96e97a5bdf886bf5e684b989b33b92886ae0c4ecb2a6f6f1d89b71b4b9f", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "b167d256-b3e5-4dc6-a6d1-65f06e3b3c6a": {"doc_hash": "01bea4cebf018e6f5d30cefad549be1ccf5fce90057d28f35a7f2c3dc81dc559", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "23a2a383-1d57-4902-8574-698e99ff81df": {"doc_hash": "6024367c4bda20fefb56ff1818a51d221188e8594f0e9eed65eab470ba2e80af", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "1ef21995-b87f-44a1-8c63-25339853d894": {"doc_hash": "8bb0a1b527f8eb2657b5bd83c0ea0465dc5134e49e2e9229e55b025da563e834", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "a2604d4a-ee67-44db-90b2-704866438a4c": {"doc_hash": "c30ea8c7211cd52b7cb327520b1955b4721f03e553f21e93db1ff58bb55125ee", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "61a83e01-7dae-40b6-8ac6-384705d0622a": {"doc_hash": "185b9e5d76093741aa79b4409147f69d757d3410cd19d716f8b8c7eecf7deec2", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "c93640b8-6072-438a-814d-f2e5a8da02ce": {"doc_hash": "3208b0023fd353b8c5ed97a79e5e24321731d0a46d5ff76d5015d3a757643c5a", "ref_doc_id": "4140dde5-cbd0-474f-8f3b-597ce01bbbea"}, "25814a57-ec6c-45bb-b159-8f0578441fe2": {"doc_hash": "9b75648930455837fa08979f1425972877d95e21d904dd88fd1f832fac5a2337", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "e1dc3eaa-932b-4d4b-8d8e-50b2cd440e7d": {"doc_hash": "3cb9179d8296856bce2ef3e79e823a7a2cf2758790c773d755db635ec394e24a", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "2539d410-ea5b-40cc-977b-d4caca3cddf4": {"doc_hash": "9184be475a7e9e50c26e5f1ff02637abed8e7d39adf210b45376503db3b3c947", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "5ccc4995-6b83-413a-a2bb-7a081b6364d6": {"doc_hash": "fe5cbfdec5e3f83ac458306dddfb41fd6add65d7a74e21f267827239bd6b19e5", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "a10e04d1-1aed-40c6-ae21-ceab48a1c682": {"doc_hash": "948878d71743b3fee1a68c3d9e5e8704727497243ddf76e1f26872b0ff12ffe5", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "7cd9719d-b368-4c78-932d-b4e003d5fc52": {"doc_hash": "6f27fd6b973c2def3db3dcfdd2ebbeee4d36a8d7296df814c5a07f4495500e4d", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "a575ea26-79c6-4340-a8e3-1b0ed1327327": {"doc_hash": "a0e2fc982558ee9b81ea2671c98222c45f44da7c253e6af1afabc3187057637d", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "6af93a8f-53f6-4b83-a156-6d5df1c43ac2": {"doc_hash": "5abbb137758c9a5482ec7ec962c24559dd32399625ca6878a371b9a61936851a", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "092fa69a-620f-41ad-8f4a-943c789a12e2": {"doc_hash": "6d6eb4200ec160c287d977619e40609a112b3c34c3feacd6c6848fc129524d1f", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "056cf365-e399-4698-af5a-8322286b2f50": {"doc_hash": "0287a2e1863a0a45e650a824914eaf06894c26dcbbf2d556addf33d37b80ef1e", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "3d0a8a59-8000-47d3-bbd7-741230fcff7a": {"doc_hash": "860571ab03c804427f9f18703196316333fd0978f19e121f90d26af09635accc", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "24455dc9-c588-448e-8282-4c9016754c86": {"doc_hash": "a64a7f193f875b66b8ce73dfa802d8ee98d5b44b6452c809c9f82c25c2a58369", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "b94eb3c3-717b-470b-951c-003bb14be91d": {"doc_hash": "705a991d761cfe7e1968dc1be967d5cb27f25f5ea338e9a2011c0e946cb692ef", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "2e7c7f36-03a5-46af-bab9-d4e2d72a2536": {"doc_hash": "339ce435ae1e59129abc23e8baa7a19c3167a590cb37248765977394604e8f42", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "6993ce6f-c10d-4eb8-881b-5721bb1f1360": {"doc_hash": "dca67037c95279c6325a24a6058cd48d4e2b0c18da69e8d9d048bcb2f0bea34d", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "59d8181f-b4e3-4b18-b545-e1fd16d34047": {"doc_hash": "9ba4a855f49db6137bda1ea2f81f5c3946e83b0ad86e3b1465517f617d6c4190", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "ecf039d8-8f1a-4450-9de4-ec1e7153a2a5": {"doc_hash": "08ad2ea704b62e4c277e07c65e0017ad9f4a63eaa7d0a1112d9d0f4800bba01a", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "38b039da-2e70-472f-b793-18571ba92d7c": {"doc_hash": "81b36432128e7e6786f6a9f82b250598ee7618d937a473649e610b7b7c6a9211", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "b5047491-fb25-4062-bfb3-c9834bd6132a": {"doc_hash": "8172e910f7bb12b897f7bffc9900c3708dc2e8566e531564ed9540298007b234", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "c10aa366-a35c-4b22-961d-a7b74cfbff5a": {"doc_hash": "a6fd26ab141123167352b70505c0d545d5be1cde6b6307d937bb4d86bf6c0c03", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "42089d29-72db-428b-8d53-a0dd1a3097ef": {"doc_hash": "a5a5f5141edcc221a93c102c31fbddcd5151a9805bb97de008fa832ba1b8923c", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "cb564e63-83c0-426f-9202-e097b43dfc77": {"doc_hash": "6830f33fc7ff9e880f0a698603dc186d2caf839d133ff2263927765d5a596555", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "fd0a4056-c930-4846-b864-4156774e8349": {"doc_hash": "9b25bf1248d41dd359fd7daa486db1bcff18dc9189ca1f371249e7de0c72a459", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "55720998-aa7f-4a42-bde5-f6877a801b93": {"doc_hash": "26d34affccc46ad78a1d21ddb229130486f394c6024f78d785c64714a301a9da", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "8062c598-6c2f-4747-a7d7-e0dca70be29c": {"doc_hash": "5698a3832e71365bceb309f03b182c390903a4fcc3caa9989ca65f5368bd1239", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "aa189654-9b0e-426e-8f26-87c09ed437ab": {"doc_hash": "e39aca750ef32a837ac8f1dda87d44d06839206d689d705715b35eaa7bed56a7", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "df237d5f-144a-458c-aa12-c67f718dedc8": {"doc_hash": "95aa228b2acf83c53bd40559c07e30990eb7120e64ee1f3989b11cf8f2eece9c", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "469985a7-f3b9-4f79-b7df-18be2a744d9d": {"doc_hash": "4b6794d87ec97af72e3ce37ea3d6f42fc9a93e3be0ecc735fd2f6cfbea1410e6", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "c9c15640-b808-4a43-8cf9-2ab78de286e0": {"doc_hash": "230906d32709619a9e6f32996a7c9a41b7a603b821752fc043d840d0e02f10ac", "ref_doc_id": "57e23f6e-dc3a-4623-8088-9486a7a2bb5e"}, "84bfe11d-c7c9-434e-812b-4e37b5a7a6a5": {"doc_hash": "8e39802bf2cc2f3cedd2b699123cbaa01ba19141d5c4911b844c3abd6b8baca2", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "4ca74d9f-b615-4165-9e10-cecd956431eb": {"doc_hash": "fc8f9b0e1da8d5e808e7f2984521037bedf672c1a997aa61b5fc13d9b30da553", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "d22967b1-0bc3-4786-a7b2-9854ab6357ea": {"doc_hash": "69b909b72c862e936b7c6ce1e4ebf1b1d0de2af9125fe797b8d7a746f943edba", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "d2c0a407-b3f6-4bbc-8f65-93a007f1c644": {"doc_hash": "acb24dd353c95c6ea0f7e714a3e2c5bfceb34a22605ac73f3e74566f83083dfa", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "8bbc8298-fe7a-42fc-b1d1-2d970d40921a": {"doc_hash": "aaa938571482229fa9c98c159bbb2209ce4724fc46416d095383945f723e7344", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "1a1f66b3-66f0-4796-9fd3-ae542dc8373f": {"doc_hash": "54e2cc522d9b2cc145d5f57cd2f6bfbd0fd995ad8377a7024ada58af2d24e225", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "64867703-8412-4d8e-ae28-7da104c26454": {"doc_hash": "39100c0626a074b2bb19137ff58dfcc8ba469d17fe3e6f49fbc7773446a6afb0", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "00100d14-7154-40ef-8449-ea5cc38788f7": {"doc_hash": "a504c53d4811b625ac3d82502076cb42478ef345cbefc2f3d723ff00394313bc", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "89a3a931-4803-42fb-b0e4-458cda89ae80": {"doc_hash": "b4345e53512236749f8607b628939d3742c82b2c52c828a91cfbaa386c6b8632", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "62b33ef7-ef38-445c-8f31-208120f09672": {"doc_hash": "b05352b9756dea344b678d15057d771a61575444a6f4a7386b82702842333705", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "406f0a3e-b4e1-4292-8f03-d5efec7a5656": {"doc_hash": "eee06af08a6670d664491c3b041f98d55a044f5240fe840e13ea3f4ec9f751a4", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "aed76bf9-61cf-40e7-9e7a-8bf7b8a6d674": {"doc_hash": "6080fda9d708548c6911fea5fed79b74521e642b362cd7cbf6c7d244febdf962", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "8bfa1b02-f2c0-4419-9b8e-db7bc42ec14c": {"doc_hash": "78ca8d034609d764e036540f244821db5bdb904888203774871c43fb54c6df06", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "b463ab99-4175-4559-a6a3-79d4efa6270d": {"doc_hash": "e762b2dd167fb1529f90a115b56a01ff48fcece9f0c33875827c9407107d4e42", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "bc03d0b4-17a5-47c1-9473-7053b78676b6": {"doc_hash": "20ec79ed2162595143c4f19169505c4193859ddee3fb1a5ac3f7b2652bc0fba6", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "a721984d-cc61-4753-89a6-972b4c5a7ec3": {"doc_hash": "87be5b7ff47692bc11d3e983272bef93fea96d6c6030604a684233633f42d3eb", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "83e1dfc7-5949-41af-8894-ccaaf3a84750": {"doc_hash": "b01ec0d748dac59b0bc0f0452d90d52d11c13792c7dd40eeb7769ed51f55e274", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "36442eb9-e1fa-4505-b842-c3c3e5b14068": {"doc_hash": "000e84674cdbac3fd86e0daaf1f0864ee59c6d0e49b5755612be8279415821a2", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "2f63297d-946c-4634-b04a-89b792e58d09": {"doc_hash": "06cb3a343b872e7d3ec7ea47ef767da09c2a8a8e76cf66608e41b93c9eddc71f", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "12ecb74e-3435-4f90-8c2e-656c463be044": {"doc_hash": "8210dbba890931469625a21cc5ea97779cb2e7a0199c40a6ddcac494ee7967f1", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "0639cb23-8eb4-4e9f-8c4d-94ad8b0983f7": {"doc_hash": "ad35c65a4ca252988a6ac0e2a9e3b5f4c2b8f77ac1b1aefeb03aceac3239e6d4", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "0b42f99d-58e6-4daa-a049-17b723489f5e": {"doc_hash": "52f598e7cfc274d69f63c3d00f7368b5494e48ccab5dbdda2c01980c77906820", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "48b7e6ae-b9e6-41e4-8e17-641f5eb32fe8": {"doc_hash": "50fb1d36a3a33eb3becdc179e943ac5acdf8b1fa924ab84b3542f6b221aba923", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "8decb527-369d-4b30-97cb-7014fe4d67e8": {"doc_hash": "65d27d6cbbbc412328d7755d01e8d9df662644689c95b0fbfaa7b25001c05919", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "85827c5b-874c-4a4b-b874-7a27e0b16a4a": {"doc_hash": "c5e43215e1a36b0d2d02784c07dfb3db509d21a1a10b86e07bfd2533c2b83ba2", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "b2431a75-d2b5-4330-8e34-bd7d554cf368": {"doc_hash": "b84b0ab529aa65a787d89d7d457402fe2d954a92fc7c527daf515c8515ba8e92", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "9a697180-fa49-46fe-9c37-f9526bda6140": {"doc_hash": "5de0a8476aea4e8772779b5ba87ba56fcc694a022556a69e12fc201e9163d7a7", "ref_doc_id": "68e87f72-df25-4aba-89e0-510d1d52d088"}, "4eb62ee7-6d5f-4d86-b553-95fc82375a51": {"doc_hash": "d478139f867c37c22253a6966e4a3ed5d444c9f3495a1fdda93b00059dc81939", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "c9ae5792-85b4-41aa-b987-1ded19854def": {"doc_hash": "8ad16d2ae603f7231493d8d27cf6b6d967d107411d32704e8970cb71e2b2ccd2", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "7be35870-7f6d-4e38-98b4-6506e1f0b1e0": {"doc_hash": "b4c2c1a821f9e1be89a0ab1081a02f20e0d56bb5d0dc20897f185bc8b7af8048", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "bd8f8396-d5ad-406a-aa50-7bea1d8810f3": {"doc_hash": "f1f2b0e1c315eb1143f662769e049d6b37bf0d737af12e8fb62d5becda702384", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "f9e2b909-4f1c-493a-ae67-9c47d1b54f5f": {"doc_hash": "326e3b99851e3ace948b92519abbaacbc619f7d1653fe36c3df5d64659c36203", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "e91bcad6-220f-4fc3-9fb0-65b08a7f1586": {"doc_hash": "0fc6c05a1689479fa075c0e512b0c3446995178b7c00e4be45a58aebc6984796", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "8f68320a-395f-44f5-9cd9-8da90486a8ad": {"doc_hash": "9ac518ab63443bd0349c72631bd7ee33afeb01e4632952bc73fd560376077582", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "e5541cea-64d0-43ae-88e7-f5196cd59fe7": {"doc_hash": "c1e25f3e691be344e8d7e155b988f0f3c8dc1bed94ed65c68427b275dcc1ed99", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "880635ba-5ce0-4cc2-876e-4413b6ea5fd7": {"doc_hash": "dc11c734bfceef6a6d9f3a2e0938ad9c5fb645d5c6a5e67552ecd4cd5534ed96", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "b4c17f8f-95f0-4abd-9b2b-d1e1a3bd315c": {"doc_hash": "ce42bf3e01ff46863e728b935bec576c7930e5a1f08ae6f5c2d382790c9f1aca", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "fd55dbd6-02d3-413e-ba6f-9d783ee7960c": {"doc_hash": "fcfcda43a1fc5a4ef865212a94439380275a85df5e46aa15348580606d00981a", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "564c3fca-68af-40dc-b1b3-f9586fcdc276": {"doc_hash": "a60bc30deb8cb6222998858f4e443618c8eb7470065d3a1a07127a8a4d191305", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "d93624e3-07ec-4533-8db0-815d1cbcab66": {"doc_hash": "cd1eda4a90ae6484f24d758fc4a72d92edd05c5d256128399dade550c54ac67b", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "2d9a048c-2401-41ae-9ca0-26f43fe844ec": {"doc_hash": "7ce258b368123fe91405c7b4cbc865418ce317fdea3a0d37143d29123d89e054", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "b29243d8-b392-4abc-82d5-cf866b1f9932": {"doc_hash": "f367fcdc717ce55cda12ba10db3721be9c7db6f0e69bc17f9e4decdba50d9f8a", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "57edf449-2a82-46a3-914c-c8cb3b9d9e51": {"doc_hash": "ffcd23623299ce5db50a494f80e8275c4692b508bd475caf1cccb64983403fda", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "94a0f273-c020-4cbe-9ff4-47c0516e7e3d": {"doc_hash": "c493e471cd13b5d95c3c0b6dbc31a993ee7af65c40016163a8a821e85e2c1bca", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "48330d5f-b16f-485d-afba-666826461e9a": {"doc_hash": "66e06254d407da1b126eeb201b98b7ef4e0d71135cc2fbda1623f2f356971cc8", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "c2cc864a-054c-4731-89be-b6d8277ad0cb": {"doc_hash": "09793d8d832fce1be6d0d632ee956ae6c57d060cb94ab447c27effbd71850f50", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "017c5c63-f51a-41d3-9dd9-61ad4ca534a7": {"doc_hash": "eaf439606846a122b245806d2daac611e0e3ae90dde68ef7b975a51c0a094257", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "917acb11-1421-4ad4-8dce-5dd967d25b8d": {"doc_hash": "f714b140c6fa3481491b6a622c00c3c5e5cc396f626542954f72db1084531777", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "7033f752-add3-4194-9ad4-2b7a6372e764": {"doc_hash": "f976b775b91ec360e29bcf18981d6d17666362c24b4093116c981e7bf06d1d90", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "c49cb09c-f691-455c-a866-d0efc541c6e7": {"doc_hash": "fd2043dfbc61583170218d19dddcefba15ab7ef1865fbaade4715e745a218bf6", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "2bb50d7a-f395-4c53-9fa0-2453ce3afebd": {"doc_hash": "bd40bb048cb48633d6e4e85d0f4b296c33ef0ed675e1e7042cca041a047cb719", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "df77c3c7-1b9c-490c-a060-4c729609871c": {"doc_hash": "a36deae2623e1f4e39799fed587463522fc66a25ca229ad911ed9a9c95b2b59f", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "b744ddd4-9af2-44c6-aa56-ac1c22de6d5d": {"doc_hash": "a86c404a61825fb39e0ff86b867a2afa9a65e2aa58bc735173c408d59e092780", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "7e9f6703-bec5-4f7e-9016-586bf00a0679": {"doc_hash": "8bda3a3d4dcf4b2aedf609a3220d17d96bd20259eea9d7f7cd1ef6ac0455e9f7", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "52bbe08f-05a8-41d2-9aee-c63eb21b57dd": {"doc_hash": "b88f78680e7b2c7e83a9b3af121380daf9c2f77edb1bdd933f6a1a66f28683f6", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "0320b8c8-ad72-4227-939f-01a3bd19a057": {"doc_hash": "49e025d837b4a907761a1bed37b9152a264bf962eb58eb861f549d307de4b072", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "f62f072a-a8d0-4725-bbc8-0e173c6c3efb": {"doc_hash": "2583246bf5661232fa0282d5aa5ecc3ebcb107a06123952b0f31af127cd63717", "ref_doc_id": "208ff8ea-f627-4d33-a125-f63b872b3558"}, "a98a1ee1-58b9-4bf3-b11f-9d25841ff767": {"doc_hash": "330b5acf2ee5e4e69991b0e8a344381d0f7f2da521952c4dcd53fd75a95b8ecd", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "b697d28c-ef28-46cb-a47d-a5ded9a054d0": {"doc_hash": "679bcf028af5c271bb136494f650c76eba8b62b6a4143a745e5e8f2c7fdc0dc8", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "4279805e-5a4d-414d-b48d-b7ac26c00023": {"doc_hash": "61f74f7c920cf7d5877d63a64670394412de06de36edf9aa89eb3dde5be44d34", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "1723b70b-938d-4699-838d-9e3362564684": {"doc_hash": "ca388641834ec9b90a51db7f87a0758edeb66b3a9d6e00e78dd0c9e99a55f1b1", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "7ee12911-2ce7-4566-90ef-9e18a868c586": {"doc_hash": "72872c28fd3a1e027877b369e2316f3a826c00298f75c2c12c8dea8d5e4608de", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "48500160-ac7f-45d5-ad01-e9d97e50fd89": {"doc_hash": "16ff3394c0b02bf640973459325f9538ce63c3fc2532f793547e6dce31ac7301", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "683e9671-98c9-4dd0-b1a4-e3f2c3a7287e": {"doc_hash": "373ab042345d00ccd41c7df3901d2a3fbd2c89c233b6db936ccf612ddc39c05c", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "04a921cf-9a49-447f-b1e4-e50d10765d5a": {"doc_hash": "dff7598933d1c9eb00d275557dee24fe2a4660b42ce147956ecf64cb5747aa6f", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "ef3f422f-be5f-4d64-8b1e-0de691604811": {"doc_hash": "f1c3bdef1c00b72526d55b678a3befad88223a6ac3d6a52aaa040f0019281305", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "1dc7ab97-b29a-443a-b3d0-c6c1d9dadcac": {"doc_hash": "122f8778adda363e63baa6bd0b7b8a568584d5d5b54367c0dc6d17625c848c89", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "666f3216-9c7f-44cc-a4e5-c045826b0e7d": {"doc_hash": "d82c208cf1b056a52c10d9b951336dd719790be09a90a98bb2fa53da80e67df0", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "e05e3961-0cce-426c-8682-6f3b0babfe52": {"doc_hash": "621c10a6d9fa8924fc6717f4c055849e8740cc96425b1c800ac258aefd045c21", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "ecaf62a5-4702-48e3-9d95-b7660adbfb1c": {"doc_hash": "f77c0b58a38c854ec0253d1eac9419b78fae3357125113c3d1f0975a34d9e2fe", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "4e4dc653-4aa7-4910-a9f5-a4d27f34f480": {"doc_hash": "14a4a986dba1194ab301a25d2f240ece57e16dad77cb9ccfc342b88297e82ca4", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "26e227b9-7c7c-4e65-b39e-9a4fcd64761a": {"doc_hash": "bc5332d228109459d553545d158da3ff5425416ae5ee92f585a0fa838d7ad035", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "a6410cd4-d6f7-425a-b8be-994ca76460cb": {"doc_hash": "4499a7d758df4f9271cca88426f7d97c462e9599229b520d921f32424f915cad", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "05889b7e-8ce4-4dc9-9c11-2662a959e978": {"doc_hash": "cd5850f4c053d2c5eda507ceff4e5032e2e8c9135bc15a5c3badc18e62ba62b9", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "83e9feb0-b9c1-4f0d-9906-338eeea99da7": {"doc_hash": "0c0500d7b74f693ded4aa3e64c1e071b6fbd782a35e2b347d70200674c3af21e", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "ba24dc12-9532-486a-be31-ae926c75856f": {"doc_hash": "02b1235ad0a7aaf66c5b1a26351ceb7b56fd46e44ead9f155b68f0fe7fe382e7", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "553cd0ce-52db-477d-8ce4-117ccfb6ca57": {"doc_hash": "81ff2e37e781f4aa1522b3476db1c734d468be6e75fe524d44371c78bd305b3d", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "b02055c9-dafd-470c-9eb1-9c2bc783305c": {"doc_hash": "910b23bb044b0b281bf743029a4b13e1720dea23d466f68cbf05f292feb457e4", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "8c43a071-de2b-4243-b610-11025703d4a2": {"doc_hash": "fbb781f5416923fd77330f462a18bf37528f33b8e8f9061a0ff82d8e5d857e73", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "ea49a3ae-a435-45f8-bf2a-3b6939262383": {"doc_hash": "572f7d959542301ab1fc6fcf30eba33a084e3ad52db9f0bd93dbdf925dc17403", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "50ab4bbc-3f99-4a21-8441-7a6036c4aeab": {"doc_hash": "cfaadce33de17297aeffaf3a096302643e5b9373561c336631197c7dc5a34e4e", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "2974cddd-e6bc-44dc-8ea0-e449ad6a4800": {"doc_hash": "4d0d19fd9a574e90e9ccd4c6efeea7f2c8ae1e787d81f2ac350a45d7ddd1db0b", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "6ced1c62-c512-4216-8b56-053683f9e2e4": {"doc_hash": "3a0664a527e746311f1f202d657f7a7430b8418f7271142a55f4afdb1c3a1057", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "b0b1f557-1aa8-4356-a7bd-f3fda876f214": {"doc_hash": "5ef938a9452a6394fd37112cb66402f21c7e981aa5c92f93bbcd0bf1fdbff908", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "47fa2038-6dfa-4237-bff0-a29a2751c1d8": {"doc_hash": "876b63d21e16461f904cd20e2739e9d0497d3ee54da3b970dcf6baa9a0ba0889", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "2ebafc20-db0b-4acc-8a94-2deadbbb5fe3": {"doc_hash": "4a4bf8006bae402cd8618e28c208bfcc55be5968d05333b8ecd0fb8fee4c5295", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "106c9c15-8215-431c-b0aa-256cf6c26851": {"doc_hash": "426721180156d1fd5a747072ef29bcfc44a8204a0febdcb23c2a56a68eea7a84", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "1ac8bb8e-2e21-491f-9f3d-b7b9793428ed": {"doc_hash": "e3d0e1703274f680dba71b5fbf3e3c3aefd0a4db06b3f9108fba24acc7306b92", "ref_doc_id": "535e8124-c88a-461c-a64c-475f3d854179"}, "84e14511-18ed-45c3-815a-57561996c153": {"doc_hash": "e3a55df0861ba64a3bfb4c9acb77a8f2c1180741871a991bc11a2e039e5f1fbd", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "28af7c38-820c-427b-be09-9f92fc51e3ea": {"doc_hash": "9bd3b43803a5933689b28966d6cb26da554e3e6b9b86ff720d0f3b243ff3df69", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "b790a42f-48d7-47aa-8f74-db1279441395": {"doc_hash": "c28caf42456ea77fdebb5e260c21f513296cef302b2a41fdbd6b5d931ed08d96", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "53e20382-39a3-4b88-890b-668b6143726b": {"doc_hash": "47c7ae934294e113f4c762a91e5aebce4628b2d3478b63d64bff6b23f3b69200", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "e031ce21-f0cf-43da-976d-bf049e0c662b": {"doc_hash": "56564415c8a62eed20b412ba86b2274df0eea6f38dea51e4244d725308815708", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "12b63ca2-37cf-4199-bf24-f0798a1928ea": {"doc_hash": "86e9cbd5c2081784b7b1a86188d4563be67ddee1130c255894758e2190f3e902", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "fa24bcd6-6e9f-4c9b-9e94-6756578bfe77": {"doc_hash": "4ddfc428b637103542de6926485c8ab20d6654cdfc0bb03874d54fde916e0c49", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "a9a5cbb7-0d34-4b4b-b932-fcfaff41c967": {"doc_hash": "3338f5eb93fda0769356befc07f983cb215f623a795b4e1f2c0a1ff8d085222d", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "dd4cb021-a161-4e62-8bde-e4af3a3f48c0": {"doc_hash": "ee1e5b437498a769422acd3a17aa7b30467515222547c4739d5dabc031d7f691", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "3315d8e0-894d-48be-890b-13e55e22cd2e": {"doc_hash": "0b0ac6e5917ca5c5bea72076c1227f6337bb4b068af765ff2b06047c1baf4839", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "8f3c86dc-9f06-4804-9728-cea7d8b6ac2a": {"doc_hash": "ab810d2d3808c41b66e6bc2cdccc5980f6032f57db1a6ff69997d2c33074d90f", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "534561ae-2758-4649-abc7-6d357b87f413": {"doc_hash": "5c82ef0081b6a21f2925a2a45fa70f9e157476632269e767e43144e35df038c2", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "fb0c494f-850e-4b86-8e36-21dbf1e6c84f": {"doc_hash": "7227187df190db98545be2454ebc6b68919df9ffa013a295508a931b6712a8f2", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "6951472e-d9aa-4678-9672-db5bdc0ac0cd": {"doc_hash": "753f093d690412202644d17f2eb472172054018be9858cf1e89c02256143cf6e", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "99fbff5f-4cbd-41d8-aaf3-44ea2e9ba34f": {"doc_hash": "beff49de07c6b5537b9653485f7426128f473331df0879176c515f084c66f0b7", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "c9e7ff88-cf6c-491d-99ed-3c3a7ccf139e": {"doc_hash": "27413303682b1760ac8cc10d9240ea0812370f4d93f9c5335d7f333f7af3cf2c", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "3e1e5318-30a6-4dcd-8749-58a7161d1827": {"doc_hash": "a067493f7f33bf31d12e796d01b1c1371f87b20dac10acdb7e463ef88e513b4d", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "7981b5fd-e5bd-4cd5-957e-e2527fd0ab07": {"doc_hash": "f2b8750efea9c84c0335b5c00f735ce3b1a0ba10c52f69408754f7805b47405b", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "ddb7ced3-8ea8-4413-a091-6d67db136b6d": {"doc_hash": "79d27ecec19e769c77080f5c5115120afb9aab984649fdaf12dcd54c979e1f48", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "d7107c50-cdeb-4806-8f0e-64de66258cdc": {"doc_hash": "a289ad7c1f5d03ace74bceaa33632e3fec90ef1600dea29b857f9b72f88a5b93", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "5d51503f-af6c-450e-b8c7-291f9a63f3f5": {"doc_hash": "340ed4820aa825a795bc42d8df0fb8d9ba323508b379eea517d4da075680351a", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "f729d1b8-d907-4629-a1a1-0deac2ea2435": {"doc_hash": "c5b458e7b411c97712ecde44d6c924a23c8a595e706411a7747253e254e722d9", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "6f3d2cab-3cd5-4978-9922-7893781d2d18": {"doc_hash": "8ca04d43f520752d8a98cb1dbde357d485d12035f35268e5f0597eb94a327f83", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "18023cbf-e69f-4a9d-8433-968c2f67ee33": {"doc_hash": "1ef3ee3c84e9423455f5a023e447cc99664cb40b235388bc468c539939cdf674", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "a639ecff-4e09-48a7-8f08-042ae2af7609": {"doc_hash": "1a1141bb920b8fe1c81922c233d6d48698d8810295351efe55432558ac0d641d", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "fd952959-baa4-42d6-932c-e5f0782251ef": {"doc_hash": "831a98b34a49cc6969f7ce2b201ef3af5015b69f459c9b21aedbcb39337dac81", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "46a793ab-0b7b-4aa8-8ddb-3c84cf3b841c": {"doc_hash": "0145a0362ae04281d49bdaadce648c5eb5f2271cbab9b2491b8460f231ec556c", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "aba50923-a485-49a8-924b-606596942162": {"doc_hash": "00e8942b4adb9aaa8023a109f28754ce038a57b9abee745a502ddf0f7c4d0927", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "d4913b27-4b2f-4801-9181-d486d6fe920a": {"doc_hash": "4776f9f5850f4e10c541fe5b33a036e9fe82e01ccb8b510563cb3707bc48e5e7", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "5a877cb2-16f6-47b7-a66d-7fca81c8c4b4": {"doc_hash": "36b97a7ebad906a192b9a403ba6d4292233b2f20befc117f164f20ac82533747", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "c47f6e7b-6f0d-4eb3-84ec-19d9f707e5f7": {"doc_hash": "2764b05e35fdc138fc1d6c4e8c3acb95f2df546745a283283bfca9442a57ec8f", "ref_doc_id": "204daa18-f611-4af9-b386-642ea97a1e42"}, "4b7520e2-48b8-4fa8-8ede-f3ed56981886": {"doc_hash": "52bc62baa9949e1b3468f938fb06d4fa7b2640cdc123eac783fe635b4a1e2017", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "226d34b0-b831-48f2-90bd-1059683b9667": {"doc_hash": "6fccf3c5355d6cc41efc5a44dc89ff2f9c17cf9eded7cd7314d18fe433ca1b7f", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "5bc7d83b-8250-4e47-a4be-f93aa1d8255c": {"doc_hash": "64e97b6c0b0ced0ea52ab17b994da45b030676bcf94319aa68c01b0d88ba1fc5", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "516e7170-65b8-479c-b5e6-c2b624609118": {"doc_hash": "7e27d8ac702d7feaf1edc8c2f752c00a44e9dddbf68b55aab4cc2ecb9dbbf15a", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "54c44b5e-4169-4582-be1f-3c23ea0a0e80": {"doc_hash": "6c6bf729c2100954b8bc67777812755a14ccba2a4220420ac9a34b592e418c35", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "596f5e9a-9ff2-4cab-a564-68c417250aac": {"doc_hash": "45238ff2275cff167b0e21127c9df8666b31eec4278ddf359c2ecd3d7105de80", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "c68548ee-bc92-4c45-b943-02ef6f38544f": {"doc_hash": "8aa69e0a175bde31a2334d961be9f585f82dfb22c6293affb6d57820879d2cda", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "3581b95c-e23d-4f25-8ee7-087cb3b767db": {"doc_hash": "44fe9e9696427dd35ac948ce577eb68b33ee1765838b1832c11b80fcb1a7f7bf", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "739ee451-e1bb-4bcb-b561-83358e60b070": {"doc_hash": "cc2e98ad2c67e85e27a7e3a6280c7475c44e7b6715120dd8568c14d083f37891", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "c04148b2-d67b-41f1-9b47-3493494ad6fe": {"doc_hash": "0b751c8299c9386f455a3ed9f1cb83866cc3f5246a58d38d100678dd972f7a10", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "65c5bd94-0a7f-4f90-ae30-5c25d728bfa0": {"doc_hash": "73eaafc6fba848c523243c143d6c6c4172c186729a0218b04c5c14b0904d03fa", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "0fcb084b-b7a1-494c-9661-bb389171f824": {"doc_hash": "47fb8799ccfdb506ac67ed24d47db9c8411645de203cfadab28ddd1e7d858afb", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "0084350b-01be-406a-ad53-61a1473f3973": {"doc_hash": "e04ac2e3f2a491d5ea6da70589d4f6233bb71c318bc2890788ebdc88657f2ec2", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "aa18f7ed-078c-46aa-9ee3-c3ab114924f7": {"doc_hash": "18093de18c390626a215ad22a28c8eb6c0ab2ec9ea24bdc635aa06780a63e8c2", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "294d3db0-3eb1-44e0-a96d-5ec68a17ca22": {"doc_hash": "edb1e52b6afb94ae7869f4ade72b945ee734616b00fd4734a6bb9c31000edd2c", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "c9f4229e-e5d9-4614-9a29-4f35c2a4b14c": {"doc_hash": "1c1cb504b212d73d04c28cb9716fc77fa1f43564f57ccf675369a9b408919ee2", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "926bde06-fe04-4777-98f8-3421139740cd": {"doc_hash": "febf1b0c18d1fadba4e3de99bb0bec5279f87d4f8c60a07165cc3143311f6e1b", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "5acbe72b-7b14-46e2-ab18-a9d5085c31e5": {"doc_hash": "719cad41ea2d496363dcf34de9994e18b0c342da7d34fd3b34bbec420eb52246", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "31396a9c-c1d5-4589-8de3-b6f0da24ebba": {"doc_hash": "d3e7fb8b115784626a2a7df0bbc45df3d9c2d032e1871c7c060dff58f4281f16", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "5132822b-52b2-48f4-a9b4-018b2877355b": {"doc_hash": "e83f568f2dfdfb5bd2dbfb843acf77f1b5cd78e5bd843625f768f8246caa560d", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "1a8bcd2f-67b6-478e-bc6b-45a6c7bf7965": {"doc_hash": "74820b2b1824d2d4d70d9b06a9e62bc613c1e28a4f07c617960a53eb1218e60a", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "49a8269b-9061-41bb-913d-d367d1f94f28": {"doc_hash": "6df80cb302e79a1ba5d3edb99ba87ffbea688d852ff630d1a6f5be10a582f7f8", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "9511f79b-1489-4056-bf5d-b2ac09ba1f40": {"doc_hash": "9245834ee0df3ce65453ab951a79bb65cd8ca00cc349e4757398d9b7b69c7486", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "7e36b966-a831-4bbb-9f02-0c16f8a5653e": {"doc_hash": "7cd54a6ca709fd10243c313528f327b56728986ba72ab46ab7b3f4cfd4b2b178", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "3dc2d2af-0900-4666-b86c-e538bcfdff88": {"doc_hash": "1c49d960add4f51105249ec4e7becf512ab9cb7585f9d78926f24aaebbf88f1d", "ref_doc_id": "c3799385-e838-4303-8560-c424e27f15f4"}, "cb2d947f-93b5-4901-9728-a6ac37e9ceb6": {"doc_hash": "355be342485ce30306647a92268b8938d1e1670a03c1db95f5340b85a1ffce81", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "d6d1e569-24dc-430f-95eb-290f9822b01e": {"doc_hash": "c998091b7fea89cf382b7facdd73b0afeea07e4ecb466eed217e53afb944fc08", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "cbb3ac72-c242-42be-a53f-b0c520f89f37": {"doc_hash": "f9a33e3a7b22694d984ad3806e3462a8bfbed8b7b235a3956beb655051ff9218", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "18d6a387-e9a9-468b-a0fc-8b758ed321c4": {"doc_hash": "a1b6f380f85f97bf636fd64a127b329af7785f8ed4eb0d78cb3c3f93162aab44", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "0b7b66c4-a638-4821-a0b9-31a1a096735d": {"doc_hash": "eaadfee61eb5aeaf8897f9859d596a73847a8d13eab00d04e6b7a158926b101a", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "1baef5f8-eb70-4f0f-a346-63c2ca3842ed": {"doc_hash": "5909241a280802549f0f7454b9d2cca080f9d26891d39da97ea515096186245e", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "3f1ec978-0cf5-4ff6-a858-411b34c2cdeb": {"doc_hash": "e455a368851dec579c0a5b5aad54849dc93e45a5ea96617fd00f5d2f69823ba9", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "814cd7ec-a158-43bd-a4ba-4a9e330d70dc": {"doc_hash": "a2ce5948252204d4ba74554111821a94c4296deee7398d3ebcd313b549983c92", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "6a482791-5899-4df3-a2d2-e8fa3a65df90": {"doc_hash": "d4792e4844d5eddab9f57fb134ea8a5e1050d463f2a33b6f035142d6aa4b2b17", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "b03afb18-1da9-437a-b741-348f3ae658c9": {"doc_hash": "44c8d81652776e81ab137fdc59c1104f89ac98b9396b4adc88e17d18ff459cb0", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "570bc289-5a95-4dc5-b03c-df2acff19a63": {"doc_hash": "7f445e49356e4964830ab00da54039de2809e6c07f599278965aaca6a7ee4fce", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "23d2a0f8-a595-4a06-88b2-4cfe97ff1268": {"doc_hash": "330cea9789fafff95bf65903a44ec22baf68c04b1f12591571ef73730a58e0c9", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "3163f572-9720-48dc-a8ae-f8348162ac5b": {"doc_hash": "4bc5056c95d6a3d26f63fc66bb27de5bca0c3d8f02bc025b832a055e554c3f38", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "2ca54a56-bc0d-4a3d-9656-e6c33d98aedf": {"doc_hash": "fdd2c2cacfa79cee70973dd8bfcc895d3e8c1764ae97e1484d95baca83318cdf", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "a1d901bc-ea8c-4a32-857f-75f35e050759": {"doc_hash": "3410cea9af9ad8c440b32a0b0c1acc419c7e1d794310711bef9c687199cefb42", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "bccf37ae-1549-47b6-b065-462b00763b8f": {"doc_hash": "b04ec15125221f70a8d3a7f31870e1ef7716693363937d2e7dd69b154112e25f", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "63e461ff-fd5b-4482-a2f4-650b838300c8": {"doc_hash": "40ef60fab7604dbb0e0f8d7b01221f4ff8a087787cf5ebc945b283a715061b55", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "e26718eb-dea8-4a82-87d1-df125d56728f": {"doc_hash": "87b47f7ffd0cdbcabf516f68c4aa97a578bdbc7e7a7f963bc965953e92d063ef", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "fd44311c-3c23-4f11-8298-f6d964f44b3a": {"doc_hash": "1ce5ce64f9d75f982f3a9faa8c6b966509858f8e9a2eaa69104f13dec92997ca", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "c0775a6d-4cac-4063-8611-980219a59b5a": {"doc_hash": "45b2d6d333f2378fbcd9c7495958ffa431c3fcd3ec2092adddcd65b64afb1870", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "9c29fb5e-5a36-45b4-8462-0015dbbba449": {"doc_hash": "bcf5747f231fd8754976d19bd6499b6e0eea146b42e15dae31eda49e5facc377", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "01d4dac7-408f-4291-907d-c6817416238c": {"doc_hash": "330d15480056f98cb9c3a08702d505d46e2685fec59636a2b351145e0f1762ba", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "feeaa33e-8b67-41d2-8255-19e052a76268": {"doc_hash": "5bf8179cc22d5ffdfb7dbeb8dcce805ec709b13dc1cb23936beb8d8444e3eba4", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "121b7b5e-698e-428a-86d7-87fc56ba58cd": {"doc_hash": "c61c64ad23f4851827dca52156090cb847ca69ac79d99abead8c36441f2e1c3d", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "73afa61d-b9f6-425c-96fa-3e634b8ae132": {"doc_hash": "407818a73883cef02a7c0f6efed3b67310e5d9d823cfe0339d9a98ff3bebf7e0", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "790c6dc2-42d5-44be-abd7-fde5705104ae": {"doc_hash": "a688c44f440932c9b6ab722bf0999470ef9edf08a864f2a49fd52b01cdeec096", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "13e74cc9-f1e3-40f2-a7d1-dc444cced94e": {"doc_hash": "a7b96f8fb569bef7bb2e7698b9d5272dbb980acb887a2e2b6c61f975a2daa42c", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "5ce09066-e7cf-4ba1-bebb-885d680cf593": {"doc_hash": "d493f25c5c114115780dea190724155dff0c27024736a9fa325b1525853bb68a", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "56aa5f67-7e5d-4b50-949e-87d7bc4425a5": {"doc_hash": "fb70dc059cf1bd2c8cf1da8f2f885965bd9bc823ccb96fd7a20e807bb5140091", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "9a9b2959-dd87-4205-abf4-c7669e422900": {"doc_hash": "bdb86d887067596d944bdc5f5a95f009d780e96f03485ab3cba09fe6e9609a4b", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "2c8c88d1-0c3c-4a67-8741-60a0e92b3df7": {"doc_hash": "a7a1b7ca158c2e42f5d78aa8715964b787be388741cbe77fa14fdcab8ab85967", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "f086c620-9a1c-4edd-ac8f-2abf57c1e051": {"doc_hash": "cd98f30415a3860ce92abd9c2e347c795359713bed1acedd9096865ab29ca5d1", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "0a23078b-c802-4ab4-ad11-0e823cb1ef29": {"doc_hash": "44fad9f51947251cbbbcd32fc652c5bb7136fb2bf95d87deb43935957054bece", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "da675109-3f0e-4875-bb7d-b8092f70ba55": {"doc_hash": "c1ff1d7a58b6f75b1d6efd9d7cc1d2091d465c9e814e36766b8f28bd32ace7a6", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "5220c6b5-453d-4d5d-abda-3178999bf891": {"doc_hash": "533913f4cff3d39d28b8655db9e1ed27c13c0436c014d5f815b4f9725db5325c", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "312f0a92-b9b2-4759-a2bb-2f05687476cf": {"doc_hash": "372f6bc2f16df6d1c9562eba63bdb175bc28521aaf94b92dbd2adec32e4cfe6a", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "172c8689-8a13-4697-9742-b7fca115af25": {"doc_hash": "b3a14159034f8c2b3bd30c29c05f20043800506d6e0fd24b2336a34f3f848961", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "97022488-253d-4e31-b934-282419554e25": {"doc_hash": "b13cf59ccc02be2bd2ba95ad27a4954f336dc0a1523937f7b51c762cccfd0f43", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "d11d8dde-c900-43cc-9f2c-ad3e30c5db15": {"doc_hash": "6c298148c3be8379280b0788f15688cc44160a22e9242be49cbb0bcbd4801f44", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "d0cb8a60-2983-4365-b1fc-7d4c3874d69e": {"doc_hash": "2573b70f01becc5bfe7071be7795cddeb65bb413b5ea888853df20c15317fa67", "ref_doc_id": "8e562867-5be9-412b-93c5-b17ff20af4b4"}, "b50509ba-7557-4587-ac96-080733d318b3": {"doc_hash": "b26b7144fa86828165aec1b0acb2b929597185f8707fcbdfcf041874a9b95435", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "a750f0e3-9fe1-428f-b5d6-a9c4cca42bc3": {"doc_hash": "fc2f46e1feee1dbaa3b21310b2116a5ec16e7d8c6fea93248207cc3c76b9823c", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "74684cf7-2e74-4fc0-94bf-db7f54d8904c": {"doc_hash": "3b82360875ad693e275919af77aea3f4735e7e691fc28e52228c037122ed61b2", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "f42aab92-12f9-4a17-9d38-22b1173bda47": {"doc_hash": "a2aa0c5c3e7cb3993b6d5a06c652baf79896eab22e60a9ccfa0283e28db5a8a3", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "f3fa2b68-b3ca-4171-af8d-f295b8715e38": {"doc_hash": "b979461bb8e3f0449e400a53a20547ce1639a077f2337998e3fa2e3fd3ce8f80", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "57e15ac2-07e0-4373-bfa2-8c44e9f9d22e": {"doc_hash": "2b648deeb744eca24d6951df4acb38d860658615b790d4ad22bb6dcab340c63e", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "df628668-1760-4f43-8bf7-143dc06a20e8": {"doc_hash": "27e0515e8e20c93ad45920e17f7ba6a212d093aa805e7b4d36102779bf74b266", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "fabe5232-b631-4156-8948-333d786a8ded": {"doc_hash": "15ad59c102cb3d6e34fe5c67e8d985eefac9bb029369acd0bb0fcf9ea42ff04b", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "a00fac8a-c47a-4e71-b1a4-738b7a72514a": {"doc_hash": "b8d787e2e8a4bf6abf372b0c0bb66963d3ad23a73f8e93e967b2149dea3b2123", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "cd9726a2-1c61-4520-abff-799bb502a75c": {"doc_hash": "5ed4c33f017d63f0a47b15f442e74073d68be8d5ebc8e87361ed48bec5157128", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "e2fd5cc8-718c-4ef3-8a32-c29d2aba11b9": {"doc_hash": "5e1ad9def181d70eaadb114b04e3fb65a59f341f89ecd0740dede10daca4b19f", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "f10cccd7-855e-4aff-9a9b-e8d1d2d9c37a": {"doc_hash": "c7b0ab7020418b7ab8ede19b04b6ef1e51373540c4fbd0808650ab514d81b63b", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "1c5329ea-c1a2-4eff-ba9a-e663537d60a6": {"doc_hash": "d8edbd6b3400e9d37b8ddf9067138dc95648bffc30c3b35d252408473a683bd6", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "8c2cec5f-43ee-4600-a379-c0304f8f3651": {"doc_hash": "d8d158a713fec0e6cb01405638793e0d60c78081f89cdd79b8f9ab96271f0c64", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "abfd454f-4353-41a2-9155-3fdccd399538": {"doc_hash": "029ac189fa5cf4f0b92bc161b2a64d1c52969b079fe8c2833b88600380ea334a", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "07c81dd9-a138-44c5-acf3-bee29ae2cbef": {"doc_hash": "d456740648bd733108ee8f78de6ad31887012fa09b94fb55057cf6d8302665e8", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "8b9e141f-ed09-4630-9d61-ebda6e0eef61": {"doc_hash": "f5f876c748214ec2360794fe361dc550ebbfa6d4063a72d651b73666eb757164", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "02d06e93-0d56-4e6b-b4db-e4165b84b048": {"doc_hash": "265bc32e94f36318f4194313f24041501cbb976ecbb7ab085a8d9348e082ff7b", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "3e0efcfd-b5c7-45f8-8c7c-e95f701fd46b": {"doc_hash": "f97ca64c8458093907a57a4b92e38df999ab97d9b76e9a514f4279c0d44be90f", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "787f2e5f-e559-4020-a578-b6e6b98381c4": {"doc_hash": "12106a569af8760ee2e34134e99374b016d7bc6d415eaae5fb9cdb27110c93ed", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "9634ea32-e42b-426c-a995-65777d409418": {"doc_hash": "ddb89b745d3ad0c139f29828e9afa7d56c4d7837579548e5d2da90bd34446433", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "b05684d6-671b-4e7d-a683-a05ff7fef3fd": {"doc_hash": "2dab052e32158eb5172a5cfb1cbfb4964365985c48b11759d3556ddb8fc8198a", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "9db8992d-9945-4023-a3c7-007b36e7d237": {"doc_hash": "03a05605b69b1edfd1d36e6c14df42cf3f5b1c6a3d1d9f98698f2943cc5857bf", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "4afa49f3-515d-428f-9624-bd95c4231c92": {"doc_hash": "d165155f1f4f0783664cdd4b7c07bf3858cd9cf94575f15e9e299c686a1d74a3", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "f25e772c-3a52-4bdb-967e-56f4c5f416fc": {"doc_hash": "7883f7cd1031e2000dd003157d539d7c5d2c03747673d41ce661fa91a05991d6", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "4bc36d4c-151e-4ecb-826f-f2b36d06d501": {"doc_hash": "49489c4019012820af195ada1d63c18126f3bec852a2f4e18ff796aaf3436614", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "72bb7f4d-88b2-4fb2-8ada-80893825a84d": {"doc_hash": "9ccd53186b4ac8134e663afb2349ca832f1be538959ba59695a37b92497b6343", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "de7d3e59-96e9-4df2-9dbd-9e621cd9653b": {"doc_hash": "d3f7a09f59f46b5c6ef0045857610bd748f4281bd9d35b631e6525bbeb42e2a4", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "51375f5a-2acd-483f-b96e-1a7f96d6c378": {"doc_hash": "e1cb66f9601b56cd6911ba6899dbe042f9b8c293994955b9b359c00e03df9aff", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "894c5bed-c081-44ee-a6ac-0246ac69ad67": {"doc_hash": "21ab3962e91c81bb68e1d9ec84ad5f63e4307ae3c26af674cb86a4b75d37fac7", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "684a8daa-aaeb-4f19-8f53-78c56f476fa3": {"doc_hash": "460e2dab2c3e1a3c0ecc6a0ea5b47d4dbb1b10ce5a5ab53709ca4d9cf08e7862", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "e518cb38-a1ee-41f3-8c06-2914ffd087bc": {"doc_hash": "6e56ad972ddee7347574962bc4e2df41100524e40b0623bab8f7a26e77f412f2", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "2acc7557-d478-41fa-9e8b-38d0faaf4689": {"doc_hash": "52020021a9253aabb151bfa44b1881542daaaa6c2c00434b69b0801f52103d3a", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "136e97ff-cb5a-4dcd-bf22-5ce24ba7246d": {"doc_hash": "276e95cfadfe770bc891c519f25a5ee2a6563b214563e72fe40da50feaed0bbf", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "eb495716-8d81-46aa-a72e-fb0a64e3794c": {"doc_hash": "3e436644835e7299005273ed5c66afd6abae85fdbd76e03f96cbdd0d7ecdb6f5", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "9ccb6a39-b3bb-4eac-9e07-123ea733f67e": {"doc_hash": "927b4b3bfe9c26575befc3bfcca93e85903656f31591cb84b6be2c5d1aee5632", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "e38cc2b3-e09b-4186-800d-cf0f4a5afa4c": {"doc_hash": "d90a59d49103ee5f427296073579e169275b87fc1f3cfd6ddb971e8abe3a4c2a", "ref_doc_id": "096242a0-3a76-47ca-a5cb-9c5ce733668a"}, "43fe314e-3350-4a79-9b3f-b8a82eedacbf": {"doc_hash": "40784802f7337d7b6065cfbde1da82d2476ba40709f1b6c575b1e13d8d0f7611", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "e01fe9d1-5c25-4f4f-9012-2e3d79caa05a": {"doc_hash": "1f419b224e12756a5e08eaa1e2230d549282b6116a7cea1b7d57a1fd44cd9ba8", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "1f059f14-bedb-4edb-8e2c-b7501dacb3d1": {"doc_hash": "d3d0481b93086249f0ed4ab16c8b71e74adea247d71e9ba159dbcb7c4fc5039e", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "7ccf2a2d-d758-439e-aeab-7b18434a24c9": {"doc_hash": "7ac8945410c0100f1db87b857ef3af65ca6d05ae84e975ef0ca9cb531520423e", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "2f4c77a8-22c9-45bb-bc87-854d5d806e44": {"doc_hash": "f7228e5485a9e4fa30e23ce474698bb382638c2fc63f512ff9c4dcc4d0d32843", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "9be9c4bf-7e29-4ef1-af53-f358f53863c9": {"doc_hash": "5b8cf8d67730e37209de764c23a256059bb0bce79fba4dbca2f900aa01e9e283", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "71a9899c-f7b5-4237-bb5d-cf653be96d6a": {"doc_hash": "89e432257f0eb092256b68b820e9b5272c5f3a4c8fc9b235bb9f4e020909ac0d", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "c5bd00d7-5035-4ee2-91db-e5120ae8bd79": {"doc_hash": "3b5878505db402f818520e8707b88b8b5209c18d6c001784c2fa79d690952776", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "75d53e53-83f8-4620-bf1e-475367c86b98": {"doc_hash": "93f28b9deaa36253f905b329642a0e2bf15fbc4a0d6164d474b4640fd1247dc5", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "d29b8bc7-1dc5-4f35-91a4-d589b9ecc1b7": {"doc_hash": "c0da7dbbe5e894e7bca3e0cf28c725b0ac732727ce98bb79685a160686490604", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "a75277aa-c271-4188-bb95-c38c8b07b59a": {"doc_hash": "4fb929025a6919ceab16f19ee53455b3cdd0c3954b12533ddca6a6bef9ba99cc", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "c91798b0-3ef2-4414-9bb1-e75fbf7f6d67": {"doc_hash": "bb476c8147c70bd9881eec5ff037afca0fb7358d1b9713b854487d719ab4b56d", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "c478b514-77b1-4052-980b-b12898d28464": {"doc_hash": "0acd17195ac5f145f00b17057de41ab023616fd5ec00fda20592e66fe42080c7", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "878e536b-9354-4d3f-ad40-da7a95aa3a6f": {"doc_hash": "a812342330c29b892cdad0b15113d404f32ba88667efe6e3c1d67f5ac427b94e", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "427d5b3e-83bc-4aec-9c8b-2d9e0fdfc826": {"doc_hash": "3bc6eae6b6a63740bc5791bca869234739559561436e9fa96a15289d5f5b3c26", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "3a3f3f9c-987e-4869-b8e8-71c1dd92b817": {"doc_hash": "dd6486897be58b3b67e4b6a18c60b6d62dc65b123b3159f9c6e309434a8a20ec", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "29a40640-a0c4-46d3-b6d0-f204b24bb3bc": {"doc_hash": "057cbd497fa0fd3d2b0e9915e93e0c57c768cc9dbb6680e2acbc5e3198ff1c27", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "0c0fcf51-81d0-4c33-9677-27a3cc007d79": {"doc_hash": "6a99b9b1bb038a20c506a6a1276517968306ed41402b8fa3c9f3d45c52418576", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "841ed584-2656-4e16-84b1-3d9c6618da03": {"doc_hash": "a01591a327e2e7a847a120b6fb522010638beb3dae151ee591171d89c47fc57d", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "4f0e59e8-07dd-4430-8261-138bad539216": {"doc_hash": "1a6517fd4ca6b850de4f0300a92436e53de51c4af3de89be4f8b145effc528c2", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "25cbe986-7530-41e9-947e-1551f2abd53d": {"doc_hash": "caa0e44fa192c89ac669bf979cd09a788f4c6a63c08f3a877611043ec21885f0", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "f097a8c9-adbc-4cd7-b998-5b6a355ce583": {"doc_hash": "2857aaeca14caf0491d17ba975d9ac88b27c20f46ea4ca06d8ff7f985f221ff3", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "2e308182-5efc-446c-b887-626f74659005": {"doc_hash": "5e5daa51047d3a7f69c720a7517ac988d80b3179fab7dd521eb9b2dc00e0962e", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "2ebbb803-64e7-4a8a-80ad-b453e554e8cf": {"doc_hash": "a4433034b0a89d19abfdb86050d2ff55d1737344df0c88811a1006a72cce2f37", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "41c687e4-6dca-472c-9400-b5942f3f2679": {"doc_hash": "1429dace9095808f8c97ba32188c480e51c4e2c0f9d7f3d3443eafd0ea1907c4", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "dcd8b5dd-d4c9-4d54-b947-87d3548ea3b5": {"doc_hash": "7eb33fc542bbf67e18b9160b1b06822eb3be8221bb2b5c6378102d041c6f51a8", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "d954a197-ed10-49a8-8616-40e5a4f02625": {"doc_hash": "f9c56bd11d17018280beb9c0a911252cb94e5cdc3fafba48bdbbe5f03426199a", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "3addae53-4ce2-4473-aeac-1ded1842df2a": {"doc_hash": "2fc6c27a8285720637a38bef050b9dd8c2ba34ebc3370653b20fc5c94520e87c", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "4a07267f-f32f-49f5-9bb2-5c13ff84e042": {"doc_hash": "602829f4e1d6896bc2aea9bd400499fff6233e9424efeb2cbb77ba4c98fb2988", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "ceacbe01-12a6-4bdd-815e-7d69676e812a": {"doc_hash": "85784bdc432f0d98fb765ba5bb46d0930ff5647a0d32fbe5e698d25496fa6bf7", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "6a4d51d3-1468-4611-a0fc-5fb5e2c9bc44": {"doc_hash": "5c61e5a63670b0f9a0f25e4b6b156400672da76d87fba365129541839280976f", "ref_doc_id": "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1"}, "12862eaf-9d55-4deb-bbcf-58d436177422": {"doc_hash": "62eb2a3736c66418ce1625e6b8af934ed75621f0e50a32056ba55fc932ab0923", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "75695894-f22e-414e-a24b-21011ded1e5c": {"doc_hash": "8b0a2c56e96b8fd6a855cdb7b2390dd6ada0a2db32dda43cb6f7b251e0046f2e", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "ba78996c-083b-49c9-9d4d-93b2a071f4cb": {"doc_hash": "f2dc7672b79bf71136accab2d3c991287eaee4a131d0c1df015c82962d94323c", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "eb44492b-c0a9-4b9c-ab8c-2a848b8fc9a4": {"doc_hash": "9992b43cb60f13ef81e7800cd9a4766a0d6cd84ab920dffdbdbb5b55abf94553", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "4da320e1-1a60-4578-83d9-f0e219e70914": {"doc_hash": "3d761549f68abb1c35044e0a453bae871e113ab0dc036c1dbdcdd2448524ccdc", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "72a88d9b-9fff-4f81-9294-c67b4005f33a": {"doc_hash": "88f6e4bbf78a350520142edc7074527e011c6cde8c593480151e43b2d7bacc66", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "ff8e15dc-c537-4198-bc93-bb899abe8240": {"doc_hash": "50f34d81d276d1a842c89a168c6332ce86eb4aeb66553204a06820f33cc1159e", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "adc3a371-fc55-48d0-ae6a-ae3836c15611": {"doc_hash": "5b3f3284a03db7237c5003294f638d3e15dc5201e3dd907ecc7f70286252f0ab", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "9e96b6c1-2b5b-469b-b99d-49c6f5e4cda5": {"doc_hash": "f64a05880d15f780de60cf6887cd61e7ca5fba57768dae1a1a1af4bffc68d853", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "d6838784-3c69-412f-9052-194c88aff515": {"doc_hash": "2c91b038a7c88f4af730c0869a71987aa5b431d986749cfb4ae5fc021df10071", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "67fd1653-9aad-46cf-ae64-27803165951e": {"doc_hash": "20e37121401ec2de5c0f7971e96e822644fead3858840c7d891a214e6f2733c7", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "a57fa331-23ef-4633-be51-66b7f301f31c": {"doc_hash": "faa3db40bfdc70eed38c6ab639f83afc7fea858334b77c0e888a53147fe0fdac", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "309590dd-f043-4e0d-b4bb-b5351fc65892": {"doc_hash": "1f56445f80bc9d38797328a0b46ccc5181fad9a61376da1c593e9f0597bff080", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "8f3d822a-238d-4716-a5be-01beb3cd987a": {"doc_hash": "9f5329563f6fb97652e321ee01ce32d7b65e7910e154ebbf72604301c0b505e3", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "b0b7157b-75b8-4614-ae79-7c615510c69b": {"doc_hash": "5e0fa7017f0e25cfcc4790d82017463ff7b26e1665c9a7d62ae39bb9972d501a", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "6f95b820-9574-4208-80a9-4cfa41f3eafa": {"doc_hash": "35d3a8ea3949aeed5afbcb1254e7d21ffec94f047782e9369b6c5eaa7a4df2dc", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "36cc7327-3700-4b92-96d0-5e3bceaa7837": {"doc_hash": "6de2ff503ab829d038347db49938abb633f0f4bb8ea074047a2d7608c42fc7f8", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}, "6270448b-c2b6-4707-a7f1-3d8be4bc2168": {"doc_hash": "0237564438bf13ef477de4c77eb5ebdc605100333b8322c2132f357a7723fa94", "ref_doc_id": "cf8e0724-513e-410b-a9fb-4fadda0011fc"}}, "docstore/ref_doc_info": {"7f1a04c9-62a9-4615-bcb1-4492e1bcee63": {"node_ids": ["1ec9f0f6-ddfb-4773-8c5b-9608fcb4639c", "c4e052e2-2bde-4d36-87b0-ebd8dd84eab5"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n02-Aug-2023  \nMcKesson Corp.   (MCK ) \nQ1 2024 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n02-Aug-2023  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ce84f197-3760-4cf2-86ad-93434da74016": {"node_ids": ["37f0b981-a739-4f4f-a0a2-4e4c7c3855ac", "767f484d-0e88-436b-8d0b-31c0f551f972", "ceb9e48e-ae8d-4c0e-a214-7f9f703c045c", "03427b1f-5b9e-47cb-8f63-ef1061960587", "452a77cd-46f4-432a-863c-55ee682bc998", "4f0072f1-57aa-4883-ae57-5d6ee9790961", "5d73c376-9867-41a9-af43-d573f6520e98", "b3a5d367-5036-4fd8-ac0b-79ed13607aef", "4489f470-6222-468c-b9b2-4b13f096175c", "004d145e-61f6-4210-830a-2d8c6e5a7342", "4204660c-9a85-4c3d-8471-38a8b2882200", "43016a68-8cb0-4f94-a247-e274775219ed", "489115f9-e3fa-40f7-aa73-982f729a742d", "2381de58-fc90-41ab-b6d8-72563f04b20d", "dbb8d283-9428-400f-ab22-bb5065cd27d6", "d7dfe3ce-80e1-4408-a81f-7ecd425997db", "214f1ff4-e754-4102-8b7a-71d5a8ff81e0", "562be26f-69b1-4a3a-bf93-ee728d91faaf", "a3e57ff7-4a27-472c-b71e-26f7d7736d47", "68b0fa61-126a-4545-b51e-7e0d71ba3c2a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "30e42cd6-369e-40f3-9804-be6c6e3c8c60": {"node_ids": ["dd3ffb9b-2b55-44e0-b69c-2e36414c3dd1", "94356b8f-c1e4-4510-9b95-681950125b4c", "7e02e8d1-4228-43a8-a524-e9f414db46b7", "0850248f-6f87-4b26-9586-444fd93b8403", "8823ca9d-82ff-4bdd-93e4-d4fcdca4d591", "7e3f3fe8-cf28-4d13-948b-ed67c19848c4", "3c5cfd06-28c0-425a-bd0c-1f05c18dcad8", "47d23fee-5c97-48c3-9e8f-eeaf7789ecdf", "0b12ae4d-890f-4cf9-9848-6308534917fa", "62805d47-3eef-4909-8940-a643268b2b4a", "5603e1b4-d0e5-40b2-8fe8-55540e6b0825", "6cc20f45-0920-40f7-8961-96c54cdb94ec", "53de1a3d-d2cb-4b16-8604-7ce5a26bf8d4", "b96d8fab-ce28-4698-bcd4-53e4fc750479", "5ddfaf67-7d5f-40a0-848c-4a1aaab48cb8", "b4f714c4-5ed4-4202-b28f-ddfdffe10a46", "1183fa0b-3e23-4f63-9825-0e4148550dd0", "efadd836-07dd-4d38-b1c0-c4ff31a876d9", "b3094e7b-3023-4ff4-8cce-f1810b4d8a97", "2a164599-b19f-436a-bc4d-cefdead83dfc", "74f6f97d-687d-429b-9845-a6977cb9a5cc", "768a9e8c-71aa-466f-bbb2-e3ffde772077", "a0753336-3aff-48f1-99e5-7668777bc474", "1b2bcba6-b682-493d-87c3-783eafd82f30", "268768c1-0610-4272-8d00-96f47f4e90f4", "fb9fabf6-7a73-4a75-942b-8c15df8f6dfb", "ad8f501a-a61c-49ef-bdb6-643bbd9a2a74", "26cd9cf4-788d-432c-aa2b-e8d3484d701b"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nInformation about non -GAAP financial measures that we wi ll discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidanc e. \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2d7274c5-67fe-4463-87fd-a9dd5be49633": {"node_ids": ["ab77c1b5-1ae4-4346-ac4b-070efee2f110", "c0fe4375-9202-49a9-83d2-0bc5d96619d1", "f279f272-842a-4ac1-93b5-a172cc3553d4", "dbd86fe3-794c-4cb8-9cd5-a5cce384cc7f", "a2afda1b-24ce-4f2f-908d-4973ac0d1b13", "b4cb1d27-9236-451f-902e-b8c07709a0ae", "e6f522ac-4300-46ea-ada4-e52ec0a4da3e", "ba43908a-dc03-4de9-bdaf-00441d642097", "141343ca-8286-4e09-b542-c8dc4bf9fdd9", "f55035d3-72ee-4adf-9b16-b138990ddf09", "d32db43b-07a9-4ce0-8f83-9efec3792a2b", "9f50d233-fae8-41bb-b4bb-a16962c03113", "ea0febec-c1a2-4d22-a012-4416d0be1fd0", "f7948fa0-84ad-4533-bb70-d25feeaf3b80", "494371e0-8d8c-4d89-b6ea-4a3f82a7c3d3", "1ae6e2af-8ec1-411e-a480-4c636660d70f", "a1e70a96-2411-4739-b14b-57c66333a7ce", "62e9fd2d-2bb8-476b-954b-656cd55c6af2", "9a050a31-ddde-4519-bccb-f45244be9364", "fa6fe6ce-66f1-4f8b-b0be-ff5507e1b09d", "e9aeef17-fb1e-44c4-b551-adbaf029e369", "a0b93953-044e-4195-b2fe-148e87f62d7e", "a742ed1b-9d14-4199-858e-66684f9d00fe", "31d39711-f0dd-4acc-aa49-94918a227756"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ninnovations in supply chain automation and technology and will allow us to better serve our customers with \nincreased productivity. \n \n In the Medical-Surgical segment we're dedicated to serving customers across alternate sites of care and we \ncontinue to look for opportunities for new partnerships.  In the past two years we've partnered closely with the US \ngovernment on important public health initiatives, and we're really quite proud of the relationships we've built at \nboth the state and the federal level through these close collaborations. \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "dc60f063-61b7-4464-aba0-74d1fa2101d3": {"node_ids": ["08d44b30-e3d0-4abe-8664-10397fdd43de", "149c365f-be9c-4bd8-a199-1a87bf41933b", "d6f7b39a-f5f1-45a9-ae33-25f8fa326c4a", "9208d2bf-fc66-4d32-9228-dd73be87cfa2", "6e55c7b6-d80b-49c6-b374-8e6cc2e0bc5f", "8804b8cc-9143-489c-add1-7d7f5e392a5f", "f592919e-849a-42b1-a49c-977946233075", "d8fae14b-75bc-4b89-a90b-ffb1d3c57103", "c02d7f6f-ef8d-4e51-9ec4-628562f94478", "06db4685-fba9-46fa-8fb2-72ca57ef9eea", "e66e1387-78e6-49e7-aa60-146bb4d541a4", "bc924b69-fc69-4624-ae9c-81ca33e6ebca", "9ead7b87-486b-40df-8b22-9f7bfa44ac33", "36627a81-bf43-427f-8a99-00781914d105", "bec63223-c37b-4753-9747-c989dfa46d01", "a51e6ff2-973a-477a-8634-931fb488aa6b", "3cf0c175-c12d-4ddf-86b8-93f92f6f0419", "e15da4ca-2600-4156-b247-72716b729aac", "21bda11e-5417-40cd-898d-d797a4de0ad7", "76f05b66-37f7-45f8-99c6-420af9cf8245", "ecf4f618-27c6-4b1f-8cf7-a1a295ae15a8", "60168cfe-8ab2-4c72-b007-88174a7ec8af", "ddc6f3f2-1b35-4b9f-a7c3-82dab78c18c8", "50c78d4c-255c-4cea-99ec-1634d6ac210e", "61c1fba8-15ca-44b3-88b2-b8b16aacea38", "95d17390-effd-473b-9f1c-ebc9af4667d3", "dc8649a8-c06b-400a-8c87-0ef33b316cae"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nprimary sponsor of this business.  We're also creating comprehensive value propositions for each of the \nstakeholders in the  continuum of care.  \n \n For providers our industry -leading technology platforms helped them understand the patient's progression along \ntheir treatment journey and helped the patients access their therapies faster. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "81beb269-f9f1-4b7d-9ef9-706128297398": {"node_ids": ["344bb069-f82f-4295-991d-beb99ee52260", "498ac1b9-733d-49ce-a2b5-83c0f06da52e", "503b7818-6fef-4926-92b1-f0e589c92ad9", "4a786c40-f7e2-46ed-9b0f-f4e2c2c43310", "8536f6fa-5430-4c33-90a6-2ca05fd0f7a6", "70fb7dcb-21bf-4ae3-9ab4-a84cf5a6c09c", "e2489bc7-9b83-4ac3-b095-d99330fd7da1", "2208d0cb-f893-45dc-9f50-70d203c97be4", "d995580b-3f11-497f-a287-9b53adec93e2", "c20bdb28-28e6-4021-8904-1664c20292e0", "c3885fc8-16e9-4ddb-9ae7-e64c8bae811e", "a1f42793-9497-446d-adf6-e7afe3bf52c6", "be479c44-2283-4830-8ff3-69b633a36a49", "dda5a64f-cd01-4429-bac6-e20387c258ac", "28436069-e16d-43b1-9ff0-cf1149931e52", "44028522-7cdc-4797-bcb7-0d6a8251d9ef", "f8b24d58-98a1-4ad8-9cd4-10fc0d59994d", "5cb75e27-f463-4ea7-9645-6ecaa3dab75a", "c1e7869b-27f3-4e56-805f-b1ea46995a4f", "eb582c7d-ffe0-4495-ae08-76c478a81e52", "5cb8912a-834f-4a96-92cf-4b73fa8d211e", "6e6a975e-ceba-4b3a-a3fa-89f77bca0667", "4d9ef24a-6f8c-471f-ba61-77acc1948741", "45112e3a-03b0-4d75-bbd4-8ee3ecca29ef"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThank you, Brian, and I'm pleased to  be here this afternoon to discuss our fiscal first quarter results, which as you \nmentioned are tracking above the full year guidance that we provided in May, and it reflects solid progress against \nour long -term growth targets.  \n \n Given the strong start to t he year, and momentum across the business, we're raising both our top and bottom line \nguidance today.  I'll first start with a review of our first quarter results and provide an overview of our fiscal 2024 \noutlook including our updated adjusted earnings per  diluted share range. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5f1ad1f6-c1cc-452a-8f3b-b95ae3ef6923": {"node_ids": ["8e7328e8-0c3d-4c22-8b4b-7b510842deba", "4042a939-53cc-4446-b156-5470138cae8c", "5409e8dd-53ef-42f8-af6a-d46fff81252c", "dcf0e9d0-cda9-44ae-a713-b5f5e8982934", "869e72ff-d78c-41a7-b009-fb212e98ab09", "dab9e6aa-83ba-4839-b45a-711aadc49aaf", "5f302c4f-8f5a-4497-bade-d6ea4b36d06f", "118cb664-9bed-4564-a773-18c84e3b5c34", "70211729-306c-49fa-b345-336404636a27", "14481372-58f4-410e-b73a-a888c64045f7", "1307c224-5d98-4f43-8315-bde30308a003", "f18310cf-3879-4f60-8971-ff3e3127f31e", "f2dfbb26-f060-44d4-a53f-5fd0a818c1ca", "e660c48d-28f8-4780-86b1-7fb4f030816a", "bfbbdccc-8eeb-4a5d-beba-250fa9a84b31", "43178e70-9803-4c6c-82a4-cbf7fe7cb1d8", "c20d6a6e-aaf5-4f40-aea4-8e55cee6d421", "547a8aa2-c4d6-48ea-860e-ac981e46f27e", "faba1044-d1dd-4c87-9e6e-91ded01030ba", "3472a94a-0fec-4df4-9a9e-4923985e7805", "f868f50a-00ae-4a8f-a9aa-4c9683fee3ba", "ebc4d77e-c6f9-4e7f-a62b-35d3a252da44", "a79def66-b7da-4220-9bda-a7a0a0546994", "9635211e-a017-4700-bb6d-ce08042d5585", "313e1abb-2d70-4831-9e4c-dcb19fcc80ad", "8cc67925-606c-4d90-bca2-caec2a45c78d", "85fbe087-f27c-4290-a0bd-16892e6c60d7", "d3580dff-3b29-4e4d-aa68-95707b01a5cf", "a52085a1-f773-4800-a20b-fd2fb90ac7e9", "b3b49551-b09d-4788-bff8-cd7e4ba8e921", "badee450-5035-42a9-8032-266c0f648e7b"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nTurning to our first quarter segmen t results, which could be found on slides 7 through 11 and I'll start with U.S. \n Pharmaceutical.  Revenue and operating profit results in the quarter exceeded our expectations. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4140dde5-cbd0-474f-8f3b-597ce01bbbea": {"node_ids": ["081cb9d3-b446-4102-964d-0e15bea0212b", "ce409c7c-12d2-4379-a7a7-a387b1b8f011", "f4547e0d-238a-4e97-83d3-b7c68330ea74", "6a9e56ce-399c-437e-9b34-1352df18d70b", "3a83d2a0-207f-411a-b4b4-5bec825aad7b", "b71ad006-aec7-42c4-9a20-e69a0159be33", "1268891f-bdd7-4d94-8a31-5440f28938cf", "0a77a990-ee66-42db-ab3c-6cf29970be1e", "fc4c0568-d9a9-4352-be98-ac4d82cf6fd6", "ed3c1bdd-0cb2-4ef2-bfda-65ddc77ae0c9", "0024a5d9-4472-4c6b-b60e-cffb9144fe0a", "c46be7a3-81a4-4cad-986f-541bc4722222", "9848bb70-5369-4f27-978e-226eb7a49de0", "1e53dd68-f6e4-4dac-8840-1c52ce89f5be", "387e23e8-b0d3-4d92-8850-5a1495cadfc0", "47fdb188-097e-4633-8f4e-8b629c17e189", "7848ab05-e927-41db-97f5-2976f0245d0a", "494fd32d-4c50-4008-b66a-c3aa6f0d5e3e", "747671b9-939f-4344-9923-f77e83dc3ffb", "fbe617d2-24e9-4c5e-ae9c-4d935c61ffc2", "b167d256-b3e5-4dc6-a6d1-65f06e3b3c6a", "23a2a383-1d57-4902-8574-698e99ff81df", "1ef21995-b87f-44a1-8c63-25339853d894", "a2604d4a-ee67-44db-90b2-704866438a4c", "61a83e01-7dae-40b6-8ac6-384705d0622a", "c93640b8-6072-438a-814d-f2e5a8da02ce"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOne examp le of this is CoverMyMeds electronic prior authorization solutions.  Historically, the prior authorization \nprocess was a tedious and time -consuming task for providers.  Through the Technology Solutions that McKesson \nhas we automate this process providing a f aster and easier way to review, complete and track prior authorization \nrequests.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "57e23f6e-dc3a-4623-8088-9486a7a2bb5e": {"node_ids": ["25814a57-ec6c-45bb-b159-8f0578441fe2", "e1dc3eaa-932b-4d4b-8d8e-50b2cd440e7d", "2539d410-ea5b-40cc-977b-d4caca3cddf4", "5ccc4995-6b83-413a-a2bb-7a081b6364d6", "a10e04d1-1aed-40c6-ae21-ceab48a1c682", "7cd9719d-b368-4c78-932d-b4e003d5fc52", "a575ea26-79c6-4340-a8e3-1b0ed1327327", "6af93a8f-53f6-4b83-a156-6d5df1c43ac2", "092fa69a-620f-41ad-8f4a-943c789a12e2", "056cf365-e399-4698-af5a-8322286b2f50", "3d0a8a59-8000-47d3-bbd7-741230fcff7a", "24455dc9-c588-448e-8282-4c9016754c86", "b94eb3c3-717b-470b-951c-003bb14be91d", "2e7c7f36-03a5-46af-bab9-d4e2d72a2536", "6993ce6f-c10d-4eb8-881b-5721bb1f1360", "59d8181f-b4e3-4b18-b545-e1fd16d34047", "ecf039d8-8f1a-4450-9de4-ec1e7153a2a5", "38b039da-2e70-472f-b793-18571ba92d7c", "b5047491-fb25-4062-bfb3-c9834bd6132a", "c10aa366-a35c-4b22-961d-a7b74cfbff5a", "42089d29-72db-428b-8d53-a0dd1a3097ef", "cb564e63-83c0-426f-9202-e097b43dfc77", "fd0a4056-c930-4846-b864-4156774e8349", "55720998-aa7f-4a42-bde5-f6877a801b93", "8062c598-6c2f-4747-a7d7-e0dca70be29c", "aa189654-9b0e-426e-8f26-87c09ed437ab", "df237d5f-144a-458c-aa12-c67f718dedc8", "469985a7-f3b9-4f79-b7df-18be2a744d9d", "c9c15640-b808-4a43-8cf9-2ab78de286e0"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nTurning now to our cash position, balance sheet and capital deployment on slide 12.  We ended the quarter with \n$2.6 billion in cash an d cash equivalents.  We made $124 million of capital expenditures, which includes \ninvestments in new and existing distribution centers, as well as investments in technology, data and analytics, to \nsupport our growth priorities.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "68e87f72-df25-4aba-89e0-510d1d52d088": {"node_ids": ["84bfe11d-c7c9-434e-812b-4e37b5a7a6a5", "4ca74d9f-b615-4165-9e10-cecd956431eb", "d22967b1-0bc3-4786-a7b2-9854ab6357ea", "d2c0a407-b3f6-4bbc-8f65-93a007f1c644", "8bbc8298-fe7a-42fc-b1d1-2d970d40921a", "1a1f66b3-66f0-4796-9fd3-ae542dc8373f", "64867703-8412-4d8e-ae28-7da104c26454", "00100d14-7154-40ef-8449-ea5cc38788f7", "89a3a931-4803-42fb-b0e4-458cda89ae80", "62b33ef7-ef38-445c-8f31-208120f09672", "406f0a3e-b4e1-4292-8f03-d5efec7a5656", "aed76bf9-61cf-40e7-9e7a-8bf7b8a6d674", "8bfa1b02-f2c0-4419-9b8e-db7bc42ec14c", "b463ab99-4175-4559-a6a3-79d4efa6270d", "bc03d0b4-17a5-47c1-9473-7053b78676b6", "a721984d-cc61-4753-89a6-972b4c5a7ec3", "83e1dfc7-5949-41af-8894-ccaaf3a84750", "36442eb9-e1fa-4505-b842-c3c3e5b14068", "2f63297d-946c-4634-b04a-89b792e58d09", "12ecb74e-3435-4f90-8c2e-656c463be044", "0639cb23-8eb4-4e9f-8c4d-94ad8b0983f7", "0b42f99d-58e6-4daa-a049-17b723489f5e", "48b7e6ae-b9e6-41e4-8e17-641f5eb32fe8", "8decb527-369d-4b30-97cb-7014fe4d67e8", "85827c5b-874c-4a4b-b874-7a27e0b16a4a", "b2431a75-d2b5-4330-8e34-bd7d554cf368", "9a697180-fa49-46fe-9c37-f9526bda6140"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWe anticipate this class of drugs will continue to be a revenue tailwind for U.S.  Pharmaceutical as we support our \ncustomers through our distribution services.  As I discussed  earlier, these drugs have a lower distribution margin \nrate profile. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "208ff8ea-f627-4d33-a125-f63b872b3558": {"node_ids": ["4eb62ee7-6d5f-4d86-b553-95fc82375a51", "c9ae5792-85b4-41aa-b987-1ded19854def", "7be35870-7f6d-4e38-98b4-6506e1f0b1e0", "bd8f8396-d5ad-406a-aa50-7bea1d8810f3", "f9e2b909-4f1c-493a-ae67-9c47d1b54f5f", "e91bcad6-220f-4fc3-9fb0-65b08a7f1586", "8f68320a-395f-44f5-9cd9-8da90486a8ad", "e5541cea-64d0-43ae-88e7-f5196cd59fe7", "880635ba-5ce0-4cc2-876e-4413b6ea5fd7", "b4c17f8f-95f0-4abd-9b2b-d1e1a3bd315c", "fd55dbd6-02d3-413e-ba6f-9d783ee7960c", "564c3fca-68af-40dc-b1b3-f9586fcdc276", "d93624e3-07ec-4533-8db0-815d1cbcab66", "2d9a048c-2401-41ae-9ca0-26f43fe844ec", "b29243d8-b392-4abc-82d5-cf866b1f9932", "57edf449-2a82-46a3-914c-c8cb3b9d9e51", "94a0f273-c020-4cbe-9ff4-47c0516e7e3d", "48330d5f-b16f-485d-afba-666826461e9a", "c2cc864a-054c-4731-89be-b6d8277ad0cb", "017c5c63-f51a-41d3-9dd9-61ad4ca534a7", "917acb11-1421-4ad4-8dce-5dd967d25b8d", "7033f752-add3-4194-9ad4-2b7a6372e764", "c49cb09c-f691-455c-a866-d0efc541c6e7", "2bb50d7a-f395-4c53-9fa0-2453ce3afebd", "df77c3c7-1b9c-490c-a060-4c729609871c", "b744ddd4-9af2-44c6-aa56-ac1c22de6d5d", "7e9f6703-bec5-4f7e-9016-586bf00a0679", "52bbe08f-05a8-41d2-9aee-c63eb21b57dd", "0320b8c8-ad72-4227-939f-01a3bd19a057", "f62f072a-a8d0-4725-bbc8-0e173c6c3efb"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOur outlook furt her demonstrates the shareholder value creation framework that we've discussed previously.  We \ncontinue to be focused on sustainable growth and efficient deployment of capital.  We're pleased with the strong \nstart to the fiscal year. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "535e8124-c88a-461c-a64c-475f3d854179": {"node_ids": ["a98a1ee1-58b9-4bf3-b11f-9d25841ff767", "b697d28c-ef28-46cb-a47d-a5ded9a054d0", "4279805e-5a4d-414d-b48d-b7ac26c00023", "1723b70b-938d-4699-838d-9e3362564684", "7ee12911-2ce7-4566-90ef-9e18a868c586", "48500160-ac7f-45d5-ad01-e9d97e50fd89", "683e9671-98c9-4dd0-b1a4-e3f2c3a7287e", "04a921cf-9a49-447f-b1e4-e50d10765d5a", "ef3f422f-be5f-4d64-8b1e-0de691604811", "1dc7ab97-b29a-443a-b3d0-c6c1d9dadcac", "666f3216-9c7f-44cc-a4e5-c045826b0e7d", "e05e3961-0cce-426c-8682-6f3b0babfe52", "ecaf62a5-4702-48e3-9d95-b7660adbfb1c", "4e4dc653-4aa7-4910-a9f5-a4d27f34f480", "26e227b9-7c7c-4e65-b39e-9a4fcd64761a", "a6410cd4-d6f7-425a-b8be-994ca76460cb", "05889b7e-8ce4-4dc9-9c11-2662a959e978", "83e9feb0-b9c1-4f0d-9906-338eeea99da7", "ba24dc12-9532-486a-be31-ae926c75856f", "553cd0ce-52db-477d-8ce4-117ccfb6ca57", "b02055c9-dafd-470c-9eb1-9c2bc783305c", "8c43a071-de2b-4243-b610-11025703d4a2", "ea49a3ae-a435-45f8-bf2a-3b6939262383", "50ab4bbc-3f99-4a21-8441-7a6036c4aeab", "2974cddd-e6bc-44dc-8ea0-e449ad6a4800", "6ced1c62-c512-4216-8b56-053683f9e2e4", "b0b1f557-1aa8-4356-a7bd-f3fda876f214", "47fa2038-6dfa-4237-bff0-a29a2751c1d8", "2ebafc20-db0b-4acc-8a94-2deadbbb5fe3", "106c9c15-8215-431c-b0aa-256cf6c26851", "1ac8bb8e-2e21-491f-9f3d-b7b9793428ed"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nwithin our technology segment and those programs like prior authorization have been very well -received.  They'r e \nproviding a lot of value to our customers.  And so there's a secondary component to the services that we provide \non behalf of those drugs.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "204daa18-f611-4af9-b386-642ea97a1e42": {"node_ids": ["84e14511-18ed-45c3-815a-57561996c153", "28af7c38-820c-427b-be09-9f92fc51e3ea", "b790a42f-48d7-47aa-8f74-db1279441395", "53e20382-39a3-4b88-890b-668b6143726b", "e031ce21-f0cf-43da-976d-bf049e0c662b", "12b63ca2-37cf-4199-bf24-f0798a1928ea", "fa24bcd6-6e9f-4c9b-9e94-6756578bfe77", "a9a5cbb7-0d34-4b4b-b932-fcfaff41c967", "dd4cb021-a161-4e62-8bde-e4af3a3f48c0", "3315d8e0-894d-48be-890b-13e55e22cd2e", "8f3c86dc-9f06-4804-9728-cea7d8b6ac2a", "534561ae-2758-4649-abc7-6d357b87f413", "fb0c494f-850e-4b86-8e36-21dbf1e6c84f", "6951472e-d9aa-4678-9672-db5bdc0ac0cd", "99fbff5f-4cbd-41d8-aaf3-44ea2e9ba34f", "c9e7ff88-cf6c-491d-99ed-3c3a7ccf139e", "3e1e5318-30a6-4dcd-8749-58a7161d1827", "7981b5fd-e5bd-4cd5-957e-e2527fd0ab07", "ddb7ced3-8ea8-4413-a091-6d67db136b6d", "d7107c50-cdeb-4806-8f0e-64de66258cdc", "5d51503f-af6c-450e-b8c7-291f9a63f3f5", "f729d1b8-d907-4629-a1a1-0deac2ea2435", "6f3d2cab-3cd5-4978-9922-7893781d2d18", "18023cbf-e69f-4a9d-8433-968c2f67ee33", "a639ecff-4e09-48a7-8f08-042ae2af7609", "fd952959-baa4-42d6-932c-e5f0782251ef", "46a793ab-0b7b-4aa8-8ddb-3c84cf3b841c", "aba50923-a485-49a8-924b-606596942162", "d4913b27-4b2f-4801-9181-d486d6fe920a", "5a877cb2-16f6-47b7-a66d-7fca81c8c4b4", "c47f6e7b-6f0d-4eb3-84ec-19d9f707e5f7"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nyou're seeing is the investments that we're  making within this segment and the additional programs and \ncapabilities that we're adding and certainly, the acquisition of Rx Savings Solutions is just adding to the growth \nthat we're seeing on a year -over-year basis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWe also continue to make investments into this segment, and the timing of those investments isn't always linear.  \n ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c3799385-e838-4303-8560-c424e27f15f4": {"node_ids": ["4b7520e2-48b8-4fa8-8ede-f3ed56981886", "226d34b0-b831-48f2-90bd-1059683b9667", "5bc7d83b-8250-4e47-a4be-f93aa1d8255c", "516e7170-65b8-479c-b5e6-c2b624609118", "54c44b5e-4169-4582-be1f-3c23ea0a0e80", "596f5e9a-9ff2-4cab-a564-68c417250aac", "c68548ee-bc92-4c45-b943-02ef6f38544f", "3581b95c-e23d-4f25-8ee7-087cb3b767db", "739ee451-e1bb-4bcb-b561-83358e60b070", "c04148b2-d67b-41f1-9b47-3493494ad6fe", "65c5bd94-0a7f-4f90-ae30-5c25d728bfa0", "0fcb084b-b7a1-494c-9661-bb389171f824", "0084350b-01be-406a-ad53-61a1473f3973", "aa18f7ed-078c-46aa-9ee3-c3ab114924f7", "294d3db0-3eb1-44e0-a96d-5ec68a17ca22", "c9f4229e-e5d9-4614-9a29-4f35c2a4b14c", "926bde06-fe04-4777-98f8-3421139740cd", "5acbe72b-7b14-46e2-ab18-a9d5085c31e5", "31396a9c-c1d5-4589-8de3-b6f0da24ebba", "5132822b-52b2-48f4-a9b4-018b2877355b", "1a8bcd2f-67b6-478e-bc6b-45a6c7bf7965", "49a8269b-9061-41bb-913d-d367d1f94f28", "9511f79b-1489-4056-bf5d-b2ac09ba1f40", "7e36b966-a831-4bbb-9f02-0c16f8a5653e", "3dc2d2af-0900-4666-b86c-e538bcfdff88"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ndrug?  Meaning have you been able to secure more supply or do you have any means?  Is your distribution  \nchannel such that you have a greater percent share of that market than you might normally, for whatever reason \nwhether it's contractually or just the way your mix is set up?  \n ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "8e562867-5be9-412b-93c5-b17ff20af4b4": {"node_ids": ["cb2d947f-93b5-4901-9728-a6ac37e9ceb6", "d6d1e569-24dc-430f-95eb-290f9822b01e", "cbb3ac72-c242-42be-a53f-b0c520f89f37", "18d6a387-e9a9-468b-a0fc-8b758ed321c4", "0b7b66c4-a638-4821-a0b9-31a1a096735d", "1baef5f8-eb70-4f0f-a346-63c2ca3842ed", "3f1ec978-0cf5-4ff6-a858-411b34c2cdeb", "814cd7ec-a158-43bd-a4ba-4a9e330d70dc", "6a482791-5899-4df3-a2d2-e8fa3a65df90", "b03afb18-1da9-437a-b741-348f3ae658c9", "570bc289-5a95-4dc5-b03c-df2acff19a63", "23d2a0f8-a595-4a06-88b2-4cfe97ff1268", "3163f572-9720-48dc-a8ae-f8348162ac5b", "2ca54a56-bc0d-4a3d-9656-e6c33d98aedf", "a1d901bc-ea8c-4a32-857f-75f35e050759", "bccf37ae-1549-47b6-b065-462b00763b8f", "63e461ff-fd5b-4482-a2f4-650b838300c8", "e26718eb-dea8-4a82-87d1-df125d56728f", "fd44311c-3c23-4f11-8298-f6d964f44b3a", "c0775a6d-4cac-4063-8611-980219a59b5a", "9c29fb5e-5a36-45b4-8462-0015dbbba449", "01d4dac7-408f-4291-907d-c6817416238c", "feeaa33e-8b67-41d2-8255-19e052a76268", "121b7b5e-698e-428a-86d7-87fc56ba58cd", "73afa61d-b9f6-425c-96fa-3e634b8ae132", "790c6dc2-42d5-44be-abd7-fde5705104ae", "13e74cc9-f1e3-40f2-a7d1-dc444cced94e", "5ce09066-e7cf-4ba1-bebb-885d680cf593", "56aa5f67-7e5d-4b50-949e-87d7bc4425a5", "9a9b2959-dd87-4205-abf4-c7669e422900", "2c8c88d1-0c3c-4a67-8741-60a0e92b3df7", "f086c620-9a1c-4edd-ac8f-2abf57c1e051", "0a23078b-c802-4ab4-ad11-0e823cb1ef29", "da675109-3f0e-4875-bb7d-b8092f70ba55", "5220c6b5-453d-4d5d-abda-3178999bf891", "312f0a92-b9b2-4759-a2bb-2f05687476cf", "172c8689-8a13-4697-9742-b7fca115af25", "97022488-253d-4e31-b934-282419554e25", "d11d8dde-c900-43cc-9f2c-ad3e30c5db15", "d0cb8a60-2983-4365-b1fc-7d4c3874d69e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ntell you employers out there are thinking about how t hey want to handle them.  That's going to be different, but for \neach of the employers, but generally, it's positive momentum for the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "096242a0-3a76-47ca-a5cb-9c5ce733668a": {"node_ids": ["b50509ba-7557-4587-ac96-080733d318b3", "a750f0e3-9fe1-428f-b5d6-a9c4cca42bc3", "74684cf7-2e74-4fc0-94bf-db7f54d8904c", "f42aab92-12f9-4a17-9d38-22b1173bda47", "f3fa2b68-b3ca-4171-af8d-f295b8715e38", "57e15ac2-07e0-4373-bfa2-8c44e9f9d22e", "df628668-1760-4f43-8bf7-143dc06a20e8", "fabe5232-b631-4156-8948-333d786a8ded", "a00fac8a-c47a-4e71-b1a4-738b7a72514a", "cd9726a2-1c61-4520-abff-799bb502a75c", "e2fd5cc8-718c-4ef3-8a32-c29d2aba11b9", "f10cccd7-855e-4aff-9a9b-e8d1d2d9c37a", "1c5329ea-c1a2-4eff-ba9a-e663537d60a6", "8c2cec5f-43ee-4600-a379-c0304f8f3651", "abfd454f-4353-41a2-9155-3fdccd399538", "07c81dd9-a138-44c5-acf3-bee29ae2cbef", "8b9e141f-ed09-4630-9d61-ebda6e0eef61", "02d06e93-0d56-4e6b-b4db-e4165b84b048", "3e0efcfd-b5c7-45f8-8c7c-e95f701fd46b", "787f2e5f-e559-4020-a578-b6e6b98381c4", "9634ea32-e42b-426c-a995-65777d409418", "b05684d6-671b-4e7d-a683-a05ff7fef3fd", "9db8992d-9945-4023-a3c7-007b36e7d237", "4afa49f3-515d-428f-9624-bd95c4231c92", "f25e772c-3a52-4bdb-967e-56f4c5f416fc", "4bc36d4c-151e-4ecb-826f-f2b36d06d501", "72bb7f4d-88b2-4fb2-8ada-80893825a84d", "de7d3e59-96e9-4df2-9dbd-9e621cd9653b", "51375f5a-2acd-483f-b96e-1a7f96d6c378", "894c5bed-c081-44ee-a6ac-0246ac69ad67", "684a8daa-aaeb-4f19-8f53-78c56f476fa3", "e518cb38-a1ee-41f3-8c06-2914ffd087bc", "2acc7557-d478-41fa-9e8b-38d0faaf4689", "136e97ff-cb5a-4dcd-bf22-5ce24ba7246d", "eb495716-8d81-46aa-a72e-fb0a64e3794c", "9ccb6a39-b3bb-4eac-9e07-123ea733f67e", "e38cc2b3-e09b-4186-800d-cf0f4a5afa4c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSo I'm just curious what in your view is d riving this better pricing environment?  How are you managing potential \nshortages that have gotten some [ph] press (00:48:20) recently?  And then for the remainder of the year, how \nshould we think about the generics environment and that impact on your revise d guidance?  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "42e5f2ab-67c0-41f3-bfed-cb1ca3e149e1": {"node_ids": ["43fe314e-3350-4a79-9b3f-b8a82eedacbf", "e01fe9d1-5c25-4f4f-9012-2e3d79caa05a", "1f059f14-bedb-4edb-8e2c-b7501dacb3d1", "7ccf2a2d-d758-439e-aeab-7b18434a24c9", "2f4c77a8-22c9-45bb-bc87-854d5d806e44", "9be9c4bf-7e29-4ef1-af53-f358f53863c9", "71a9899c-f7b5-4237-bb5d-cf653be96d6a", "c5bd00d7-5035-4ee2-91db-e5120ae8bd79", "75d53e53-83f8-4620-bf1e-475367c86b98", "d29b8bc7-1dc5-4f35-91a4-d589b9ecc1b7", "a75277aa-c271-4188-bb95-c38c8b07b59a", "c91798b0-3ef2-4414-9bb1-e75fbf7f6d67", "c478b514-77b1-4052-980b-b12898d28464", "878e536b-9354-4d3f-ad40-da7a95aa3a6f", "427d5b3e-83bc-4aec-9c8b-2d9e0fdfc826", "3a3f3f9c-987e-4869-b8e8-71c1dd92b817", "29a40640-a0c4-46d3-b6d0-f204b24bb3bc", "0c0fcf51-81d0-4c33-9677-27a3cc007d79", "841ed584-2656-4e16-84b1-3d9c6618da03", "4f0e59e8-07dd-4430-8261-138bad539216", "25cbe986-7530-41e9-947e-1551f2abd53d", "f097a8c9-adbc-4cd7-b998-5b6a355ce583", "2e308182-5efc-446c-b887-626f74659005", "2ebbb803-64e7-4a8a-80ad-b453e554e8cf", "41c687e4-6dca-472c-9400-b5942f3f2679", "dcd8b5dd-d4c9-4d54-b947-87d3548ea3b5", "d954a197-ed10-49a8-8616-40e5a4f02625", "3addae53-4ce2-4473-aeac-1ded1842df2a", "4a07267f-f32f-49f5-9bb2-5c13ff84e042", "ceacbe01-12a6-4bdd-815e-7d69676e812a", "6a4d51d3-1468-4611-a0fc-5fb5e2c9bc44"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust on the other side I would say we have often referred to this as an ecosystem because we think abou t the \nvery broad and diverse set of solutions that we offer here, and it's not just the practice management.  It's the \niKnowMed EMR, it's the GPO services, it's the revenue cycle management services, it's the contributions of those \nsystems to managing the c linical practice of oncology effectively. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "cf8e0724-513e-410b-a9fb-4fadda0011fc": {"node_ids": ["12862eaf-9d55-4deb-bbcf-58d436177422", "75695894-f22e-414e-a24b-21011ded1e5c", "ba78996c-083b-49c9-9d4d-93b2a071f4cb", "eb44492b-c0a9-4b9c-ab8c-2a848b8fc9a4", "4da320e1-1a60-4578-83d9-f0e219e70914", "72a88d9b-9fff-4f81-9294-c67b4005f33a", "ff8e15dc-c537-4198-bc93-bb899abe8240", "adc3a371-fc55-48d0-ae6a-ae3836c15611", "9e96b6c1-2b5b-469b-b99d-49c6f5e4cda5", "d6838784-3c69-412f-9052-194c88aff515", "67fd1653-9aad-46cf-ae64-27803165951e", "a57fa331-23ef-4633-be51-66b7f301f31c", "309590dd-f043-4e0d-b4bb-b5351fc65892", "8f3d822a-238d-4716-a5be-01beb3cd987a", "b0b7157b-75b8-4614-ae79-7c615510c69b", "6f95b820-9574-4208-80a9-4cfa41f3eafa", "36cc7327-3700-4b92-96d0-5e3bceaa7837", "6270448b-c2b6-4707-a7f1-3d8be4bc2168"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2024 Earnings Call  Corrected Transcript  \n02-Aug-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThanks again for joining us.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 349896, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}